
<div>
<div>
</div>
</div>
<div>
<div><div><img><div>1</div><div>TABLE OF CONTENTS</div><div>I.   CONTACT INFORMATION  3</div><div>II. DISEASE PROCESSES &amp; SURGICAL PROCEDURES</div><div>  Transcatheter Aortic Valve Replacement (TAVR)  6</div><div>  Cardiac: TAVR  9</div><div>  Aortic Regurgitation  10</div><div>  Mitral Valve Disease  12</div><div>  Tricuspid Valve Disease  16</div><div>  Coronary Artery Disease and CABG  17</div><div>  Diseases Of The Aorta  19</div><div>  Atrial Fibrillation (AF)  23</div><div>  Hypertrophic Cardiomyopathy   24</div><div>  Infective Endocarditis/ Root Abscess   27</div><div>  Myocardial Bridge  29</div><div>  Constrictive Pericarditis  31</div><div>  Advanced Heart Failure: Ventricular Assist Device (VAD)  32</div><div>  Heart Transplant  34</div><div>  Extracorporeal Membrane Oxygenation (ECMO)  37</div><div>  Lung Transplant  40</div><div>III. POST-OP MANAGEMENT</div><div>1.  NEUROLOGIC</div><div>  Delirium  44</div><div>  Pain Control  45</div><div>  Seizures  47</div><div>  Spinal Cord Ischemia   50</div><div>  Stroke / CVA  52</div><div>2.  CARDIAC</div><div>  Atrial Fibrillation &amp; Electrolyte Replacement  53</div><div>  Heart Blocks  57</div><div>  Chest Pain  58</div><div>  Pericardial Tamponade  59</div><div>  Right Ventricular Failure  60</div><div>  Systolic Anterior Motion (SAM)  62</div><div>  Vasoplegia  62</div><div>  Heart Failure  63</div><div>3.  PULMONARY</div><div>   </div><div>  Pneumothorax  65</div><div>  Pulmonary Hypertension  65</div><div>  Acute Respiratory Distress Syndrome (ARDS)  66</div><div>  Atelectasis  68</div><div>4.  GI</div><div>  Acute Hepatic Dysfunction  69</div><div>  Constipation And Illeus  71</div><div>  GI Bleeding  71</div><div>  Malnutrition (Tube Feeding/TPN)  73 </div><div>5.  GU/FEN </div><div>  Acid Base Disturbances  74</div><div>  Kidney Disease  77</div><div>  Sodium Imbalances  79</div></div><div></div></div>
<div><div><img><div>2 Contact Information 3</div><div>6.  HEMATOLOGY</div><div>  Acute Blood Loss Anemia And Post-Operative Bleeding  80</div><div>  TEG  83</div><div>  Heparin Induced Thrombocytopenia (Hit)  84</div><div>  Deep Vein Thrombosis  85</div><div>7.  INFECTIOUS DISEASE</div><div>  Sepsis  86 </div><div>  Cellulitis  88</div><div>  Pneumonia  89</div><div>  </div><div>  Urinary Tract Infection  91 </div><div>8.  ENDOCRINE</div><div>  Acute Hyperglycemia And Diabetes Management  92</div><div>  </div><div>IV. PROCEDURES/DEVICES</div><div>1.  PROCEDURES </div><div>  Atrial Electrograms  97 </div><div>  Direct Current Cardioversion (DCCV)  97</div><div>  Pacer Wire (PW) Removal  99</div><div>  Rapid Sequence Induction  101</div><div>  Bronchoscopy  103</div><div>2.  DEVICES</div><div>  IABP  103 </div><div>  Lumbar Drains  106</div><div>  Temporary Pacemakers  106</div><div>  On Q Pumps  109</div><div>  Wound Vac  110</div><div>V.  REFERENCE MATERIAL</div><div>  Surgeon Preferences  112 </div><div>  Cardiac Surgery Procedure Clearance  114 </div><div>1.  PRE-OP</div><div>  Check List  115</div><div>  Cardiac Surgery Patient Blood Management Program  116</div><div>  </div><div>  Obtaining Consent Procedure List  120</div><div>  </div><div>  Periprocedural Anticoagulation Bridging  122</div><div>2.  POST-OP </div><div>  Imaging  123</div><div>  ABG Interpretation  124</div><div>  Advanced Hemodynamic Monitoring &amp; Pulmary Artery Catheters  125</div><div>  Common ICU Drips  127</div><div>  Common PO Meds  128</div><div>  Diagnosis Translation Examples  130</div><div>  IICU Admission Requirements  131</div><div>  INR Goals  132</div><div>  Prophylactic Medications (GI, VA-PNA, DVT, Infection)  134</div><div>  Supplemental O2 &amp; Ventilator Management  134</div><div>  Vad Bowel Regimen Protocol  138</div><div>  End of Life Care  139</div><div>  Patient Progression Checklist  140 </div><div>  Notes   141</div><div>PHONE NUMBERS</div><div>Emergency</div><div>Code Blue 211</div><div>Stroke Code 211</div><div>Transfusion STAT 3-6445</div><div>X-ray STAT 3-7030</div><div>Units</div><div>A31 Cardiac Clinic  1-8999</div><div>SAU  3-5163</div><div>ICU Team 1  650-206-3620 or 42829 *</div><div>8-9220</div><div>8-9218</div><div>ICU Team 2 1-6454*</div><div>6-7749</div><div>8-9223</div><div>North ICU Front Desk 3-6081</div><div>iICU Blue  650-850-1830</div><div>iICU Green  650-308-6625</div><div>iICU Float 650-304-9193</div><div>D3 Fax 650-725-4520</div><div>C1 5-8106</div><div>D1 CCU</div><div>D1 CSU</div><div>ED Unit Secretary</div><div>ED Charge RN</div><div>ED Triage RN</div><div>CDU</div><div>8-4662</div><div>4-2243</div><div>5-4492</div><div>4-1710, NP: 39904</div><div>OR Front Desk 3-7251</div><div>OR #8 5-7208</div><div>OR #9 5-7209</div><div>PACU 3-6631</div><div>Resident Desk-Falk 5-3832, 5-3835</div><div>Pharmacy/Lab</div><div>D3 Rx</div><div>D2 Rx</div><div>ICU Rx</div><div>B2 Rx</div><div>16777</div><div>55203</div><div>55923</div><div>36098</div><div>Core Lab 3-6111/3-8891</div><div>Micro Lab 4-4588/4-4589</div><div>Transfusion (Blood Bank) 3-6444</div></div><div></div></div>
<div><div><img><div>4 Contact Information Contact Information 5</div><div>Hillview Lab (HIT studies) 650-723-4813</div><div>Cytology 4-0077</div><div>TEG</div><div>Imaging</div><div>See page 123</div><div>Ancillary Sta</div><div>PT Scheduler 5-0299</div><div>Dialysis RN BAT phone 4-5350</div><div>PICC RN 6-8322</div><div>RT Supervisor 3-7709</div><div> 3-6940</div><div>Chaplain 3-5151</div><div>E-29 Social Worker 650-701-5397</div><div>Admin</div><div>Admitting</div><div>Transfer Center</div><div>Bed Control (Rooming)</div><div>ANS (for beds)</div><div>3-6221</div><div>3-4696</div><div>3-5327 (part of transfer center)</div><div>6-1767</div><div>Central service supply 3-5047</div><div>Service Desk 3-3333</div><div>Food services 3-5538</div><div>Facilities 8-4400</div><div>Main Hospital</div><div>Page Operator 723-4000</div><div>723-6661, x288 in house</div><div>Security 3-7222</div><div>Human Resources 650-723-4748</div><div>Guest Services 8-3333</div><div>House keeping 8-4400</div><div>Medical Records 3-5721</div><div>Misc</div><div>Pager Numbers</div><div>Main Hospital page operator 723-4000, 723-6661, x288 in house</div><div>Department Pager #</div><div>Spanish Interpreter 17726</div><div>RT (Trach weaning) 17709</div><div>Nephrology Consult 24309</div><div>IR Consult, Body 27237</div><div>Urology 27155</div><div>Weekend CM 16292</div><div>Acute Pain 27150 (2-PAIN)</div><div>Psych Consult 15984</div><div>Wound RN 11003</div><div>EP NP 15590</div><div>IR NP (Line placement 35463 (3-LINE)</div><div>Neuro Critical Care 14061 </div><div>Cardiac Surgery Consult 12182</div><div>Extensions</div><div>1- xxxx……..650-721-xxxx</div><div>3- xxxx……..650-723-xxxx</div><div>4- xxxx……..650-724-xxxx</div><div>5- xxxx……..650-725- xxxx</div><div>6- xxxx……..650- 736- xxxx</div><div>7- xxxx……..650- 497- xxxx</div><div>8- xxxx……..650-498- xxxx</div></div><div></div></div>
<div><div><img><div>6 Disease Processes &amp; Surgical Procedures Disease Processes &amp; Surgical Procedures 7</div><div>AORTIC STENOSIS</div><div>Pathology:</div><div> </div><div></div><div></div><div> </div><div></div><div>hypertrophy and decreased LV compliance</div><div> </div><div>Patients with LVH are at increased risk for subendocardial ischemia</div><div>Clinical Manifestations:</div><div> </div><div>Angina</div><div> </div><div>CHF symptoms (SOB, Edema)</div><div> </div><div>Syncope</div><div> </div><div></div><div>Physical Examination:</div><div> </div><div>high pitched mid systolic crescendo-decrescendo murmur at the right upper </div><div>sternal border, which can radiate to the carotids, sternal notch, and apex </div><div></div><div> </div><div>ejection click sometimes heard with a bicuspid aortic valve</div><div>Diagnostic Studies:</div><div> </div><div>Echocardiogram:  </div><div>Severity Grade</div><div>Indicator Mild Moderate Severe</div><div>Jet velocity (m/s) &lt; 3.0 3.0 - 4.0 &gt; 4.0</div><div>Mean gradient (mmHg) &lt; 25 25 - 40 &gt; 40</div><div>Aortic valve area (cm2/m2)</div><div> </div><div>Cardiac catheterization: Allows for direct measurement of gradient by </div><div>crossing valve.  If critical aortic stenosis, sometimes impossible to cross valve </div><div>with catheter</div><div>Indications for Surgery:</div><div> </div><div>Presence of symptoms</div><div> </div><div>Asymptomatic with any of the following:</div><div> presence of LV systolic dysfunction, LVH &gt;15mm, and/or dilation </div><div> Vtach</div><div> LVH&gt; 15 mm</div><div> AVA &lt;0.6 cm squared, peak gradient &gt; 50 mmHg </div><div> </div><div>If undergoing surgery for another indication (ie CABG), and AVA &lt;1.1 cm </div><div>squared </div><div>Preoperative Considerations:</div><div> </div><div>Cardiac catheterization in anyone over age 40 or in younger patient with risk </div><div>factors, angina, or a positive stress test</div><div> </div><div></div><div> </div><div>If bicuspid aortic valve, CTA chest to evaluate for aortic root enlargement </div><div>Surgical Options:</div><div> </div><div>Aortic valve repair or replacement via median sternotomy, minimally invasive, </div><div>or transcatheter (transluminal or transapical) approach.  Bioprosthetic </div><div></div><div>valve conduit (CVG).</div><div>Postoperative Considerations:</div><div> </div><div>Immediate post op Considerations: </div><div> </div><div></div><div>volume replacement. </div><div> Use vasodilators as needed for HTN and to protect the suture line</div><div> Maintain NSR</div><div> </div><div>Aspirin on all patients unless contraindicated</div><div> </div><div>Mechanical valves require anticoagulation with Coumadin.  Consider Heparin </div><div></div><div>op (see “INR Goals” reference chart on page 132)</div><div> </div><div>TRANSCATHETER AORTIC  </div><div>VALVE REPLACEMENT (TAVR)</div><div>Transfemoral    Transapical </div><div>Approach:    Approach:</div><div> </div><div>Indications for Surgery:</div><div>AS &gt; 1/0cm2/</div><div>&lt;.05cm2/m</div><div>SYMPTOMS</div><div>NO SYMPTOMS</div><div>Evaluate for surgery </div><div>↓ LVEF/ LA &gt; </div><div>4.5cm/ LV &gt; 180g/</div><div>m2</div><div>Consider ???Co-Morbidty?</div><div>No </div><div>Yes</div><div>CATH</div><div>PFTs</div><div>CATH</div><div>PFTs</div><div>Dobutamine Stress </div><div>Echo</div><div>Fragility Assessment</div><div>PET for ischemic</div><div>Technical options </div><div>evaluation </div><div>Open AVR via Full </div><div>sternotomy or mini</div><div>Low risk </div><div>High Risk* Inoperable**</div><div>Vascular Access</div><div>Yes No </div><div>TF TAVR</div><div>TA TAVR</div><div>AS &lt; 0.8cm2</div><div>+ VEL &gt; 4m/s</div><div>Or gradiant &gt; 40</div><div>TF AVI BAV</div><div>Apico-</div><div>Descending</div><div>* Currently defined as surgeon assessed &gt; </div><div>15% risk of deat at STS &gt; 8%</div><div>** Defined as &gt; 50% risk of death or </div><div>irreversible serious post operative </div><div>mobidity as assessed by two surgeons </div><div>Indication for TAVR</div><div>References: </div><div>Up to Date, 2015</div></div><div></div></div>
<div><div><img><div>8 Disease Processes &amp; Surgical Procedures Disease Processes &amp; Surgical Procedures 9</div><div>Approaches:</div><div> </div><div>Transfemoral</div><div> </div><div></div><div> </div><div>Transaortic via small sternotomy</div><div>Potential Complications:</div><div> </div><div>Stroke</div><div> </div><div>Distal Embolization</div><div> </div><div>Paravalvular Leak</div><div> </div><div>Heart Block</div><div> </div><div>Thoracic Aortic Dissection:</div><div> </div><div>Local Vascular Injury</div><div> </div><div>Local bleeding/hematoma</div><div> </div><div>Inadvertent blockage of the coronary ostia.</div><div>Post-op Care/Considerations:</div><div>LVH and diastolic dysfunction</div><div> </div><div></div><div>HTN</div><div> </div><div>Especially concerning for transapical/transaortic approach. </div><div> </div><div>First line agent Clevidipine </div><div>Conduction abnormalities</div><div> </div><div>Higher risk with CoreValve, Evolut valves </div><div> </div><div>removed by ICU team if no pacing required</div><div> </div><div>May require PPM</div><div>AVOID ALL NODAL BLOCKING AGENTS IN THE POST OPERATIVE PERIOD </div><div>(no beta blockers, calcium channel blockers, digoxin, or amiodarone)</div><div>Anticoagulation:</div><div>Post-TAVR Antiplatelet and Anticoagulation Recommendations</div><div><div>Confidential – For Discussion Purposes Only</div><div>Post-TAVR Antiplatelet and Anticoagulation Recommendations </div></div><div>•P la vix 75 mg daily x 6 months post-TAVR</div><div>•ASA 81 m g daily indefinitely </div><div>•C o nsider ASA 81 mg alone if high bleeding risk or o ther   </div><div>extenuating circumstance</div><div>No CAD </div><div>No AF </div><div>•Continue pre-TAVR anticoagulation regimen for AF</div><div>•No additional a ntiplatelet necessary</div><div>•C o nsider bridging with heparin or lovenox if high CVA </div><div>ris k</div><div>AF</div><div>•I f concomitant PCI with  DES + TAVR, Plavix 75 mg daily </div><div>x 1 year minimum with ASA 81 mg indefinitely </div><div>•CAD +/- Remote PCI: Plavix 75 mg daily for a minimum </div><div>of 6 months (or min 1 year if recently post DES) and ASA </div><div>81  mg daily indefinitely </div><div>CAD</div><div>•Resume pre-TAVR anticoagulation regimen</div><div>•I f concomitant PCI with DES + TAVR, Plavix 75 mg daily </div><div>x 1 year with anticoagulation and no ASA necessary; if </div><div>no t on anticoagulation, then Plavix 75 mg daily for a </div><div>m inimum of one year and ASA 81 mg daily indefinitely</div><div>AF/CAD</div><div><div>Revised 2/10/16 MS/BF </div></div><div>• If there is concern about high  risk for bleeding, discuss regimen with primary cardiologist before discharge</div><div>• If platelet count &lt;100K, discuss with TAVR team</div><div>TAVR, CONTINUED</div><div></div><div>&lt;1 cm2 and a mean aortic valve gradient greater than 40 mmHg or a jet velocity </div><div>greater than 4 meters a second.</div><div>TAVR work-up</div><div>Orders include:</div><div> </div><div>CTA of chest, abdomen, and pelvis (TAVR protocol: includes Gated process, </div><div>evaluation of iliofemoral arteries with 3-D enhancement and measurements, </div><div>and Dr. Fleischman’s low dose contrast protocol) </div><div>Rationale: Annulus sizing: The aortic annulus is a complex 3-D structure.  </div><div>It is a three-pronged coronet rather than a circular structure.  It has three </div><div>anchor points at the nadir of each aortic cusp.  CT provides reproducible </div><div>measurements of the annulus that provide a granular assessment of </div><div>aortic root geometry and annulus sizing.  CT also reduces vascular access </div><div>complications and allows for assessment of luminal diameters, vessel </div><div></div><div>identify other high-risk features such as dissections and atheromas.</div><div> </div><div>Transthoracic echocardiogram </div><div>Rationale: Recommended in the initial evaluation of patients with known </div><div></div><div>severity, assess hemodynamic consequences, determine prognosis, and </div><div>evaluate timing of intervention (AHA/ACC, 2014)</div><div> </div><div>Coronary angiogram </div><div>Rationale: In the setting of AS, exertional dyspnea and chest pain may be </div><div>due to the combination of AS and CAD.  Coronary angiogram with PCI alone </div><div>may resolve symptoms.  (Ramee et al., 2016)</div><div> </div><div>Pulmonary Function Testing </div><div>Rationale: In patients with AS evaluated for AVR, the STS risk score is </div><div></div><div>predominantly by PFT results. Even when lung disease is not suspected, </div><div>PFTs are abnormal in many patients undergoing AVR. Moderate/severe lung </div><div>disease, diagnosed predominantly by PFTs, is an independent predictor of </div><div></div><div></div><div>AVR. (Henn et al., 2016)</div><div> </div><div>Objective Frailty </div><div>Rationale: Identifying frailty has important implications for clinical care. </div><div>The presence of frailty, worse health status, and more comorbid conditions </div><div>identify a subset of elderly patients at higher risk of dying during the follow-</div><div></div><div> </div><div>Electrocardiogram </div><div>Rationale: </div><div>existing conduction abnormalities such as arrhythmias and heart block.</div><div>Common valves used at Stanford:</div><div>1.  Medtronic: CoreValve Evolut R: Sheath delivered retrievable and </div><div></div><div>to higher incidence of heart block associated with this device, a temporary </div><div></div><div>2.  Edwards Lifesciences: SAPIEN 3: A balloon expanded non-retrievable </div><div></div><div>ventricles is required to reduced turbulence prior to deployment of the valve.  </div><div>Antiplatelet and anticoagulation considerations</div><div></div><div>of heart disease and the risk of thrombus formation on the new valve.  Aspirin </div><div>81 mg a day and Plavix 75 mg a day is a standard regimen unless the patient has </div><div>a condition that precludes it, e.g., GI bleeding.  If a patient is already taking an </div></div><div></div></div>
<div><div><img><div>10 Disease Processes &amp; Surgical Procedures Disease Processes &amp; Surgical Procedures 11</div><div></div><div>condition and to prevent valve thrombus.  Please review full guideline posted in </div><div>your department.</div><div>Please see below for which meds pre-TAVR should be held and when. </div><div>Of note, Plavix and ASA should still be ordered for morning of surgery on TF </div><div>patients when they are on C1. </div><div>THV Pre-procedure Medication Guideline</div><div>Medications to hold TransFemoral (TF) TransApical (TA) TransAortic (TAo)</div><div>Warfarin (lovenox </div><div>ridging per MD’s  </div><div>discretion)</div><div>Hold 5 days before Hold 7 days before Hold 7 days before</div><div>Pradaxa Hold 4 days before Hold 4 days before Hold 4 days before</div><div>Eliquis Hold 48h before Hold 48h before Hold 48h before</div><div>Xarelto Hold 48h before Hold 48h before Hold 48h before</div><div>Eient Continue Hold 7 days before Hold 7 days before</div><div>Plavix Continue Hold 7 days before Hold 7 days before</div><div>Ticagrelor Continue Hold 7 days before Hold 7 days before</div><div>Oral Diabetic </div><div>Medications</div><div>Hold Metformin 48 hours before the procedure. Hold all other oral </div><div>diabetic medicine the morning of the procedure.</div><div>Insulin Take half of the evening dose.  Hold the morning of the procedure.</div><div>Nodal blocking </div><div>agent</div><div> </div><div>Ca Channel </div><div>blockers</div><div> </div><div>Beta Blockers</div><div> </div><div>Cardiac glycoside </div><div>(Digoxin)</div><div> </div><div>Amiodarone</div><div> </div><div>Clonidine</div><div>Hold the morning of the procedure.</div><div> </div><div>AORTIC REGURGITATION</div><div>Pathology:</div><div> </div><div></div><div>aortic root dilation, or ascending aortic dissection.</div><div> </div><div></div><div></div><div>which over time will contribute to decreased ejection fraction. </div><div>Clinical Manifestations:</div><div> </div><div>CHF symptoms</div><div>Physical Examination:</div><div> </div><div>Early diastolic decrescendo murmur at LUSB. Increased with leaning forward </div><div>and expiration</div><div>Diagnostic Studies:</div><div> </div><div>Echocardiogram: </div><div>AR Grading Central Jet </div><div>width*</div><div>Regurgitant </div><div>Volume (per </div><div>beat) </div><div>EROA (eective </div><div>Regurgitant </div><div>oriace area)</div><div>Mild &lt; 25% of LVOT </div><div>width</div><div>&lt; 30mL &lt;0.1cm2</div><div>Moderate 25-65% of LVOT </div><div>width</div><div>30-59mL 0.1-0.3cm2</div><div>Severe &gt;65% of LVOT </div><div>width</div><div>&gt;60mL &gt;0.3cm</div><div>Indications for Surgery:</div><div> </div><div>For severe Chronic AR:</div><div>Chronic Severe Mitral </div><div>Regurgitation </div><div>Clinical </div><div>Evaluation = </div><div>Echo</div><div>Symptoms? No Yes </div><div>LV Function  LV Function </div><div>Normal LV </div><div>Function </div><div>EF &gt; 60%</div><div>ESD &lt; 40mm</div><div>LV Dysfunction </div><div>EF &lt; 60%</div><div>and/or</div><div>ESD &gt; 40mm</div><div>EF &gt; 30%</div><div>ESD &lt; 55mm</div><div>EF &lt;30 %</div><div>and/or</div><div>ESD &gt; 55mm</div><div>New Onset Afib? </div><div>Pulmonary HTN? </div><div>Class I</div><div>Class I</div><div>MV Repair,</div><div>If not possible </div><div>MVR</div><div>Chordal </div><div>preservation </div><div>likely? </div><div>Yes </div><div>No? </div><div>Medical </div><div>therapy</div><div>Yes </div><div>No</div><div>MV repair </div><div>likely?</div><div>Class </div><div>IIa</div><div>Class </div><div>IIa</div><div>No? Clinical </div><div>eval/Echo every </div><div>6 months </div><div>Yes</div><div>Class </div><div>IIIA</div><div>Reference:</div><div>Nishimura, et. al. (2014). A Report of the American </div><div>College of Cardiology/American Heart Association Task </div><div>Focus on Practice Guidelines. AHA/ACC Valvular heart </div><div>disease guidelines, page 487.   </div><div> </div><div>For Mild to Moderate AR: </div><div> LV dysfunction or dilation</div><div> Symptoms only is not an indication to operate</div><div> </div><div>Endocarditis with hemodynamic compromise or embolic events</div><div> </div><div>If undergoing surgery for another indication, valve replacement is indicated </div><div>for anything greater than mild AR </div><div>Preoperative Considerations:</div><div> </div><div>Control hypertension. Avoid bradycardia. </div><div> </div><div>Intra-aortic balloon pump is contraindicated </div><div>Surgical Procedures:</div><div> </div><div>Aortic valve repair or replacement via median sternotomy or minimally </div><div>invasive approach.  </div><div> Bioprosthetic or mechanical valve.</div><div> </div><div>If AR due to root dilatation</div><div> Valve sparing aortic root replacement (Tirone David)</div><div> </div><div>Postoperative Considerations:</div><div> </div><div>Immediate post op Considerations: </div><div> </div><div>secondary to dilated LV</div><div> </div><div> Maintain NSR</div></div><div></div></div>
<div><div><img><div>12 Disease Processes &amp; Surgical Procedures Disease Processes &amp; Surgical Procedures 13</div><div> </div><div>Aspirin on all patients unless contraindicated</div><div> </div><div>Mechanical valves require anticoagulation with Coumadin.  Consider Heparin </div><div></div><div>op. (see “INR Goals” reference chart on page 132)</div><div>References:</div><div>Otto, C.M., Gaaasch, W.H, Yeon, S.B. (2016). Clinical manifestations and diagnosis of aortic stenosis in </div><div>adults. Up to Date. </div><div>MITRAL VALVE DISEASE</div><div>Mitral Stenosis (MS):</div><div>3.  </div><div>4.  </div><div>pulmonary hypertension and subsequently right ventricular failure and </div><div>tricuspid regurgitation.</div><div>5.  Causes:</div><div>• </div><div>Rheumatic valve disease; most common cause (causes thickening  </div><div>and shortening of the chordae tendineae).</div><div>• </div><div></div><div>common in older patients or those exposed to heavy radiation </div><div>treatment), Congenital Mitral Valve deformities, Carcinoid syndrome, </div><div></div><div>Mitral Regurgitation/Insuiciency (MR): </div><div>1.  Acute MR </div><div>• </div><div></div><div>which may lead to acute pulmonary edema and cardiogenic shock</div><div>• </div><div>Causes: Papillary muscle rupture/ischemic injury, endocarditis, chordae </div><div>rupture</div><div>2.  Chronic MR </div><div>• </div><div></div><div>decreased LA/LV compliance.</div><div>• </div><div>Causes:</div><div>i.  </div><div></div><div>1.  Rheumatic fever, ruptured chordae tendineae or chordae elongation, </div><div></div><div>annular dilatation, focal myocardial dysfunction</div><div> </div><div> </div><div>is thickened, complex MR</div><div> </div><div></div><div>syndrome, or an ostium primum ASD)</div><div>ii.  Functional Disease (Secondary MR): not due to valve itself, but </div><div>dysfunction of structures that hold valve</div><div> </div><div>2.  Mitral valve prolapse (MVP): </div><div></div><div>allowing a small amount of blood to leak backward</div><div>b. Causes: myxomatous degeneration, Barlow’s syndrome, Marfan’s </div><div>syndrome, and rheumatic heart disease</div><div>iii.  Infective Endocarditis </div><div>iv.  Ischemic Cardiomyopathy</div><div>v.  </div><div>Clinical Manifestations, Diagnostic Studies/ Classication</div><div> </div><div>Echo: test of choice for diagnosis</div><div>Mitral Valve Echo Values</div><div>MS grading Valve Area Mean gradient Pulmonary </div><div>artery pressure </div><div>(mmHg)</div><div>Mild &gt;1.5 cm2 &lt;5mmHg &lt;30mmHg</div><div>Moderate 1.0-1.5 cm2 5-10mmHg 30-50mmHg</div><div>Severe &lt;1.0cm2 &gt;10mmHg &gt;50mmHg</div><div>MR grading  Jet area Regurgitant </div><div>Volume</div><div>EROA (eective </div><div>Regurgitant </div><div>oriace area)</div><div>Mild &lt;20% of LA area &lt;30mL &lt;0.2cm2</div><div>Moderate 20-40% of LA area 30-59mL 0.2-0.39 </div><div>Severe &gt;40% of LA area &gt;60mL &gt;0.40cm2</div><div> </div><div>MS: </div><div> </div><div>Murmur: Loud S1, opening snap, diastolic low-pitched rumble/murmur </div><div>best heard at the apex</div></div><div></div></div>
<div><div><img><div>14 Disease Processes &amp; Surgical Procedures Disease Processes &amp; Surgical Procedures 15</div><div> </div><div>MR: </div><div> pan-systolic murmur, sometimes a late-systolic murmur, best heard at </div><div></div><div>Indications for Surgery:</div><div> </div><div>MS: </div><div> Severely symptomatic patients (NYHA class III or IV) with severe mitral </div><div></div><div> Patients who have failed previous percutaneous balloon mitral </div><div>commissurotomy</div><div> </div><div>MR: </div><div>Chronic Severe Mitral </div><div>Regurgitation </div><div>Clinical </div><div>Evaluation = </div><div>Echo</div><div>Symptoms? No Yes </div><div>LV Function  LV Function </div><div>Normal LV </div><div>Function </div><div>EF &gt; 60%</div><div>ESD &lt; 40mm</div><div>LV Dysfunction </div><div>EF &lt; 60%</div><div>and/or</div><div>ESD &gt; 40mm</div><div>EF &gt; 30%</div><div>ESD &lt; 55mm</div><div>EF &lt;30 %</div><div>and/or</div><div>ESD &gt; 55mm</div><div>New Onset Afib? </div><div>Pulmonary HTN? </div><div>Class I</div><div>Class I</div><div>MV Repair,</div><div>If not possible </div><div>MVR</div><div>Chordal </div><div>preservation </div><div>likely? </div><div>Yes </div><div>No? </div><div>Medical </div><div>therapy</div><div>Yes </div><div>No</div><div>MV repair </div><div>likely?</div><div>Class </div><div>IIa</div><div>Class </div><div>IIa</div><div>No? Clinical </div><div>eval/Echo every </div><div>6 months </div><div>Yes</div><div>Class </div><div>IIIA</div><div>Reference:</div><div>Nishimura, et. al. (2014). A Report of the American </div><div>College of Cardiology/American Heart Association Task </div><div>Focus on Practice Guidelines. AHA/ACC Valvular heart </div><div>disease guidelines, page 487.   </div><div>Mitral Stenosis</div><div>Symptomatic  Asymptomatic </div><div>MVA &gt;/= </div><div>1.5cm2</div><div>Exercise </div><div>Moderate to </div><div>Severe MS</div><div>MVA &lt; 1.5cm2</div><div>PASP &gt; 60mmHg</div><div>PAWP &gt;/= 25</div><div>No</div><div>Yes</div><div>Moderate to </div><div>severe MS</div><div>MVA &lt; 1.5cm2</div><div>Mild MS</div><div>MVA &gt;/= 1.5cm2</div><div>Medical </div><div>Management </div><div>Follow up every </div><div>12 months </div><div>Favorable </div><div>Morphology? </div><div>No</div><div>Yes </div><div>PSAP &gt; 50mmHg?</div><div>Yes</div><div> Investigation of </div><div>possible other </div><div>source of </div><div>symptoms </div><div>Consider PBMV </div><div>(exclude LA </div><div>clot, 3-4+ MR)</div><div>Favorable </div><div>Morphology</div><div>No</div><div>No</div><div>Consider </div><div>MVR/MV </div><div>Repair </div><div>MVA= mitral valve area</div><div>PMV = percutaneous mitral balloon valvotomy</div><div>PASP = pulmonary artery systolic </div><div>PAWP= pulmonary artery wedge pressure</div><div>Surgical Procedures:  </div><div>1.  Repair is preferred over replacement</div><div>2.  Replacement (bioprosthetic or mechanical valve):</div><div>i.  Indications for replacement over repair:</div><div> </div><div> </div><div> </div><div>3.   Surgical approaches:</div><div>i.  Median Sternotomy</div><div>ii.  Mini-Sternotomy </div><div>iii.  Minimally Invasive via Right Thoracotomy and groin cannulation </div><div>Intra Op Considerations:</div><div> </div><div>When performing concomitant coronary bypass, the distal anastomoses are </div><div>completed before mitral valve intervention</div><div> </div><div>When performing concomitant aortic valve replacement, the aortic valve </div><div></div><div>cutting of mitral annular sutures. Then the mitral procedure is performed </div><div>before the aortic valve replacement. </div><div> </div><div>When performing concomitant tricuspid valve surgery, a trans-septal </div><div></div><div>(Sellke &amp; del Nido &amp; Swanson; chap 80</div><div> </div><div>Minimally Invasive Mitral: consider size and presence of calcium in femoral </div><div>artery for cannulation; consider calcium in descending aorta for cannulation</div><div>Post op considerations:</div><div> </div><div>Immediate Post-op Considerations:</div><div> For MS:</div><div> </div><div>Maintain NSR</div><div> </div><div></div><div>pressures vary with degree of pre-existing pulmonary hypertension</div><div> </div><div></div><div>diuresis</div><div> For MR:</div><div> </div><div>Maintain NSR</div><div> </div><div>Resolution of MR leads to increased LV wall stress leading to LV </div><div></div><div> </div><div>Adequate volume resuscitation and inotropic support may be </div><div>required.  Be cautious with volume resuscitation in patients with RV </div><div>dysfunction. </div><div> </div><div>Closely monitor RV function especially in patients with pre-existing </div><div>pulmonary hypertension.  Inotropic support, pulmonary vasodilators, </div><div>and diuresis may be required.</div><div> </div><div></div><div>following MVR.  Ensure adequate preload and avoid hypotension with </div><div>the use of vasoconstrictors as necessary.  Avoid inotropes.</div><div> </div><div>Systolic anterior motion (SAM) that produces LVOTO may be present </div><div>following mitral valve repair.  Management same as LVOTO.</div><div> </div><div>Minimally Invasive Mitral: REMOVE SUTURE  </div><div>POD #3</div><div> </div><div>ASA unless contraindicatesd</div><div> </div><div>Mechanical valves require anticoagulation with </div><div>Coumadin. Bridge with heparin drip.</div><div> </div><div>Mechanical valves in mitral position require higher </div><div></div><div> </div><div>See “INR Goals” reference chart on page 132)</div><div> </div><div>References:</div><div>Sabiston, D. C., Sellke, F. W., J., D. N., &amp; Swanson, S. J. (2010). Sabiston &amp; Spencer surgery of the chest. </div><div>Philadelphia: Saunders/Elsevier.</div><div> </div></div><div></div></div>
<div><div><img><div>16 Disease Processes &amp; Surgical Procedures Disease Processes &amp; Surgical Procedures 17</div><div>TRICUSPID VALVE DISEASE</div><div>Etiology &amp; Pathology</div><div> </div><div>TS (tricuspid stenosis) is rare, usually develops as a result of rheumatic </div><div>disease or associated with mitral stenosis</div><div> </div><div>TR (tricuspid regurgitation) is usually “functional” in nature. Occurs as a </div><div>complication of mitral valve disease causing pulmonary hypertension, RV </div><div>dilation, and tricuspid annular dilation.  A small degree of TR is present is </div><div>almost 70% of normal adults. </div><div> </div><div>A common cause of TR is endocarditis (usually caused by IV drug abuse, an </div><div>indwelling pacemaker wire, or hemodialysis catheter)</div><div>Clinical Manifestations</div><div> </div><div></div><div> </div><div>Fatigue</div><div> </div><div>With severe disease, right heart failure symptoms may be present (right </div><div>abdominal pain, shortness of breath, swelling in legs or abdomen)</div><div>Physical Exam</div><div> </div><div>Systolic murmur that increases with inspiration, prominent jugular </div><div>pulsations, and occasionally a pulsatile liver. </div><div> </div><div></div><div>Diagnostic Studies/Classication (Via Echocardiogram)</div><div>Signicant tricuspid stenosis</div><div>Mean pressure gradient &gt;/= 5mmHg</div><div>Tricuspid </div><div>Regurgitation</div><div>MILD MODERATE SEVERE</div><div>Jet area &lt; 5 5-10 &gt;10</div><div>RV/RA/IVC Size Normal Normal or dilated Usually dialates</div><div> </div><div>Indications for Surgery</div><div>Tricuspid stenosis:  Surgery is indicated for class III-IV symptoms including </div><div>hepatic congestion, ascites, and peripheral edema that are refractory to salt </div><div>restriction and diuretics. </div><div>Tricuspid Regurgitation:</div><div> </div><div>Class I: TV repair is indicated when severe TR is present with mitral valve </div><div>disease requiring mitral valve surgery</div><div> </div><div>Class II: TV repair or replacement is reasonable for symptomatic, severe </div><div>primary TR.</div><div> </div><div>Class III: TV repair is reasonable is less than severe TR is noted at the time of </div><div>mitral surgery, but pulmonary hypertension or dilated tricuspid annulus is </div><div>present. </div><div> </div><div>Persistent sepsis or recurrent pulmonary embolization from tricuspid valve </div><div>vegetation is an indication for surgery</div><div> </div><div>Class III: surgery should NOT be considered in asymptomatic patients with a </div><div>PA pressure &lt;60 and no mitral valve disease</div><div>Surgical Procedures</div><div> </div><div>Tricuspid commissurotomy can be performed for rheumatic TS</div><div> </div><div>Tricuspid ring annuloplasty with a ring or suture technique is feasible and </div><div>preferred for the majority of patients with functional TR</div><div> </div><div></div><div>coaptation prevent an annuloplasty technique from eliminating the TR. </div><div>Intra op &amp; Post op Considerations</div><div> </div><div>During TV repair, sutures are placed near the conduction system, thus </div><div>patients are more likely to develop heart block. If there are concerns that </div><div>permanent pacing may be required, epicardial pacing leads should be placed </div><div></div><div>TVRepair surgery) </div><div> </div><div>ASA unless contraindicated</div><div> </div><div>Mechanical valve requires anticoagulation with Coumadin (See “INR Goals” </div><div>reference chart on page 132)</div><div>References:</div><div>Bojar, Robert M. (2011) Manual of Perioperative Care in Adult Cardiac Surgery. (5th edition).  </div><div>CORONARY ARTERY DISEASE AND CABG</div><div>Pathophysiology:</div><div> </div><div></div><div>but typically occurs at points of turbulence (e.g., vessel bifurcations)</div><div> </div><div>Risk Factors for atherosclerotic coronary artery disease: hypertension, </div><div>smoking, high LDL, low HDL, obesity, diabetes, family history.</div><div>Clinical manifestations:</div><div> </div><div>CAD manifested by MI, angina, or CHF</div><div> </div><div>Angina (stable vs unstable)</div><div> Stable angina = chest pain that occurs predictably and is reproducible</div></div><div></div></div>
<div><div><img><div>18 Disease Processes &amp; Surgical Procedures Disease Processes &amp; Surgical Procedures 19</div><div>CCS Functional Classication of Angina</div><div>Class Description</div><div>Class I Angina only during strenuous or prolonged physical activity</div><div>Class II Slight limitation, with angina only during vigorous physical activity</div><div>Class III Symptoms with everyday living activities   </div><div>(i.e. moderate limitation)</div><div>Class IV Inability to perform any activity without angina or  </div><div>angina at rest (i.e. severe limitation)</div><div>Physical Exam: </div><div></div><div>Diagnostic studies:</div><div> </div><div>Cardiac catheterization is the gold standard for diagnosing CAD</div><div> </div><div>Myocardial perfusion scan </div><div> </div><div>Echocardiogram </div><div> </div><div>Stress testing </div><div>Indications for surgery:</div><div> </div><div></div><div> </div><div></div><div></div><div> </div><div>Presence of 3 vessel disease (especially if EF &lt; 40%)</div><div> </div><div>Presence of 2 vessel disease with 70% stenosis of LAD</div><div>Surgical procedures: </div><div>(LIMA to LAD) is the single most important determinant of long-term </div><div>and event-free survival for patients who have undergone CABG</div><div> </div><div>Traditional on pump CABG (via median sternotomy) </div><div> Conduit choice: </div><div> Arterial: LIMA (1st choice), RIMA,  Radial artery via endoscopic harvest</div><div> Venous: Greater Saphenous Vein via Open or endoscopic vein harvest</div><div> </div><div></div><div> Consider for high risk patients (&gt; 70 years old, CKD, increased risk stroke </div><div>or carotid stenosis)  </div><div> </div><div>Minimally invasive direct coronary artery bypass (MIDCAB) </div><div> LIMA to LAD only</div><div> LIMA is harvested endoscopically though three small ports placed in the </div><div></div><div>through which the LIMA to LAD anastomoses is constructed via direct </div><div>vision</div><div> </div><div>to remaining lesion by interventional cardiologist </div><div>Preoperative Considerations:</div><div> </div><div>All patients with CAD must take beta blocker within 24 hours of induction for </div><div>surgery (or document why contraindicated)</div><div> </div><div></div><div>narrowing/steal which precludes the use of the LIMA, diagnosed with carotid </div><div>ultrasound.</div><div> </div><div> IF L radial pulse &lt;2+ or faint compared to R, needs testing </div><div> </div><div></div><div> Carotid ultrasound for those with history of prior CVA</div><div> Radial artery harvest work up for those &lt; 70 </div><div> Vein mapping (previous vein stripping, CABG, diabetes)</div><div>Post-operative Considerations</div><div>Immediate post-operative care: </div><div> </div><div> If EVH or RAH completed, ACE wrap to extremity for 24 hours post op</div><div> </div><div>ASA unless contraindicated </div><div>Beta blocker and statin therapy initiated prior to discharge (or document why </div><div>contraindicated) </div><div>References:</div><div>Cutlip, D., Levin, T., Aroesty, J.M. (2016) Revascularization in patients with stable coronary artery disease: </div><div></div><div>DISEASES OF THE AORTA</div><div>Denitions</div><div> </div><div>Aortic aneurysm – localized dilation (&gt; 50% increase in diameter) of the aortic </div><div>wall </div><div> </div><div>Aortic dissection – intimal tear of the aorta separating intima from the medial </div><div>layers and creating a false lumen</div><div> </div><div>Aortic intramural hematoma (IMH) – hematoma within the medial layer of the </div><div>aorta that occurs when the vasa vasorum ruptures.  Does not involve intimal </div><div>tear.</div><div> </div><div>Penetrating atherosclerotic aortic ulcer (PAU) – atherosclerotic ulcer that </div><div>penetrates through the intima layer of the aorta and dissects into the median </div><div>wall and forms a pseudoaneurysm.             </div><div>Risk Factors</div><div> </div><div>Atherosclerosis</div><div> </div><div>Hypertension</div><div> </div><div>Connective tissue disorders (i.e. Marfan, Loeys-Dietz, Ehler’s-Danlos syndrome)</div><div> </div><div>Drug abuse (cocaine, meth)</div><div> </div><div>Trauma: blunt, IABP, cardiac or aortic surgery, cardiac catheterization</div><div> </div><div>Bicuspid aortic valve</div><div> </div><div>Aortitis (ie giant cell arteritis)</div><div> </div><div>Pregnancy</div><div>Clinical Manifestations</div><div> </div><div></div><div>ripping, chest pain that radiates to the back</div><div> </div><div></div><div>ischemia</div></div><div></div></div>
<div><div><img><div>20 Disease Processes &amp; Surgical Procedures Disease Processes &amp; Surgical Procedures 21</div><div>Physical Exam</div><div> </div><div>Note carotid, radial, and </div><div>femoral pulses bilaterally</div><div> </div><div>Change in neurological status indicating compromise of cerebral perfusion</div><div> </div><div>Abdominal pain indicating bowel ischemia</div><div>Dissection Classications:</div><div> </div><div></div><div> Type I – Dissection originates in the ascending aorta and may extend </div><div>down to the descending aorta and/or abdominal aorta</div><div> Type II – Dissection is limited to ascending aorta only</div><div> Type III – Dissection originates in the descending aorta and extends to </div><div>just above the diaphragm (type IIIa) or below the diaphragm (type IIIb)</div><div> </div><div></div><div> Type A – Dissection originates in ascending aorta and may extend into </div><div>descending aorta</div><div> Type B – Dissection originates in descending aorta however may </div><div>retrograde into the aortic arch </div><div>Aneurysm Classications:</div><div> </div><div></div><div> </div><div>extends to the celiac axis and mesenteric arteries</div><div> Type II – Dissection includes type 1 but extends into infrarenal aorta</div><div> Type III – Dissection originates in the lower descending thoracic aorta </div><div>and involves remainder of the aorta</div><div> Type IV – Dissection originates at the diaphragm and involves the entire </div><div>abdominal aorta</div><div>Management</div><div> </div><div>Inpatient/ICU Care:</div><div> Obtain blood pressure in both arms.  </div><div> </div><div>Insert arterial line in right arm</div><div> Control heart rate and blood pressure</div><div> </div><div></div><div>otherwise)</div><div> </div><div></div><div>otherwise)</div><div> Manage pain </div><div> Follow up with surgical team regarding whether or not acute surgical </div><div>intervention is indicated</div><div> </div><div>Acute type A aortic dissections are always a surgical emergency.  </div><div> </div><div>Uncomplicated type B dissections are medically managed</div><div> </div><div>Outpatient care:</div><div> </div><div> BP control</div><div> </div><div></div><div> </div><div></div><div> </div><div>No burst activity/exercise requiring Valsalva</div><div> Follow up: </div><div> </div><div>Expansion rate ~0.1cm/yr for TAA, ~_.4cm/yr for AAA</div><div> </div><div></div><div> </div><div>Screening for CAD, PAD, Aneurysm elsewhere, esp popliteal. 25% of pts </div><div>with TAA Will also have AAA. </div><div>Surgical indications for Aortic Aneurysms: </div><div>of note, when looking at aortic measurements, must consider ASI (aortic size index, </div><div>relation of height and weight to maximum aortic diameter)</div><div> </div><div>TAA growing &gt; 1cm/yr</div><div> </div><div>Ascending &gt; 5.5cm; descending &gt;6cm.</div><div> </div><div>Marfan’s/Loey Dietz patient &gt; 4.5-5cm</div><div> </div><div>For any aneurysm &gt; 4cm if planning for AoV surgery</div><div> </div><div>Other Surgical Triggers:</div><div> 4.5 cm in the setting of a family hx positive for rupture or dissection</div><div> 5.0 cm with moderate or worse aortic valve disease</div><div> Primary failure of aortic valve (AS/AI)</div><div>Surgical indications for Aortic Dissections</div><div> Type A: emergent surgery indicated in all acute type A dissections as well </div><div>as chronic type A</div><div> Type B: usually treated medically. Endovascular or surgical repairs in </div><div>complicated patients with chronic pain, uncontrolled hypertension, </div><div>evidence of aneurysmal expansion or rupture, or vascular compromise</div><div>Surgical intervention </div><div>OPEN REPAIR</div><div> </div><div>Ascending aortic dissection/aneurysm: aortic valve repair/replacement, </div><div></div><div>place valve conduit. If tear extends across arch, may replace entire arch </div><div></div><div></div><div> </div><div>Descending aortic dissection/aneurysm:</div><div>replacement.  </div><div>Intra-operative considerations</div><div> </div><div>DHCP: deep hypothermic circulatory arrest</div><div> Used when aorta cannot be clamped to perform aortic anastomosis</div><div> Patient is cooled for neuroprotection</div><div> SACP: selective antegrade cerebral perfusion</div><div> </div><div></div><div>arrest to perfuse brain</div><div> RCP: retrograde cerebral perfusion</div><div> </div><div>Cold, oxygenated blood into SVC to maintain cerebral hypothermia</div><div> Extensive cooling and rewarming is associated with coagulopathy and </div><div>bleeding</div><div> Neurologic recovery may take up to 24 hours</div><div> Decadron, mannitol and or Lasix may also be given for neuroprotection</div></div><div></div></div>
<div><div><img><div>22 Disease Processes &amp; Surgical Procedures Disease Processes &amp; Surgical Procedures 23</div><div> </div><div>Cross-clamping of the distal aorta can result in paraplegia or renal failure </div><div>(Reference: section 3 post-operative management of spinal cord ischemia)</div><div>MINIMALLY INVASIVE REPAIR</div><div> </div><div>Endovascular stenting for complicated type B via TEVAR</div><div>i.  </div><div></div><div>ii.  On pre-op CT, look for communication between the true and false lumen </div><div>to help determine what areas can be safely stented.    </div><div>iii.  It is also important to look at the diameter of the femoral vessels to </div><div>determine whether access needs to be gained higher than the groin </div><div>(typically accessed somewhere near the level of the belly button or </div><div>slightly lower).   </div><div>iv.  Indications for TEVAR</div><div>a.  Asymptomatic patients with thoracic aortic aneurysms</div><div>b.  Patients with descending thoracic aortic aneurysms that is at least </div><div>2 times greater than the adjacent aorta, measuring at least 5cm.  </div><div></div><div>of the aneurysm in order to </div><div>aortic walls.</div><div>c.  Patients that are elderly and/or in poor overall health and would be </div><div>unlikely to survive an open operation</div><div>d.  Can be used in chronic or acute dissections </div><div>v.  Contraindications for TEVAR</div><div>a.  Symptomatic patients – those with symptoms typically require open </div><div>repair of TAA </div><div>b.  Patients with access vessels less than 8mm or vessels that are tortuous.</div><div> </div><div>(patients that do not have 2cm of suitable aortic dimension on either </div><div>side of the aneurysm).</div><div>d.  Patients who have branch vessels that will be occluded by the stent-</div><div></div><div>e.  Patients with connective tissue disorders such as Marfan’s in which it is </div><div>expected further tissue degeneration may occur.   </div><div>Postoperative Management</div><div> </div><div>Blood pressure management: </div><div> Must balance risk of expansion of residual dissection/aneurysm (if </div><div>present) with risk of end organ/spinal cord ischemia</div><div> Establish hemodynamic goals with CT Surgery attending and ICU team</div><div> </div><div>Monitor for bleeding and correct coagulopathy</div><div> </div><div>Neuro monitoring:</div><div> Q1H Pupillometry for patients who underwent circulatory arrest</div><div> Lumbar drain: placed preoperatively for patients undergoing descending </div><div>aorta repair at high risk for paraplegia (for more detail, see Reference: Post-</div><div>operative management: Spinal cord ischemia; Devices: Lumbar drains).  </div><div> </div><div></div><div>perfusion pressure &gt;80mmHg  </div><div> </div><div></div><div>exam intact</div><div> </div><div>Monitor for end organ ischemia: </div><div> Trend UOP</div><div> Serial lactate, BMP, LFT, SvO2</div><div>References</div><div>Bojar, Robert M. (2011) Manual of Perioperative Care in Adult Cardiac Surgery. (5th edition). </div><div>ATRIAL FIBRILLATION (AF)</div><div>Pathology:</div><div> </div><div></div><div>rapid rates, producing an exceedingly rapid, erratic rhythm. </div><div> </div><div>Post-operative atrial brillation: occurs in 30-40% of post op cardiac </div><div></div><div></div><div>Clinical manifestations:  </div><div> </div><div>Can be asymptomatic</div><div> </div><div>Fatigue, palpitations, dyspnea, lightheadedness, chest pain</div><div>Physical Exam: </div><div> </div><div>Discrepancy between auscultated heart rate and palpable pulse rate (minimal </div><div></div><div>Diagnostic Studies:</div><div> </div><div>12-lead EKG: </div><div>Disorganized atrial activity between QRS complexes occurring in an irregular </div><div>pattern. RVR = rapid ventricular response HR&gt; 150bpm</div><div>Classication</div><div>New onset   1st detected vs reoccurrence &gt; 2 episodes</div><div>Paroxysmal  </div><div>  within 7-days or spontaneously</div><div>Persistent  </div><div>  with cardioversion</div><div>Permanent/ Chronic  </div><div>  or no plans for cardioversion</div><div>Secondary  Caused by a separate underlying condition: </div><div>  MI, cardiac surgery, pulmonary disease.</div><div>Lone atrial brillation  Age &lt; 60; no clinical or echocardiographic reasons  </div><div>  are found</div><div>Non-valvular  Not caused by valvular disease, prosthetic heart  </div><div>  valves,  or valve repair </div><div> </div><div>Risk of stroke from atrial brillation – calculated with CHA2DS2VASc score.</div><div>CHADS2 VASc Score (&gt;2 pts equals indication for anticoagulation)</div><div>C (1) </div><div>H (1) Hypertension</div><div>A  (2) Age &gt;74 years old </div><div>D (1) DM</div><div>S (2) Prior stroke or TIA or thromboembolism</div><div>V (1) Vascular disease (PAD, MI)</div><div>A (1) Age 65-74 years old</div><div>S (1) Sex category female</div><div>Indications for Surgery</div><div> </div><div></div><div>advanced disease patients</div><div> </div><div></div><div>who have failed prior catheter ablations</div></div><div></div></div>
<div><div><img><div>24 Disease Processes &amp; Surgical Procedures Disease Processes &amp; Surgical Procedures 25</div><div> </div><div>Cox Maze procedure: can be performed for patients with non paroxysmal </div><div></div><div>replacement, CABG)</div><div>Surgical Procedures</div><div>Atrial Fibrillation Treatment Options </div><div>Medication </div><div>Therapy</div><div>(Drugs)</div><div>Direct Current </div><div>Cardioversion </div><div>(Shock)</div><div>Catheter Ablation</div><div>Typically used to treat:</div><div>1. Paroxysmal atrial fibrillation</div><div>2. Duration &lt; 1 year</div><div>3. Left Atrium size &lt; 4.0cm </div><div>Hybrid Ablation </div><div>CATHETER + SURGERY</div><div>Typically used to treat:</div><div>1. Non-paroxysmal atrial fibrillation</div><div>2. Average Duration ~ 4 years</div><div>3. Average Left Atrium size ~ 4.5cm </div><div>Cox Maze Procedure</div><div>Typically used to treat:</div><div>1. Non-paroxysmal atrial fibrillation</div><div>2. Average Duration ~ 6.5 years</div><div>3. Left Atrium size &gt; 5.0cm</div><div>“Internal  Ablation”</div><div>Completed by </div><div>Electrophysiologist</div><div>LEAST INVASIVE                                                                                                                                                                                    MOST EFFECTIVE         </div><div><div> </div></div><div>“Open heart surgery” </div><div>Requires heart lung- </div><div>bypass machine </div><div>Part 1: “External </div><div>Ablation” </div><div>Completed by </div><div>Cardiac Surgery</div><div>Part 2: “ Internal </div><div>Ablation” </div><div>Completed by </div><div>Electrophysiologist</div><div>Performed </div><div>by Cardiac </div><div>Surgeon </div><div>(Dr. Lee)</div><div>“Minimally Invasive” </div><div>Bilateral video assisted </div><div>thoracospic (VATS)</div><div>My information </div><div>TYPE: _______________</div><div>DURATION: ___________</div><div>LA SIZE:_______________</div><div> </div><div>Anson M. Lee, MD</div><div>Assistant Professor of Cardiothoracic Surgery (Adult</div><div><div>C</div></div><div>ardiac Surgery) at the Stanford University Medical Center</div><div>Internal &amp; </div><div>External Ablation</div><div>Completed by </div><div>Cardiac Surgeon </div><div>Anterior Thoracotomy Incision </div><div>Traditional Sternotomy </div><div><div>Incision </div></div><div>Video Assisted Thoracoscopic Surgery (VATS) </div><div>Incision </div><div>Post-operative considerations: </div><div> </div><div></div><div>heart surgery</div><div> </div><div>All patients will need to resume home antiarrhythmic agents and </div><div>anticoagulation (regardless of rhythm)</div><div> </div><div>Only consider DCCV for post op Maze patients if unstable or rate is very fast </div><div></div><div> </div><div></div><div>will be in NSR at 1 year post operatively.</div><div> </div><div>Consider starting Inspra (Aldactone) 25mg PO BID, once creatinine, </div><div>potassium, and blood pressure will tolerate and continue on discharge. </div><div>Reference:</div><div>Bojar, Robert, M., (2011) Manual of Perioperative Care in Adult Cardiac Surgery. (5th edition). </div><div>Am Fam Physician. 2011;83(1):61-68. American Academy of Family Physicians.</div><div>Lawrance, Christopher P. (2015) Curr Opin Cardiol. January: 30(1): 58-64. </div><div>Pison MD, Laurent, La Meir MD PhD, Mark, Crijns MD PhD, Harry. (2013) Journal of Atrial Fibrillation  </div><div>Vol-6; Issue2: 49-56.</div><div>HYPERTROPHIC CARDIOMYOPATHY </div><div>Etiology</div><div> </div><div>HCM is the most common genetic cardiac disease, occurs in ~ 1/500 young </div><div>adults</div><div> </div><div>ie  HTN or valvular  </div><div>aortic stenosis)</div><div>Pathology</div><div> </div><div>In the obstructive form of HCM (~70% of patients w/ HCM), septal hypertrophy </div><div>and abnormal SAM of the MV produce LVOT obstruction and variable degrees </div><div>of MR</div><div> SAM is the abrupt anterior motion of the mitral valve in which the </div><div> </div><div>le ventricular outow tract obstruction (LVOTO) </div><div> </div><div>Consider SAM in setting of worsening hypotension with increased </div><div>inotropic support</div><div> </div><div></div><div>intraventricular septum, papillary muscle displacement, and </div><div></div><div> </div><div>SAM of the mitral valve may also be present secondary to mitral valve </div><div>repair</div><div> </div><div>LVOT obstruction produces markedly increased intraventricular </div><div>pressures thereby increasing myocardial wall stress and oxygen </div><div>demand</div><div> </div><div> </div><div> </div><div></div><div>coaptation</div><div> </div><div>Diastolic dysfunction with increased LVEDP (dependent on atrial contraction)</div><div>Clinical manifestations</div><div> </div><div>Syncope</div><div> </div><div>Dyspnea (LV diastolic dysfxn/ MR)</div><div> </div><div>Fatigability</div><div> </div><div>Angina </div><div>Important History Questions:</div><div> </div><div>History of vtach/ cardiac arrest? AICD? </div><div> </div><div>Family Hx sudden cardiac death</div><div> </div><div>Has genetic testing been performed? If so are they positive for gene? </div><div>Physical Exam</div><div> </div><div>Systolic murmur @ LSB (can radiate across precordium),  standing/</div><div></div><div> </div><div>Crescendo-decrescendo peak mid-late S1, end before S2</div><div> </div><div>MR may produce separate holosystolic murmur at apex </div><div> </div><div>4th heat sound if LVH </div><div> </div><div></div></div><div></div></div>
<div><div><img><div>26 Disease Processes &amp; Surgical Procedures Disease Processes &amp; Surgical Procedures 27</div><div>Diagnostic Studies</div><div> </div><div>Echo:</div><div> Presence of SAM? MR? If MR, dilated LA? </div><div> Dx of HCM based on LVOT gradients:  (rest, Valsalva, peak exercise)</div><div> </div><div>peak gradient @ rest &gt; 50 + symptoms (not improved w/ med therapy) </div><div>(others say resting gradient as low as 30 mmHg)</div><div> </div><div>peak gradient @ rest &gt; 80 + asymptomatic </div><div> </div><div>Stress/Exercise- induced gradient &gt;100mmHg</div><div> </div><div> </div><div>Exercise Stress Echo </div><div> BP response:  should increase &gt;20 mmHg w/ exercise or pt @ higher risk </div><div>for SCD</div><div> </div><div></div><div> If no delayed gadolinium enhancement (DGE), means no scarring, likely </div><div>don’t need ICD if no history of VT </div><div> </div><div>thick)</div><div> </div><div>CATH:</div><div> Pulm HTN (RVSP &gt; 35) in 50%, severe ( &gt;50) in 17% patients </div><div>Surgical Indications: </div><div> </div><div>Septal thickness &gt;18mm</div><div> </div><div>Atypical septal morphology</div><div> </div><div></div><div> </div><div></div><div>Surgical Procedures</div><div>1. Septal Ablation (done in cath lab by interventional Cards)</div><div> </div><div></div><div>myocardial infarction within the proximal ventricular septum</div><div> </div><div>Leads to progressive thinning and reduction of the LVOT obstruction</div><div>2. Septal Myotomy/Myectomy with possible MV repair/replacement </div><div> </div><div>Considered “gold standard” for the treatment for HCM patients refractory to </div><div>optimal medical therapies</div><div> </div><div>Surgical procedure that relieves the LVOT obstruction by resection of a small </div><div>portion of muscle from the basal septum in order to</div><div>obstruction</div><div> </div><div>Some patients may also require mitral valve repair if they also demonstrate </div><div>systolic anterior motion (SAM) of the mitral valve that is also contributing the </div><div>LVOT obstruction.</div><div>Benet of surgical intervention vs. ablation: </div><div> </div><div>SURGERY: resultant lower gradient and less requirement for post-op PPM</div><div> </div><div></div><div></div><div>creates “mush-like” infarcted tissue </div><div>Pre- op considerations</div><div> </div><div>Pre-load dependent (gradient worse if dehydrated)(Avoid Jacuzzis; Avoid </div><div>lasix/diuretics)</div><div> </div><div>AVOID inotropes</div><div> </div><div></div><div> </div><div></div><div></div><div></div><div> </div><div>Dual-chamber pacing with a short AV delay (or V-pacing) to ensure complete </div><div></div><div>approximately 35%. Septal dyssynchrony may actually pull septum out  </div><div>of LVOT</div><div>Intra-op considerations</div><div> </div><div>95% cases don’t require MV repair if septum adequately excised (SAM will </div><div>improve w/ myectomy alone)</div><div> </div><div>RISKS: Need for PPM (can’t see bundle His/ looks like muscle)</div><div>Post op considerations</div><div> </div><div></div><div>caution</div><div> </div><div>Avoid inotropes if possible</div><div> </div><div>Avoid tachycardia (HR 60-80)</div><div> </div><div></div><div> </div><div></div><div>slow-normal HR)</div><div> </div><div>If no ICD pre-op &amp; plan to place prophylactic ICD post-op (if risks for sudden </div><div>cardiac death (SCD)) </div><div>Reference:</div><div>Bojar, Robert, M., (2011) Manual of Perioperative Care in Adult Cardiac Surgery. (5th edition). </div><div>Indian Journal of Anaesthesia, Vol. 58, No. 1, January-February, 2014, pp. 51-54</div><div>INFECTIVE ENDOCARDITIS/ ROOT ABSCESS </div><div>Etiology</div><div> </div><div>Native valve endocarditis is most commonly caused by Streptococcus </div><div>viridans, Staphylococcus aureus, or coagulase-negative staph. </div><div> </div><div>Tricuspid valve endocarditis is usually caused by IV drug abuse</div><div> </div><div>Incidence of prosthetic valve endocarditis is approximately 0.5-1% per </div><div>patient-year. Most common cause is by staph organism</div><div>Pathology </div><div> </div><div></div><div>myo-cardial tissue, systemic embolization of valve vegetations, or persistent </div><div>systemic sepsis. </div><div> </div><div>Embolization is more common with mitral valve involvement, staphylococcal </div><div>organ-ism, and large or mobile vegetations.</div><div>Clinical manifestations</div><div> </div><div>Presence of moderate to severe congestive heart failure maybe present from </div><div>re-gurgitant lesions. </div></div><div></div></div>
<div><div><img><div>28 Disease Processes &amp; Surgical Procedures Disease Processes &amp; Surgical Procedures 29</div><div> </div><div></div><div></div><div>pulmo-nary hypertension</div><div> </div><div>Complete heart block: More common in aortic valve endocarditis or annular </div><div>ab-scess</div><div> </div><div>Physical Exam</div><div> </div><div>Splinter hemorrhages, Osler’s nodes may be present</div><div>Diagnostic Studies/ Classication</div><div> </div><div>TEE (transesophogeal echocardiogram) is gold standard for identifying </div><div></div><div>echocardiogram) in identi-fying and quantifying the size and mobility of </div><div>the vegetations, detecting annular destruction, and identifying valvular </div><div>abnormalities. </div><div> </div><div>Coronary angiography should be avoided, if possible, if mobile aortic valve </div><div></div><div> </div><div>Duke Criteria:</div><div>Dente Infective Endocarditis is established in the presence of any of the </div><div>following:</div><div>Pathologic criteria Pathologic lesions: vegetation or intracardiac abscess </div><div>demonstrating active en-docartitis on histology</div><div>Microorganism: on culture/histology of a vegetation or </div><div>intracardiac abscess</div><div>Clinical criteria </div><div>(See major &amp; minor </div><div>clinical criteria under </div><div>References)</div><div>2 major clinical criteria OR</div><div>1 major and 3 minor clinical criteria OR</div><div>5 minor clinical criteria</div><div>Possible Infective endocarditis</div><div> </div><div>Presence of 1 major and 1 minor clinical criteria OR presence of 3 minor </div><div>clinical criteria</div><div>Rejected Infective Endocarditis</div><div> </div><div>OR</div><div> </div><div></div><div>therapy OR</div><div> </div><div>No pathologic evidence of infective endocarditis is found at surgery or </div><div></div><div>Preoperative considerations</div><div> </div><div>Patients should ideally receive 6weeks of antibiotic therapy prior to surgery </div><div>(de-creases risk for prosthetic valve endocarditis)</div><div> </div><div>Antibiotics decrease incidence of embolization</div><div> </div><div>Increasing in vegetation size while on antibiotic therapy may predict later </div><div>emboli-zation. </div><div> </div><div>Patients with aortic valve endocarditis have a greater chance of heart block </div><div>due to the involvement of the conduction system by periannular infection. </div><div>Therefore, a preoperative placement of a transvenous pacing wire may be </div><div>necessary. </div><div>Indications for Surgery</div><div> </div><div>Native Valve Endocarditis </div><div> Class I indications:</div><div> </div><div>Surgery should not be delayed if the patient is in cardiogenic shock</div><div> </div><div></div><div>LVEDP, elevated LA pressures, or moderate to severe pulmonary </div><div>hypertension</div><div> </div><div>Evidence of local extension resulting in aortic or annular abscess, or </div><div></div><div>from aortic valve endocarditis) </div><div> </div><div>Organisms unlikely to be adequately treated with antibiotic therapy </div><div>alone, especially fungal endocarditis. </div><div> </div><div>Persistent sepsis or bacteremia despite antibiotic treatment for at </div><div>least 1 week, especially with staph infections. However, it should be </div><div>noted that sur-gery during septic shock have a poor prognosis, with an </div><div>operative mortality rate exceeding 50%. </div><div> Class II indications</div><div> </div><div>Recurrent embolization and persistent vegetation despite antibiotic </div><div>treat-ment. </div><div> Class IIb indications</div><div> </div><div>Mobile vegetations &gt;10mm in diameter, even if embolization is absent. </div><div>These vegetations, especially on the mitral valve, have a greater risk of </div><div>emboliza-tion. </div><div>Indications for surgery in prosthetic valve endocarditis </div><div> </div><div>Class I </div><div> Heart failure, valve dehiscence (unstable prosthesis or perivalvular leak), </div><div>evi-dence of increasing valvular obstruction or worsening regurgitation, </div><div>abscess formation or heart block, or fungal etiology. </div><div> </div><div>Class II</div><div> Persistent bacteremia or recurrent emboli despite antibiotics, or </div><div>relapsing in-fection. </div><div>Surgical Procedures</div><div> </div><div>Removal of all infected valve tissue, drainage and debridement of abscess </div><div>cavities.</div><div> </div><div>Aortic valve replacement, mitral valve replacement.</div><div> </div><div>Tricuspid valve repair is recommended for tricuspid endocarditis, and should </div><div>be aggressively attempted especially in IV drug abusers who are more prone </div><div>to rein-fection if a valve replacement is performed. </div><div>Post op considerations</div><div> </div><div>If intra-operative cultures are positive, 6 weeks of post-operative antibiotic </div><div>treat-ment is recommended. </div><div> </div><div>Reference:</div><div>Bojar, Robert, M., (2011) Manual of Perioperative Care in Adult Cardiac Surgery. (5th edition). </div><div>MYOCARDIAL BRIDGE</div><div>Pathology:</div><div> </div><div>Myocardial muscle bride overlying coronary artery. Most are clinically </div><div></div><div> </div><div>Severe bridging of the major coronary arteries can produce myocardial </div><div>ischemia/infarction, coronary thrombosis, and pre dispose the patient to </div><div>atherosclerosis or sudden cardiac death. </div><div> </div><div>As the muscle bridge contracts, it can cause hypo perfusion of the underlying </div><div>myocardium due to a buckling in the artery giving the patients angina</div></div><div></div></div>
<div><div><img><div>30 Disease Processes &amp; Surgical Procedures Disease Processes &amp; Surgical Procedures 31</div><div>Clinical Manifestations:</div><div> </div><div> The most typical symptoms are chest pain, dyspnea, and dizziness, but can </div><div>be any typical or atypical angina. </div><div>Physical Exam:</div><div> </div><div></div><div>Diagnostic studies:  Most commonly diagnosed by cardiac catherization. </div><div>Cardiac cath: compression of a segment of coronary artery during systole </div><div>resulting in narrowing that reverses during diastole </div><div>EKG: usually normal    </div><div>Echo: demonstrates septal buckling and apical sparing </div><div>CT angiogram:</div><div>Angiogram with FFR and Ivus: to document and further map the length and </div><div> </div><div> </div><div>Example 1: Bridge during diastole  Example 2: Bridge during systole </div><div>Management:</div><div> </div><div>Prior to surgery, patients should be trialed on beta blockers and/or non </div><div>dihydropyridine calcium channel blockers (ie. diltiazem, verapamil)</div><div> </div><div>Nitrates may exacerbate symptoms and are contraindicated </div><div>Indications for surgery</div><div> </div><div>Surgical therapy for those with persistent symptoms in whom ischemic </div><div>changes are proven, and for those with a high risk marker (such as life </div><div>threatening ventricular arrhythmias, myocardial infarction)</div><div> </div><div>Trial of medical therapy has failed</div><div>Surgical procedure: </div><div> </div><div>Myocardial bridge   (supra-arterial myotomy): The muscle bridge </div><div>is divided directly over the coronary artery.  The surgery can be done either </div><div></div><div></div><div>stand-by. </div><div>Post-operative management: </div><div> </div><div>Pain control: </div><div> Pre-operative placement of paravertebral nerve blocks. </div><div> </div><div>Placed day prior to surgery as outpatient procedure by pain service. </div><div> </div><div>Post operatively patient will receive continuous infusion of </div><div>bupivacaine + q6 hour boluses. </div><div> </div><div>Avoid OnQ pump or lidocaine infusion for patients with paravertebral </div><div>block</div><div> </div><div>Paravertebral block discontinued day before discharge to ensure </div><div>adequate pain control with oral medications</div><div> </div><div>Otherwise, standard post cardiac surgery management</div><div>References</div><div>Sorajja, P., Iskandrian, A.E. (2016). Myocardial bridge of the coronary arteries. Up to date. </div><div>CONSTRICTIVE PERICARDITIS</div><div>Constrictive pericarditis results from scarring of the pericardial sac leading to </div><div></div><div>Etiology/Pathophysiology </div><div> </div><div>Idiopathic or viral </div><div> </div><div>Post-cardiac surgery </div><div> </div><div>Post-radiation therapy </div><div> </div><div>Connective tissue disorder </div><div> </div><div>Post-infectious (tuberculous or purulent pericarditis) </div><div> </div><div>Miscellaneous causes (malignancy, trauma, drug-induced, asbestosis, </div><div>sarcoidosis, uremic pericarditis)</div><div>Clinical manifestations</div><div> </div><div></div><div> </div><div>Symptoms related to low cardiac output: dyspnea on exertion, fatigue</div><div>Physical Exam</div><div> </div><div>Elevated JVP</div><div> </div><div>Pulsus paradoxus, Kussmaul’s sign, pericardial knock, pericardial friction rub, </div><div>edema, ascites, and/or cachexia </div><div>Diagnosis</div><div> </div><div></div><div> </div><div>Echocardiogram/CTscan gold standard</div><div>Operative Procedures: Pericardiectomy</div><div> </div><div></div><div> </div><div>As much of the thickened pericardium is removed as possible  </div><div>(“pericardial stripping”)</div><div> </div><div></div><div> Prior radiation is associated with poorer post-operative outcomes</div><div>Post-op Management</div><div> </div><div></div><div>surfaces</div><div> </div><div>May have low cardiac output and require inotropic support due to:</div><div> myocardial contractile dysfunction </div><div> longstanding, irreversible ventricular remodeling </div><div> </div><div></div><div>present prior to surgery</div><div>References</div><div>Bojar, Robert M. (2011) Manual of Perioperative Care in Adult Cardiac Surgery. (5th edition). </div></div><div></div></div>
<div><div><img><div>32 Disease Processes &amp; Surgical Procedures Disease Processes &amp; Surgical Procedures 33</div><div>ADVANCED HEART FAILURE:  </div><div>VENTRICULAR ASSIST DEVICE (VAD)</div><div>Le Ventricular Assist Device (LVAD)</div><div> </div><div>Provides cardiac support and o loading of the LV for patients with </div><div>advanced heart failure (acute or chronic). Can be used for bridge to </div><div>recovery, bridge-to-transplant or destination therapy </div><div> </div><div>These two are the most common LVADs implanted. Most VAD systems contain </div><div>driveline/percutaneous lead, external controller and external battery/power </div><div>source </div><div>Thoratec HeartMate 2 (HM2) HeartWare Ventricular Assist Device </div><div>(HW, HVAD)</div><div> </div><div></div><div></div><div> </div><div></div><div>of LV to Axial pump. Blood is then </div><div>propelled to ascending aorta </div><div></div><div> </div><div>Flow: 3 to 10 L/min </div><div> </div><div>Speed: 6000 -15000 RPM, 200 RPM </div><div>adjustment interval </div><div> </div><div>Flow estimation is by pump speed </div><div>and power</div><div> </div><div>Pulsatility index (PI): the magnitude </div><div></div><div>pump relating to degree of </div><div>contractility during cardiac cycle </div><div>over intervals of 15 seconds</div><div> </div><div>Insertion: Median sternotomy; new </div><div>approach such as combination </div><div></div><div>thoracotomy</div><div></div><div>assist-device/</div><div> </div><div></div><div>Centrifugal Pump directly sits at </div><div>apex of LV and pumps blood to </div><div></div><div></div><div> </div><div>Small, no abdominal pocket </div><div>needed </div><div> </div><div>Flow: 2 to 10 L/min  </div><div> </div><div>Speed: 1800-4000 RPM, 20 RPM </div><div>adjustment interval </div><div> </div><div>Flow estimation is by speed, power </div><div>and blood viscosity </div><div> </div><div></div><div></div><div>(delta) </div><div> </div><div>Insertion: Median sternotomy; new </div><div></div><div>or bilateral thoracotomy</div><div> </div><div>https://www.heartware.com/</div><div>products-technology</div><div>VAD Parameters:</div><div>Speed (optimal)</div><div> </div><div>Produces normal CI</div><div> </div><div>Allows for normal LV size</div><div> </div><div></div><div> </div><div>Allows for intermittent opening of aortic valve (mitigates against stasis of </div><div>blood in LV)</div><div>Power</div><div> </div><div>Measured in watts</div><div> </div><div></div><div> </div><div></div><div> </div><div>Important to monitor trends (rising watts worrisome for thrombus)</div><div>Flow</div><div> </div><div>Calculated, not measured (derived from motor power and speed)</div><div> </div><div></div><div> </div><div></div><div>Pulsatility Index (HM2)/ </div><div>Pulsatility on ow wave </div><div>(HW)</div><div> </div><div>Determined by pump speed and the degree of native LV contractility</div><div> </div><div>Pump speed determines the amount of LV unloading (increased speed, </div><div>increased unloading)</div><div> </div><div>As speed increases the PI/pulsatility decreases, as speed decreases the PI/</div><div>pulsatility increases</div><div> </div><div></div><div> Increased preload = increased PI/pulsatility</div><div> Decreased preload = decreased PI/pulsatility</div><div>Post-op Care Considerations:</div><div>Main tenants of post-operative care:</div><div> </div><div>Adjust speed for optimal output (liters per min) and optimal bi-ventricular </div><div>shape, interatrial/interventricular septal alignment</div><div> </div><div>Monitor and trend PI (HM2) or Flow pulsatility (HW)</div><div> </div><div>Monitor and trend power </div><div>Right Heart Failure</div><div> </div><div>Elevated CVP, decreased step-up or PAPI</div><div> </div><div></div><div> </div><div></div><div> </div><div>Elevated Lactate, Cr, LFTs and other end-organ enzymes</div><div> </div><div>monitor urine output </div><div> </div><div>TTE or TEE </div><div> </div><div>consider more inotrope, iNO, Flolan; IABP and/or RVAD implantation, consult </div><div>with Cardiac Surgery</div><div>Hypovolemia </div><div> </div><div>Ensure adequate pre-load</div><div> </div><div></div><div> </div><div>monitor urine output</div><div> </div><div>if suctioning, may turn down VAD speed temporarily, consult with ICU </div><div>Attending/Cardiac Surgery </div><div> </div><div>administer volume PRN: may need to slow down bolus rate to protect RV </div><div>from overload</div><div>Blood Pressure</div><div> </div><div></div><div> </div><div>Treat with clevidipine, milrinone, NTG or SNP</div><div> </div><div>However, need to maintain MAP&gt;60 (even &gt;70) for RV and end-organ </div><div>perfusion</div></div><div></div></div>
<div><div><img><div>34 Disease Processes &amp; Surgical Procedures Disease Processes &amp; Surgical Procedures 35</div><div>Bleeding</div><div> </div><div>Check cannulation, invasive procedural sites </div><div> </div><div>May need to delay or pause anticoagulation, consult with Cardiac Surgery </div><div> </div><div>PRN blood products transfusion</div><div> </div><div>consult with Cardiac Surgery before giving any procoagulant</div><div>Anticoagulation (when bleeding stops)</div><div> </div><div>ASA 81mg daily for HM2, ASA 325mg daily for HW</div><div> </div><div>Heparin infusion; if HIT positive, consider Argatroban infusion</div><div> </div><div>  Titrate to PTT goal (usually starts at 40-60, then 60-80), refer to Cardiac </div><div>Surgery Team  </div><div> </div><div>Transition to warfarin when stable, adjust for INR goal (usually 2-3)</div><div> </div><div>Be cautious if invasive procedures are needed </div><div>Thrombosis </div><div> </div><div>If thrombus present pre-pump</div><div> </div><div>If thrombus present intra- or post-pump: power spikes, increased power and </div><div></div><div> </div><div>May need to increase PTT or INR goal </div><div> </div><div>Consider integrelin infusion, tPA thrombolysis or VAD exchange, consult with </div><div>Cardiac Surgery </div><div>Hemolysis</div><div> </div><div>Monitor CBC (with blood smear), coagulation panel, LDH, haptoglobin, free </div><div>plasma hemoglobin</div><div> </div><div>Check LFTs, renal panel, CK</div><div> </div><div>May need to increase PTT or INR goal </div><div> </div><div></div><div>Surgery  </div><div>References</div><div>Bojar, R. (2011). Manual of Perioperative Care in Adult Cardiac Surgery.</div><div> </div><div>HEART TRANSPLANT</div><div>General Care Guidelines:</div><div>I.  Hemodynamic Parameters</div><div> </div><div>Tachycardia is normal and preferred</div><div> </div><div>Generally MAPs&gt;65 and up to 100 (if not bleeding) are acceptable</div><div>II.  Inotropes</div><div> </div><div>Almost all patients will arrive on Epinephrine and Dopamine</div><div> </div><div>Inotropes are not to be weaned w/out discussion with transplant surgeons </div><div></div><div> </div><div></div><div>Clevidipine rather than weaning inotropes</div><div>III.  Immunosuppression</div><div>A. Induction Agents: to be managed primarily by transplant cardiology team</div><div> </div><div>RATG 1mg/kg on POD# 1, 2, 3</div><div> Requires premedication with hydrocortisone, diphenhydramine, and </div><div>acetaminophen</div><div> </div><div>Methylprednisolone</div><div> 500mg IV in OR followed by 125mg q8 x 3</div><div>B. Maintenance Immunosuppression</div><div> </div><div>Tacrolimus (Prograf)</div><div> Started on POD #1</div><div> Goal 12-hour trough 10-15</div><div> </div><div>goal trough and dosing adjusted for renal dysfunction</div><div> </div><div></div><div> Started on POD #0</div><div> IV and PO doses equivalent</div><div> May be held for leukopenia</div><div> </div><div>Prednisone</div><div> Started once induction methylprednisolone completed</div><div>IV.  Opportunistic Infection Prophylaxis</div><div> </div><div>CMV: dependent on Donor vs. Recipient CMV status</div><div> CMV IGG </div><div> ganciclovir/valganciclovir</div><div> Acyclovir</div><div> </div><div>Aspergillus</div><div> Inhaled amphotericin</div><div> Itraconazole</div><div> </div><div>PCP</div><div> Bactrim</div><div> Atovaquone if sulfa allergy</div><div>Post-operative Care: Critical Concepts</div><div>I.  Right Heart Dysfunction/Failure </div><div>A. Etiology</div><div> </div><div>Pre-Existing pulmonary hypertension</div><div> </div><div>Sub-optimal preservation during procurement (prolonged ischemic time)</div><div> </div><div>Coronary spasm</div><div> </div><div>Air down the coronary arteries</div><div>B. Clinical Manifestations</div><div> </div><div>CVP &gt;15 or rising CVP</div><div> </div><div>Hypotension</div><div> </div><div>CVP tracing suspicious of TR</div><div> </div><div>Signs of end organ hypoperfusion</div><div> Low UOP</div><div> Rising creatinine and LFTs</div><div> Rising lactate</div><div>C. Diagnositc Studies</div><div> </div><div>TTE</div><div> Tricuspid regurgitation</div><div> Elevated RVSP</div><div> Assessment of bi-ventricular function</div><div> Septum bowing towards LV</div><div>D. Treatment</div><div> </div><div>Management of patient’s volume status</div><div> Aggressive diuresis</div><div> </div><div>Lasix or Bumex gtt</div></div><div></div></div>
<div><div><img><div>36 Disease Processes &amp; Surgical Procedures Disease Processes &amp; Surgical Procedures 37</div><div> </div><div>Diuril in addition to loop diuretic</div><div> </div><div>Nesiritide infusion</div><div> </div><div>Consider early initiation of CVVH if inadequate  response to diuretics</div><div> </div><div>Escalation of inotropic support</div><div> Consider increasing HR (Isuprel vs. pacing)</div><div> Restart or increase epinephrine</div><div> Consider milrinone </div><div> </div><div>Hypotensive or vasodilated patient may not be able to tolerate</div><div> </div><div>Use cautiously in patients with renal failure</div><div> </div><div>Pulmonary vasodilatation</div><div> Inhaled Nitric Oxide/Flolan</div><div> </div><div>II.  Bradycardia</div><div> </div><div>Transplanted heart is denervated therefore the resting heart rate should be </div><div>higher</div><div> </div><div>Faster heart rate allows less time in diastole thereby protecting the R heart </div><div>from over-distention</div><div> </div><div></div><div> </div><div>Monitor HR as inotropes are being weaned. Bradycardia may not become </div><div>evident until then.</div><div> </div><div></div><div>A. Etiology </div><div> </div><div>Mechanical injury to the conduction system of the heart</div><div> </div><div>Suture line edema</div><div> </div><div>Rejection </div><div>B. Treatment</div><div> </div><div>Isuproterinol</div><div> </div><div>Oral theophylline +/- albuterol</div><div> </div><div>Epicardial pacing if available</div><div>III.  Rejection</div><div>Rare in the early post-transplant phase due to induction immunosuppression and </div><div>crossmatching of the donor and recipient</div><div>A. Clinical Manifestations</div><div> </div><div>Hypotension, poor cardiac output</div><div> </div><div>New S3 or S4</div><div> </div><div>Unexplained heart failure symptoms</div><div>B. Diagnostic Studies</div><div> </div><div>TTE</div><div> Diminished LVEF</div><div> LV thickening</div><div> </div><div>Endomyocardial Biopsy</div><div> Normally done weekly beginning 14 days post-transplant</div><div> Can be done earlier if high index of suspicion for rejection</div><div>IV.  Primary Gra Dysfunction</div><div> </div><div></div><div>of transplant and is not associated with a diagnosable cause . PGD is a </div><div>diagnosis of exclusion. </div><div> </div><div>Unclear etiology, the following may contribute to the development of PGD: </div><div>existing donor heart disease, injury to the donor heart during brain death, </div><div>organ ischemia during recovery and reimplantation, or re-perfusion injury</div><div> </div><div>Management</div><div> High dose inotropy</div><div> Addition of IABP</div><div> ECMO if the above treatments fail </div><div>References</div><div>Bojar, R. (2011). Manual of Perioperative Care in Adult Cardiac Surgery.</div><div></div><div>EXTRACORPOREAL MEMBRANE  </div><div>OXYGENATION (ECMO)</div><div>Veno-Arterial ECMO</div><div>Provides cardiopulmonary support (end-organ perfusion, ventilation/</div><div>oxygenation and potentially  LV depends on cannulation sites) for </div><div>patients with severe acute cardiogenic shock.</div><div>Peripheral Cannulation Strategies Central Cannulation Strategies</div><div> </div><div>Peripheral cannulated VA ECMO </div><div>mostly provides end-organ </div><div>perfusion and oxygenation </div><div> </div><div></div><div></div><div> </div><div></div><div>artery (B)</div><div> </div><div></div><div>femoral artery</div><div> </div><div></div><div>artery</div><div> </div><div>Central cannulated VA ECMO can </div><div></div><div>in addition to providing end-organ </div><div>perfusion and oxygenation</div><div> </div><div></div><div></div><div> </div><div></div><div> </div><div></div><div> </div><div>Potential Complications</div><div> </div><div>Hemorrhage due to systemic anticoagulation </div><div> </div><div>Local Vascular Injury from cannulation</div><div> </div><div>Local bleeding/hematoma</div><div> </div><div>Stroke </div><div> </div><div>PE</div><div> </div><div>Distal Embolization</div><div> </div><div>Infection</div><div>Post-op Care Considerations:</div><div>General Considerations:</div><div> </div><div>Adjust speed for blood ow/desired cardiac output (liters per min)</div><div> </div><div>Adjust sweep rate for CO2 removal (liters per min)</div></div><div></div></div>
<div><div><img><div>38 Disease Processes &amp; Surgical Procedures Disease Processes &amp; Surgical Procedures 39</div><div> </div><div>Keep negative venous drainage pressures (pVein) 0 to -100</div><div> </div><div>Know Pre and Post oxygenator pressures and their trends</div><div> “Delta P” = Pre oxygenator pressure – Post oxygenator pressure</div><div> Increase Delta P could mean thrombus within oxygenator</div><div> Increase in Pre and Post oxygenator pressures may be indicative of </div><div>increased resistance distal to oxygenator (thrombus or kink in cannula)</div><div> </div><div>Can control temperature circuit (heat exchanger)</div><div> </div><div>Hypovolemia </div><div> </div><div>Ensure adequate pre-load</div><div> </div><div></div><div> </div><div></div><div>Cardiac Surgery </div><div> </div><div>administer volume PRN</div><div>HTN</div><div> </div><div></div><div>function </div><div> </div><div>Treat with clevedipine, NTG or SNP</div><div>Anticoagulation</div><div> </div><div>consider ASA 81mg daily </div><div> </div><div>Heparin infusion; if HIT positive, consider Argatroban infusion</div><div> Titrate to PTT or ACT goal (typically ACT goal 140-160), refer to Cardiac </div><div>Surgery Team</div><div> </div><div>formation in the circuit  </div><div> </div><div>Be cautious if invasive procedures are needed </div><div> </div><div>Inspect for clots in circuit, oxygenator and pump</div><div>Bleeding</div><div> </div><div>Check cannulation, invasive procedural sites </div><div> </div><div>May need to pause anticoagulation, consult with Cardiac Surgery </div><div> </div><div>PRN blood products transfusion</div><div> </div><div>Consult with Cardiac Surgery before give any procoagulant</div><div> Feiba can be given by the perfusionist post-oxygenator</div><div>Hypoxemia</div><div> </div><div></div><div> </div><div>Inspect for clots in oxygenator </div><div> </div><div>Trend Pre and Post oxygenator pressures</div><div> </div><div>Maintain adequate Hgb for O2 carrying capacity</div><div>Hemolysis</div><div> </div><div>Monitor CBCs, coagulation panels, LDH, haptoglobin, Free plasma </div><div>hemoglobin </div><div> </div><div>Check LFTs, renal panels, CK </div><div> </div><div>May need to increase PTT or ACT goal </div><div> </div><div></div><div>Surgery  </div><div>Veno-Venous ECMO</div><div>It only provides pulmonary support (oxygenation) for patients with severe </div><div>respiratory failure (ARDS, end-stage lung disease bridge to transplant, acute </div><div>lung injury by H1N1 etc). It does NOT contribute to any cardiac output. </div><div>Peripheral cannulation strategies:</div><div> </div><div>Internal jugular – femoral vein</div><div> </div><div>Internal jugular only (Dual lumen catheter, Avalon, Protek Duo)</div><div> </div><div>Femoral -femoral (uncommon)</div><div>Potential Complications</div><div> </div><div>Hemorrhage due to systemic anticoagulation </div><div> </div><div>Local Vascular Injury</div><div> </div><div>Local bleeding/hematoma</div><div> </div><div>PE</div><div> </div><div>Distal Embolization</div><div> </div><div>Infection</div><div> </div><div>Stroke</div><div>Post-op Care/Considerations:</div><div>General Considerations</div><div> </div><div>Adjust speed/ow for blood ow (liters per min)</div><div> </div><div>Adjust sweep rate for CO2 removal (liters per min)</div><div> </div><div>Keep negative venous drainage pressures 0 to -100</div><div> Patient neck/head position can greatly aect negative venous pressure </div><div>and ow</div><div> </div><div>Know Pre and Post oxygenator pressures and their trends</div><div> “Delta P” = Pre oxygenator pressure – Post oxygenator pressure</div><div> Increase Delta P could mean thrombus within oxygenator</div><div> Increase in Pre and Post oxygenator pressures may be indicative of </div><div>increased resistance distal to oxygenator (thrombus or kink in cannula)</div><div> </div><div>Can control temperature through circuit (heat exchanger)</div><div>Hypoxemia</div><div> </div><div></div><div> </div><div>Inspect for clots in oxygenator </div><div> </div><div>Trend Pre and Post oxygenator pressures</div><div>Hypovolemia </div><div> </div><div>Ensure adequate pre-load</div></div><div></div></div>
<div><div><img><div>40 Disease Processes &amp; Surgical Procedures Disease Processes &amp; Surgical Procedures 41</div><div> </div><div></div><div> </div><div></div><div>Cardiac Surgery </div><div> </div><div></div><div>Avalon cannula</div><div>Bleeding</div><div> </div><div>Check cannulation, invasive procedural sites </div><div> </div><div>May need to pause anticoagulation, consult with Cardiac Surgery </div><div> </div><div>PRN blood products transfusion</div><div> </div><div>Consult with Cardiac Surgery before giving any procoagulant</div><div> Feiba can be administered by perfusionist post-oxygenator</div><div>Hemolysis</div><div> </div><div>Monitor CBCs, coagulation panels, LDH, haptoglobin, Free plasma </div><div>hemoglobin</div><div> </div><div>Check LFTs, renal panels, CK </div><div> </div><div>May need to increase PTT or ACT goal </div><div> </div><div></div><div>Surgery  </div><div>Anticoagulation</div><div> </div><div>consider ASA 81mg daily </div><div> </div><div>Heparin infusion; if HIT positive, consider Argatroban infusion titrate to PTT </div><div>or ACT goal, refer to Cardiac Surgery Team  </div><div> </div><div>Be cautious if invasive procedures are needed </div><div> </div><div>Inspect for clots in circuit, oxygenator and pump</div><div> </div><div>References</div><div>Cont Education Anesthesia Critical Care &amp; Pain (2012). Oxford University Press</div><div> </div><div>LUNG TRANSPLANT</div><div>Fluid and Hemodynamic Management</div><div> </div><div></div><div>which are susceptible to pulmonary edema as a result of disruption to the </div><div></div><div> </div><div></div><div> </div><div></div><div>Monitor indicators of adequate perfusion such as lactate, ScVO2, urine </div><div>output, and mental status.</div><div> A PA catheter is helpful to guide therapy</div><div> If cardiac function is normal, low-dose phenylephrine is preferred since it </div><div></div><div>Respiratory Management</div><div> </div><div>Ventilator </div><div> Set initial tidal volume (VT) at 8-10 mL/kg</div><div> Titrate FiO2 to achieve a PaO2 &gt; 80 mmHg.  Attempt to wean FiO2 as </div><div>much as possible in order to minimize oxygen toxicity and atelectasis.</div><div> Keep peak airway and plateau pressures &lt; 30 mmHg. Utilize PEEP for </div><div>hypoxia (keep in mind airway anastomosis).  </div><div> </div><div> Extremely Important: Monitor native lung hyperination in patient’s </div><div>with single lung transplant (e.g. COPD)</div><div> </div><div>Respiratory care post extubation</div><div> Encourage frequent coughing and use of incentive spirometer.  The </div><div></div><div>susceptibility to respiratory infection and aspiration.</div><div> Start Albuteral and Atrovent for bronchospasms which is common </div><div>secondary to reperfusion injury</div><div>Pain Control</div><div> </div><div>An epidural is preferred for pain (e.g. thoracotomy or clamshell)</div><div> </div><div>Avoid medications that are sedating or cause respiratory depression</div><div>Bleeding</div><div> </div><div>Monitor chest output (Call surgeons/pulmonologist if output &gt; 200 cc/h x 2 h) </div><div> </div><div>Correct coagulopathy</div><div> Consider blood products for Hgb &lt; 7, platelet count &lt; 100, INR &gt; 1.5 </div><div> </div><div>Keep chest tubes stripped</div><div>Immunosuppresion</div><div> </div><div>Induction therapy </div><div> </div><div> </div><div>Maintenance therapy </div><div> Methylprednisone</div><div> </div><div>In OR - Methylprednisolone 500 mg x1 per lung (i.e. for double lung </div><div>transplant, administer 1000 mg IV x1)</div><div> </div><div>POD #0 - Methylprednisolone 125 mg IV Q8H x 3 </div><div> </div><div>POD #1 - Start Prednisone 0.5mg/kg BID on </div><div> Cellcept (mycophenolate mofetil)</div><div> </div><div></div><div> </div><div>Start Tacrolimus 0.5 mg BID (Adjust by 12-hour trough levels) on POD # 1.</div><div> </div><div>  Goal trough 12-15-ng/ml</div><div>Infection Prophylaxis</div><div> </div><div>Bacterial </div><div> Vancomycin1 gm. IV Q12H.  Adjust dose to goal trough levels 15-20</div><div> Cefepime 1000 mg IV Q8H</div><div> </div><div>PCP (choose one)</div><div> Bactrim DS Q MWF  (1st choice therapy)</div><div> Dapsone 100 mg PO QD </div><div> Pentamidine inhaled 300 mg Q month via nebulizer.  Need to use with </div><div></div><div> Mepron (Atovaquone) 1500 mg PO QD</div><div> </div><div>Fungal</div><div> Start Itraconazole 100 mg PO BID on POD #2-3</div><div> Inhaled Amphotericin B 20 mg BID via nebulizer (as inpatient only).  Need </div><div></div><div> </div><div>CMV</div><div> Donor CMV (-) / Recipient CMV (-)</div><div> </div><div>Acyclovir 200 mg PO BID </div><div> Donor CMV (+) / Recipient CMV (-)</div><div> </div><div>Cytogam 150 mg/kg PO.  Taper cytogam to 100 mg/kg on POD #14</div><div> </div><div>POD #1 - DHPG / Ganciclovir (if unable to tolerate PO meds) 5 mg/kg </div><div>BID</div><div> </div><div>Change to Valcyte if taking orals</div></div><div></div></div>
<div><div><img><div>42 Disease Processes &amp; Surgical Procedures Disease Processes &amp; Surgical Procedures 43</div><div> </div><div>Valcyte 900 mg PO BID x 14 days then 900 mg QD through 6 months </div><div></div><div> Donor CMV (+ or -) / Recipient CMV (+)</div><div> </div><div>POD #1 - DHPG / Ganciclovir (if unable to tolerate PO meds) 5 mg/kg BID</div><div> </div><div>Change to Valcyte if taking orals</div><div> </div><div>Valcyte 900 mg PO BID x 14 days then 900 mg QD through 6 months </div><div></div><div> </div><div>Oral Candida Albicans (choose one)</div><div> </div><div> Nystatin 5 ml, swish and swallow, TID</div><div> </div><div>Toxoplasmosis</div><div> Donor (+) / Recipient (-) and not on Bactrim</div><div> </div><div>Pyrimethamine 25 mg QD for 6 weeks</div><div> </div><div>Folinic Acid 10 mg QD for 6 weeks</div><div>Postoperative Complications in Lung Transplant</div><div> </div><div></div><div> </div><div> </div><div></div><div></div><div></div><div></div><div>transplantation.</div><div> Risk Factors</div><div> </div><div>Lung injury related to organ procurement, storage, and reperfusion</div><div> </div><div>Donor characteristics include female, African-American race, age &gt; 45</div><div> </div><div>Recipient characteristics include preexisting pulmonary HTN and </div><div></div><div> Grade severity</div><div> </div><div>Grade 0 - PaO2/FiO2 &gt;300 and normal chest radiograph</div><div> </div><div></div><div> </div><div>Grade 2 - PaO2/FiO2 between 200 and 300</div><div> </div><div>Grade 3 - PaO2/FiO2 &lt;200</div><div> Treatment</div><div> </div><div>Treatment is focused on providing supportive care</div><div> </div><div>For hypoxemia, increase FiO2 and PEEP.  </div><div> </div><div>Consider increasing sedation to improve ventilator synchrony</div><div> </div><div>Avoid neuromuscular blockade (risk for myopathy)</div><div> </div><div>Inhaled pulmonary vasodilators such as iNO and Flolan are used to </div><div>improve ventilation-perfusion mismatch and lower mean pulmonary </div><div>artery pressures</div><div> </div><div>Use lung protective ventilation strategies with low tidal volume</div><div> </div><div>Diuresis for goal CVP &lt; 5</div><div> </div><div>Consider extracorporeal membrane oxygenation (ECMO) for patients </div><div>with severe PGD who do not respond to maximal conventional </div><div>treatment and inhaled pulmonary vasodilators</div><div> </div><div></div><div> </div><div>Acute Rejection</div><div> Acute cellular rejection</div><div> </div><div>A1 – Repeat biopsy in 4-6 weeks</div><div> </div><div>Treat based on clinical symptoms</div><div> </div><div>A2-A3</div><div> </div><div>Methylprednisone 10 mg/kg IV daily x 3d</div><div> </div><div>Valvyte 900 mg PO daily x14d</div><div> </div><div>Repeat biopsy in 4-6 weeks</div><div> </div><div>A4</div><div> </div><div>Methylprednisone 10 mg/kg IV daily x3d</div><div> </div><div>Valcyte 900 mg PO daily x14d</div><div> </div><div>Prednisone taper dose 1 mg/kg over 14d then back to baseline dose</div><div> </div><div>Repeat biopsy in 4-6 weeks</div><div> Acute antibody mediated rejection (AMR)</div><div> </div><div>Day 1-5</div><div> </div><div>Plasmapheresis daily x5d.  One volume exchange with albumin.  If </div><div></div><div> </div><div>Day 6-7</div><div> </div><div>IVIG 1 gm/kg (IBW) x2d.  </div><div> </div><div>Premedicate with Tylenol 650 mg PO and Benadryl 50 mg PO/IV </div><div>with each dose</div><div> </div><div>Days 8 &amp; 15</div><div> </div><div>Rituximab 375 mg/sq meter BSA IV weekly x2 weeks</div><div> </div><div>For refractory AMR</div><div> </div><div>Consider the following:</div><div> </div><div></div><div>Rituximab and RATG dose.</div><div> </div><div>If patient has worsening AMR, can give 3-5 doses of RATG (1.5mg/</div><div>kg/day) QOD.        </div><div> </div><div>Bortezomib IV</div><div> </div><div>Photopheresis  </div><div>References:</div><div>Moten et al. (2013). Postoperative Transplant in the Critical Care Unit. American Association of Critical </div><div>Care Nurses, 24(4): 345-350. </div><div></div><div>Lung Transplant Protocol        </div></div><div></div></div>
<div><div><img><div>44 Post-Op Management Post-Op Management 45</div><div>POST-OP: NEUROLOGIC: DELIRIUM</div><div> </div><div>Represents an acute change in a patient’s mental status that is associated </div><div>with a global impairment in cognitive function</div><div> </div><div>Common, incidence 8-10% overall (up to 20% in elderly patients)</div><div> </div><div>Etiology frequently not clear</div><div> may result from microembolization associated with CPB and associated </div><div>aortic manipulations</div><div> may result from mild cerebral hypo perfusion</div><div> </div><div></div><div>Common Contributing Causes:</div><div> </div><div>medication toxicity (including benzodiazepines and analgesics_</div><div> </div><div>metabolic disturbances</div><div> </div><div>Prolonged ICU stay</div><div> </div><div>alcohol withdrawal</div><div> </div><div>low cardiac output syndromes</div><div> </div><div></div><div>threshold for cerebral infarction</div><div> </div><div>hypoxia</div><div> </div><div>sepsis</div><div> </div><div>recent/new stroke</div><div>Manifestations:</div><div> </div><div></div><div>wake cycle</div><div> </div><div>lethargy or agitation</div><div> </div><div>paranoia and hallucinations</div><div>Evaluation:</div><div> </div><div>Consider psych consult for severe delirium </div><div> </div><div>review of current medications and drug levels</div><div> </div><div>identify possible history of recent alcoholism or substance abuse</div><div> </div><div></div><div> </div><div>ABG, electrolytes, BUN, creatinine, CBC, Mg, calcium, cultures</div><div>Management:</div><div> </div><div></div><div> </div><div>correct metabolic abnormalities</div><div> </div><div>stop inappropriate medications</div><div> </div><div>select appropriate medication to control agitation in the delirious state</div><div> Haldol 2.5-5mg PO/IV q6h most commonly prescribed (risk of torsades)</div><div> </div><div>check daily EKG to eval QTC</div><div> </div><div>sometimes makes delirium worse!</div><div> Seroquel 12.5-50mg, TID </div><div> Precedex drip may be needed while in the ICU. Consider PO version </div><div>(Tenex) </div><div> Zyprexa 5-10 mg daily</div><div> </div><div></div><div> </div><div>Use melatonin 3-6 mg qhs to help reorient sleep/wake cycle</div><div> </div><div>When in doubt, call psychiatry to aid in management</div><div> </div><div>Benzos may exacerbate acute delirium and should be used only when </div><div>managing concurrent alcohol withdrawal</div><div> </div><div>Manage suspected alcohol withdrawal</div><div> Benzos usually indicated for several days then should be gradually </div><div>tapered</div><div> </div><div>extubation if self-destructive behavior</div><div> Also give thiamine 100 mg bid and folic acid 1 mg daily</div><div>References:</div><div>Bojar, Robert M. (2011) Manual of Perioperative Care in Adult Cardiac Surgery. (5th  edition).</div><div>POST-OP: NEUROLOGIC: PAIN CONTROL</div><div>Standing Pain medication orders:</div><div>Acetaminophen</div><div>Dosing:</div><div> </div><div>650 - 1000 mg, oral/rectal, every 6-8 hours (IV Tylenol should never be used)</div><div> Abnormal liver function: 500 mg every 6 hours</div><div>Gabapentin</div><div>Dosing:</div><div> </div><div>CrCl &gt; 60: 300 mg, oral, three times daily</div><div> </div><div>CrCl &gt; 15 but &lt; 60: 100 mg, oral, three times daily</div><div> </div><div>CrCl &lt; 15 and dialysis: 100 mg, oral, daily</div><div> If patient not sedated and having pain, it is reasonable to titrate </div><div>gabapentin to 600 mg TID or higher over 2-3 days</div><div> </div><div>Works well in adjunt with Tylenol</div><div> </div><div></div><div>discharge</div><div> </div><div></div><div>PRN Pain Medication Orders:  </div><div>(must specify indication mild, moderate, or severe)</div><div>Oxycodone  5-15 mg, oral, every 3 hours as needed </div><div>Hydromorphone  0.2-0.5 mg, intravenous, every 2 hours as needed</div><div>Tramadol  50 mg q6h prn CrCl &lt;30: avoid use</div><div> Next step if Tylenol not enough. Usually best for mild to moderate pain</div><div> </div><div>Roxicodone  5-15 mg q4h prn</div><div> Next step if Tylenol and tramadol not enough for pain. Usually best for </div><div>moderate to severe pain. </div><div> </div><div>drowsiness/delirium </div><div> </div><div>Delirium more prevalent in elderly</div><div>Percocet  5/325 mg 1-2 tab PO q4h prn pain</div><div> Good for severe pain not relieved with roxicodone</div><div> Do not use if patient already on standing Tylenol given risk of Tylenol </div><div>overdose</div></div><div></div></div>
<div><div><img><div>46 Post-Op Management Post-Op Management 47</div><div>Dilaudid  2-4 mg PO q4h prn pain, 0.5-1mg IV q3h prn pain, PCA</div><div> Used if pain not relieved by roxicodone</div><div> Also great for acute pain exacerbations</div><div> If require PCA, contact pain service to help manage </div><div>Oxycodone 10-20mg PO q12 hours</div><div> Consider if not achieving adequate PO pain control with short acting </div><div>Roxicodone</div><div> Scheduled q12 intervals. Short acting Roxicodone can be taken in </div><div>addition for breakthrough pain</div><div>Ibuprofen  400 mg, oral, every 6 hours as needed (Needs surgical team approval)</div><div> CrCl &gt; 30 but &lt; 60 or age &gt; 65: 200 mg, oral, every 6 hours as needed</div><div> CrCl &lt;30: avoid use</div><div> Avoid use with dual antiplatelet therapy</div><div>Ketorolac  15-30 mg, intravenous, every 6 hours as needed (Needs surgical team </div><div>approval)</div><div></div><div> CrCl &lt;30: avoid use</div><div> Avoid use with dual antiplatelet therapy</div><div> Only if oral route unavailable; otherwise give oral pain medication</div><div>IV pain medication IS NOT the rst line for patients on the oor. Consider increasing </div><div>the dose of oral meds for better control. The goal is to prepare the patient for </div><div>discharge to home.</div><div>Additional medications you may see that you can consider:</div><div>Fentanyl  25-50mg IV </div><div> Reserve for severe pain not relieved by roxicodone</div><div> Commonly given prior to chest tube removal for pain prevention, but the </div><div>jury is out on whether this is necessary or not!</div><div> Caution with this given heavily sedating </div><div>Lidocaine infusion  </div><div> Commonly started by ICU team</div><div> Requires checking daily lidocaine levels</div><div> Contraindications:</div><div> </div><div>First and second degree heart block due to risk of worsening heart </div><div>block. </div><div> </div><div> </div><div></div><div>numbness and unusual sensations around mouth, metallic taste in </div><div>mouth, ringing in the ears, or lightheadedness and dizziness</div><div> </div><div></div><div>nausea and vomiting, severe dizziness, decreased hearing, tremors, </div><div>changes in blood pressure and pulse. </div><div> </div><div>At serum levels greater than 12 mcg/ml: drowsiness, confusion, </div><div>muscle twitching, convulsions, loss of consciousness, cardiac </div><div>arrhythmias, cardiac arrest</div><div> </div><div>Ketamine  0.1 mg/kg/hr drip, intravenous, continuous</div><div> Consult acute pain service</div><div>Local/Regional anesthetic pain modalities</div><div>Epidural</div><div> Managed by pain service</div><div> Commonly used for TAAA</div><div>Bupivacaine via On Q pump</div><div> See reference page 109</div><div> Commonly used for anterior thoracotomy</div><div>Paravertebral Nerve Block</div><div> Managed by pain service</div><div> Commonly used for myocardial bridge </div><div>POST-OP: NEUROLOGIC: SEIZURES</div><div>A seizure is a “single event characterized by the abnormal excessive synchronized </div><div></div><div>(Kurle, 2010). </div><div>Etiology:</div><div> </div><div>The most common cause of seizures is stroke, 43% within 24 hours of the </div><div>stroke</div><div> 8.9% - hemispheric stroke</div><div> 8.6% – ischemic stroke</div><div> 10.6% - hemorrhagic stroke</div><div> </div><div>Intraoperative hypoxia, or air or particulate emboli, metabolic </div><div>encephalopathy, cerebral edema</div><div> </div><div>Medications</div><div> Lidocaine</div><div> Tranexamic acid (a pro-coagulant not used at SHC).  Amicar is used at </div><div></div><div>seizures (though higher rates of renal dysfunction) (Martin, 2011).</div><div> Cefazolin (a rare complication), especially in patients with renal </div><div></div><div>function</div><div>Incidence:</div><div> </div><div>0.1% (CABG) to 5% (complex aortic) (Goldstone et al, 2011, Manji et al, 2011, </div><div>McGarvey et al, 2013)</div><div> </div><div>59% experience 1 recurrence (Manji, 2011), 89% of those are within 24 hours</div><div> </div><div>Most likely to occur between hours 5-8 postoperatively (Manji, 2012)</div><div>Risk factors </div><div> </div><div>Intraop:</div><div> Duration of aortic cross-clamp time</div><div> </div><div> Deep hypothermic circulatory arrest</div><div> Open chamber surgery</div><div> Complex aortic repair (Sharma, 2014, Goldstone, 2011)</div><div> </div><div>Postop:</div><div> Metabolic derangements (McGarvey, 2013)</div></div><div></div></div>
<div><div><img><div>48 Post-Op Management Post-Op Management 49</div><div>Considerations</div><div>Preoperative Note patients with preexisting seizure disorders and consult Neuro </div><div>Critical Care prior to surgery to make a postop plan.</div><div>Intraoperative These procedures may decrease the incidence of neurologic </div><div>complications (Goldstone et al, 2011):</div><div> </div><div>Epi-aortic scanning before aortic cannulation</div><div> </div><div></div><div> </div><div>Cerebral oxygen saturation monitoring</div><div> </div><div>Retrograde cerebral perfusion with hypothermia or deep </div><div>hypothermia during circulatory arrest</div><div> </div><div>Echocardiography-guided de-airing</div><div>Postoperative</div><div> </div><div>Review of medications and labs to identify  </div><div>pro-convulsive agents or toxic serum levels</div><div> </div><div>Generally are isolated events.  </div><div> </div><div></div><div></div><div>Neuro Critical Care team</div><div>* The terms simple partial, complex partial, and secondarily generalized are no </div><div>longer used</div><div>Classication Origin Clinical </div><div>manifestations</div><div>Guide to </div><div>treatment</div><div>Focal seizure </div><div>(previously </div><div>‘partial’)</div><div>Origin and spread </div><div>limited to one </div><div>hemisphere, </div><div>arising from the </div><div>subcortical or </div><div>neocortical regions</div><div>Can involve twitching of </div><div>a limb, a sense of fear, an </div><div>unpleasant smell (aura) </div><div>and patients may be </div><div>conscious of having them </div><div>(Schachter, 2016).</div><div>EEG, CT head, </div><div>consider Keppra </div><div>load and BID </div><div>therapy. Lorazepam </div><div>if not self-limiting.</div><div>Generalized Starts in both </div><div>hemispheres </div><div>at once, arising </div><div>from a cortical </div><div>or subcortical </div><div>region, may be </div><div>asymmetric</div><div>Most commonly tonic-</div><div>clonic (previously known </div><div>as grand mal, with </div><div>convulsive jerking in all </div><div>limbs), absence (previously </div><div>known as petit mal, with </div><div>staring or lip smacking, </div><div>and myoclonic seizures </div><div>(muscle spasms, can be </div><div></div><div>EEG, CT head, </div><div>consider Keppra </div><div>load and </div><div>BID therapy. </div><div>Lorazepam, if not </div><div>self-limiting.</div><div>Status epilepticus </div><div>(SE)</div><div>Any type of seizure </div><div>can evolve into </div><div></div><div>“more than 30 </div><div>minutes of either </div><div>continuous seizure </div><div>activity or two or </div><div>more sequential </div><div>seizures without </div><div>full recovery of </div><div>consciousness </div><div>between </div><div>(American Epilepsy </div><div>Society Guideline, </div><div>2016)”.</div><div>Characterized as </div><div>convulsive or non-</div><div>convulsive.  This is a </div><div>medical emergency.</div><div>1st line – lorazepam </div><div>or diazepam</div><div>2nd line – </div><div>fosphenytoin</div><div>3rd line –  </div><div>general anesthesia</div><div>* See below for </div><div>doses</div><div>Treatment</div><div> </div><div>Pharmacologic treatment is not always necessary</div><div>seizure, especially if the etiology is obvious and addressed (ie, metabolic </div><div>derangement).</div><div> </div><div>Patients with focal neurological decits, epileptiform discharges on </div><div>EEG or structural brain lesions are at higher risk for repeat seizures and </div><div>should receive anticonvulsive therapy (Kurle &amp; Rutecki, 2010).</div><div>Pharmacological treatment:</div><div> </div><div>Loading followed by a maintenance dose of levetiracetam (Keppra) is </div><div></div><div></div><div> Do</div><div> </div><div>Additional antiepileptic pharmacotherapy based on the EEG, CT, and clinical </div><div>manifestations of the seizure(s) and response to treatment.</div><div> </div><div>To break a seizure:</div><div> 1st line: IV lorazepam</div><div></div><div> </div><div></div><div>depression</div><div> 2nd line: IV fosphenytoin at 20mg/kg, (can also do VPA 40mg/kg or </div><div>Keppra 60mg/kg load – discuss with NCC). Fosphenytoin is better </div><div>tolerated over Phenytoin.</div><div> 3rd line, general anesthesia with propofol or Versed gtts.</div><div>Seizures must be dierentiated from myoclonus (4 types)</div><div> </div><div>Physiologic (muscle jerks when falling asleep, causes no disability)</div><div> </div><div></div><div> </div><div>Epileptic (myoclonic jerks in the setting of epilepsy)</div><div> </div><div>Symptomatic (occurring in the setting of a separate neurological disorder) </div><div>(Caviness, 2015).</div><div>Calling a consult:</div><div> </div><div>Neuro Critical Care Pager number: 14061</div><div> </div><div>Describe the seizure-like activity</div><div> Evolution: describe the pattern (ie did it start with gaze deviation and </div><div>unilateral shaking which then spread to the opposite side)</div><div> Bilateral or convulsive involvement</div><div> What were the eyes doing (nystagmus, gaze deviation etc)</div><div> Termination: spontaneously or with Ativan</div><div> Physical exam ndings</div><div> </div><div>Autonomic changes in absence or focal seizures: tachycardia, </div><div>diaphoresis, excess salivation, pupillary dilation, incontinence (Kurle &amp; </div><div>Rutecki, 2010).</div><div> </div><div>Tonic-clonic seizures: hypertension, tachycardia, metabolic acidosis, </div><div>hypoxia, hypercarbia (Kurle &amp; Rutecki, 2010).</div><div>Diagnostic studies:</div><div> </div><div>Head CT without contrast: Perform early to identify potentially reversible </div><div>causes (Goldstone, 2011)</div><div> </div><div>Continuous EEG: identify a focal area of seizure activity or the presence of </div><div>non-convulsive status epilepticus (Marcuse, 2014)</div><div> </div><div>MRI: </div><div>devices (LVAD, ECMO etc), Epicardial wires, certain ICD/PPMs etc.</div></div><div></div></div>
<div><div><img><div>50 Post-Op Management Post-Op Management 51</div><div>POST-OP: NEUROLOGIC: SPINAL CORD ISCHEMIA </div><div>Who’s at risk? </div><div></div><div>branching arteries (Intercostal arteries) providing blood supply to the spinal cord, </div><div>potentially resulting in spinal cord hypoperfusion, ischemia and infarction</div><div>4.  Endovascular repair </div><div>a.  Incidence: SCI may occur in up to 4% of cases</div><div>b.  </div><div>5.  Open repair</div><div>a.  Incidence: SCI may occur in up to 8% of cases</div><div>b.  </div><div>Intra-op Measures to prevent spinal cord ischemia:</div><div>1.  Minimize spinal cord ischemic time</div><div>2.  Increase tolerance to ischemia </div><div>a.  Deliberate mild systemic hypothermia</div><div>b.  Ischemic preconditioning (“staged repair”) to allow development of </div><div>collateralization of blood supply</div><div>3.  Augment spinal cord perfusion</div><div>a.  Deliberate proximal and distal HTN</div><div>b.  CSF drainage (via lumbar drain placement pre-procedure)</div><div>c.  Reimplantation of spinal arteries</div><div>d.  Preserve subclavian artery and hypogastric artery</div><div>4.  Early detection of spinal cord ischemia</div><div>a.  Intra-operative neurophysical monitoring (MEP motor evoked potentials, </div><div>SSEP somatosensory evoked potentials)</div><div>b.  Early and serial post-op neuro exam</div><div>Post-op ICU Measures to prevent spinal cord ischemia</div><div>1.  CSF Drainage:</div><div>a.  Lumbar drain typically placed pre-operatively by anesthesia.  </div><div>See page 106.</div><div>b.  Goal to optimize cerebral perfusion pressure (CPP): perfusion to spinal </div><div>cord</div><div>1. Measured as CPP = Mean Arterial Pressure – ICP</div><div>2. We can decrease ICP by removing CSF, thus improving CPP</div><div>c.  Goal ICP ~10 mmHg (refer to ICU Lumbar drain protocol)</div><div>1. Lumbar drain is set open to drain at 10mmHg (14cm H20)</div><div>2. When/if ICP is greater than 10mmHg, the lumbar drain will act as a </div><div>“pop-o” valve and CSF will drain</div><div>d.  Must be careful to not OVER DRAIN CSF too rapidly</div><div>1. Symptomatic intracranial hypotension:</div><div>a. Headache</div><div>b. Subdural hematoma</div><div>2. Goal: may drain up to 10mL at a time, not to exceed 20mL/hr</div><div>2.  Augment Mean Arterial Blood Pressure</div><div>a.  Goal hemodynamic parameters must be discussed with the surgical </div><div>attending, as the patient may have residual aneurysm/dissection or </div><div>bleeding to take into consideration when establishing goal MAP</div><div>b.  </div><div>used to augment MAP</div><div>c.  Typical MAP goal 90-100, CPP goal &gt;80</div><div>3.  Early detection through close neurologic monitoring</div><div>a.  </div><div>b.  Q1H Pupillometry while CSF is drained</div><div>4.  May establish blood transfusion goal for Hct &gt;25 to optimize perfusion</div><div>5.  Lumbar drain removal</div><div>a.  </div><div>b.  POD 2: Clamp x 24 hours</div><div>1. Continue to monitor neuro exam, if changes, resume CSF drainage</div><div>c.  POD 3: Remove if neuro exam intact, monitor for HA or CSF drainage post </div><div>removal. Flat for 6 hours post drain removal </div><div>If The Exam Changes:</div><div>1.  Alert ICU attending and surgical team immediately</div><div>2.  Increase MAP/CPP</div><div>a.  Increase dose of vasopressors</div><div>b.  Consider blood/volume transfusion</div><div>3.  Drain CSF (safely) to decrease ICP and increase CPP</div><div>a.  Goal ICP &lt;10 </div><div>b.  Drainage not to exceed 20mL/hr</div><div>4.  Perform thorough neurologic exam</div><div>a.  </div><div>b.  </div><div>5.  Consider consult to neurocritical care</div><div>6.  Consider advanced imaging (CT/MRI) when stabilized to assess extent of </div><div>infarct</div><div>References:</div><div>References Bojar, Robert M. (2011) Manual of Perioperative Care in Adult Cardiac Surgery. (5th edition).</div><div> </div></div><div></div></div>
<div><div><img><div>52 Post-Op Management Post-Op Management 53</div><div>POST-OP: NEUROLOGIC: STROKE / CVA</div><div>Risk Factors:</div><div>Pre-Op: </div><div> </div><div>History of previous stroke or TIA (44% of patients with history of stroke </div><div></div><div> </div><div>Comorbidities: HTN, DM, Smoking, PVD, Renal dysfunction</div><div> </div><div></div><div> </div><div>Age &gt; 75 (risk of up to 10%)</div><div> </div><div>Carotid disease (Risk is less in unilateral stenosis but as high as 10-15% in </div><div>bilateral stenosis &gt; 75%)</div><div> </div><div>Emergent surgery (Type A dissection)</div><div>Intra Op: </div><div> </div><div></div><div>CBP &gt; 2 hours</div><div> </div><div>High transfusion requirement (especially platelets)</div><div> </div><div>LV thrombus</div><div> </div><div>Air embolization from opening of cardiac chamber</div><div> </div><div>Peri-operative HTN or cardiac arrest</div><div>Post op:</div><div> </div><div></div><div>Pre-Op &amp; Perioperative prevention:</div><div> </div><div>Avoid hypotension, continue pre-operative ASA, consider need for pre-op </div><div>carotid studies </div><div>Incidence/Mechanism:</div><div> </div><div>Embolic, most common (~ 2/3 of post op strokes)</div><div> </div><div>Cerebral hyper perfusion  </div><div> </div><div>Hemorrhagic  </div><div>Presentation:</div><div> </div><div>Think BE FAST (Balance, Eyes (vision changes), Face drooping, Arm </div><div>weakness, STime — how long since onset of symptoms)</div><div>Physical Exam:</div><div> </div><div>Full Neuro exam (CN 2-12)</div><div> Strengths of extremities</div><div> Pupil exam</div><div> </div><div>“ Blown pupil:” something acutely bad is happening on one side (rising </div><div>ICP compresses area that holds one of optic nerves)</div><div> </div><div>“Fixed and dilated” pupils – indicate a prolonged hypoxic injury to the </div><div>brain. </div><div> Tongue midline</div><div>Work-up:</div><div> </div><div>Call Stroke code (dial 211)</div><div> </div><div>CT head without contrast, to rule in/out hemorrhage</div><div> </div><div></div><div> </div><div>MRI/MRA brain with perfusion sequences (Stroke protocol) </div><div> </div><div>Carotid Doppler US study to evaluate for carotid occlusive disease</div><div>Medical Management</div><div> </div><div>Blood pressure parameters as determined by consulting teams, but </div><div>SBP should not exceed 180mmHg for ischemic and 140-160mmHg for </div><div>hemorrhagic cases</div><div> </div><div>Glucose control between 80-140 mg/dL as elevated levels &gt; 200 mg/dL during </div><div></div><div>neurologic outcome</div><div> </div><div>Avoid hyperthermia</div><div> </div><div>DC all anticoagulation as patient’s condition can worsen, or can be </div><div>contraindication for tPA administration</div><div> </div><div>ASA 162mg or 325mg orally or rectally</div><div> </div><div>Antiepileptic therapy as determined by consulting teams</div><div>Indications for surgery</div><div>General guidelines:</div><div> </div><div>Patients with large hemispheric stroke involving more than two-thirds of MCA </div><div>territory (usually only on right-side)</div><div> </div><div>Development of herniation syndrome (i.e. ipsilateral weakness on side of </div><div>stroke, lower cranial neuropathies, lethargy)</div><div> </div><div>Uncontrolled intracranial pressure, as dictated by monitor</div><div>Surgical Procedures: </div><div> </div><div>Suboccipital craniectomy/craniotomy (for posterior circulation)</div><div> </div><div>Craniotomy/Craniectomy for evacuation of hematoma</div><div> </div><div>Hemicraniectomy</div><div> </div><div>Carotid endarterectomy</div><div>Reference:</div><div>Winn, H. Richard.  Youman’s Neurological Surgery, 6th ed.  2011.</div><div>CARDIAC: ATRIAL FIBRILLATION &amp;  </div><div>ELECTROLYTE REPLACEMENT</div><div>Classication of AF:</div><div> </div><div>Paroxysmal (self-terminating) vs Persistent (sustained &gt; 7d) vs Permanent  </div><div>(typically &gt; 1 year and when cardioversion has failed or is forgone)</div><div> </div><div>Valvular (rheumatic MV disease, prosthetic valve, or valve repair) vs Non </div><div>valvular</div><div> </div><div>Lone AF = age &lt; 60 and w/o clinical or echo evidence of cardiac disease </div><div>(including HTN)</div><div> </div><div></div><div>patients</div><div>Management of AF: (see below for treatment algorithm)</div><div> </div><div></div><div> </div><div>For unstable patient, cardiovert immediately if able</div><div> </div><div>If the patient continues to have episodes, consider anticoagulation  </div><div>(see CHADs score below)</div><div>Post-operative Electrolyte Goals:</div><div>Potassium (K+) 5.0</div><div>Magnesium (Mg+) 2.5</div><div>Calcium (CA+) 8.0</div></div><div></div></div>
<div><div><img><div>54 Post-Op Management Post-Op Management 55</div><div>Rate Control for AF: (goal HR 60-80, 90-115 with exertion)</div><div>Agent Acute IV Maint (PO) Comments</div><div>Metoprolol (BB) 5mg over 2min, </div><div>may repeat </div><div>q5min x3</div><div>25-100mg BID </div><div>or TID</div><div>↓BP (Rx w/</div><div>glucagon). </div><div>Watch for CHF &amp; </div><div>Bronchospasm </div><div>Preferred if CAD</div><div>Amiodarone 150mg over 10 </div><div>min. Then 1mg/</div><div>min 6 hours, </div><div>0.5mg/min for </div><div>18 hours</div><div>400mg TID with </div><div>taper</div><div>Diltiazem (CCB) 0.25mg/kg over </div><div>2 min, may </div><div></div><div>min. 5-15mg/h </div><div>infusion</div><div>120-360mg/d in </div><div>divided doses</div><div></div><div>gluc). Watch for </div><div>CHF. Preferred if </div><div></div><div>levels</div><div>Verapamil (CCB) 5-10mg over 2 </div><div>min, may repeat </div><div>in 30 min</div><div>120-360mg/d in </div><div>divided doses</div><div></div><div>gluc). Watch for </div><div>CHF. Preferred if </div><div></div><div>levels</div><div>Propranolol (BB) 1mg q2min 80-240mg/d in </div><div>divided doses</div><div></div><div>glucagon). </div><div>Watch for CHF &amp; </div><div>Bronchospasm</div><div>Preferred if CAD</div><div>Digoxin  0.25mg q2h up to </div><div>1.5mg</div><div>0.125- 0.375mg </div><div>qday (adjust for </div><div>CrCl)</div><div>Consider in HR </div><div>or Low BP. Poor </div><div>exertional HR crtl.</div><div>Rhythm Control: </div><div>Amiodarone </div><div>(Class III)</div><div>5-7mg/kg IV </div><div>over 30-60min </div><div>1mg/min to </div><div>achieve 10g load</div><div>200-400mg qD </div><div>(most eective </div><div>drug)</div><div>↑QT but TdP </div><div>rare. Pulm, liver, </div><div>thyroid toxicity. </div><div>Check PFTs, </div><div>LFTs, TFTs</div><div>Sotalol (Class III) n/a 90-160mg BID </div><div></div><div>Propafenone </div><div>(Class IC)</div><div>600mg PO x1 150-300mg TID PreRx w/</div><div>AVN blocker. </div><div>Contraindic. If </div><div>structural or </div><div>ischemic heart </div><div>disease</div><div>Procainamide 10-15mg/kg IV </div><div>over 1 hr</div><div>1-2g bid of slow </div><div>release</div><div></div><div>PreRx w/AVN </div><div>blocker</div><div>Consider need for Anticoagulation:</div><div> </div><div></div><div> </div><div>Risk of stroke ~ 4.5% per year in non valvular AF. Risk factors include: prior </div><div>stroke, TIA, DM, HTN, Older age (&gt;/= 65), HF, CAD, EF &lt; 35%</div><div> </div><div>Who to treat: </div><div> Utilize CHAD Score to evaluate patient’s risk and need for anticoagulation</div><div> </div><div>(with no history), consider need for short term (2-3 months post op) </div><div>anticoagulation (discuss with attending)</div><div>Agent Class Dosing Time to </div><div>Peak  </div><div>Anticoag- </div><div>ulation</div><div>Half-</div><div>life</div><div>Renal </div><div>Excretion </div><div>(%)</div><div>Antidote</div><div>Warfarin </div><div>(Coumadin)</div><div>Vit K </div><div>Antagonist</div><div>0.5-10mg </div><div>QD</div><div>3-5 days 40 </div><div>hours</div><div>0 Vitamin K</div><div>Clopidogrel (Plavix) Platelet </div><div>inhibitor</div><div>75mg  </div><div>QD</div><div>Prasugrel (Effient) Platelet </div><div>inhibitor</div><div>5-10mg </div><div>QD</div><div>7  </div><div>hours</div><div>Dabigatran </div><div>(Pradaxa)</div><div>Direct </div><div>Thrombin </div><div>inhibitor</div><div>150mg </div><div>BID</div><div>1-2 hours 14-17 </div><div>hours</div><div>-80 None</div><div>Rivaroxaban </div><div>(Xarelto)</div><div>Factor-Xa </div><div>Inhibitor</div><div>15-20mg </div><div>QD</div><div>2.5-4hours 11-13 </div><div>hours</div><div>35 None</div><div>Apixaban </div><div>(Eliquis)</div><div>Factor-Xa </div><div>Inhibitor</div><div>2.5-5mg </div><div>BID</div><div>3 hours 8-15 </div><div>hours</div><div>25 None</div><div>Endoxaban </div><div>(Savaysa)</div><div>Factor-Xa </div><div>Inhibitor</div><div>60mg  </div><div>QD</div><div>1-2 hours 9-12 </div><div>hours</div><div>60 None</div><div>CHAD Score (&gt;2 equals indication for anticoagulation)</div><div>C </div><div>dysfunction)</div><div>H Hypertension</div><div>A  (2) Age &gt;/= 75</div><div>D DM</div><div>S (2) Prior stroke or TIA or thromboembolism</div><div>V Vascular disease (PAD, MI)</div><div>A Age 65-74</div><div>Sc Sex category female</div><div>References:</div><div>Bojar, Robert M. (2011) Manual of Perioperative Care in Adult Cardiac Surgery. (5th  edition).</div></div><div></div></div>
<div><div><img><div>56 Post-Op Management Post-Op Management 57</div><div>CT Surgery Post</div><div>Op Atrial</div><div>Fibrillation</div><div>Treatment</div><div>Algorithm</div><div>CHRONIC?</div><div>NEW ONSET? (will occur in 30-</div><div>40% of patients)</div><div>-The goal is always first NSR</div><div>-If NSR cannot be attained, the</div><div>goal then becomes rate control</div><div>STABLE?</div><div>UNSTABLE?</div><div>Amiodarone</div><div>150mg/min bolus +</div><div>drip @ 1mg/min</div><div>OR</div><div>Diltiazem 0.25mg/</div><div>kg bolus + drip @</div><div>5mg/hr (titrate to</div><div>heart rate)</div><div>DCCV</div><div>(direct current</div><div>cardioversion)</div><div>Successful =</div><div>Converts to</div><div>Sinus</div><div>Unsuccessful</div><div>= Remains in</div><div>Afib</div><div>Continue Amio/</div><div>Diltiazem drip until</div><div>loaded</div><div>Repeat DCCV</div><div>Continue Amio/</div><div>Diltiazem drip until</div><div>loaded</div><div>Transition to PO</div><div>Amiodarone</div><div>starting with</div><div>400mg PO TID</div><div>Consider Daily</div><div>EKG to eval QT</div><div>interval.</div><div>AF reoccurs?</div><div>1. Restart Amio/</div><div>Diltiazem bolus +</div><div>drip</div><div>2. Consider</div><div>DCCV</div><div>3. Evaluate the </div><div>need for </div><div>Anticoagulation </div><div>Remains in NSR &gt;</div><div>24-48 hours</div><div>Discharge home</div><div>with amio taper</div><div>Amiodarone</div><div>150mg/min bolus +</div><div>drip @ 1mg/min</div><div>OR</div><div>Diltiazem 0.25mg/</div><div>kg bolus + drip @</div><div>5mg/hr (titrate to</div><div>heart rate)</div><div>Afib persists</div><div>&gt; 24 hours</div><div>Converts to</div><div>Sinus</div><div>Continue amio drip</div><div>@ 1mg/min for 6</div><div>hours followed by</div><div>0.5mg/min for 18</div><div>hours</div><div>If HR or BP ↓, first</div><div>decrease drip to</div><div>0.5mg early. If no</div><div>resolution, stop</div><div>drip.</div><div>S/P MAZE</div><div>Goal is RATE</div><div>CONTROL</div><div>1. Restart Home</div><div>meds</div><div>2. Restart home</div><div>anticoagulation</div><div>NSR</div><div>Heart rate &gt; 60</div><div>Heart rate &lt; 60</div><div>Hold home rate</div><div>controlling/</div><div>antiarrhythmic</div><div>medications</div><div>Restart home rate</div><div>controlling/</div><div>antiarrhythmic</div><div>medications</div><div>(Amio, Sotolol, etc)</div><div>NO MAZE</div><div>Atrial fibrillation</div><div>(will occur in 30%</div><div>of patients)</div><div>Restart home</div><div>Antiarrhythmic/</div><div>anticoagulation</div><div>medications</div><div>MEDICATION DOSING  </div><div>Amiodarone bolus = 150mg/min over 10 min (max 6-8 boluses in first </div><div>24 hours)</div><div>Amiodarone drip = 1mg/min x 6 hours, then decrease to 0.5mg/min </div><div>x 18 hours (this will load the patient with 1g in the first 24 hours)</div><div>If patient becomes hypotensive (occurs in 25% of patients) decrease </div><div>the drip to 0.5mg/min early. </div><div>After 24 hours on the drip, transition to 400-1200mg PO per day in 2-</div><div>3 divided doses. Continue</div><div> this loading dose until you have reached </div><div>10g total (between IV and PO). Then decrease to maintenance dose </div><div>of 200-400mg/day</div><div>If QTC interval &gt; 500ms, decrease or discontinue Amiodarone. </div><div>Hypotension is more likely to occur in daily doses of Amiodarone &gt; </div><div>2g/day. Amiodarone drip should be stopped if 2</div><div>nd</div><div> degree heart </div><div>block or higher occurs or if long pauses are present. </div><div>Loading dose of Amiodarone = 10g</div><div>D</div><div>iltiazem bolus = 0.25mg/kg over 2 min</div><div>Diltiazem drip = 5mg/hour and titrate based on heart rate</div><div>Due to strong negative inotropic effect, IV Beta blockers should be </div><div>avoided. </div><div>For patients with</div><div>chronic atrial</div><div>fibrillation who have</div><div>undergone MAZE</div><div>procedure, 90% will</div><div>be in NSR at 1 year</div><div>post operatively</div><div>Restart home</div><div>medications/</div><div>anticoagulation</div><div>References</div><div>Lee, Richard. Atrial fibrillation and flutter </div><div>after cardiac surgery. In: UpToDate, Saperia, </div><div>SM (Ed.), UpToDate, Waltham, MA, 2016. </div><div>Only consider DCCV for post op</div><div>MAZE patients if patient is</div><div>unstable or rate is very fast</div><div>(DCCV will usually not work until</div><div>patient is 4 weeks post op)</div><div>Continue to</div><div>use IV Amio</div><div>bolus until</div><div>HR &lt; 10</div><div>ANTICOAGULATION</div><div>1. Depends on attending preferences </div><div>2. Should be considered for any patient having paroxysmal atrial </div><div>fibrillation with CHAD score &gt; 2</div><div>SPECIAL CONSIDERATIONS</div><div>Those with a Low EF or mechanical Mitral valve may benefit from </div><div>early DCCV even if they are stable. </div><div>CARDIAC: HEART BLOCKS</div><div>Post-operative transient disturbances of AV nodal conduction are </div><div>more common in patients with:</div><div> </div><div>Low EF, HTN</div><div> </div><div>Severe CAD </div><div> </div><div>Long Aortic clamp time</div><div> </div><div>Low intra-op myocardial temperatures</div><div> </div><div>Aortic/mitral/tricuspid valve replacement/repair</div><div>Post-operative conduction abnormalities may occur because of:</div><div> </div><div>Myocardial edema</div><div> </div><div>Suturing</div><div> </div><div>Debridement near AV node/His bundle</div><div>First Degree AV Block</div><div> </div><div>Prolongation of PR interval</div><div> </div><div>Treatment considerations: </div><div> Epicardial DDD pacing</div><div> Avoid nodal-blocking agents</div><div>Second Degree AV Block: Mobitz Type I (Wenckebach)</div><div> </div><div>Progressive PR prolongation leading to non-conducting P wave with no QRS </div><div>complex</div><div> </div><div>Treatment considerations:</div><div> Epicardial DDD pacing </div><div> Avoid nodal blocking agents</div><div>         http://www.zuniv.net/physiology/book/chapter11.html</div><div>Second Degree AV Block: Mobitz Type II</div><div> </div><div>Constant PR intervals and  </div><div>intermittent dropped QRS  </div><div>complexes (no warning!)</div><div> </div><div></div><div>system</div><div> </div><div>More likely to progress to  </div><div>complete heart block</div><div> </div><div>Treatment considerations:</div><div> Epicardial DDD pacing</div><div> Stop all nodal blocking agents</div><div> Consider permanent </div><div>pacemaker</div><div>Third Degree (Complete) Heart Block:</div><div> </div><div>Failure of AV conduction of any atrial activity (AV disassociation)</div><div> </div><div>Variable rates for P and QRS complexes</div><div> </div><div>Treatment considerations:</div><div> Epicardial DDD Pacing</div><div> </div><div>If atria in AF/A.utter must use VVI pacing</div><div> Stop all nodal blocking agents</div><div> Consider permanent pacemaker</div><div>Heart Block Poem</div><div>If the R is far from P,  </div><div>then you have a First Degree</div><div>Longer, longer, longer—DROP! </div><div>Then you have a Wenckebach</div><div>If some P’s don’t go through,  </div><div>then you have a Mobitz II</div><div>If P’s and Q’s don’t agree,  </div><div>then you have a Third Degree </div></div><div></div></div>
<div><div><img><div>58 Post-Op Management Post-Op Management 59</div><div>AV Junctional Rhythm/Junctional Tachycardia</div><div> </div><div>Occurs when junctional tissue has faster intrinsic rate than the sinus node</div><div> </div><div>“Junctional escape rhythm:” HR &lt; 60bpm </div><div> </div><div>“Junctional tachycardia:” HR 70-130 bpm</div><div> </div><div>Could be associated with decreased cardiac output due to lack of </div><div>synchronous atrial and ventricular contractions</div><div> </div><div>Diagnosis: regular rate with no visible P-waves or retrograde P waves</div><div> </div><div>Treatment considerations:</div><div> Stop all nodal blocking agents</div><div> Chronotropic Beta-1 agonists to stimulate SA node (ie Isuprel, Dopamine, </div><div>Epinephrine)</div><div> Epicardial atrial or DDD pacing</div><div>For more information on Medtronic temporary pacemaker box,</div><div> See page 106.</div><div>CARDIAC: CHEST PAIN</div><div>The most important etiology in the dierential diagnosis is myocardial ischemia. </div><div>Fortunately, it is very uncommon in the post op cardiac surgery patient.</div><div>Patient Exam:</div><div> </div><div>Can the pain be reproduced by palpitation, positional changes, or deep </div><div>inspiration? If so, much less likely to be ischemic in nature. The most </div><div>common cause of chest pain following cardiac surgery is musculoskeletal in </div><div>nature. </div><div>Obtain Ekg: </div><div> </div><div>Compare with pre op and early post op EKGs</div><div> </div><div></div><div>If You Suspect True Angina Follow Mona:</div><div> </div><div>Morphine</div><div> </div><div>O2 via Nasal Cannula</div><div> </div><div>Nitroglycerin (0.4 SL or 1” Nitro Paste)</div><div> </div><div>ASA 325mg</div><div> </div><div>Beta Blocker (metoprolol 5mg IV, may repeat in 5 min. </div><div> </div><div>Cardiac Enzymes for 24 hours (q8H x3) --Troponin/Ck-MB, CK</div><div>Consider: </div><div> </div><div>Did the patient of angina pre op? If so, is the pain the same as the pain now? </div><div> </div><div>Any pre operative cath to review? </div><div> </div><div></div><div> </div><div></div><div>pneumothorax, pneumonia, pulmonary embolism, sternal wound infection, </div><div>aortic dissection, GERD</div><div>For inpatient cardiac catherization procedures, page the interventional </div><div>cardiology fellow on call to arrange.</div><div>CARDIAC: PERICARDIAL TAMPONADE</div><div>Pathophysiology: </div><div> </div><div></div><div></div><div> </div><div></div><div>Manifestations / Physical Exam:</div><div> </div><div></div><div> </div><div></div><div> </div><div>Sudden stop in chest tube output</div><div> </div><div>Equilibration diastolic pressures</div><div> </div><div></div><div>early diastole) </div><div> </div><div></div><div>Diagnostics:</div><div> </div><div></div><div> (If you have started 2 inotropes, and given volume, and the patient is </div><div>doing badly (CI &lt; 2.0), you must rule out tamponade)</div><div> </div><div>Chest xray (widened mediastinum)</div><div> </div><div>CBC, Coagulation studies </div><div>Treatment:</div><div> </div><div>Give volume, start an inotrope, alert surgical team</div><div> </div><div>Assure chest tube patency</div><div> If visible clot within chest tube obstructing drainage, discuss with surgical </div><div>resident/fellow about using suction catheter to suction out the chest </div><div>tube with sterile technique</div><div> </div><div>If patient acutely decompensating, may require re-sternotomy in the  </div><div>ICU or OR</div><div>Delayed tamponade: </div><div> </div><div></div><div>usually resolve completely</div><div> </div><div></div><div>clinical symptoms as patients enter a low cardiac output state </div><div> Gradual increase in creatinine/BUN</div><div> Gradual increase in heart rate</div><div> Gradual decrease in urine output</div><div> Decrease in exercise tolerance</div><div> </div><div>Diagnostics: Echocardiogram gold standard</div><div> </div><div>Treatment: as above if unstable. If stable, consider pericardial window vs </div><div>need to re-open chest in operating room</div><div> </div></div><div></div></div>
<div><div><img><div>60 Post-Op Management Post-Op Management 61</div><div>CARDIAC: RIGHT VENTRICULAR FAILURE</div><div>Pathophysiology</div><div> </div><div>The RV is a thin-walled, crescent-shaped structure characterized by low </div><div>resistance, high compliance, and low impedence</div><div> </div><div></div><div> </div><div>Ventriculoarterial coupling is a major determinant of RV function</div><div>Etiology</div><div>1.  Preexisting RV dysfunction secondary to severe coronary disease, pulmonary </div><div>hypertension, valvular heart disease, and/or RV infarction</div><div>2.  Postsurgical RV dysfunction secondary to long cardiopulmonary bypass </div><div>(CPB) time, suboptimal myocardial protection, and/or coronary embolism</div><div>3.  </div><div>excessive blood transfusions, pulmonary embolism, protamine reaction, </div><div>ischemia-reperfusion injury, tension pneumothorax</div><div>4.  RV pressure overload secondary to intrinsic pulmonary disease, pulmonary </div><div>embolism, and/or acute respiratory distress syndrome (ARDS)</div><div>Diagnosis</div><div> </div><div>High right atrial pressure (RAP) and pulmonary capillary wedge (PCW) </div><div>pressure.  Note this is unreliable when LV dysfunction is also present</div><div> </div><div>May consider TTE to assess IVC, tricuspid regurgitation, right ventricle size, </div><div>and septal positioning to guide volume status.  </div><div> </div><div>Monitor CVP tracing.  With worsening TR and RV dilation, will see rising V </div><div>wave on CVP tracing.  </div><div> </div><div>Calculate step-up (mean PA pressure - CVP pressure)</div><div> Goal &gt; 10</div><div> </div><div>Calculate pulmonary artery pulsatility index (PAPi)</div><div> Studied to predict RVAD need in LVAD patients</div><div> PAPi = (systolic PA pressure - diastolic PA pressure) / CVP</div><div> </div><div>PAPi &gt;2: good RV function</div><div> </div><div>PAPi 1-2: at risk for RV failure</div><div> </div><div>PAPi &lt;1: RV failure</div><div> </div><div>For more information on Advanced hemodynamic monitoring and PA </div><div>catheters see page 125.</div><div>Management</div><div>1.  Prevent elevated pulmonary vascular resistance</div><div>a.  Avoid hypoxemia, hypercapnia, and acidosis which increase PVR</div><div>2.  Optimize preload</div><div>a.  Fluid Administration</div><div>i.  Administer crystalloids/colloids and/or blood products slowly for low </div><div>cardiac output as long as CVP is low or within target range  </div><div>ii.  Do not give additional volume if the cardiac output/blood pressure </div><div>does not improve since additional volume may lead to worsening RV </div><div>function according to Frank-Starling mechanism</div><div>b.  Fluid removal</div><div>i.  Initiate diuretics promptly for volume overload and RV dilation/TR.  </div><div>Start with Lasix bolus of 10-50 mg IV.  If no response to bolus, consider </div><div>rebolus, starting Lasix infusion, and/or adding Diuril IV.  </div><div>ii.  If no response to Lasix/Diuril, consider switching to Bumex infusion </div><div>or starting Nesiritide infusion.  (Note Nesiritide causes systemic </div><div></div><div>with loop diuretics).  </div><div>iii. If all the above interventions fail, initiate dialysis.</div><div>3.  </div><div>a.  Flolan: inhaled epoprostenol </div><div>i.  Prostacyclin inhibitor that is a pulmonary vasodilator</div><div>ii.  Starting dose 0.05 mcg/kg/min.  When weaning therapy, titrate down </div><div>by 0.01 mcg/kg/min as tolerated</div><div></div><div>be stopped if suspected </div><div>b.  iNO</div><div>i.  Selective pulmonary vasodilator only available in aerosol </div><div>administration.  </div><div>ii.  Use only if patient not responsive to inhaled Flolan</div><div>iii. Starting dose 20 ppm.  When weaning therapy, titrate down by 5 </div><div></div><div></div><div>c.  </div><div>i.  Phosphodiesterase (PDE) inhibitor that is both a pulmonary and </div><div>systemic vasodilator.</div><div>ii.  Available in oral doses of 5-20 mg TID</div><div>4.  Optimize cardiac output</div><div>a.  Dopamine</div><div> </div><div>doses.</div><div>ii.  Drip rate ranges between 1-5 mcg/kg/min.  May transfer out of ICU on </div><div>4 mcg/kg/min</div><div>b.  Epinephrine</div><div> </div><div>kg/min</div><div>ii.  Drip rate ranges between 0.01-0.2 mcg/kg/min.  Drip titrated by 0.01 </div><div>mcg/kg/min</div><div>iii. Important considerations</div><div>1.  May cause arrthymias at higher doses</div><div>2.  Closely monitor CVP/CI/lactates when titrating drip rate</div><div>c.  Milrinone </div><div>i.  PDE III inhibitor. Provides inotropy and reduces PVR/SVR</div><div>ii.  Drip rate ranges between 0.1 – 0.5 mcg/kg/min</div><div>iii. Important considerations</div><div>1.  Long half-life of 1.5-2 hours</div><div>d.  Dobutamine</div><div> </div><div>SVR</div><div>ii.  Drip rate ranges between 1-20 mcg/kg/min.  Half-life 2 minutes</div><div>iii. Important considerations</div><div>1.  Causes mild tachycardia and hypotension</div><div>2.  Increases myocardial oxygen demand</div><div> </div><div>5.  Optimize right heart perfusion pressure</div></div><div></div></div>
<div><div><img><div>62 Post-Op Management Post-Op Management 63</div><div>a.  </div><div>b.  Vasopressin</div><div>i.  May cause pulmonary vasodilation at low doses</div><div>ii.  Drip rate ranges between 0.01-0.04 units/min</div><div>c.  Norepinephrine</div><div> </div><div>ii.  Does increase PVR at higher doses</div><div>iii. Drip rate ranges between 1-20 mcg/min</div><div>d.  Phenylephrine</div><div> </div><div>ii.  Like Norepinephrine dose increase PVR at high doses</div><div>iii. Infusion rates 5-200 mcg/min</div><div>6.  Monitor adequate end organ perfusion:</div><div>a.  SvO2 (either from CCO swan or VBG)</div><div>b.  Lactate </div><div>c.  UOP/Creatinine</div><div>d.  LFT’s (R heart failure leads to hepatic congestion)</div><div>7.  </div><div>consider mechanical circulatory support</div><div>a.  RVAD</div><div>b.  VA ECMO</div><div>CARDIAC: SYSTOLIC ANTERIOR MOTION (SAM) </div><div>OF THE MITRAL VALVE</div><div> </div><div></div><div>systole.  Typically seen in patients with HOCM or mitral valve repair.</div><div> </div><div>Consider in setting of worsening hypotension with increased inotropic </div><div>support</div><div> </div><div></div><div>intraventricular septum, papillary muscle displacement, and redundant </div><div></div><div>Clinical pearls:</div><div>To prevent SAM, the goal is to slow the heart rate to prolong the LV lling time </div><div> </div><div>Avoid inotropic support, use vasopressors in setting of hypotension</div><div> </div><div>Avoid hypovolemia, cautious use of diuretic therapy</div><div> </div><div>Once stabilized, consider beta blocker therapy for long term treatment </div><div> </div><div>Reference page 24  </div><div>CARDIAC: VASOPLEGIA</div><div> </div><div>Persistent hypotension despite adequate cardiac output from low systemic </div><div>vascular resistance</div><div> </div><div></div><div>response. Risk factors include history of use of ACE inhibitors, ARBs, CCBs, </div><div>Amiodarone, B-blockers, and Heparin.</div><div> </div><div>Treatment:</div><div> </div><div> PhenylephrineNorepinephrine</div><div></div><div>needed</div><div> Methylene Blue (1-2mg/kg bolus) inhibits NO synthase and is used in </div><div>the treatment of refractory hypotension</div><div>CARDIAC: HEART FAILURE</div><div>post surgery because most </div><div>post surgical state. However </div><div>there are some principals that can help you manage the patients. </div><div>Medications: </div><div> </div><div>Do not hold heart failure medications (beta blockers, ACE inhibitors, </div><div>spironolactone) for low blood pressure. Accept a lower blood pressure </div><div>for heart failure patients consider giving them even if your systolic blood </div><div>pressure is in the 90’s (even in the high 80’s in some cases). </div><div> </div><div></div><div>may be harmful in asymptomatic patients with low LVEF and no symptoms of </div><div></div><div> </div><div>Beta blockers: </div><div> Beta blockers should be used in all patients with a reduced EF to prevent </div><div>symptomatic HF, even if they do not have a history of MI.  </div><div> Consider Coreg instead of Metoprolol for beta blockade: one study </div><div></div><div>Metoprolol for heart failure with reduced EF </div><div> </div><div>Aerload reduction:</div><div> </div><div>reduction due to kidney dysfunction. The kidneys will appreciate better </div><div></div><div>problem</div><div> </div><div>patients who cannot tolerated ACEs or ARBs or who are African American </div><div> ACE inhibitors should be used in all patients with a reduced EF to prevent </div><div>symptomatic HF, even if they do not have a history of MI. </div><div> </div><div>Diuretics: See volume management below </div><div>Volume Management: </div><div> </div><div>Don’t over-diurese patients with preserved ejection fraction. They are very </div><div>responsive to volume and cardiac output can disproportionately drop with </div><div>minimal changes in preload. </div><div> </div><div>Consider Aldactone or Eplerenone for patients that are on a beta blocker and </div><div>ace inhibitor without hyperkalemia</div><div> </div><div>Lasix is a threshold drug- titrate daily dose until you see a response (for </div><div>example- if no response to 20mg daily, increase40mg daily instead of 20mg </div><div>BID). While inpatient, use IV. </div><div> </div><div>20mg lasix IV = 40 PO = 1 Bumex IV= 10 Torsemide PO </div><div> </div><div>Consider Diuril or Metolazone for patients who are diuretic resistant</div><div> </div><div>If hyponatremic, it is likely a hypervolemic issue. Diuresis is the appropriate </div><div>response, rather than giving salt tabs</div><div> </div><div>No pre hydration for cardiac catheterization or CT scan</div><div>Consults: </div><div> </div><div>Consider consult to heart failure CNS for assistance with complex patients or </div><div>if you have questions. They are also a great education resource for patients. </div><div>Enter as epic order.</div></div><div></div></div>
<div><div><img><div>64 Post-Op Management Post-Op Management 65</div><div>PULMONARY: PLEURAL EFFUSIONS</div><div>Type of </div><div>Pleural </div><div>Eusion</div><div>Denition Presentation: Common </div><div>causes</div><div>Pleural Fluid </div><div>Interpretation </div><div>(Lights Criteria)</div><div>Diagnosis Treatment </div><div>Transudate</div><div> </div><div></div><div>capillaries from: hydrostatic </div><div>psi/increased pressure </div><div>(CHF, etc) </div><div> </div><div></div><div>from nutrition, nephrotic </div><div>syndrome, cirrhosis)</div><div> </div><div>Usually occurs bilaterally </div><div>Small eusion: </div><div>likely </div><div>asymptomatic </div><div>Larger eusion: </div><div>dyspnea, cough, </div><div>hypoxia</div><div>Physical exam: </div><div>percussion </div><div></div><div></div><div>absent breath </div><div>sounds over </div><div></div><div> </div><div>CHF (most </div><div>common - </div><div>90%)</div><div> </div><div>Cirrhosis</div><div> </div><div>Nephrosis</div><div> </div><div>Protein ≤ 3 gm% </div><div> </div><div></div><div>protein/serum </div><div>protein&lt;0.5</div><div> </div><div></div><div>serum LDH &lt; 0.6 </div><div> </div><div></div><div>&lt; 2/3 upper limit </div><div>normal</div><div> </div><div>CXR PA &amp; Lateral, </div><div>lateral decubitus</div><div> </div><div>CT may be indicated </div><div>to evaluate etiology of </div><div></div><div> </div><div>US-Guided Diagnostic </div><div>horacentesis  </div><div>c.  </div><div>protein &amp; lactate </div><div>hydrogenase </div><div></div><div>transudates vs. </div><div>exudates. </div><div>d. b) PH, total &amp; </div><div></div><div>counts, glucose, </div><div>cytology, gram </div><div>stain, culture, etc </div><div></div><div>exudate subtypes (if </div><div>indicated)</div><div> </div><div>Correct underlying condition</div><div> </div><div>Common in immediate post op setting, </div><div>consider need for diuresis</div><div> </div><div>Therapeutic thoracentesis for severe dyspnea</div><div>Exudate</div><div> </div><div></div><div>abnormal capillaries leaking </div><div></div><div>drainage such as cancer).</div><div> </div><div>Exudates imply local pleural </div><div>diseases</div><div> </div><div>Exudates – subtypes: </div><div>e.  Empyema’s: direct </div><div>infection of an exudates. </div><div>f.  Hemothorax: gross blood </div><div>in pleural space from </div><div>trauma. </div><div>g.  Chylothorax: thoracic </div><div>duct disruption causes </div><div>cholesterol complex </div><div>accumulation, usually </div><div>associated with </div><div>lymphoma and thoracic </div><div>surgery.</div><div> </div><div>Can occur bilaterally or </div><div>Unilaterally </div><div>Usually </div><div>inammatory </div><div>causes:</div><div> </div><div>Bacterial </div><div>Pneumonia</div><div> </div><div>Cancer</div><div> </div><div>Trauma</div><div> </div><div>Protein ≥ 3 gm% </div><div> </div><div></div><div>protein/serum </div><div>protein &gt; 0.5</div><div> </div><div></div><div>serum LDH &gt; 0.6</div><div> </div><div></div><div>&gt; 2/3 upper limit </div><div>normal</div><div>Exudates associated with pneumonias = </div><div>parapneumonic pleural eusions. </div><div>Step 1: treat pneumonia. </div><div></div><div> </div><div></div><div></div><div>antibiotic.  </div><div> </div><div></div><div></div><div>thoracostomy  (chest tube) or surgery. </div><div> </div><div></div><div>decortication usually)</div><div>Exudates associated with malignancy = </div><div>malignant pleural eusions (Lung or breast </div><div>cancer common)</div><div>Treatment options:</div><div> </div><div>Treat the cancer</div><div> </div><div></div><div>may help with symptoms (shortness of breath, </div><div>dyspnea, etc). </div><div> </div><div>Pleurodesis.</div><div>PULMONARY: PNEUMOTHORAX</div><div>Presence of air or gas in the pleural cavity (ie, the potential space between the </div><div>visceral and parietal pleura of the lung), which can impair oxygenation and/or </div><div>ventilation</div><div>1.  Etiology</div><div>a.  Entering the pleural space during surgery or with sternal wire placement</div><div>b.  Ruptured bleb in patient with underlying lung disease</div><div>c.  Barotrauma from alveolar overdistention during mechanical ventilation </div><div>may manifest as pneumothorax, subcutaneous emphysema or </div><div>pneumomediastinum </div><div>2.  Clinical manifestations</div><div>a.  Hypoxia, dyspnea, tachypnea</div><div>b.  Airleak on chest tube: may indicate loose connections along the drainage </div><div>system or pneumothorax</div><div>c.  Subcutaneous emphysema: may develop if air exists under positive </div><div>pressure where the pleura has been violated. </div><div>d.  Tension pneumothorax: collapsed lung causing cardiac compression, </div><div></div><div>output</div><div>e.  </div><div> </div><div>3.   Treatment considerations</div><div>a.  </div><div>assure chest tube is attached to suction, look for kinks in tubing</div><div>b.  </div><div>oxygen and consider placement of chest tube/pigtail </div><div>c.  If patient asymptomatic and pneumothorax small, appropriate to </div><div>observe with serial chest x-rays</div><div>References:</div><div>Bojar, Robert M. (2011) Manual of Perioperative Care in Adult Cardiac Surgery. (5th  edition).</div><div> </div><div>PULMONARY: PULMONARY HYPERTENSION</div><div>1.  Etiology: related to primary pulmonary arterial HTN or secondary to </div><div>elevations of pressure in the pulmonary venous and capillary systems</div><div>a.  Chronic Pulmonary HTN</div><div>i.  Congenital heart disease, Connective tissue disease (lupus, </div><div>rheumatoid arthritis, scleroderma), Medication/toxin induced</div><div>ii.  Chronic thromboembolic disease</div><div>iii. Lung disease: </div><div> </div><div>OSA</div><div>2.  Result of pulmonary vascular remodeling from chronic hypoxia and </div><div></div><div>iv. Le Heart Disease: </div><div>venous pressure</div><div>1.  LV systolic or diastolic heart failure</div><div>2.  Mitral and aortic valve disease </div><div>b.  Acute Pulmonary HTN</div><div>i.  Protamine reaction</div><div>1.  Type 3 protamine reaction may result in severe pulmonary </div><div>vasoconstriction, systemic vasodilation and acute right heart </div><div>failure </div></div><div></div></div>
<div><div><img><div>66 Post-Op Management Post-Op Management 67</div><div>2.  Typically improves within 10 minutes of stopping protamine</div><div>ii.  Acidosis/Hypoxemia: lead to increased pulmonary vascular </div><div>resistance</div><div>iii. Tension Pneumothorax</div><div>iv. Pulmonary embolism</div><div>v.  Acute MR (ie papillary muscle rupture)/LV failure leading to high LA </div><div>pressure and pulmonary edema</div><div></div><div>2.  Treatment in the acute setting</div><div>a.  Identify underlying cause/contributing factors</div><div>b.  Pulmonary Vasodilators</div><div>i.  Indications: severe pulmonary hypertension (mPAP &gt; 25 mmHg; RAP &gt; </div><div>15 mmHg; CI &lt; 2.0 L/min), right ventricular failure, ARDS with persistent </div><div>hypoxia (P:F &lt; 200), and post-op lung transplant with reperfusion </div><div></div><div>ii.  Inhaled aerosol results in dilation of the pulmonary vascular bed </div><div>thereby reducing pulmonary artery pressure, pulmonary vascular </div><div>resistance, and right ventricular aerload. This results in improved </div><div>in VQ mismatch and oxygenation.  </div><div>1.  Flolan (epoprosteronol) *Preferred*</div><div>  a.  Available as IV or aerosol administration.  IV administration  </div><div> (rarely used) causes systemic vasodilation</div><div>  b.  Starting dose 0.05 mcg/kg/min.  When weaning therapy,  </div><div> titrate down by 0.01 mcg/kg/min every hour as tolerated </div><div>2.  iNO</div><div>  a.  Only available in aerosol administration.  </div><div>  b.  Starting dose 20 ppm.  When weaning therapy, titrate down by </div><div></div><div></div><div>iii. Sildenal: PDE inhibitor prevents degradation of cGMP and reduces </div><div>pulmonary vascular tone</div><div>a.  Starting dose 10-20mg TID</div><div> </div><div></div><div>Sussex, UK: Wiley-Blackwell</div><div> </div><div>PULMONARY: ACUTE RESPIRATORY DISTRESS </div><div>SYNDROME (ARDS)</div><div>1.  Pathophysiology</div><div>a.  </div><div>lungs</div><div>b.  </div><div>capillaries</div><div>c.  Results in non-cardiogenic interstitial edema</div><div>d.  </div><div>e.  Hypoxic and ventilator failure </div><div>2.  Pre-disposing conditions: </div><div>a.  </div><div> </div><div>however ARDS only occurs in &lt;1% of patients undergoing open heart </div><div>surgery</div><div>ii.  Sepsis</div><div>3.  Diagnostic Criteria</div><div>a.  Acute onset</div><div>b.  </div><div>c.  PCWP &lt;18, or no clinical evidence of L heart failure, non-cardiogenic </div><div>pulmonary edema</div><div>d.  </div><div>i.  P/F ratio = PaO2 ÷ FiO</div><div>1.  Ex: PaO2 90 on FiO2 40% = 90 ÷ 0.4 = 225</div><div>ii.  P/F &lt; 200 is associated with signicant shunt and indicates ARDS</div><div>iii. P/F 200-300 indicates acute lung injury</div><div>4.  Management</div><div>a.  Optimize hemodynamics and volume status, diurese when indicated</div><div>b.  Optimize nutrition</div><div>c.  </div><div></div><div>d.  Lung Protective Ventilation (LPV) Protocol: Limits ventilator induced </div><div>lung injury</div><div>i.  Purpose: To maximize gas exchange using low tidal volumes (4-6 mL/</div><div>kg) and minimizing plateau pressures (&lt; 30 cm H2O) in all patients </div><div>with ARDS</div><div> </div><div></div><div>iii. Goals: VT 6 mL/kg, pH 7.30 – 7.45, Pplat &gt; 30 cm H2O, EIP</div><div>iv. Prescriber must determine ventilator mode (VCV or PCV) and PEEP </div><div>(standard or high)</div><div>v.  Volume Control Ventilation (VCV)</div><div>1.  Set VT at 8 mL/kg using patient’s predicted body weight (PBW).  </div><div>Slowly decrease VT by 1 mL/kg until target VT is achieved </div><div>2.  Set respiratory rate to baseline minute ventilation (do not exceed 35 </div><div>breaths/min)</div><div>3.  Add PEEP at 5-7 cm H2O to goal PaO2 &gt; 55 and SaO2 &gt; 88% (see </div><div>table below)</div><div>4.  Adjust VT to achieve target plateau pressure (Pplat)</div><div>  a.  If Pplat &gt; 30 cm H2O, decrease VT by 1 mL/kg until Pplat &lt; 30 or  </div><div> VT 4 mL/kg</div><div>  b.  If Pplat &lt; 25 and VT &lt; 6 mL/kg, increase VT by 1 mL/kg until Pplat  </div><div> &gt; 25 or VT 6 mL/kg</div><div>  c.  If Pplat &lt; 30 and vent dysnchrony, may increase VT by 1 mL/kg to  </div><div> 8 mL/kg and/or increase sedation</div><div>5.  Adjust respiratory rate to achieve target pH </div><div>6.  If pH &lt; 7.30, increase RR to max 35 breaths/min</div><div>7.  If pH &lt; 7.15 and RR 35 breaths/min, increase VT by 1 mL/kg to a max </div><div>of 8 mL/kg until pH &gt; 7.15</div><div>vi.  Pressure Control Ventilation (PCV)</div><div>1.  PCV is similar to above however end-inspiratory pressure (EIP) is </div><div>adjusted to achieve goal VT (tidal volume).</div><div>2.  If EIP &lt; 10 cm H2O and VT &gt; 7 mL/kg, increase EIP in order to </div><div>increase to a maximum EIP 35 cm H2O </div><div>3.  If EIP is decreased to 10 cm H2O &gt; PEEP and VT &gt; 7 mL/kg or if </div><div>patient exhibiting increased work of breathing, consider increasing </div><div>sedation.  If unable to increase sedation, may increase VT by 1 mL/</div><div>kg to max VT 8 mL/kg.</div><div>4.  Once work of breathing decreased, decreased EIP back to target VT </div><div>5-7 mL/kg</div></div><div></div></div>
<div><div><img><div>68 Post-Op Management Post-Op Management 69</div><div>vii. PEEP/FiO2 titration</div><div>1.  Goal SaO2 88-95% or PaO2 55-80%</div><div>FiO2 30% 40% 50% 60% 70% 80% 90% 100%</div><div>Standard PEEP 5 5-8 8-10 10 10-14 14 14-18 18-20</div><div>High PEEP 8-10 10-12 12-14 14-16 16-18 18-20 20-22 22-24</div><div>Sources:</div><div></div><div>UK: Wiley-Blackwell</div><div>Marino, P. (2009). The Little ICU Book. Philadelphia, PA: Lippincott Williams &amp; Wilkins</div><div> </div><div>PULMONARY: ATELECTASIS</div><div>Atelectasis: collapse or closure of a lung resulting in reduced or absent gas </div><div>exchange</div><div>1.  Etiology:</div><div>a.  Obstructive: blockage in the proximal airway leads to nonventilated </div><div>alveoli that collapse</div><div>b.  Passive/Compressive:</div><div></div><div>c.    pain (splinting), over-sedation, or prolonged </div><div>supine positioning</div><div>2.  Clinical manifestations</div><div>a.  Hypoxia, dyspnea</div><div>b.  </div><div>c.  Fever, elevated WBC count, PNA</div><div>3.  Treatment considerations</div><div>a.  Identify and address underlying causes: </div><div>i.  Achieve adequate pain control, decrease sedation</div><div> </div><div>iii. Assess for evidence of PNA and treat appropriately</div><div>b.  Alveolar Recruitment Maneuvers: </div><div>i.  Using increased PEEP via ventilator or CPAP </div><div>1.  Increase mean airway pressure to open closed alveoli to increase </div><div>surface area for gas exchange</div><div>2.  Decrease VQ mismatch/intrapulmonary shunting (improves </div><div>ventilation to perfused areas)</div><div>ii.  Incentive spirometer. Goal volume &gt;1L.</div><div>1.  Maintains Functional Reserve Capacity (FRC)</div><div>2.  Prevents and improves atelectasis</div><div>c.  Bronchial Hygiene Therapy (“Pulmonary Toilet”)</div><div>1.  Purpose: To help loosen and mobilize pulmonary secretions </div><div>2.  Indications: mobilization of retained secretions, atelectasis, optimize </div><div>delivery of bronchodilators</div><div>3.  Contraindications: hemodynamic instability, recent facial/oral/cranial </div><div></div><div>active hemoptysis, nausea/vomiting, radiographic evidence of bled/</div><div>bullae, fractured ribs or unstable chest, untreated pneumothorax, and </div><div>compromised cardiac status or arrhythmias.</div><div>4.  Therapies (may be combined with bronchodilating nebulizers for  </div><div></div><div>Acapella Intrapulmonary Percussive </div><div>Ventilation (IPV)</div><div>Chest Physiotherapy (CPT)</div><div>A resistive/vibratory device </div><div>that is used to open the </div><div>airways and provide </div><div>oscillating vibrations to help </div><div>loosen secretions</div><div>Pneumatic device that </div><div>delivers pressurized </div><div>minibursts of gas at rates of </div><div>100-225 cycles per minute </div><div>through a mouthpiece to </div><div>achieve alveolar recruitment</div><div>Technique that uses manual </div><div>or mechanical external </div><div>percussion and vibration </div><div>to loosen secretions and </div><div>promote clearance</div><div>Sources:</div><div></div><div>UK: Wiley-Blackwell</div><div>Adams, G. (2006). On Call Surgery, 3rd Edition. Philadelphia, PA: Saunders Elsevier</div><div>Marino, P. (2009). The Little ICU Book. Philadelphia, PA: Lippincott Williams &amp; Wilkins</div><div>GI: ACUTE HEPATIC DYSFUNCTION</div><div>About 25% of patients will develop transient hyperbilirubinemia aer open heart </div><div>surgery, but fewer than 1% of patients will have signicant hepatocellular damage </div><div>leading to chronic hepatitis or liver failure</div><div>1.  Risk Factors</div><div>a.  Preexisting liver disease: </div><div>i.  Elevated liver enzymes (AST/ALT), elevated bilirubin, or evidence of </div><div>synthetic dysfunction (low albumin, high INR)</div><div>ii.  Elevated bilirubin in patient w/hx CHF is strongest predictor of post-op </div><div>liver dysfunction</div><div>b.  Comorbidities: CHF (high right sided pressure leading to congestive </div><div>hepatomegaly), DM, HTN</div><div>c.  Preoperative cardiogenic shock: may have evidence of “shock liver” prior </div><div>to surgery</div><div>d.  Operative risk factors:</div><div>i.  Long cardiopulmonary bypass time</div><div>ii.  Complex operations (ie combined CABG-valve, multiple valves)</div><div>iii. Multiple blood transfusions</div><div>e.  Post-operative risk factors</div><div>i.  Low cardiac output syndrome</div><div>ii.  Use of multiple inotropes/IABP</div><div>II.  Etiology: may result from either decreased liver perfusion or systemic </div><div>congestion</div><div>Hepatocellular Necrosis Hyperbilirubinemia</div><div> </div><div>Low cardiac output states (requiring </div><div>inotropes/vasopressors) </div><div> decreased </div><div>hepatic perfusion</div><div> </div><div>Right heart failure/severe TR </div><div>chronic passive hepatic congestion</div><div> </div><div>Medications (Tylenol, Plavix, statins)</div><div> </div><div>Post-transfusion hepatitis/CMV (late </div><div>manifestation)</div><div> </div><div>Hemolysis (paravalvular leak, long </div><div>pump run, sepsis, multiple transfusions, </div><div>ECMO, drugs)</div><div> </div><div>Intrahepatic cholestasis (hepatitis, </div><div>hepatocellular necrosis, TPN, bacterial </div><div>infections, medications, benign </div><div>cholestasis)</div><div> </div><div>Extrahepatic congestion (biliary tract </div><div>obstruction)</div></div><div></div></div>
<div><div><img><div>70 Post-Op Management Post-Op Management 71</div><div>2.  Clinical manifestations</div><div>a.  Jaundice</div><div>b.  Coagulopathy</div><div>c.  Refractory acidosis</div><div>d.  Hypoglycemia</div><div>e.  Renal failure (hepatorenal syndrome)</div><div>f.  Encephalopathy</div><div>3.  Work-up: in addition to basic labs/LFT’s consider further investigation with the </div><div>following</div><div>a.  Order Total and Fractionated bilirubin: </div><div>i.  Mostly Conjugated (Direct): biliary obstruction (stone, mass, PSC) or </div><div>cholestasis (sepsis/hypoperfusion states, cholestasis, TPN)</div><div>ii.  Mostly Unconjugated (Indirect): hemolysis, hepatic congestion/</div><div>decreased bili uptake (heart failure)</div><div>b.  Assess for hemolysis: LDH, haptoglobin, plasma free hemoblogin, </div><div>reticulocyte count</div><div>c.  Assess for right heart failure/ </div><div>TR: echo</div><div>d.  Assess for biliary obstruction/cholecystitis: Alk Phos, right upper </div><div></div><div>i.  Acute Cholecystitis: gall bladder wall thickening, stranding, </div><div></div><div>ii.  Stone/obstruction: stone, ductal dilitation</div><div>e.  Review medications for hepatotoxicity</div><div>f.  Assess for acute hepatitis: hepatitis panel</div><div>g.  Assess for synthetic dysfunction: coag panel, albumin, glucose, lactate</div><div>h.  Assess for encephalopathy: exam, ammonia level</div><div>4.  Management: elevated bilirubin usually benign and self-limited post-operative </div><div>occurrence. Will gradually improve with normal hemodynamics unless severe </div><div>underlying liver pathology is present</div><div>a.  Address underlying cause</div><div>i.  Right heart failure/TR: Refer to “Right Heart Failure” section</div><div>ii.  Bilary obstruction, consider:</div><div>1.  ERCP/MRCP: for stone in common bile duct w/acute cholangitis (GI </div><div>medicine consult)</div><div>2.  Percutaneous cholecystostomy tube (placed by IR)</div><div>3.  Cholecystectomy (General surgery consult)</div><div>b.  Monitor and treat hypoglycemia</div><div>c.  Judicious reversal of coagulopathy if present</div><div>d.  Avoid hepatotoxic medications</div><div>e.  If Ammonia elevated and evidence of encephalopathy: consider </div><div>Lactulose 30 Q8</div><div>f.  Monitor for lactic acidosis (impaired lactate metabolism) and correct pH </div><div>with sodium bicarb when indicated</div><div>Sources:</div><div></div><div>UK: Wiley-Blackwell</div><div>Roy-Chowdhury, N. Diagnostic approach to the adult with jaundice or asymptomatic </div><div>hyperbilirubinemia. www.uptodate.com</div><div>GI: CONSTIPATION AND ILLEUS</div><div>Cardiac Surgery Post-Operative Bowel regimen:</div><div>Medication Dose Frequency Onset of Action</div><div>Docusate (Colace)  200mg PO BID 24-72 hours</div><div>Polyethylene Glycol (Miralax) 17g Packet Daily 1-4 days</div><div>Senna (Senokot) 2 tabs PO qHS PRN 6-12 hours</div><div>Bisacodyl (Dulcolax) Suppository 10mg Rectal Daily PRN 15-60 minutes</div><div>Magnesium hydroxide (MOM) 30mL Oral Q8 hours PRN</div><div>Magnesium Citrate 150-300mL Oral Once 30 minutes- 3 hours</div><div>Lactulose 20mg TID Up to 24 -48 hours</div><div>Stanford BOMB Sterile water for </div><div>irrigation 300mL, </div><div>magnesium citrate </div><div>200mL, Glucerin Bulk </div><div>100% 199mL</div><div>Once Immediate</div><div> </div><div>*For VAD bowel regimen protocol see reference materials VAD BOWEL REGIMEN </div><div>page 138.</div><div>Ileus Management:</div><div> </div><div>Management of ileus starts with correction of underlying medical conditions, </div><div>such as sepsis, electrolyte abnormalities, particularly hypokalemia, </div><div>hyponatremia, and hypomagnesemia. </div><div> </div><div>Consider need for NG or rectal tube for decompression. For severe illeus- </div><div>consider consult to general surgery or GI. </div><div> </div><div>Bowel regimen for ileus management can include BID suppository/enema. </div><div>DO NOT USE PERISTALTIC AGENTS FOR ILLEUS MANAGEMENT. </div><div> </div><div>For protracted ileus, contrast studies may be required to rule out mechanical </div><div>obstruction.</div><div> </div><div>Discontinue and limit the use of medications that produce ileus (eg, opiates, </div><div>narcotics), and use (NSAIDs) instead (unless contraindicated). </div><div> </div><div>Advisable to delay oral feeding until ileus resolves clinically. Consider need </div><div></div><div> </div><div>Most cases of postoperative ileus resolve with watchful waiting and </div><div>supportive treatment. </div><div>see page 91.</div><div>GI: POST-OPERATIVE GI BLEEDING</div><div>1.  Upper GIB: may present as hematemesis, bloody NG/OG tube output, or melena </div><div>a.  Most commonly from: </div><div>i.  Stress ulcers (peptic, duodenal, gastric)</div><div>ii.  Esophagogastritis</div><div>b.  </div><div>reperfusion injury and increased gastric acidity from any of the following:</div><div> </div><div> </div><div>3.  Low cardiac output states</div></div><div></div></div>
<div><div><img><div>72 Post-Op Management Post-Op Management 73</div><div>4.  Critical illness</div><div>c.  Risk Factors</div><div>i.  Pre-operative: older age, history if PUD/GERD</div><div>ii.  Intra-operative: long duration of CPB, valve operations, re-operations</div><div>iii. Post-operative: low CO, prolonged mechanical ventilation (&gt;48 hours), </div><div>coagulopathy, anticoagulation, anti-platelet therapy</div><div>d.  Preventative measures</div><div> </div><div>mucosa that helps maintain mucosal structural and functional </div><div>integrity </div><div>ii.  Acid suppression</div><div>1. Indications for stress ulcer prophylaxis</div><div> </div><div>echanical ventilation for </div><div>&gt;48 hours</div><div> </div><div>Spinal cord injury</div><div> </div><div>Use of 2 anti-plt agents </div><div>(Plavix, ASA, cilostazol, </div><div>ticagrelor, dipyridamole)</div><div> </div><div>Coagulopathy (Plt &lt;50, INR </div><div>&gt;1.5, or PTT 2x baseline)</div><div> </div><div>Solid organ transplant in </div><div>ICU setting</div><div> </div><div>Any 2 of the following:</div><div> Sepsis</div><div> ICU stay &gt;7 days</div><div> Occult bleed lasting &gt;6 days</div><div> High dose steroids w/daily dose </div><div> </div><div> &gt;250mg hydrocortisone</div><div> </div><div> &gt;50mg </div><div>methylprednisolone</div><div> </div><div>&gt;60mg prednisone</div><div> </div><div>&gt;10mg dexamethasone</div><div> </div><div>Hx GERD/GI ulcers/acid suppressant </div><div>therapy</div><div>2. Proton pump inhibitors (PPI’s):</div><div>H2 blockers in reducing incidence of hemorrhagic gastritis and </div><div>ulceration</div><div>a.  Pantoprazole 40mg IV/PO daily</div><div>b.  Use is not without risk!</div><div> </div><div> ii.  PPI use is independent risk factor for nosocomial PNA</div><div> iii.  May cause hypomagnasemia</div><div>3. H2 Blockers: </div><div>a.  Famotidine 20mg IV Q12</div><div>b.  Associated with thrombocytopenia</div><div>e.  Treatment considerations:</div><div> </div><div>1. Correct coagulopathy when indicated</div><div>2. Consider DDAVP for suspected platelet dysfunction if uremia is present</div><div>3. Transfuse blood if hemodynamically unstable </div><div>ii.  Monitor vital signs for shock. Assess volume status</div><div>iii. Flush NG/OG tube if present</div><div>iv. If bleeding continues, patient is hemodynamically unstable and/or </div><div>there is an inappropriate response to blood transfusion consider </div><div>GI consult for EGD (esophagogastroduodenoscopy)</div><div> </div><div></div><div>vi. Acid suppression (treatment dosing):</div><div>1. Pepcid 20mg IV q8</div><div>2. Protonix 80mg IV push + continuous infusion 8mg/hr </div><div>2.  Lower GIB: dark to bright red blood from the rectum. Color of blood is </div><div>associated with the length of time in the GI tract</div><div>a.  Etiologies: </div><div>i.  Hemorrhoids</div><div>ii.  Mesenteric ischemia/ischemic colitis</div><div>1.  Periods of prolonged hypoperfusion from</div><div>a.  Low cardiac output state</div><div>b.  Atherosclerotic embolism or mesenteric thrombosis</div><div>2.  May present as profound ileus, abdominal pain out of proportion </div><div>3.  May be associated with elevated lactate, GIB, sepsis (bacterial </div><div>translocation)</div><div>iii. Diverticulosis</div><div>iv. Arteriovenous malformations (AVM’s): See LVAD post-operative </div><div>considerations</div><div>v.  Ulceration/tissue breakdown from rectal tube</div><div>b.  Work up:</div><div>i.  Examine patient looking for hemorrhoid or tissue breakdown</div><div>ii.  Consider placing NG/OG tube to assess for presence of upper GIB</div><div>iii. </div><div>1. Correct coagulopathy when indicated</div><div>2. Consider DDAVP for suspected platelet dysfunction if uremia is </div><div>present</div><div>3. Transfuse blood if hemodynamically unstable </div><div>iv. If bleeding continues, patient is hemodynamically unstable and/or </div><div>there is an inappropriate response to blood transfusion consider </div><div>GI consult for EGD and/or sigmoidoscopy/colonoscopy </div><div>1.  If these are negative, source may be small bowel</div><div>v.  KUB/CT scan to assess for evidence of ischemic bowel</div><div>1.  Pneumotosis (air in the bowel wall), venous gas, bowel wall </div><div>thickening</div><div> </div><div>vi. Radionuclide scanning (ie tagged RBC scan) to localize source of bleed</div><div>vii. Angiography: </div><div>1.  May be diagnostic and therapeutic if bleeding can be localized</div><div> </div><div>detection</div><div>Sources:</div><div></div><div>UK: Wiley-Blackwell</div><div>Adams, G. (2006). On Call Surgery, 3rd Edition. Philadelphia, PA: Saunders Elsevier</div><div>Marino, P. (2009). The Little ICU Book. Philadelphia, PA: Lippincott Williams &amp; Wilkins</div><div>GI: MALNUTRITION (TUBE FEEDING/TPN)</div><div>Tube Feeding: </div><div> </div><div>Consult with dietician to evaluate adequate oral intake vs need for tube </div><div>feeding.</div><div> </div><div>Use IP GEN Tube Feeding order set to place the following orders:</div><div> Consult to nutrition </div><div> Place KOF (Small bore feeding tube)</div><div> </div><div>If Feeding tube placed via super user RN with Cortrak, no need for KUB </div></div><div></div></div>
<div><div><img><div>74 Post-Op Management Post-Op Management 75</div><div>to evaluate location</div><div> </div><div>If feeding tube is placed without use of Cortrak, obtain KUB to ensure tip </div><div>of feeding tube is post pyloric</div><div> </div><div>If feeding tube is unable to be placed post pyloric, consider use of </div><div>Reglan to promote motility. </div><div> </div><div>In some cases, trickle tube feeds may be started while the tip </div><div>of feeding tube is in the stomach (beware of increased risk of </div><div>aspiration)</div><div> Tube feeds are typically started @ 20cc/hr and increased by 20 q8 hours </div><div>until goal rate is achieved. (Trickle or trophic TF rate 10-20cc/hr)</div><div> Obtain daily labs: CMP, Phos, Mag, Pre albumin (3x weekly)</div><div> Glucose management via subQ insulin (Glucose checks q6) or insulin drip </div><div>TPN= Total parenteral nutrition </div><div> </div><div></div><div>Prolonged ileus. Consult with dietician to assess nutrition needs. </div><div> </div><div>Needs central access (TPN is administered via dedicated line), consider need </div><div>for PICC line placement. </div><div> </div><div>TPN must be ordered by 1400.  Use IP GEN TPN/PPN Adult Protocol order set  </div><div>to place the following orders</div><div> Consult to nutrition  </div><div> PICC Line placement if needed for adequate access</div><div> TPN + Lipids</div><div> Obtain daily labs: CMP, Phos, Mag, Triglycerides</div><div> Glucose control via insulin placed in TPN mixture or Insulin drip (some </div><div>patients may require both)</div><div> </div><div></div><div>dysturbances, loss of gut barrier, acalculus cholecystitis, refeeding syndrome, </div><div>&amp;  hyperosmolality</div><div>GU/FEN: ACID BASE DISTURBANCES </div><div>The normal buering systems of the body (bicarbonate, hemoglobin, phosphate, </div><div>and protein) are frequently overwhelmed by disease states or altered from the </div><div>eects of cardiopulmonary bypass.</div><div>reference see page 124.</div><div>Metabolic Acidosis: </div><div>accumulation of acids in the serum. </div><div>1.  Anion Gap = Na – (Cl + HCO3).  Normal AG 8-12 mmol/L. </div><div>a.  Correct for hypoalbuminemia.  AG + (2.5 x (4-albumin)).   </div><div>Elevated AG &gt; 13 mmol/L</div><div>High Anion Gap Acidosis Normal Anion Gap Acidosis</div><div> </div><div>Lactic acidosis (see below)</div><div> </div><div>Renal failure (reduced acid </div><div>secretion)</div><div> </div><div>Rhabdomyolysis</div><div> </div><div>Medications (ASA, ethylene, </div><div>methanol)</div><div> </div><div>Ketoacidosis</div><div> </div><div>Diarrhea (high bicarb loss)</div><div> </div><div>Renal Tubular Acidosis (loss of bicarb </div><div>resorption)</div><div> </div><div>Carbonic anhydrase inhibitors (ie Diamox, </div><div>increased bicarb secretion by kidneys)</div><div> </div><div>Hyperchloremia (increased HCl acid in </div><div>blood)</div><div> </div><div>Blood transfusions (addition of aci</div><div>2.  Lactic acidosis</div><div>a.  Type A: Impaired tissue oxygenation and anaerobic metabolism from </div><div>circulatory failure </div><div>i.  ICU, immediate post-op considerations—May be result of:</div><div>1.  Pre-existing renal dysfunction</div><div>2.  Long pump runs</div><div>3.  Intraoperative vasopressor use</div><div>4.  Inadequate O2 delivery during bypass that contributes to </div><div>splanchnic and renal ischemia with acidosis perpetuated by a low </div><div>cardiac output syndrome</div><div>ii.  Several days post-op—May be result of:</div><div>1.  Mesenteric ischemia</div><div>2.  Sepsis</div><div>3.  Acute hepatic dysfunction (decreased lactate utilization)</div><div>4.  Low cardiac output state, malperfusion</div><div>b.  Type B: Not associated with tissue hypoxia. Low-dose Epinephrine </div><div></div><div>acid production. </div><div>i.  Not commonly seen</div><div>ii.  Consider when cardiac output is adequate and lactic acidosis seems </div><div>out of proportion with tissue perfusion</div><div>3.  Adverse Eects of Acidosis: typically do not occur until pH is &lt; 7.2</div><div>a.  Cardiovascular: </div><div>i.  Decreased contractility and cardiac output, decreased liver and renal </div><div>perfusion</div><div> </div><div>iii. Increased Pulmonary Vascular Resistance (may lead to Right heart </div><div>failure)</div><div></div><div>decreased SVR</div><div>v.  Increased risk of ventricular arrhythmias</div><div>b.  Respiratory:</div><div>i.  Decreased respiratory muscle strength</div><div>ii.  Dyspnea/tachypnea from compensatory mechanism</div><div>c.  Metabolic:</div><div>i.  Hyperglycemia (tissue insulin resistance)</div><div>ii.  Hyperkalemia</div><div>d.  Neurologic:</div><div>i.  Inhibition of brain metabolism</div><div>ii.  Obtundation/coma</div><div>4.  Treatment of Metabolic Acidosis</div><div>a.  Identify and treat the underlying cause</div><div>i.  Assess tissue perfusion and cardiac output: VBG/SvO2, Echo, PA </div><div>catheter CO/CI</div><div> </div><div>iii. Assess for mesenteric ischemia: lactate, abdominal exam, KUB/CT</div><div>iv. Assess for sepsis: CBC, pro-calcitonin, cultures, fever curve</div><div>b.  Bicarbonate supplementation</div><div>i.  Normalizing pH may improve cardiac function, improve </div><div></div><div>ii.  Goal is to raise the pH, not to correct bicarbonate levels</div><div>iii. Keep in mind that IV Sodium bicarb may result in:</div><div>1.  Hypernatremia—monitor serial labs, consider D5W/free water </div><div>supplementation</div></div><div></div></div>
<div><div><img><div>76 Post-Op Management Post-Op Management 77</div><div>2.  Fluid overload from hyperosmolarity—monitor CVP/exam, diurese </div><div>when appropriate</div><div> </div><div>SvO2</div><div>4.  Increased CO2 production from metabolism of bicarbonate</div><div>a.  May result in respiratory acidosis if patient not adequately </div><div>ventilated</div><div>b.  Monitor ABG, increase respiratory rate on ventilator if able</div><div>Respiratory Acidosis</div><div>1.  Common etiologies: accumulation of CO2 in blood due to hypoventilation</div><div>a.  Medications: narcotics, benzodiazepines, residual anesthesia, paralytics</div><div>b.  Stroke/intracranial bleed</div><div>c.  Acute airway obstruction: sleep apnea, aspiration</div><div>d.  Hx parenchymal lung disease (O2 delivery may decrease respiratory </div><div>drive): COPD</div><div>e.  Splinting/Limit of inspiration due to pain</div><div>f.  Pneumothorax</div><div>Management:</div><div>a.  Treat reversible causes: obtain CXR, consider head CT for acutely altered </div><div>mental status</div><div>b.  Consider Narcan for narcotic overdose: Narcan 0.1-0.2 mg q2 minutes </div><div>for partial reversal</div><div>c.  umazenil 0.2mg IV q30 </div><div>seconds-1min</div><div>d.  Treat hypoventilation</div><div>i.  BiPap support ventilation (See Respiratory Care under references)</div><div>ii.  Consider intubation </div><div>Metabolic Alkalosis</div><div>1.  Common etiologies:</div><div>a.  Excessive diuresis leading to</div><div>i.  Potassium loss: directly increases bicarb resorption</div><div>ii.  Depletion of H+ ions and Chloride (acid loss)</div><div>iii. “Contraction alkalosis” = Hypovolemia: stimulates aldosterone </div><div></div><div>increased bicarb resorption</div><div>b.  Acid loss from high NG tube output/emesis</div><div>c.  Sub-Acute/Chronic respiratory acidosis: renal response to chronic </div><div>acidosis (ie increased bicarbonate synthesis) takes 12 hours to become </div><div>apparent and is maximum at 3-5 days</div><div>d.  Excessive bicarbonate administration, or administration of agents </div><div>metabolized to bicarb </div><div>i.  Citrate (in blood products) may result in metabolic alkalosis</div><div>ii.  Lactate (in LR)</div><div>2.  Adverse Eects of Alkalosis (pH &gt;7.45)</div><div>a.  </div><div>b.  </div><div>acidosis)</div><div>c.  </div><div>d.  </div><div>potential hypoxia</div><div>3.  Treatment of Acute Metabolic Alkalosis</div><div>a.  </div><div>b.  Gastris losses: acid suppressant therapy (H2 blockers or PPI’s)</div><div>c.  Patients with total body water overload (ie post-operative or CHF) </div><div>consider:</div><div>i.  Diamox (acetazolamide): carbonic anhydrase inhibitor that inhibits </div><div>bicarbonate resorption in proximal tubule</div><div>1.  Weak diuretic when used alone</div><div>2.  Consider use in conjunction with loop diuretic</div><div>ii.  K-sparing diuretic (spironolactone/eplerenone)</div><div>Respiratory Alkalosis</div><div>1.  Common Etiologies: decreased CO2 in blood stream due to hypoventilation</div><div>a.  Hypoxia (increased respiratory drive)</div><div>b.  Anxiety</div><div>c.  Pain</div><div>d.  Fever/infection/sepsis</div><div>2.   Management: treat underlying cause  </div><div>Sources: </div><div></div><div>UK: Wiley-Blackwell</div><div>Adams, G. (2006). On Call Surgery, 3rd Edition. Philadelphia, PA: Saunders Elsevier </div><div>GU/FEN: KIDNEY DISEASE</div><div>Acute Kidney Injury</div><div>Denition:</div><div> </div><div>Increase in serum creatinine by 0.3mg/dL or more within 48 hours  </div><div>or</div><div> </div><div>Increase in serum creatinine to 1.5 times baseline or more within the last 7 days  </div><div>or</div><div> </div><div>Urine output less than 0.5 mL/kg/h for 6 hours</div><div>Cause:</div><div> </div><div></div><div>hypotension, hypovolemic, HF, renal artery stenosis, renal vein thrombosis, </div><div>Cardiac tamponade</div><div> </div><div>due to</div><div> </div><div></div><div> </div><div></div><div> </div><div></div><div> </div><div>Intra Renal: Problems with the kidney itself, ATN/AIN</div><div> </div><div>Postrenal:</div><div>kidney stone, BPH, obstructed urinary catheter etc; a bladder scan or a post </div><div>void residual to rule out urinary retention</div><div>Diagnosis:</div><div> </div><div></div><div> </div><div>Urinalysis: presence of protein (albumin), hemoglobin, granular casts, or </div><div>epithelial cell casts may indicate AKI</div><div> </div><div>Urine sodium:</div><div> FENa:</div><div>an oliguric patient (not accurate if patient has received recent diuretic </div><div>therapy) </div><div>FENa, % = (UNA x SCr/ SNA X UCr) x 100 </div><div>  FENa &lt; 1 = pre renal disease </div><div>  FENa &gt; 2 = ATN </div></div><div></div></div>
<div><div><img><div>78 Post-Op Management Post-Op Management 79</div><div> FEU-rea (used for patient who have received recent diuretic therapy) </div><div>FEU-rea, % = ((SCr x Urine Urea) x 100)) / BUN x Urine Creatinine </div><div>  FEU-rea &lt; 35% = pre renal disease </div><div>  FEU-rea &gt; 50% = ATN</div><div> </div><div>Oliguria: &lt; 0.3ml/kg per hour or &lt; 500mL/day of urine output</div><div> </div><div>Anuria: </div><div> </div><div>Renal US: evaluate for urinary tract obstruction, renal mass, and kidney size </div><div>(diagnosis hydronephrosis)</div><div>Treatment: </div><div> </div><div> Focused on removing the cause of the kidney injury/ failure. </div><div> Discontinue nephrotoxic medications (NSAIDS, Iodinated contrast, </div><div>metformin, some antibiotics such as gentamicin.)</div><div> Correct low BP or use inotropic meds to increase heart function to </div><div>provide good renal perfusion </div><div> Avoid IV contrast if possible while creatinine is still up trending</div><div> Correct urinary tract obstruction if present (ie insertion of foley catheter)</div><div> </div><div>Continue to trend creatinine and electrolytes closely (cautious electrolyte </div><div>replacement)</div><div> </div><div>Monitor volume status closely to ensure adequate hydration without volume </div><div>overload  </div><div> Diuretics may be used for a limited period to relive signs and symptoms </div><div>of volume overload. </div><div> </div><div> </div><div>Indications for dialysis: (consult renal) A-E-I-O-U! </div><div> A: Acidosis (pH &lt; 7.1 in those that cannot tolerate correction with sodium </div><div>bicarb)</div><div> E: Electrolyte Disturbances (ie. Hyperkalemia when k &gt; 6.5 and refractory </div><div>to medical management)</div><div> I: Ingestion/Intoxication</div><div> O: Overload. (Refractory to diuretics)</div><div> U: Uremia (altered mental status, uremic platelets)</div><div>Chronic Kidney Disease  </div><div>Denition:</div><div>Stage Description </div><div>Stage I With normal of high GFR (GFR &gt; 90mL/min)</div><div>Stage II Mild CKD (GFR = 60-89mL/min)</div><div>Stage IIIa Moderate CKD (GFR = 45-59mL/min)</div><div>Stage IIIb Moderate CKD (GFR = 30-44mL/min)</div><div>Stage IV Severe CKD (GFR = 15-29mL/min)</div><div>Stage V End Stage CKD (GFR &lt; 15mL/min)</div><div>Always document stage 3 ckd or higher in h&amp;p, progress notes, and </div><div>discharge summary</div><div>Post op management: </div><div> </div><div>Monitor post op creatinine closely. Not uncommon to see rising creatinine </div><div>in the initial post op period (Acute on Chronic Kidney Injury) but creatinine </div><div>should return to baseline by discharge if managed properly </div><div> Ensure adequate blood pressure for renal perfusion</div><div> Avoid nephrotoxic agents (NSAIDs, metformin, certain antibiotics)</div><div>References: </div><div>Okusa, M.D., Palevsky, P.M., &amp; Scheidan, A.M. (2016). Overview of the management of acute kidney injury </div><div>(acute renal failure). Up to date. </div><div>GU/FEN:SODIUM IMBALANCES</div><div>HYPERNATREMIA, serum NA &gt;145</div><div> </div><div>Etiologies:</div><div> Tube feeding due to lack of free water</div><div> Excessive water loss from diuresis or diarrhea</div><div> Salt loading from medications (saline drips, sodium bicarb, albumin)</div><div> </div><div>To treat</div><div> Add free water to tube feed formula in divided doses (ie 200mL q6h)</div><div> Add D5W infusion</div><div> And/or encourage water intake if able to take PO</div><div> </div><div></div><div> </div><div>Determine Rate of Correction</div><div> Chronic Hypernatremia: present for &gt;48 hours</div><div> </div><div>Correct Sodium by NO MORE THAN 10-12mEq/day</div><div> </div><div>Rapid correction—at risk for cerebral edema (encephalopathy, </div><div>lethargy, seizures)</div><div> Acute Hypernatremia: present for &lt; 48 hours</div><div> </div><div>Correct Sodium to normal over 24 hours</div><div> </div><div>Monitor serum sodium frequently and adjust free water intake as necessary </div><div>HYPONATREMIA, serum NA &lt;135 </div><div>[mild 130-135, moderate 120-129, severe &lt;120]</div><div> </div><div>Need to determine type of hyponatremia:</div><div> Hypervolemic: Na dilution from excessive total body water</div><div> </div><div>Volume overload, CHF, cirrhosis</div><div> Hypovolemic: Na and/or water loss</div><div> </div><div>Diarrhea, thiazide diuretics</div><div> Normovolemic hyponatremia </div><div> </div><div>Low salt intake, SIADH: syndrome of inappropriate antidiuretic </div><div>hormone (Dx of exclusion)</div><div> </div><div>Low serum sodium in our postop patients usually indicates total body water </div><div>overload (hypervolemic hyponatremia)</div><div> </div><div>In our patient population, most of concern when Na &lt;130. Otherwise usually </div><div>just monitor</div><div> </div><div>Symptoms help determine need to treat (ie headache, nausea, vomiting, </div><div>fatigue, gait disturbances, and confusion)</div><div> </div><div>Aim to correct serum Sodium by 4-6mEq/day, no more than 8mEq/day</div><div> </div><div>Risk of rapid correction: osmotic demyelination </div><div> </div><div></div><div> </div><div>If on IV medications, consider giving them in NS versus the standing D5W – </div><div>will need to discuss this with the pharmacy</div><div> If euvomic/hypovolemic hyponatremia: also consider giving salt tablets </div><div>three times daily with meals.</div><div> Also can treat with hypertonic 3% saline. If have to go this route, consult </div><div>nephrology. </div><div> </div><div>Monitor serum sodium frequently</div><div> </div></div><div></div></div>
<div><div><img><div>80 Post-Op Management Post-Op Management 81</div><div>HEMATOLOGY: ACUTE BLOOD LOSS ANEMIA AND </div><div>POST-OPERATIVE BLEEDING</div><div>Acute blood loss anemia and bleeding are expected aer cardiac surgery </div><div>(especially for cases on cardiopulmonary bypass)</div><div>Contributing factors to post op bleeding: </div><div>Platelets</div><div>Hemodilution occurs when the circuit is primed and this alone can reduce </div><div>platelets by 30-50% (Bojar, 2011).  And the longer a patient is on bypass, the more </div><div></div><div>mechanical stress of going through the circuit, as well.</div><div>Heparinization: </div><div>protamine itself can will transiently reduce the platelet count by about 30%.  </div><div></div><div>on board.  HIT always becomes a concern in a patient who is thrombocytopenic </div><div>and has received heparin.  This is an even higher risk in pts who have been on </div><div>heparin gtts prior to going into surgery and should be evaluated by testing for </div><div>antibodies if the patient is showing signs of both bleeding and clotting. (For more </div><div>information on HIT see page *** Section IV &gt; 6 &gt; 3. HIT)</div><div>Fibrinolysis: </div><div>extent can be evaluated using aPTT, INR and D-Dimer but those are very non-</div><div></div><div>Incomplete surgical hemostasis: with accompanying chest wall bleeding or </div><div></div><div>anyone with friable tissues.</div><div>Preop medications can also play a role in postop bleeding.  Any patient who’s </div><div>had ASA in the last 7 days will have circulating platelets that are no longer </div><div></div><div>fondiparanux within 48hrs prior to surgery may have worse postop bleeding since </div><div>neither can be completely reversed with heparin. </div><div>Managing a bleeding patient:  </div><div>Chest Tubes</div><div> </div><div>Milk tubes as needed </div><div> </div><div>Careful assessment of hourly output</div><div>Warm patient</div><div> </div><div>Hypothermia causes impaired platelet function and suppression of </div><div>coagulation cascade</div><div> </div><div>Active warming may be contraindicated in some patients</div><div>Control HTN</div><div> </div><div>SNP, NTG, nicardipine, etc.</div><div>Sedation/Pain Control</div><div> </div><div>Continue sedation/analgesia until bleeding slows and patient is stable for </div><div>weaning/extubation</div><div>Re-Exploration</div><div> </div><div>Consider re-exploration for</div><div> &gt;400ml/hr x 1hr</div><div> &gt;300ml/hr x 2-3hrs</div><div> &gt;200ml/hr x 4 hrs</div><div>Always consider Cardiac Tamponade as a dierential diagnosis, especially in the </div><div>immediate post-operative period. For more information on pericardial tamponade </div><div>see see page 59.</div><div>Lab Values to monitor:</div><div>PT/INR</div><div> </div><div></div><div> </div><div></div><div> </div><div>Treat elevated INR with FFP</div><div>PTT</div><div> </div><div></div><div> </div><div>If elevated PTT in isolation or with slight elevation in INR consider treatment </div><div>with Protamine </div><div>Platelet Count</div><div> </div><div>CPB can decrease platelet count as well as cause platelet dysfunction</div><div> </div><div>Consider platelet transfusion in bleeding patient with platelet &lt;100k or if </div><div>patients were taking ASA , Plavix, or IIB/IIIA inhibitors pre-op or are uremic</div><div>Fibrinogen</div><div> </div><div>Promotes platelet aggregation and enhances platelet adhesion to the </div><div>endothelium</div><div> </div><div>Consider transfusion of cryo if Fibrinogen &lt;100 in bleeding patient</div><div>TEG</div><div>For TEG interpretation see page 83.</div><div>Blood Products/Transfusion Threshold</div><div>PRBCs</div><div> </div><div>Clarify transfusion threshold with surgeon</div><div> </div><div>Consider maintaining Hct  ~25 in an actively bleeding patient</div><div> </div><div>Each unit should increase Hct by ~3%</div><div>CellSaver</div><div> </div><div>May contain a small amount of heparin but is devoid of clotting factors</div><div> </div><div></div><div>Platelets</div><div> </div><div>Each unit should increase platelet count by ~42-60k per 6-pk</div><div>FFP</div><div> </div><div>Contains all clotting factors</div><div> </div><div>4 units of FFP will increase clotting factors by~10%</div><div>Cryoprecipitate</div><div> </div><div></div><div> </div><div></div><div> </div><div></div><div>Medications</div><div>Protamine</div><div> </div><div>Given for elevated PTT d/t residual heparin or release of heparin from tissue </div><div>stores</div><div> </div><div>25-50mg</div><div> </div><div>Half-life 5min, elimination from blood stream in 20-30min</div><div> </div><div>Excessive use of Protamine may increase ACT, cause platelet dysfunction, </div><div></div></div><div></div></div>
<div><div><img><div>82 Post-Op Management Post-Op Management 83</div><div>DDAVP</div><div> </div><div>Increases the levels of certain factors (VIII precursors, von Wildebrand’s, </div><div>tissue-type plasminogen activator)</div><div> </div><div></div><div> </div><div>Can cause hypotension and peripheral vasodilatation</div><div>Feiba</div><div> </div><div>Factor Eight Inhibitor Bypassing Activity</div><div> </div><div>Developed to treat bleeding in pts with Hemophilia A/B. </div><div> </div><div></div><div></div><div> </div><div></div><div>mostly when pts are given &gt;200units/kg/day.  </div><div> </div><div>Start with a quarter dose, or 250 units, up to a full dose of 1000 units for </div><div>severe bleeding.  </div><div> </div><div>FEIBA is made from human plasma, so the same risk of transmission of </div><div>infectious disease is present as when you are giving blood products. </div><div> </div><div>Novo Seven</div><div> </div><div>Promotes localized hemostasis at site of tissue injury and improves INR</div><div> </div><div>Can cause systemic thrombosis</div><div>Imaging</div><div>CXR</div><div> </div><div></div><div>indicative of clot around the great vessels</div><div>Echo</div><div> </div><div>TTE or TEE </div><div>Stable acute blood loss anemia</div><div> </div><div></div><div>like “Expected acute blood loss anemia”</div><div> </div><div>Cont to monitor H/H daily or every other day. H/H usually returns to patients </div><div></div><div> </div><div>Treatment: (once able to tolerate PO medications)</div><div> Ferrous Sulfate, Slow FE 140mg PO BID</div><div> Vitamin C 500mg PO BID</div><div> Consider need for epogen injection for severe anemia</div><div> Oral Iron and Vit C are usually continued for 1 month post operatively </div><div>HEMATOLOGY: TEG</div><div>TEG® Clot phase Normal Values Abnormalities Treatment</div><div>R Time Clot initiation</div><div></div><div>4.6 - 8.8 min </div><div>Shortened in hypercoagulable states.</div><div>Increased R time </div><div>= FFP</div><div>K Clot Kinetics</div><div>Time taken to achieve a certain level of clot strength</div><div>1.2 - 2.4 min </div><div>and platelet dysfunction.</div><div>Alpha </div><div>Angle</div><div>Clot Kinetics</div><div></div><div>takes place ( rate of clot formation)</div><div>57.7 - 72.9 deg </div><div>thrombocytopenia, and platelet dysfunction.</div><div>Decreased Angle </div><div>= Cryo</div><div>MA Clot Strength</div><div>Maximal clot strength achieved via GP IIb/IIIa-</div><div></div><div>59.3 - 76.5 mm </div><div></div><div>thrombocytopenia</div><div>Decreased MA = </div><div>Platelets</div><div>G Clot Strength</div><div>Maximal clot strength achieved via GP IIb/IIIa-</div><div></div><div>6.4 - 15.0 k d/</div><div>sec</div><div>Abnormally high in platelet hypercoagulability.</div><div>EPL </div><div>(Estimated </div><div>Percent of </div><div>Lysis)</div><div>Clot Lysis</div><div></div><div>0 - 15 %  Fibrinolysis  = </div><div>Aprotonin or </div><div>Transexamic Acid</div></div><div></div></div>
<div><div><img><div>84 Post-Op Management Post-Op Management 85</div><div>HEMATOLOGY: HEPARIN INDUCED </div><div>THROMBOCYTOPENIA (HIT)</div><div>Epidemiology:</div><div> </div><div>1-5% of adults treated with heparin, and a smaller proportion of those who </div><div>are treated with low-molecular weight heparin, will develop heparin-induced </div><div>thrombocytopenia (HIT).</div><div> </div><div>HIT is associated with a high risk of venous and arterial thrombosis if heparin </div><div>is not withdrawn</div><div>Diagnosis:</div><div> </div><div>The initial signal is a drop in</div><div>noticed, use the 4 T’s score to calculate the likelihood of HIT. </div><div> </div><div>If post op platelet count is low, continue to observe and wait until at least POD </div><div>#3 prior to sending HIT panel</div><div>1.  Thrombocytopenia</div><div> </div><div> </div><div> </div><div>2.  Timing</div><div> </div><div></div><div> </div><div></div><div> </div><div></div><div>3.  Thrombosis</div><div> </div><div> </div><div></div><div> Other causes of thrombocytopenia  </div><div> </div><div> </div><div> </div><div>4.  Other causes of thrombocytopenia: </div><div> </div><div> </div><div> </div><div>Clinical Manifestations</div><div> </div><div>Thrombocytopenia, but rarely with bleeding events</div><div> </div><div>Markedly elevated rate of thromboembolic events (venous &gt; arterial [4:1 </div><div>ratio])</div><div> </div><div></div><div>7 days)</div><div>Diagnosis</div><div> </div><div>HIT functional assay</div><div> </div><div>To order: User HIT panel to order HIT antibody (anti-platelet factor 4 or PF4) </div><div>AND Functional assay</div><div> </div><div>Interpretation:</div><div>0-3 points = Low probability</div><div>4-5 points = Intermediate </div><div>probability</div><div>6-8 points = High probability </div><div> </div><div> If the PF4 results are indeterminate (0.4-2.0), the functional assay may be </div><div> </div><div>We typically sent functional assay at the same time as HIT antibody as </div><div>the functional assay is a send out lab that requires 48-72 hours for results. </div><div>Acute Treatment:</div><div> </div><div>When HIT is suspected, a HIT antibody and functional assay should be sent, </div><div>and all heparin should be discontinued immediately. </div><div> </div><div>An alternative anticoagulant should be started, EVEN IF THERE IS NO OTHER </div><div>REASON FOR ANTICOAGULATION. We typically use Argatroban.</div><div> </div><div>Obtain bilateral LE ultrasounds to rule out occult DVT, which can dictate a </div><div>longer course of anticoagulation (3-6 months if thrombosis present vs &lt; 1 </div><div>month if no thrombosis present)</div><div>Long term treatment</div><div> </div><div></div><div> </div><div></div><div>until platelet recovery (usually greater than 100). Early initiation of coumadin </div><div>has been shown to exacerbate thrombosis and should be avoided. </div><div> </div><div></div><div>be overlapped for 3-5 days. Coumadin should be continued for at least 1 </div><div>month. </div><div> </div><div>As a general rule, patients with documented HIT should not be exposed to </div><div>heparin again.</div><div> </div><div>However, it has been shown that heparin may be used again in patients who </div><div>were previously HIT antibody positive if the patient no longer has a positive </div><div>HIT ELISA antibody titer and the use of heparin is absolutely necessary (ex </div><div>cardiopulmonary bypass) </div><div>References: </div><div>Cuker A &amp; Clines DB. (2012). How I treat heparin induced thrombocytopenia. Blood.  119: 2209-2218. </div><div> </div><div>HEMATOLOGY: DEEP VEIN THROMBOSIS</div><div>Denition:</div><div> </div><div>Condition in which a blood clot (thrombus) forms in a view. The clot can limit </div><div></div><div> </div><div>Thrombus most commonly occurs in the deep veins in the legs, thigh, or </div><div>pelvis (Deep Vein Thrombosis, or DVT)</div><div>Risk Factors: </div><div> </div><div>Obesity, smoking, heart failure, history of previous DVT, immobility, cancer, </div><div>some medications (such as: erythropoietin, birth control pills, hormone </div><div>replacement therapy)</div><div> </div><div>Undergoing a surgical procedure increases risk of DVT development</div><div> </div><div>Diagnosis: </div><div> </div><div>Classis symptoms include: swelling, pain, warmth, and redness of the </div><div></div><div> </div><div>Symptoms are usually asymmetrical. Symmetrical swelling is unlike to </div><div>represent DVT</div><div> </div><div></div><div></div><div>increase risk of developing a DVT (therefore treatment with anticoagulation is </div><div>not indicated)</div><div> </div><div>US RADIOLOGY VEIN (UPPER/</div><div>LOWER/BILATERAL) EXTERMITIES RULE OUT DVT</div></div><div></div></div>
<div><div><img><div>86 Post-Op Management Post-Op Management 87</div><div> </div><div></div><div> </div><div>D-dimer may also be elevated in patients with DVT </div><div>Prevention &amp; Treatment </div><div> </div><div>The main goal of treatment is to prevent a pulmonary embolism, preventing </div><div>DVT from becoming larger, and preventing new blood clots from forming</div><div> </div><div>Primary treatment is anticoagulation for a minimum of 3 months</div><div> Low molecular weight heparin (SubQ heparin or lovenox)</div><div> Unfractionated heparin (continuous heparin drip)</div><div> Direct oral anticoagulation: Rivaroxaban (Xarelto), Dabigatran (Sayaysa), </div><div>and Apixaban (Eliquis) </div><div> Coumadin with goal INR 2-3</div><div> </div><div>Post op DVT prevention includes</div><div> Bilatearl LE SCDs on all patients</div><div> SubQ heparin (if no contraindication) on patients while in the ICU. </div><div>Continue for high risk patients while on iICU. </div><div> See reference material see page 134.</div><div>References: </div><div>Pai, M, Douketis, J. (2017) Patient education: deep vein thrombosis (DVT) beyond the basics. Up to date. </div><div> </div><div>INFECTIOUS DISEASE: SEPSIS</div><div>Sepsis</div><div> </div><div></div><div> </div><div>Include two or more of the following:</div><div> Temperature &gt; 38°C or &lt; 36°C</div><div> Heart rate &gt; 90 bpm</div><div> Respiratory rate &gt; 20 bpm</div><div> WBC count &gt; 12,000/mm3 or &lt; 4,000/mm3 or &gt; 10% immature </div><div>neutrophils</div><div> </div><div>Clinical signs of organ dysfunction</div><div> Neuro: altered LOC, hypo/hyperthermia</div><div> Pulmonary: hypoxemia, ARDS</div><div> Cardiac: hypotension</div><div> Renal: AKI (Cr &gt; 2 mg/dL)</div><div> GI: hyperbilirubinemia &gt; 2 mg/dL</div><div> </div><div> Hyperlactatemia </div><div>Septic Shock</div><div> </div><div>Severe sepsis with hypotension that does not resolve with adequate volume </div><div>resuscitation</div><div> </div><div></div><div>Sepsis Screening Tool</div><div> </div><div>Goals of Resuscitation</div><div> </div><div></div><div> </div><div>Goals:</div><div> CVP 8-12 mmHg, MAP &gt; 65 mmHg, urine output &gt; 0.5 mL/kg/hr, ScvO2 &gt; </div><div>70% or SvO2 &gt; 65%, normal lactate levels</div><div>Surviving Sepsis Bundle</div><div> </div><div>Resuscitation</div><div> </div><div>large volumes of crystalloids are required</div><div> </div><div>to maintain MAP &gt; 65</div><div> </div><div> Add Epinephrine if additional agent needed to maintain MAP</div><div> Vasopressin can be used in combination with Norepinephrine if unable </div><div>to maintain MAP</div><div> Consider Dopamine in selected patients with marked LV dysfunction.  Not </div><div>recommended for renal protection</div><div> </div><div>or CO suboptimal</div><div> </div><div>pressures and MAP.  </div><div> </div><div>Diagnosis</div><div> Obtain cultures before start of antimicrobial therapy if does not delay </div><div>treatment (&gt; 45 min)</div><div> Blood cultures (one percutaneous and one from each vascular device in </div><div>place &gt; 48 hours)</div><div> Other possible sites of infection (CSF, sputum, urine, etc.)</div><div> </div><div> </div><div>Antimicrobial Therapy</div><div> Administer broad spectrum antibiotics within one hour of diagnosis</div><div> Empiric combination antimicrobial therapy for neutropenic patients or </div><div>highly multidrug-resistant infections</div><div> Empiric antifungal therapy for high risk invasive candidiasis</div><div> Reassess antibiotics daily for descalation</div><div> Limit antimicrobial therapy to 7-10 days *</div><div> Limit empiric combination therapy to 3-5 days</div><div> Narrow coverage following susceptibility results</div><div> Stop antimicrobial therapy if cause of SIRS is uninfectious</div><div> </div><div>Source Control</div><div> </div><div> Radiographic imaging if needed</div><div> Remove intravascular devices if potentially infected</div><div> </div><div> Surgical resection of infected tissues</div><div> </div><div>Other Support Modalities</div><div> Mechanical ventilation</div><div> Glucose control</div><div> Renal replacement therapy</div><div> Blood product administration</div><div> Nutrition</div><div> Deep vein thrombus prophylaxis</div><div> Stress ulcer prophylaxis</div><div> </div><div>resuscitation and vasopressor therapy.  Indicated if random cortisol level </div><div>&lt;18 mg/dL in patients with septic shock</div><div> </div></div><div></div></div>
<div><div><img><div>88 Post-Op Management Post-Op Management 89</div><div>INFECTIOUS DISEASE: CELLULITIS</div><div>Microbiology:</div><div> </div><div>Most common pathogens are beta-hemolytic streptococci (groups A, B, C, G, </div><div>and F), Staphylococcus aureus, including MRSA and gram-negative aerobic </div><div>bacilli</div><div> </div><div>Staphylococcus aureus: Periorbital and orbital cellulitis and IV drug users</div><div> </div><div>Pseudomonas aeruginosa: Diabetics and other immunocompromised </div><div>patients</div><div> </div><div>Aeromonas hydrophila and Vibrio vulnicus: Cellulitis caused by waterborne </div><div>pathogens</div><div> </div><div>Pasteurella multocida and Capnocytophaga canimorsus: Cellulitis preceded </div><div>by bites</div><div> </div><div>Streptococcus iniae: Immunocompromised hosts</div><div> </div><div>Rare causes: Mycobacterium, fungal (mucormycosis, aspergillosis, syphilis)</div><div>Diagnosis: </div><div> </div><div>For patients with signs of systemic disease (fever or hypothermia, hear rate </div><div>[HR] &gt;100 bpm, or systolic blood pressure [SBP] &lt;90 mm Hg) include blood </div><div>cultures, drug susceptibility, CBC, creatinine, bicarbonate, CPK, and CRP </div><div>levels </div><div> </div><div>Consider use of CT or MRI if suspicious for deeper infection (osteomyelitis/</div><div>mediastinis)</div><div>Treatment</div><div>Medication (see Stanford Antibiogram).</div><div>First Line</div><div>Treat 5–15 days or longer, depending on response, and guided by culture when </div><div></div><div>cellulitis (5) [B]. Empiric therapy should be guided by local resistance patterns. </div><div></div><div> </div><div></div><div>streptococci and methicillin-susceptible S. aureus)</div><div>  Oral dicloxacillin, cephalexin, clindamycin, or IV cefazolin, oxacillin, or </div><div>nafcillin.</div><div> </div><div>Parenteral therapy if severely ill or unable to tolerate oral therapy</div><div> </div><div>cephalosporin; if penicillin-allergic, use clindamycin or vancomycin.</div><div> </div><div>Necrotizing fasciitis and gas gangrene</div><div> Parenteral clindamycin and penicillin.</div><div> </div><div>In patients with recurrent infection underlying predisposing conditions, </div><div>previous episode of proven MRSA infection, or systemic toxicity, use agents </div><div>with activity against MRSA</div><div> Parenteral vancomycin, daptomycin, linezolid or oral trimethoprim-</div><div>sulfamethoxazole (TMP/SMX), doxycycline or minocycline, or clindamycin </div><div>(3)[C].</div><div> </div><div>Mild early-suspected streptococcal etiology</div><div> Penicillin G, 600,000 U, and then IM procaine penicillin at 600,000 U </div><div>q8h–12h.</div><div> </div><div>Recurrent streptococcal cellulitis</div><div> Penicillin IV 250 mg b.i.d., or if penicillin-allergic, use erythromycin 250 </div><div>mg b.i.d.</div><div>Alert</div><div> </div><div>If community-acquired MRSA is a concern, treatment options (7–14 days) </div><div>include trimethoprim/sulfamethoxazole: DS (160 mg TMP and 800 mg of SMX) </div><div>1–2 PO b.i.d. daily; doxycycline: 100 mg PO b.i.d., or clindamycin: 300–600 mg </div><div>PO t.i.d.</div><div>Second Line</div><div> </div><div>Mild infection:</div><div> </div><div>If Penicillin allergy: Erythromycin 500 mg PO q6h</div><div> </div><div></div><div>cellulitis at current estimated MRSA levels.</div><div> </div><div>0.5 mg/kg/d for 5–8 days) if partial response to antibiotics in hemorrhagic or </div><div>bullous cellulitis</div><div>Ongoing Care</div><div>Follow-Up Recommendations</div><div> </div><div>Repeat blood count if patient is toxic. Repeat lumbar puncture in case of </div><div>meningitis.</div><div> </div><div>Consider prophylaxis of deep vein thrombosis.</div><div> </div><div></div><div>bacterial antigens. Symptomatic improvement usually occurs in 24–48 hours, </div><div>but visible improvement may take up to 72 hours.</div><div> </div><div>INFECTIOUS DISEASE: PNEUMONIA</div><div>Description</div><div>Community-acquired pneumonia (CAP): Lower-respiratory tract infection not </div><div>acquired in a hospital, long-term care facility, or during other recent contact with </div><div>the health care system </div><div>Hospital-acquired pneumonia (HAP): Pneumonia that occurs 48 hours or more </div><div></div><div>Ventilator-associated pneumonia (VAP): Pneumonia that develops more than </div><div></div><div>Health care–associated pneumonia (HCAP): Pneumonia that occurs in a </div><div>nonhospitalized patient with extensive health care contact, such as:</div><div> </div><div>IV therapy or wound care within the past 30 days</div><div> </div><div>Residing in a nursing home or long-term care facility</div><div> </div><div>Hospitalization in an acute care hospital for 2 or more days within the  </div><div>past 90 days</div><div> </div><div>Visited a hospital or hemodialysis clinic within the past 30 days (2)</div><div>Evaluation</div><div> </div><div>Symptoms: fever, chills, cough, increased sputum, SOB, pleuritic CP. Note </div><div>that the presenting symptoms can be subtle – weakness, malaise, AMS</div><div> </div><div></div><div> </div><div>Other studies:</div><div> Blood culture – before antibiotic administration</div><div> ABG when patient is severely dyspneic or tachypneic</div><div> Consider testing for Legionella (culture and urinary assay), Mycoplasma </div><div>(cold agglutinins), Pneumoccocus (urine antigen), Chlamydia (acute and </div><div>convalescent serology), or respiratory viral panel if clinical course atypical </div><div>or enigmatic</div></div><div></div></div>
<div><div><img><div>90 Post-Op Management Post-Op Management 91</div><div> Sputum gram stain and culture: while controversial, it is helpful if </div><div>performed before antibiotics; an adequate sample has &gt;25 PMNs and &lt; </div><div>10 epithelial cells.</div><div> Consider HIV testing if never previously tested or risk factors for HIV</div><div> In Immunocompromised patients, consider diagnostic workup for </div><div>opportunistic pathogens (PCP, TB, fungi)</div><div> </div><div></div><div>microbiologic diagnosis reduces mortality compared to empiric treatment. </div><div>Management</div><div> </div><div>Antibiotic regimen depends on severity of illness, potential for resistant </div><div>organisms or opportunistic pathogens</div><div> </div><div>Consult hospital antibiogram and antibiotic guidelines. Adjust for renal/</div><div></div><div>within 4-6 hours of presentation</div><div> </div><div>Pseudomonas risk factors: structural lung disease (bronchiectasis), </div><div>corticosteroid therapy (&gt;10 mg of prednisone per day), broad spectrum </div><div>antibiotics for &gt; 7 d in the past month, recent hospitalization, malnutrition</div><div> </div><div>Community acquired MRSA risk: immunocompromised, injection drug use, </div><div></div><div>necrotizing pneumonia</div><div> </div><div>High risk of multi-drug resistant (MDR) pathogens: late-onset HAP or VAP </div><div></div><div>last 90 days, high frequency of antibiotic resistance in the community, </div><div>immunocompromised, or any risk factor for HCAP above. </div><div>Medication</div><div>Patient Subset Common organisms Example empiric antibiotic therapy</div><div>CAP</div><div>- Inpatient</div><div>- Not in ICU</div><div> </div><div>Typical: Streptococcus </div><div>pneumoniae, Haemophilus </div><div>inuenzae, </div><div> </div><div>Atypical: Legionella sp., </div><div>Mycoplasma pneumoniae, </div><div>Chlamydophila pneumoniae</div><div></div><div>Doxycycline 100mg PO BID</div><div>(if severe penicillin allergy, consider </div><div></div><div>CAP</div><div>- Inpatient</div><div>- In ICU</div><div>ASSESS risk of </div><div>MDR pathogen </div><div>(see above)</div><div>As above plus drug resistant S. </div><div>penumoniae, Staphylococcus </div><div>aureus, other gram-negative rods</div><div></div><div>Azithromycin 500mg PO/IV x 1 then</div><div>250mg PO/IV qday</div><div>If risk for CAMRSA: ADD Vancomycin</div><div>If risk for Pseudomonas, Pipercillin/</div><div>tazobactam 4.5 gm IV q 6h replaces </div><div></div><div>HCAP, HAP, VAP </div><div>(any acuity)</div><div>Assess risk of </div><div>MDR pathogen </div><div>(see above)</div><div>Staphylococcus aureus, </div><div>Pseudomonas aeruginosa, </div><div>drug-resistant Streptococcus </div><div>pneumoniae, and other resistant </div><div>gram-negative rods. </div><div></div><div>risk factors for MDR pathogens – </div><div>empiric therapy should account for </div><div>each individual’s risk factors and </div><div>level of acuity. </div><div>Low Risk of MDR pathogens:</div><div></div><div>Doxycycline 100mg PO BID AND</div><div>Vancomycin and change doxycycline to </div><div>azithromycin in ICU patients. </div><div>High Risk of MDR pathogens:</div><div>Vancomycin AND</div><div>Pipercillin/tazobactam 4.5gm IV q6h AND</div><div></div><div>INFECTIOUS DISEASE:  </div><div>C. DIFF (CLOSTRIDIUM DIFFICULT)</div><div>Causes: </div><div> </div><div>Produces enterotoxin ( toxin A ) and cytotoxic ( toxin B )</div><div> </div><div>Associated with ALL antibiotics and hospitalization itself</div><div>Symptoms:  a variety of syndromes are possible from asymptomatic infection -&gt; </div><div>diarrhea -&gt; pseudomembranous (PMC) -&gt; toxin mega colon -&gt; fulminant colitis. </div><div> </div><div>Flu-like symptoms:  Fever, chills, abdominal pain, watery diarrhea. </div><div> </div><div>Fecal incontinence common.</div><div>Diagnose: </div><div> </div><div></div><div> </div><div></div><div>a false positive sample</div><div> </div><div>Order only for patients who have had several watery stools. Cannot be </div><div>retested before 7 days.</div><div> </div><div></div><div>48 hours. </div><div>Treatment:  </div><div> </div><div>d/c antibiotic if possible</div><div> </div><div>place in contact isolation</div><div> </div><div>Mild: Metronidazole ( Flagyl ) IV</div><div> </div><div>Moderate –severe: Vancomycin oral</div><div>DO NOT USE ANTI-PERISTALTIC AGENTS FOR C-DIFF. </div><div>INFECTIOUS DISEASE: </div><div>URINARY TRACT INFECTION</div><div>Denitions:</div><div> </div><div>Lower UTI: Urethritis, cystitis</div><div> </div><div>Upper UTI: Pyelonephritis, renal/perinephric abscess</div><div> </div><div>Uncomplicated UTI: Lower UTI in a non-pregnant woman with normal GU </div><div>anatomy</div><div> </div><div>Complicated UTI: Anyone else including upper UTI in women, any UTI in men, </div><div>pregnant women or women with structural or neurological GU disease.</div><div>Etiology/Risk Factors:</div><div> </div><div>Organisms: SEEEKS PP: Serratia, E.Coli (80%), Enterobacter, Entercoccus, </div><div>Klebsiella, Staph. Saprophyticus, Proteus, Pseudomonas</div><div> </div><div>Risk Factors: Female (short urethra), sexual intercourse, indwelling </div><div>urinary catheters, or recent instrumentation, diaphragm/spermicide use, </div><div></div></div><div></div></div>
<div><div><img><div>92 Post-Op Management Post-Op Management 93</div><div>Treatment:</div><div> </div><div>Uncomplicated UTI: </div><div> </div><div>resistance is &gt; 20%</div><div> </div><div>Lower UTI in Pregnant women: </div><div> Amoxicillin/Clauvulanate (Augmentin) and Cephalexin are preferred</div><div> </div><div>Complicated lower UTI: Remove catheter/stent if present (high incidence of </div><div>Pseudomonas and Candida). </div><div> </div><div> </div><div>Uncomplicated pyelonephritis: Low grade fever, WBC count only slightly </div><div>elevated, no nausea/vomiting. </div><div> </div><div>Augmentin for 14 days. </div><div>ENDOCRINE: ACUTE HYPERGLYCEMIA AND </div><div>DIABETES MANAGEMENT</div><div>1.  General Pre op considerations: </div><div>a.  Always obtain hemoglobin A1c on pre op labwork</div><div>b.  For outpatients: instruct them to hold oral meds on the same morning </div><div>of OR day; if they are on basal  insulin, only give 1/3 -1/2 does the night </div><div>before or on the same morning of OR. </div><div>c.  </div><div>continue home DM meds( except metformin) &amp; insulin the night before </div><div>surgery; hold oral meds and only give 1/2 -1/3 does basal insulin on the </div><div>same morning  of OR.</div><div>2.  Hyperglycemia occurs in virtually all CT surgery patients due to:</div><div>a.  A.  Increased extracellular glucose, decreased insulin secretions and </div><div>increase peripheral resistance to insulin due to: </div><div>o  exposure to extracorporeal circulation</div><div>o  hypothermia</div><div>o  release of endogenous catecholamines, cortisol, and glucagon</div><div>b.  Post-op goal blood glucose is &lt; 180 mg/dL</div><div>c.  For patients with known high HgbA1c pre op or for any patient </div><div>whose glucose is diicult to manage, low threshold to consult </div><div>Endocrine. </div><div>3.  Patients will be admitted to the CVICU on an insulin drip. Patient should </div><div>remain on an insulin drip until blood glucose remains within target range </div><div>with stable drip titrations (+/- no more than 1 for past 4 hours)</div><div>a.  </div><div> </div><div>b.  </div><div>NS @ 50mL/hr and d/c D5 ½ NS.</div><div>Preparation Onset Peak action Duration</div><div>Rapid Acting</div><div>Insulin Lispro (Humulog)</div><div>Insulin aspart (NovoLog)</div><div> </div><div>9-30 min </div><div>15 min</div><div> </div><div>30 min-2.5 hrs </div><div>30 min-1 hr</div><div> </div><div>3-4 hrs </div><div>1-3 hrs</div><div>Short Acting</div><div>Regular insulin </div><div>30 min- 1 hr 2-5 hrs 3-8 hrs</div><div>Intermediate Acting</div><div>NPH</div><div>1-4 hrs 4-10 hrs 10-16 hrs</div><div>Long Acting</div><div>Insulin glargine (Lantus)</div><div>2-4 hrs None 24 hrs</div></div><div></div></div>
<div><div><img><div>94 Post-Op Management Post-Op Management 95</div><div>c.  Special Circumstances</div><div>4.  Preparing for discharge: </div><div>a.  For patients with no previous history of diabetes, the goal is to wean </div><div></div><div>i.  If no formal diagnosis of Diabetes, but pre op A1C &gt; 6.4%, consider </div><div>consult to endocrine or initiation of oral anti diabetic agents</div><div>ii.  If  a patient is being discharged home with any new diabetic </div><div>medications (oral or injection), Diabetes education must be ordered </div><div>(~2 days prior to discharge) and completed by with DM Nurse or the </div><div>bedside RN</div><div>iii. Diabetic teach orders in Epic</div><div>1.  “Diabetes education” = Bedside Nursing</div><div>a.  Can also place nursing communication order for RN to initiate </div><div>DM Teaching Video</div><div>2.  Nsg Referral to Diabetes RN = CNS Specialist (*Preferred)</div><div>b.  For those patients with diabetes, slowly restart any oral anti-diabetic </div><div>agents and or insulin. Patients will likely be on much lower doses of </div><div>medications or insulin at discharge than at pre op</div><div>i.  Medications can slowly be up titrated as needed in the outpatient </div><div>setting as patients diet and appetite returns to normal</div><div>ii.  Oral Antidiabetic agents: </div><div>1.  Metformin</div><div>a.  Contraindicated in the prescence of renal dysfunction (Creat &gt; </div><div>~1.5)</div><div>b.  Metformin should temporarily be held pre and post </div><div>administration of IV contrast </div><div>c.  Typically held 48 hours prior to any major surgery. Resume </div><div></div><div>returned to baseline. </div><div>2.  Sulfonylureas (Glipizide, Glimepiride, Glyburide)</div><div>a.  Stimulates insulin release from pancreas</div><div>b.  Glipizide does not have an active metabolite, better choice for </div><div>those with renal failure</div><div>c.  Overall, increased incidence of causing hypoglycemia</div><div>3.  Thiazolidinediones ( Actos, Avandia)</div><div>a.  May exacerbate heart failure! Avoid use in most cardiac patients </div></div><div></div></div>
<div><div><img><div>96 Post-Op Management</div><div>ENDOCRINE: ADRENAL INSUFFICIENCY</div><div>Denition:</div><div> </div><div>Most commonly occurs in critically ill patients due to subnormal </div><div>corticosteroid production. </div><div>Diagnosis: </div><div> </div><div>Total (random) serum cortisol: Low </div><div> </div><div>Morning serum cortisol concentration: Low (&gt; 3mch/dL)</div><div> </div><div>CTH Stimulation test:</div><div> </div><div> Administration of ACTH (1-24) or Cosyntropin:</div><div> </div><div>Stanford high dose test (250mcg)</div><div> </div><div>A normal response is a rise in serum cortisol concentration 30-60 </div><div></div><div> </div><div>A normal response to high dose ACTH stimulation test excludes </div><div></div><div> </div><div>Low dose test (1mcg)</div><div> </div><div>A normal response is a rise in serum cortisol concentration 20-30 </div><div></div><div>Treatment: Stress Dose Steroids</div><div> </div><div>Consider treatment when patient on &gt;2 pressors with hemodynamic </div><div>instability</div><div> </div><div>Replacement with hydrocortisone:</div><div> 50mg IV Q6 hours or 100mg IV q8 hours</div><div> </div><div>Consider quick taper (over 3-5 days) once hemodynamics improve </div><div>References: </div><div></div></div><div></div></div>
<div><div><img><div>Procedures/Devices 97</div><div>PROCEDURES: ATRIAL ELECTROGRAMS</div><div> </div><div></div><div></div><div> </div><div>Requires the presceince of atrial temporary epicardial wires </div><div>To perform:</div><div> </div><div>Obtain standard ECG for baseline/comparison</div><div> </div><div>For Atrial ECG: Attach the two arm leads to the atrial wires (all other leads </div><div>attached normally)</div><div> A bipolar ECG will be recorded in Lead I and unipolar ECG in Lead II or III</div><div> </div><div>Interpretation: Evaluate atrial activity in relation to QRS complex </div><div>Interpretation examples:</div><div> </div><div>Normal Sinus rhythm: Large atrial spike on Atrial ECG will correlate  </div><div>with P waves</div><div> </div><div>Junctional: No atrial spike present on Atrial ECG</div><div> </div><div></div><div>PROCEDURES:  </div><div>DIRECT CURRENT CARDIOVERSION (DCCV)</div><div>Supplies/Equipment</div><div>5.  </div><div>6.  </div><div>7.  EKG machine </div><div>8.  Monitoring equipment at bedside (bedside telemetry with 5 lead system, </div><div></div><div>oxygen access and mask, pulse oximetry, ambubag)</div><div>Procedure</div><div>Pre-Procedure Care Steps:</div><div>1.  </div><div>a. 12 lead EKG</div><div>b. Patent intravenous venous line (IV)</div><div>c.  Patient is connected to the following: telemetry with a 5-lead EKG </div><div></div><div>equipment, oxygen is available/operational, ambu bag at bedside</div><div>2.  Keep patient NPO for approximately 6 hours prior to procedure</div><div>3.  </div><div>4.  Obtain written informed consent</div><div>5.  </div><div></div></div><div></div></div>
<div><div><img><div>98 Procedures/Devices Procedures/Devices 99</div><div>For patients on Telemetry unit requiring DCCV: (must be performed by </div><div>Cardiac Anesthesia)</div><div>1.  Page, call, or text ICU Cardiac Anesthesia Attending on call directly to set </div><div>up cardioversion</div><div>2.  Call OR to book the case in the OR (this is for ICU attending billing </div><div>purposes)</div><div>Cardiac anesthesia on call for the OR should only be contacted for cardioversion </div><div>if ICU Attending is unable to perform the procedure.</div><div>PROCEDURES: PACER WIRE (PW) REMOVAL</div><div>Pre Removal Checklist: </div><div>1.  Are PW capped with no evidence of rhythm issues on telemetry for 24 hours? </div><div></div><div>2.  If pacing wires have not been capped yet, any pacing activity in last 24 hrs? </div><div>(Check with primary nurse and telemetry monitor). If not &gt; cap pacing wires. </div><div>3.  If PW already capped, for how long? (Usually require wires to be capped for at </div><div>least 4-6 hours before removal)</div><div>4.  Is patient on any anti-coagulation including Heparin sub Q/ IV infusion, </div><div>Argatroban, Plavix, Coumadin, Pradaxa, Xarelto, Eliquis etc?</div><div>i.  In general, we do not start non-reversible anticoagulant agents (Plavix/</div><div>Pradaxa/Eliquis/Xarelto, etc.) until PW already removed</div><div>ii.  If novel OAC agent has been started, check with surgical team regarding </div><div>timing of holding medication prior to PW removal </div><div>iii.  If on SubQ heparin, hold Sub Q heparin 6-8 hrs before PW removal</div><div>iv.  If on heparin/argatroban gtt, hold gtt for 6 hrs before PW removal, and </div><div></div><div>v.  If on Coumadin, slowly titrate Coumadin dose until PW out, and only </div><div>remove PW with INR &lt; 2.0.</div><div>5.  Was PW sutured in or oversewn to heart? Double check sign-out list and </div><div>notes. *** In this case PW are to be CUT AT SKIN, not pulled ***</div><div>6.  Has plan to remove PW been discussed with attending or chief resident? </div><div>During Removal:</div><div> </div><div>Maintain smooth and steady strength</div><div> </div><div></div><div></div><div>swab</div><div>Aer Removal:</div><div> </div><div>Notify both patient &amp; primary RN to keep patient in bed for at least 1 hour </div><div></div><div> </div><div>Instruct RN to watch for warning signs and symptoms of tamponade such as:</div><div> Lightheadedness</div><div> Dizziness</div><div> Diaphoresis</div><div> Chest discomfort</div><div> Decreased BP</div><div> Increased HR</div><div> </div><div></div><div>6.  </div><div>i.  Anticoagulation:</div><div>•  If duration of atrial arrhythmia &lt; 48 hours, no anticoagulation required</div><div>•  If duration of atrial arrhythmia &gt; 48 hours, consider anticoagulation in </div><div>conjunction with CHADs score</div><div>ii.  K+ - consider replacement if K+ &lt; 3.4</div><div>7.  Review baseline vital signs and SaO2 from pulse oximeter</div><div>8.  </div><div>9.  If temporary pacing wires present- ensure attached to external pacemaker </div><div>box and turn pacemaker box on (consider placing patient on back up VVI </div><div>mode)</div><div>10. </div><div></div><div>placement is at least six (6) inches away from implanted device</div><div>11. </div><div>i.  </div><div></div><div>attending provider’s discretion)</div><div>ii.  </div><div>iii.  Press “Sync” button and ensure R wave aligns with synchronized </div><div>marker</div><div>iv.  Press record button to ensure recording paper is operational</div><div>Procedure Steps:</div><div>1.  Perform “Time out”</div><div>2.  Anesthesiologist/ICU APP administers anesthetic agent via IV with O2 on </div><div>patient</div><div>3.  Vitals signs and SaO2 are recorded every minute by RN</div><div>4.  When anesthesiologist/ICU APP determines patient is adequately sedated, </div><div>he/she acknowledges to the APP that patient is ready for DCCV</div><div>5.  The APP performs the following:</div><div>i.  Press the “Charge” button and states loudly, “Charging”</div><div>ii.  States loudly, “All clear!” and visually sweeps the bed to ensure no one </div><div>is touching the bed and waits for other team members to verify they are </div><div>clear</div><div>iii.  Press and hold the “Shock” button</div><div>6.  </div><div>communicates with anesthesiologist to verify vital signs are stable</div><div>7.  If patient remains in sinus rhythm, anterior/posterior pads are removed from </div><div></div><div>from patient</div><div>8.  If patient has early re-initiation of atrial arrhythmia or remains in an atrial </div><div>arrhythmia, DCCV procedure is repeated with a higher number of joules.  APP </div><div></div><div>energy for the maximum of 3 shocks.</div><div>9.  The APP follows current ACLS protocol for asystole, high degree AV block or </div><div>ventricular arrhythmias and pages Attending Physician</div><div>10. The APP completes the following:</div><div>i.  Reviews post procedure EKG</div><div>ii.  Any medication reconciliation, if applicable</div><div>iii.  Document via Procedure Note: Include medication administered, # of </div><div>joules, # of shocks, post procedure rhythm, and any adverse events. </div></div><div></div></div>
<div><div><img><div>100 Procedures/Devices Procedures/Devices 101</div><div>If the chest tube has purse strings: </div><div>1.  With scalpel, cut the holding suture which is tied around the chest tube and </div><div>the purse strings on the distal end, make sure leave enough purse string </div><div>length to tie. </div><div>2.  </div><div>3.  Instruct the patient to take deep breath in and hold breath. (*Tubes may be </div><div>pulled at end inspiration or end expiration, the important point is that the </div><div>patient is not inspiring as the tube comes out) </div><div>4.  Pull chest tube smoothly and quickly</div><div>5.  </div><div>removal, operator immediately tie down the purse string with surgical knots </div><div>X3 and cut excess string with scalpel </div><div>6.  Remind patient to breath normally as soon as chest tube is removed </div><div>7.  Cover the CT site vaseline gauze with dry dressing and tape </div><div>If the patient does not have purse string to tie:</div><div>1.  Cut the holding string and cover the insertion site with Vaseline gauze quickly </div><div>while removing  the chest tube </div><div>2.  Cover the Vaseline gauze with dry dressing and make sure the whole dressing </div><div>is sealed well with 2inch paper tapes for @ least 48 hrs before remove </div><div>dressing or shower</div><div>If chest tube is pigtail catheter placed per IR</div><div>1.  See Pigtail removal</div><div>Check list post chest tube removal:</div><div> </div><div>Dispose all sharps in sharps container; dispose CT drainage unit into doubled </div><div>red trash bag</div><div> </div><div>If concern or suspect post CT removal PTX, need to check CXR immediately; if </div><div>no concern for PTX, do not need to check CXR</div><div> </div><div></div><div>extreme pain, postop PTX etc.) during or postop procedure</div><div>Post chest tube removal patient education:</div><div> </div><div>Keep occlusive dressing or stiches on for at least 48 hrs, then remove and </div><div>clean site in shower (CT stich could be removed prior to discharge or on clinic </div><div>visit time)</div><div> </div><div>No soaking in bathtub for 1 week</div><div> </div><div>CT insertion site will be assessed at follow up MD visit in 1-2 weeks </div><div> </div><div></div><div>increasing erythema on CT sites</div><div>Pigtail Removal (placed by IR) </div><div>PROCEDURES: RAPID SEQUENCE INDUCTION</div><div>Simultaneous administration of a sedative and a neuromuscular blocking </div><div></div><div>to facilitate emergent endotracheal intubation and to minimize the risk of </div><div>aspiration.  </div><div>Administer:  </div><div>1) SEDATIVE; 2) PARALYTIC; 3) FLUSH</div><div>(Most Common combination is Etomidate and Rocuronium +/- propofol for side </div><div>eect prole)</div><div>If the patient starts to exhibit s/sx of tamponade  </div><div>follow these steps:</div><div>1.  1.  If patient only has symptoms, but BP and HR are stable:</div><div>i.  Order STAT Echo </div><div>ii.  Call Echo lab (x54160) to notify them of order and that the purpose is to </div><div>rule out tamponade</div><div>iii.  Continue to monitor patient &amp; vitals closely. Run BP checks Q15 min.</div><div>iv.  Notify chief resident or attending</div><div>v.  As soon as there is a change in vital signs, follow step 3. </div><div>2.  If the patient’s BP starts to drop, but general condition is OK</div><div>i.  </div><div>ii.    Order STAT Echo, call Echo lab and notify as above.  </div><div>iii.    Notify chief resident and attending that you have suspicion for </div><div>possible tamponade </div><div>iv.    Call ICU team for possible transfer to back to ICU</div><div>3.  </div><div>decompensating quickly, take all steps as listed above but notify on call </div><div>attending and OR that emergent surgery is needed. If patient goes into </div><div>cardiac arrest or mental status starts to change, etc </div><div>i.  Activate Open chest code and rapid transfusion protocol. </div><div>ii.  Open chest at bedside ASAP to release pressure on heart  </div><div>• </div><div>•  Direct CPR/cardiac massage if cardiac arrest</div><div>•  Straight to OR</div><div>Chest Tube Removal:  </div><div>Things to consider before CT removal:</div><div> </div><div>If drainage &lt; 150 cc/24 hrs (some surgeons are OK with drainage&lt;  200cc/24 </div><div></div><div> </div><div>Is there any air leak from chest tube? </div><div> </div><div> If chest tube with persistent air leak, may switch to  water seal overnight </div><div>and check CXR next AM, if no new  PTX or previous existing PTX in stable </div><div>size-&gt; may remove chest tube (sometimes needs to  clamp chest tube 1st </div><div>and repeat CXR to rule out new PTX/increasing  PTX size before removal)</div><div> </div><div>Is there any PTX on CXR?</div><div> </div><div>Assess pain control need: usually give fentanyl 25-50 mcg IV or dilaudid 0.2mg </div><div>IV before procedure </div><div> </div><div>Grab materials to use: suture removal set or scalpel; multiple 4x4 gauzes; </div><div>Vaseline gauze; hem clamp;  2 inch wide paper tapes; blue chux ; 2 red </div><div>biohazard trash bag</div><div> </div><div>Usually needs a 2nd person (RN or PA/NP colleague to hold chest tube site </div><div>tissue together before knots are tied or Vaseline gauze is placed)</div><div>Procedure:</div><div> </div><div>Place patient in bed with comfortable position and explain to the patient </div><div>about the procedure process </div><div> </div><div>Remove chest tube site dressing and assess the wound</div><div> </div><div>If there are 2-3  tubes connected together with  Y-connector, need to clamp </div><div></div><div>chest tube removal </div></div><div></div></div>
<div><div><img><div>102 Procedures/Devices Procedures/Devices 103</div><div>PROCEDURES: BRONCHOSCOPY</div><div>Indications for bronchoscopy:</div><div> </div><div>Hypoxemia</div><div> </div><div>Suspected airway obstruction</div><div> </div><div>New CXR opacity</div><div> </div><div>Copious secretions</div><div> </div><div>To obtain Bronchial Alveolar Lavage (BAL)/sputum culture</div><div> </div><div>Pulmonary toileting</div><div>Setting up a bronchoscopy:</div><div> </div><div>Discuss with attending on ideal time and indication</div><div> </div><div>Decide bronchoscope (full cart) vs ambuscope (smaller screen, smaller </div><div>scope)</div><div> Full cart bronchoscope indicated for:</div><div> </div><div>Thick secretions, copious secretions</div><div> </div><div>Copious bloody secretions</div><div> </div><div>Attending preference</div><div> </div><div>Call x37709 (RT bat phone for charge RT). They will ask the following:</div><div> Patient name, location</div><div> Attending provider</div><div> Indication</div><div> Scope required (ambuscope vs bronchoscope)</div><div>Aer the bronchoscopy:</div><div> </div><div></div><div> </div><div>Fill out the order requisition:</div><div> Pneumonia diagnosis code: 498</div><div> Gram stain and culture for BAL </div><div> </div><div> </div><div>Order post-bronchoscopy CXR </div><div>DEVICES: IABP</div><div>Indications</div><div> </div><div>Cardiogenic shock</div><div> </div><div>Unstable angina</div><div> </div><div>Intractable ventricular dysrhythmias</div><div> </div><div>Threatening extension of MI</div><div> </div><div>Prophylactic support for PCI</div><div> </div><div>Prophylactic support for OR induction</div><div> </div><div>Post-op myocardial dysfunction</div><div> </div><div>Inability to wean from CPB</div><div> </div><div>RV support during LVAD implantation</div><div> </div><div>Contraindicated in Aortic regurgitation, Aortic dissection, or with severe aortic </div><div>of peripheral atherosclerosis </div><div>Placement/Position</div><div> </div><div>1-2cm below L subclavian artery and above the renal artery branches</div><div> </div><div>Tip should be between the 2nd &amp; 3rd Intercostal space on CXR</div><div>Sedatives</div><div>Drug </div><div>Name</div><div>Class Benets Contra-</div><div>indications</div><div>Notes Dose</div><div>Etomidate Imidazole </div><div>derivative</div><div>Excellent </div><div>sedation </div><div>with little </div><div>hypotension</div><div>Known to </div><div>suppress </div><div>adrenal cortisol </div><div>production</div><div>Use cautiously </div><div>if patient </div><div>has sepsis; </div><div>initial dose of </div><div>glucocorticoid </div><div>may be needed</div><div>0.3 mg/kg</div><div>Ketamine Phencyclidine </div><div>derivative, </div><div>dissociative </div><div>anesthetic</div><div>Stimulates  </div><div>catecholamine </div><div>release </div><div>Bronchodilation</div><div>Use in patients </div><div>with elevated </div><div>ICP or elevated </div><div>blood pressure is </div><div>controversial</div><div>May be an </div><div>excellent </div><div>induction agent </div><div>for patients with </div><div>bronchospasm, </div><div>septic </div><div>shock, AND </div><div>hemodynamic </div><div>compromise</div><div>1 to 2 mg/kg</div><div>Midazolam Benzo- </div><div>diazepines</div><div>Potent dose-</div><div>related amnesic </div><div>properties</div><div>Dose-related </div><div>myocardial </div><div>depression </div><div>can result in </div><div>hypotension</div><div>0.2 to 0.3 </div><div>mg/kg</div><div>Propofol Alkylphenol </div><div>derivative</div><div>Bronchodilation No absolute </div><div>contraindications </div><div>Dose-related </div><div>hypotension</div><div>Paralytics</div><div>Drug Name Class Contraindications Notes Dose</div><div>Succinylcholine Depolarizing </div><div>agent binds to </div><div>postsynaptic ACh </div><div>receptors causing </div><div>continuous </div><div>stimulation</div><div>Hx or family hx of malignant </div><div>hyperthermia </div><div>Hyperkalemia or risk of </div><div>developing hyperkalemia </div><div>Upregulation of ACh </div><div>receptors predisposes pts to </div><div>hyperkalemia</div><div>Neuromuscular disease </div><div>involving denervation </div><div>(muscular dystrophy, stroke </div><div>&gt;72hrs, spinal cord injury </div><div>&gt;72hrs, muscular dystrophy, </div><div>ALS)</div><div>Rhabdomyolysis</div><div>Burn &gt; 72 hours old</div><div>Inherited myopathies</div><div>Crush injuries &gt;72hrs</div><div>Severe infection w/ exotoxin </div><div>(tetanus, botulism)</div><div>Note: Succinylcholine is safe </div><div>in myasthenia gravis</div><div>paralysis occurs </div><div>in 45 to 60 </div><div>seconds</div><div>duration approx. </div><div>6- 10 min. </div><div>1.5 mg/kg IV</div><div>Rocuronium Nondepolarizing </div><div>agent.</div><div>Competitively </div><div>inhibits ACh </div><div>receptors </div><div>preventing </div><div>depolarization </div><div>Paralysis occurs </div><div>in approximately </div><div>45 to 60 seconds</div><div>duration approx. </div><div>45 minutes</div><div>1.0 mg/kg</div><div>IBW</div><div>Vecuronium Nondepolarizing </div><div>agent.</div><div>Paralysis occurs </div><div>w/in 2.5-3 min</div><div>Duration 25-40 </div><div>min.</div><div>0.08-0.1 </div><div>mg/kg</div></div><div></div></div>
<div><div><img><div>104 Procedures/Devices Procedures/Devices 105</div><div>Possible Reasons for Poor Augmentation</div><div> </div><div>Patient’s native stroke volume &gt; IABP volume</div><div> </div><div>Indication of readiness to wean from IABP</div><div> </div><div>Balloon too small?</div><div> </div><div>Low SVR</div><div> </div><div>Hypovolemia</div><div> </div><div>IABP positioned too low</div><div> </div><div>Kinked catheter</div><div>Triggers</div><div>Autopilot Mode </div><div> </div><div>Machine selects EKG and AP (arterial pressure) source, trigger mode and </div><div>timing method as well as optimizes timing</div><div> </div><div>Machine continuously monitors the patient and chooses the best trigger </div><div>mode based on patient condition</div><div>EKG</div><div> </div><div>Pre-set trigger mode</div><div>EKG Peak</div><div> </div><div>Best for wide complex rhythm</div><div> </div><div>Best for HR&gt;130bpm</div><div> </div><div>A Fib</div><div> </div><div>Best choice for varying R-R intervals</div><div> </div><div></div><div>Arterial Pressure</div><div> </div><div>Best trigger when EKG is unavailable or has lots of artifact</div><div> </div><div>Triggered by the systolic up-stoke of the arterial pressure waveform</div><div> </div><div>Should be used during CPR</div><div>A Pace</div><div> </div><div>Triggered by the atrial pacing spike</div><div> </div><div>Can only be used if patient 100% A paced</div><div>V Pace</div><div> </div><div>Triggered by the ventricular spike</div><div> </div><div>Can be used if patient V paced or AV paced</div><div> </div><div>Pt must be 100% paced</div><div>Internal </div><div> </div><div></div><div>activity</div><div> </div><div>Used in situation when there is no cardiac output and no EKG</div><div>During CPR</div><div> </div><div>Arterial pressure trigger should be selected as this will synchronize counter </div><div>pulsation to cardiac compressions</div><div>IABP Complications:</div><div> </div><div>Distal limb ischemia (most common complication occurring in 10-15% of </div><div>patients) and compartment syndrome</div><div> </div><div>Infection and sepsis </div><div> </div><div>Thrombocytopenia</div><div> </div><div> </div><div> Balloon rupture, may lead to helium embolus</div><div> </div><div>Risk and complications of insertion:</div><div> </div><div>coverage</div><div> If balloon is too low = decreased visceral organ perfusion (decreased </div><div>urine output) </div><div> Aortic dissection during insertion </div><div>Basic Principles</div><div> </div><div></div><div>just prior to systole</div><div> </div><div></div><div>aortic valve closure</div><div> </div><div>This combination favorable alters the myocardial oxygen supply: demand </div><div>ratio (Increased myocardial perfusion with less work)</div><div> </div><div></div><div> </div><div>May be indicated in RV failure:</div><div> Improvement in RV perfusion from diastolic augmentation </div><div> Improvement in LV function from unloading </div><div>Deation phase of IABP leads to</div><div> </div><div></div><div> </div><div>Increased stroke volume</div><div> </div><div>Enhanced forward cardiac output</div><div>Ination phase of IABP leads to</div><div> </div><div></div><div> </div><div>Increased diastolic pressure</div><div> </div><div>Potential for increased coronary collateral circulation</div><div> </div><div>Increased systemic perfusion</div><div>Timing</div><div>Ination</div><div> </div><div>Rapid rise in aortic pressure which increases O2 supply to coronaries</div><div> </div><div></div><div> </div><div>Augmented pressure should be &gt; systolic pressure</div><div>Deation</div><div> </div><div>Reduce aortic and end diastolic pressure, improving CO</div><div> </div><div>Assisted end diastolic blood pressure &lt;/= unassisted end diastolic blood pressure</div><div> </div><div>Assisted peak systolic pressure should be &lt;unassisted peak systolic pressure   </div><div>IABP tracing at 1:2 ratio. IABP end diastolic pressure is lower than the patient’s </div><div>aortic end diastolic pressure. The balloon assisted peak systolic pressure is lower </div><div>than the systolic pressure that is generated without a preceding assisted beat. </div></div><div></div></div>
<div><div><img><div>106 Procedures/Devices Procedures/Devices 107</div><div>placed. The ventricular wire is the shorter one. Occasionally, 2 ventricular </div><div>wires are placed (will be equal length) » either one can be used as the ground </div><div>lead.</div><div> </div><div>The ventricular wire is inserted into the negative pole of the temporary </div><div>external pacemaker. The skin wire is inserted in the positive pole.</div><div>Unipolar vs. Bipolar </div><div> </div><div>Unipolar wires consist of a single negative wire attached to the epicardium </div><div>and an additional wire in the subcutaneous tissue (positive). </div><div> </div><div>Bipolar system  consist of a single wire with two conductors (positive and </div><div>negative) which are both attached directly to the epicardium</div><div> </div><div>threshold to obtain capture and is less sensitive to electrical interference </div><div>when sensing compared to unipolar system. </div><div>General Concepts </div><div>Stimulation or Capture Threshold</div><div> </div><div>Refers to the amount of energy delivered by the pulse generator in order to </div><div>initiate depolarization  (measured in milliamps).</div><div> The usual starting point is 10mA and slowly increased until capture is </div><div>achieved.  </div><div> </div><div></div><div>electrodes.</div><div>How to determine appropriate output threshold setting:</div><div> </div><div>Set RATE at least 10 ppm above patient’s intrinsic rate.</div><div> </div><div>Decrease OUTPUT: Slowly turn OUTPUT dial counterclockwise until ECG </div><div>shows loss of capture.</div><div> </div><div>Increase OUTPUT: Slowly turn OUTPUT dial clockwise until ECG shows </div><div>consistent capture.</div><div>This value is the stimulation threshold.</div><div> </div><div>Set OUTPUT to a value 1.5-2 times greater than the stimulation Threshold value.</div><div>This provides at least a 2:1 safety margin.</div><div>Troubleshooting Failure to Capture</div><div> </div><div>Possible Causes</div><div> </div><div> </div><div>Increase mA till capture</div><div> Low battery</div><div>IABP removal </div><div>See IABP removal Hosptial Protocol on IntraNet. </div><div>References</div><div>Bojar, Robert M. (2011) Manual of Perioperative Care in Adult Cardiac Surgery. (5th edition). </div><div> </div><div>DEVICES: LUMBAR DRAINS</div><div>1.  Placed pre-operatively by cardiac anesthesia or Neuro IR if patient has </div><div>complex anatomy</div><div>2.  Use “Lumbar Drain” order set</div><div>3.  Post-operative lumbar drain management:</div><div>i.  Zero the transducer at right atrium phlebostatic level</div><div>ii.  Set the Transducer to 10mmHg</div><div>•  Leave the stopcock closed to the transducer except when measuring </div><div>hourly pressure</div><div>•  Keep the drain open to the patient to allow to continuous drainage</div><div>•  When the ICP is above 10mmHg, the drain will act as a pressure  </div><div></div><div>iii.  Goal is to drain ~10mL/hr when ICP &gt;10. Not to exceed drainage  </div><div>of 20mL/hr</div><div>iv.  </div><div>v.  Maintain strict bed rest with HOB at 30 degrees or less while actively </div><div>draining</div><div>vi.  </div><div>patient and reopen when destination reached.</div><div>4.  For more information on ICP and prevention of spinal cord ischemia see </div><div>“Spinal Cord Ischemia page 50 under III. Post-operative Managament</div><div> </div><div>DEVICES: TEMPORARY PACEMAKERS</div><div>Nomenclature</div><div>1st letter — chamber/chambers paced: A= atria, V= ventricle,  </div><div>D- dual (atria and ventricle)</div><div>2nd letter — chamber/chambers sensed: A= atria, V= ventricle,  </div><div>D- dual (atria and ventricle)</div><div>3rd letter — how the pacemaker responds to an event:  I= inhibit, T- trigger</div><div>Temporary  Pacing Techniques </div><div>Transvenous</div><div>Placed through introducer into the right ventricle. Routinely placed in TAVR pts </div><div>with Corevalves d/t increased risk for the development of heart block as the valve </div><div>continues to expand post deployment.</div><div>Transcutaneous</div><div></div><div>positions. Disadvantages include requiring higher pacing thresholds and patient </div><div>discomfort.</div><div>Epicardial Leads</div><div> </div><div>The wires in the right subcostal region are atrial and in the  subcostal </div><div>region are ventricular.</div><div> Minimally invasive valve surgeries the A and V wires will be in the same position. </div><div> </div><div>Typically, a single ventricular wire (pacing lead) and a skin wire (ground) are </div></div><div></div></div>
<div><div><img><div>108 Procedures/Devices Procedures/Devices 109</div><div>Modes of Pacing:     </div><div>Mode Advantages Disadvantages</div><div>AAI</div><div> </div><div>Single lead</div><div> </div><div>AV synchrony maintained</div><div> </div><div>Able to assess ST changes</div><div> </div><div>Unable to use in AF</div><div> </div><div>Ventricular bradycardia may </div><div>occur in prescense of high </div><div>grade AV block</div><div> </div><div>Instability of single atrial lead</div><div> </div><div>Higher risk of thin atrial wall</div><div>VVI</div><div> </div><div>Requires a single lead</div><div> </div><div>Useful in prescense of AF and </div><div>high grade AV block</div><div> </div><div>AV synchrony lost </div><div> </div><div>Unable to assess ST changes</div><div> </div><div>Loss of atrial kick</div><div> </div><div>Risk of pacemaker syndrome</div><div>DDO</div><div> </div><div>AV synchrony maintained</div><div> </div><div>Use in AF and high grade AV </div><div>block</div><div> </div><div>Heart rate responsive</div><div> </div><div>Possible decreased </div><div>thrombotic events</div><div> </div><div>Pacemaker mediate endless-</div><div>loop tachycardia possible</div><div> </div><div>Pacemaker syndrome if </div><div>incorrectly set up</div><div> </div><div>May not be able to assess ST’s</div><div>DDI</div><div> </div><div>Uses two pacing leads (right </div><div>atrium and right ventricle) to </div><div>maintain minimum rate in </div><div>each cavity</div><div> </div><div>Used in the presence of sinus </div><div>bradycardia with possible AV </div><div>conduction disorders or with </div><div>frequent atrial arrhythmia</div><div> </div><div>Must feel comfortable setting </div><div>rate and AV node delay</div><div> </div><div></div><div> </div><div>For removal of temporary pacing wires, page 99 (section V, procedures, CT and </div><div>PW removal) </div><div>References: http://www.medtronic.com/us-en/index.html</div><div> </div><div>DEVICES: ON Q PUMPS</div><div> </div><div>Non-narcotic pain relief system designed to deliver local anesthetic to or near </div><div>the surgical site via catheters. </div><div> </div><div>The epidural or intrathecal route uses small quantities of medication to </div><div></div><div>provide targeted pain relief via multiple holes along the infusion segment of </div><div></div><div>distribution. </div><div> </div><div>Placed intra-operatively by the surgeon or APP for primarily patients receiving </div><div>anterior thoracotomy incisions</div><div>Placing the Catheter</div><div>1.  Gently hold T-handle and remove protective guard. </div><div>2.  Introducer Needle: Insert (bevel up) through the skin approximately 3-5 cm </div><div>from surgical site </div><div>3.  Advance introducer to desired location for catheter placement. Introducers </div><div>with Luer lock may be connected to a syringe to aspirate or inject a bolus of </div><div></div><div>4.  While holding T-handle 1, withdraw trocar 2 from sheath </div><div> </div><div>Change battery</div><div> </div><div> </div><div>Attempt to reverse the polarity of the leads by swapping the position </div><div>of the metal leads into the pacemaker cord</div><div> Electrolyte abnormalities</div><div>Sensitivity</div><div> </div><div>Sensing refers to the ability of the generator to detect (“see”) and recognize </div><div>the intrinsic impulses of the myocardial tissue and to appropriately respond </div><div>to what it detects.</div><div> </div><div>Sensitivity setting is measured in millivolts. </div><div> Typical atrial 0.4 mV</div><div> Typical ventricular 2.0 mV</div><div> </div><div>Programming a higher sensitivity (higher number) makes the pacemaker  </div><div>less sensitive to intrinsic cardiac activity.</div><div> </div><div>Programming a lower sensitivity (lower number) causes the pacemaker to be </div><div>more sensitive to intrinsic cardiac activity.</div><div>How to determine appropriate sensitivity setting:</div><div>1.  Set rate at least 10 ppm below patient’s intrinsic rate.</div><div>2.  Adjust output: Set OUTPUT to 0.1 mA (A OUTPUT for atrial threshold; V </div><div>OUTPUT for ventricular threshold).</div><div>3.  Highlight SENSITIVITY (atrial or ventricular) </div><div>4.  Decrease SENSITIVITY: Slowly turn MENU PARAMETER dial </div><div></div><div>5.  Increase SENSITIVITY: Slowly turn MENU PARAMETER dial clockwise </div><div> </div><div>This value is the sensing threshold.</div><div>6.  Set SENSITIVITY to half (or less) the threshold value. </div><div>This provides at least a 2:1 safety margin.</div><div>7.  Restore RATE and OUTPUT to previous values.</div><div>Trouble Shooting Sensitivity</div><div>Failure to sense is when the generator does not recognize the heart’s intrinsic </div><div>impulses.</div><div> </div><div>Pacemaker not sensitive enough to patient’s intrinsic rhythm.</div><div> Increase the sensitivity by lowering the mV</div><div> </div><div></div><div> </div><div></div><div> Attempt to reverse the polarity of the leads by swapping the position of </div><div>the metal leads into the pacemaker cord</div><div> </div><div>Low battery.</div><div> </div><div>Malfunction of pacemaker or cable.</div><div>Over-sensing: Pacer sees too much (QRS, T wave, P wave and baseline)</div><div> </div><div>Decrease sensitivity by increasing the mV</div><div>Checking underlying rhythm</div><div> </div><div>Safest method is to slowly turn down the rate as opposed to  disconnecting </div><div>the leads from generator or pausing the pacemaker as this gives time for the </div><div>patient’s native conduction system to emerge</div></div><div></div></div>
<div><div><img><div>110 Procedures/Devices Procedures/Devices 111</div><div> Sponge (item # 195925)</div><div> </div><div></div><div>regular wound vac upon discharge</div><div>Discharging a patient home with Wound VAC</div><div> </div><div>Ensure Case management is involved early to ensure insurance authorization </div><div>and supply delivery</div><div> </div><div>If short term Vac therapy is needed, consider Vac Via</div><div> Can use placed on a patient for up to 4 days and then switched to wet-to-</div><div>dry dressings if Vac is no longer needed</div><div>Vac Tips:</div><div> </div><div>Stanford Policy states wound Vac changes are to be done Monday, </div><div>Wednesday and Friday.</div><div> Use clinical judgment if wound vac was placed at an odd time. Product </div><div></div><div> </div><div>Cut the sponge to the size of the wound or larger never smaller than the </div><div>wound so that the drape does not stick directly to the wound.</div><div> </div><div>Cut a big hole for track pad at least the size of a quarter.</div><div> </div><div></div><div> </div><div>When placing Wound VAC in clinic:</div><div> </div><div>If the VAC is a new placement- the patient will be Admitted to Observation for </div><div>wound vac placement and supply authorization via case manager (DO NOT </div><div>ADMIT VIA ED)</div><div> </div><div>If the VAC is established- patient should bring own supplies from home for in </div><div>clinic changes</div><div>Prevena:</div><div> </div><div>For use with closed incisions</div><div> </div><div>Should be placed at the time of wound closure in the OR, can also be placed </div><div>later</div><div> </div><div>The pump battery lasts for 7 days.</div><div> </div><div>Dressing should be removed and wound checked prior to discharge </div><div>(even if before battery dies)</div><div> </div><div>When the battery dies, the pump can be thrown away and the patient </div><div>removes the dressing and resumes normal wound care</div><div> </div><div>Risk for poor wound healing criteria (i.e. use of provena should be </div><div>considered)</div><div> Obesity (BMI&gt;36)</div><div> Diabetes (insulin-dependent, dialysis, or previous diabetic-induced  </div><div>organ damage) </div><div> COPD (forced expiratory volume in 1 second &lt; 80%)  </div><div> Bilateral IMA take-down  </div><div> COPD history</div><div> Corticosteroid use</div><div> Abnormally high preoperative creatinine ( &gt; 90th percentile) </div><div> More intraoperative blood transfusions (3 or more)  </div><div> Longer length of operation (&gt;4 hrs.) </div><div> Previous known poor wound healing episode </div><div>5.  Advance catheter through sheath until entire infusion segment is within </div><div>desired location </div><div>6.  Coil catheter and secure with adhesive strips </div><div>7.  Apply occlusive dressing over insertion site and coiled catheter. Keep </div><div></div><div>8.  Connect catheter to pump tubing.</div><div>Post-operative period: </div><div> </div><div>Pumps are not managed by pain service (do not page Pain service with </div><div>questions), they are managed by the primary team</div><div> </div><div>The pump works by administering a continuous infusion of bupivacaine </div><div>locally at the site of the incision. </div><div> </div><div>The pump is used in adjunct with analgesics (Tylenol, oxycodone, fentanyl, </div><div>dilaudid). While OnQ pump in place avoid concurrent use with other </div><div>similar agents, i.e. Lidocaine infusions </div><div> </div><div>Medication order: Bupivacaine 0.25% in 270mL @ 2mL/hr</div><div>Removal: </div><div> </div><div></div><div>medicine moving through the tubing. You may notice the outside bag on the </div><div>ball getting looser with wrinkles over time</div><div> </div><div>The pump should be removed 24 hours before discharge to allow for time to </div><div>ensure adequate pain control using oral pain medications</div><div> </div><div>To Remove: remove the dressing, remove small suture anchoring pump to </div><div>skin, and pull the clear catheter. The tube should come out easily. If it is hard </div><div>to remove or starts to stretch, stop and call your doctor right away.</div><div> The end of the tube should have a colored tip so you know that it is all </div><div>out. If the end of the tube does not have a colored tip, call your doctor </div><div>right away.</div><div> The entire unit should be disposed of in the red biohazard bins.</div><div>References: Clark, K. (2010). On-q catheters and introducers. ON-Q Pain Relief System. Retrieved </div><div>from http://www.halyardhealth.com/media/155090/14-60-603-0-04.pdf. </div><div>DEVICES: WOUND VAC</div><div>Vera o:</div><div> </div><div>Preferred over regular wound Vac for inpatients (may heal area faster)</div><div> Normal saline is the solution of choice. Any topically approved solution </div><div>can be placed into the Vac</div><div> </div><div> </div><div>Typical Settings: </div><div> -125mmHg</div><div> 0-20 min wash every 2-4 hours</div><div> </div><div>Grey foam can be used for packing tunneling areas or undermining that is </div><div>hard to visualize</div><div> </div><div>General principles: </div><div> When changing the Vac, use the pad to estimate how much saline is </div><div></div><div> </div><div> </div><div></div><div> </div><div>Supplies needed (Central supply # 35047</div><div> 1000mL container (item # 86309)</div><div> Cassette ( item #195927)</div></div><div></div></div>
<div><div><img><div>112 Reference Material Reference Material 113</div><div>SURGEON PREFERENCES</div><div>Surgeon </div><div>Preferences</div><div>Clinic</div><div>Woo</div><div>o  Review all images and review surgical plan prior to clinic</div><div> </div><div>o  2 week</div><div>Boyd</div><div>o  Echo within 3-6 months for Valves</div><div>o  Cath within 6 months (if CAD), within 1 year if most recent was clean/Valve</div><div>o  CTa within 3-6 months for Ascending aorta</div><div>o  Calculate STS score on all patients pre clinic (use most recent or normal </div><div>creatinine)</div><div>o  Calculate Syntax score for all CAD patients </div><div>o  All notes completed same day of clinic</div><div> </div><div>thromboembolic event </div><div>For inpatient CABG consults— see Boyd Consult H&amp;P document</div><div>Lee</div><div>o  Calculate STS score on all patients pre clinic (use most recent or normal creatinine)</div><div>o  Echo within 3 months</div><div>o  Cath within 6 months (if CAD), within 1 year if most recent was clean/Valve</div><div>o  CTa within 3-6 months for Ascending aorta</div><div>o  CTa (vs CT L atrial mapping) needed for all patient with prior history of ablation/</div><div>MAZE</div><div>o  If pacemaker, obtain make, model, implantation date</div><div>o  Calculate STS score on all patients pre-clinic (use most recent or normal </div><div>creatinine)</div><div>o  PFTs if any smoking history in last 10 years</div><div>o  Carotid US if carotid bruit on exam, h/o prior TAI or stroke, age &gt; 65, smoking </div><div>history, or family history of stroke </div><div>o  Obtain bilateral LE duplex US if history of vein stripping </div><div>o  All notes completed same day of clinic</div><div>o  DO NOT HOLD ASA PRE-OPERATIVELY</div><div>o  Post ops: </div><div>  o  MAZE:</div><div>  o  1-month POV – need ECG during clinic visit (may need TTE if patient’s  </div><div> most recent TTE prior to discharge had LVEF&lt; 40%). </div><div>  o  3-month POV -needs 72 hour Ziopatch as close to clinic visit as possible  </div><div> and a TTE prior to visit. </div><div>  o  6-month POV – needs 72 hour Ziopatch as close to clinic visit as possible. </div><div>  o  12- month POV –needs 72 hour Ziopatch as close to clinic visit as possible. </div><div>  o  Annually with 72 hour Ziopatch. VALVE follow up at 1 mos with Echo,  </div><div> then annually</div><div>  o  CABG fu at 1 mos (Echo only needed if EF decreased at discharge or  </div><div>  &lt; 40% pre op)</div><div>  o  Aortic surgery patients: FU @ 1, 3,6, and 12 months with CT scan</div><div>Fischbein o  Pre op</div><div>o  No Tissue consent for Aorta patients </div><div>Miller</div><div>Hiesinger o  Review all images and review surgical plan prior to clinic</div><div>SURGEON PREFERENCES, CONTINUED</div><div>Surgeon </div><div>Preferences</div><div>ICU Tele</div><div>Woo o  DC labs early if able</div><div>o  Post op CT c/a/p prior to discharge on </div><div>Acute Type A dissections only</div><div>o  Ok to DC home same day PW removed</div><div>Boyd</div><div>o  CABG patients 75mg Plavix daily x1 </div><div>year</div><div>o  All patients 200mg PO amio daily </div><div></div><div>o  SubQ heparin for  DVT prophylaxis </div><div>if no contraindication</div><div>o  Endocrine consult to manage DM if </div><div>elevated A1c</div><div>o  Daily senna started while in ICU</div><div>o  FAST TRACK (all uncomplicated </div><div>CABG with normal EF)</div><div>POD #1:0600;  Cordis/</div><div>Swan out by 1000 (even if still on </div><div></div><div></div><div></div><div>and Plavix</div><div>POD #2: Daily labs on case by case </div><div>basis. Transfer out of ICU</div><div>Overall considerations:</div><div>insulin gtt and start diet as early </div><div>as possible, ok to eat POD #0. Ok </div><div>to remove foley POD 1 even if on </div><div>diuretics. If waiting in ICU for tele </div><div>bed, ensure PT/OT and patient </div><div>mobilization.</div><div>o  DC labs early if able </div><div>o  CABG patients 75mg Plavix daily x1 year</div><div>o  All patients 200mg PO amio daily for </div><div></div><div>o  No Iron on discharge</div><div>o  Remove PW prior to CT</div><div>o  SubQ heparin for DVT prophylaxis if no </div><div>contraindication </div><div>o  No imaging needed prior to discharge</div><div>o  Acute Type A dissection post op CT @ </div><div>1month follow up appointment </div><div>o  Endocrine consult to manage DM if </div><div>elevated A1c</div><div>o  For routine CABG, goal is discharge by </div><div>at least POD #5</div><div>o  For myocardial bridge, DC Paravertebral </div><div>catheter POD #3 with goal of discharge </div><div>by POD #4 </div><div>Lee o  No IV amio gtt, boluses only</div><div>o  No nicotine patch for CABG</div><div>o  Avoid Reglan (due to black box </div><div>warning and association with </div><div>tardive dyskinesia)</div><div>o  No IV amio gtt, boluses only</div><div>o  No nicotine patch for CABG</div><div>o  Coreg no better than metoprolol for </div><div>Heart failure patients </div><div>o  For LAA excision:  Inspra 25mg BID </div><div>o  Avoid Reglan (due to black box warning </div><div>and association with tardive dyskinesia)</div><div>Fischbein o  Do not wean inotropes without </div><div>discussing directly </div><div>o  For patients on high dose pressors </div><div>or with high oxygen requirements, </div><div>discuss PO diet directly before </div><div>initiating </div><div>o  For post op CABG patients, </div><div>continue NTG while on Epi if blood </div><div>pressure allows</div><div>o  Start Epogen/Iron/Vit C in ICU for </div><div>post op anemia </div><div>o  IV Lasix and KCL while inpatient</div><div>o  Leave central line in place</div><div>o  PW remain in place until day prior to </div><div>discharge</div><div>o  Prior to discharge:</div><div>  o  Echo all valves </div><div>  o  CT all aortas (with 3D    </div><div>  measurements </div><div>o  Must approve all discharges</div><div>o  No IV hydralazine in dissections</div><div>o  PW out prior to CT if possible </div><div>Miller o   Avoid hydralazine in Aortic </div><div>Dissections/Aneurysm</div><div>o  Prior to discharge:</div><div>  o  Echo all valves (once PW removed </div><div>and within 2kg pre op wt)</div><div>  o  CT all aortas (with 3D </div><div>  measurements</div><div>o  Must approve all discharges</div><div>o  No IV hydralazine dissections</div><div>o  For LAA excision: Inspra 25mg BID</div><div>Hiesinger o  Post op imaging per patient- not </div><div>standard</div></div><div></div></div>
<div><div><img><div>114 Reference Material Reference Material 115</div><div>CARDIAC SURGERY PROCEDURE CLEARANCE</div><div>Dental Guidelines</div><div>Pre-op:</div><div> </div><div>Dental clearance will be obtained by schedules via clearance letter</div><div> </div><div>To be cleared for cardiac surgery: </div><div> Dental exam in last 6 months</div><div> No evidence of current dental infection or anticipated dental care needed </div><div>within the next 6 months (Excluding restoration or dentures) </div><div>Post-Op:</div><div> </div><div>Patients with valve repair or CABG SHOULD NOT have dental cleaning or work </div><div>done for at least 3 months post-op.</div><div> </div><div></div><div>material implanted SHOULD NOT have dental cleaning or work done for </div><div>at least 6 months post-op and should take prophylactic oral antibiotics, </div><div>prescribed from their dentist, before any procedures. (AHA guidelines)</div><div> </div><div>Patients are encouraged to follow up with their cardiologist recommendation </div><div>before proceeding with dental work and regarding the need for prophylactic </div><div>antibiotics. </div><div>Colonoscopy/Sigmoidoscopy Guidelines</div><div>Post-Op:</div><div> </div><div>Patients SHOULD NOT have an elective colonoscopy for at least 6 months  </div><div>post op</div><div> </div><div>Prophylactic antibiotics (usually IV given within 30 minutes of procedure) </div><div>should be considered for high risk patients only (presence of prosthetic heart </div><div></div><div>history of endocarditis)</div><div> </div><div>Prophylaxis IS NOT recommended for patients with the following: isolated </div><div>ASD, ASD s/p repair with patch, post op CABG, valvar dysfunction, mitral valve </div><div>prolapse, presence of cardiac pacemaker </div><div>References:</div><div>Oliver, G., Lowry, A., Vernava, A., Hicks, T., Burnstein, M., et. Al. (2000).  Antibiotics prophylaxis clinical </div><div>practice guideline: supporting documentation. The American Society of Colon and Rectal Surgeons. </div><div>PRE-OP: CHECK LIST</div><div> </div><div>H&amp;P </div><div> Completed within 24 hours of procedure</div><div>OR</div><div> Completed within 30 days, with H&amp;P interval within 24 hours of </div><div>procedure</div><div> </div><div>Consent (good for 1 year) </div><div> Procedure</div><div> ICU</div><div> Tissue/Study</div><div> Refusal of blood products if patient does NOT consent to blood </div><div>transfusion</div><div> </div><div>Pre op labs/imaging (must be completed at Stanford within 30 days of </div><div>surgery)</div><div> </div><div> CMP</div><div> PT, PTT</div><div> HgbA1c</div><div> Phosphorus</div><div> Urinalysis, screen for culture</div><div> Type and Screen (for outpatient, clot should be extended for 30 days.  </div><div>For inpatient, must be within 72 hours of procedure)</div><div> RBCS (Refer to page 116 to know how many units to order ahead)</div><div> EKG</div><div> CXR (2V preferred) </div><div> </div><div>Day of surgery orders (found in order set #4658): </div><div> Surgical preparation- clipping, antimicrobial showers x 2, Mepilex to </div><div>sacrum</div><div> Surgical prophylaxis with antibiotics (ON CALL)</div><div> Peridex mouthwash (ON CALL)</div><div> DVT prophylaxis </div><div> </div><div>Misc pre op</div><div> Anticoagulation bridging with Lovenox</div><div> Radial artery harvest work up</div><div> Dental clearance </div><div> Any other studies needed (Cath, Echo, CT, etc)</div><div>TAAA Repair specic:</div><div>Patients are pre-admitted day before surgery for lumbar drain, epidural, and </div><div>bowel prep.</div><div> Page pain service to place epidural preferably day before it is needed </div><div>(2-PAIN)</div><div> </div><div> Clear diet</div><div> Bowel prep</div><div> </div></div><div></div></div>
<div><div><img><div>116 Reference Material Reference Material 117</div><div>PRE-OP:CARDIAC SURGERY PATIENT BLOOD </div><div>MANAGEMENT PROGRAM</div><div>(Ref: Info redistributed from CV Clinical Outcomes; 2011: Stanford Maximum Surgical </div><div>Blood Order Schedule (MSBOS) Criteria)</div><div>Procedure: Type &amp; Screen and </div><div>Type &amp; Cross (Y/N)</div><div>Cardiac Surgery </div><div>recommended # RBC </div><div>units order pre-op</div><div>Combo Sx: “Low Risk” Group:   </div><div>(Includes: Iso CABG, Open &amp; Mini Valve Repair/Replace)</div><div>1st Sx: IsoCABG</div><div>Y 2</div><div>1st Sx: Open AVR</div><div>Y 2</div><div>TAVR (TFem, TApical, </div><div>TAortic)</div><div>Y 4</div><div>1st Sx: Valve + CABG OR </div><div>Multiple Valves</div><div>Y 4</div><div>1st Sx: AoRoot (no arch) </div><div>Combo TD, CVG, AscAo</div><div>Y 4</div><div>1st Sx: TD +/- Asc Arch</div><div>Y 4</div><div>1st Sx: CVG +/- Acs Arch </div><div>Y 4</div><div> 1st Sx: Asc + Arch (no valve) </div><div>+/- descending </div><div>Y 4</div><div>Redo Sx:  CABG + Valve </div><div>Y 4</div><div>Combo Sx: “High Risk” Group:  </div><div>(Includes: Redo TD, Redo CVG, any 1st or Redo Arch Replace, Open Desc Ao, </div><div>and 1st or Redo TAAA)  </div><div>Redo Sx:  TD +/- Arch</div><div>Y 6</div><div>Redo Sx:  CVG +/- Arch</div><div>Y 6</div><div>Redo Sx:  CVG, No Arch</div><div>Y 6</div><div>Redo Sx:  Asc +/- Arch</div><div>Y 6</div><div>Open Desc. Ao (All)</div><div>Y 6</div><div>Open TAAA (All)</div><div>Y 6</div><div> </div><div>*Key:</div><div></div><div></div><div>TD= Tyrone David (aka: David V, Valve Sparing)</div><div>Patients with Heparin allergy or HIT; document in H&amp;P note and inform perfusion on </div><div>surgical day. (Patient with Heparin allergy will receive Argatroban, Bivalirudin  </div><div>or heparin.)</div><div>Pre-Op Blood Saving:</div><div> </div><div>Autologous Donation: Patients can donate their own blood, can donate 6 </div><div>weeks before surgery, increase folic acid, vitamin C, iron supply (ask your </div><div>attending surgeon if this is preferred)</div><div> </div><div>Jehovah’s Witness: Patients Witnesses’ refusal of transfusions of whole </div><div>blood or its four primary components—red cells, white cells, platelets and </div><div>plasma; can use use of fractions such as albumin, immunoglobulins and </div><div>hemophiliac preparations &amp; cell saver. (WatchTower Society)</div><div> Bloodless medicine program in process 1/2017. Refer to updated protocol </div><div>for current pre-operative guidelines for patients who refuse blood </div><div>transfusion.</div><div> </div><div>Herbal Products: Potential interactions to avoid (JACC, 2010), (Alfalfa, </div><div>Angelica, Bilberry, Garlic, Ginger, Ginko, Ginseng, Echinacea, Licorice, St. </div><div>Johns Wart).  Can cause interactions with cardiac medications &amp; increase </div><div>bleeding during surgery.</div><div>Intra-Op Blood Saving:</div><div> </div><div>Blood clotting agent/blood derived fraction agents (Coseal/Tisseal/Floseal)</div><div> </div><div>Perfusion: </div><div> Cell Saver:  recovering blood lost during surgery and re-infusing it into </div><div>the patient. It is a major form of autotransfusion. Cell processors are </div><div>red cell washing devices that collect anticoagulated shed or recovered </div><div>blood, wash and separate the red blood cells (RBC) by centrifugation, and </div><div>reinfuse the RBC. </div><div> </div><div> </div><div>PRE-OP: CLASSIFICATIONS</div><div>CCS Functional Classication of Angina</div><div>Class Description</div><div>Class I Angina only during strenuous or prolonged physical activity</div><div>Class II Slight limitation, with angina only during vigorous physical activity</div><div>Class III Symptoms with everyday living activities  (i.e. moderate limitation)</div><div>Class IV Inability to perform any activity without angina or angina at rest </div><div>(i.e. severe limitation)</div><div>Staging Kidney Disease: always document CKD Stage 3 or greater</div><div>Stage Description</div><div>Stage I With normal of high GFR (GFR &gt; 90mL/min)</div><div>Stage II Mild CKD (GFR = 60-89mL/min)</div><div>Stage IIIa Moderate CKD (GFR = 45-59mL/min)</div><div>Stage IIIb Moderate CKD (GFR = 30-44mL/min)</div><div>Stage IV Severe CKD (GFR = 15-29mL/min)</div><div>Stage V End Stage CKD (GFR &lt; 15mL/min)</div><div>GFR calculator Website:</div><div>http://www.davita.com/gfr-calculator/</div><div>http://www.kidney.org/professionals/KDOQI/gfr_calculator</div></div><div></div></div>
<div><div><img><div>118 Reference Material Reference Material 119</div><div>ACC/AHA Classication of CHF</div><div>The ACC/AHA created four classications from risk for develop the </div><div>disease to severe disability.</div><div>Stage Description</div><div>A (High risk for </div><div>developing CHF)</div><div>Hypertension, DM, Family history, CAD</div><div>B (Asymptomatic HF) Previous myocardial infarction (heart attack), valvular </div><div></div><div>C (Symptomatic HF) Structural heart disease, fatigue, low tolerance level for </div><div>physical activity</div><div>D (Refractory  </div><div>end-stage HF)</div><div>Severe limitations. Experience symptoms even  </div><div>while at rest.</div><div>NYHA Functional Classication</div><div>The NYHA classied heart failure into classes base on functional </div><div>limitations and severity.</div><div>Class FUNCTIONAL CAPACITY: Patient Symptoms</div><div>I (Normal) Few observable sx, no limitations in ordinary physical activity</div><div>II (Mild) Mild observable sx and slight limitation during ordinary activity. </div><div>Comfortable at rest.</div><div>III (Moderate) Marked limitation in physical activity due to symptoms even </div><div>during less than ordinary activity. Comfortable only at rest.</div><div>IV (Severe) End-stage heart failure. Severe limitations. Experience </div><div>symptoms even while at rest.</div><div>Class OBJECTIVE ASSESSMENT</div><div>A No evidence of cardiovascular disease. No symptoms and no </div><div>limitation in ordinary physical activity.</div><div>B Objective evidence of minimal cardiovascular disease. Mild </div><div>symptoms and slight limitation during ordinary activity. </div><div>Comfortable at rest.</div><div>C Objective evidence of moderately severe cardiac disease. </div><div>Marked limitation in activity due to symptoms, even during less </div><div>than ordinary activity. Comfortable only at rest.</div><div>D Objective evidence of severe cardiovascular disease. Severe </div><div>limitations. Experiences symptoms even while at rest.</div><div>For Example:</div><div>A patient with minimal or no symptoms but a large pressure gradient across the </div><div></div><div>Function capacity I, Objective Assessment D</div><div>A patient with severe angina syndrome but angiographically normal coronary </div><div>Functional Capacity IV, Objective Assessment A</div><div>Other Helpful Scores/Resources</div><div>NYHA Class </div><div>Website:</div><div>http://www.heart.org/HEARTORG/Conditions/</div><div>HeartFailure/AboutHeartFailure/Classes-of-Heart-</div><div>Failure_UCM_306328_Article.jsp</div><div>Griepp Score The 1997 ATS paper by Randy Griepp and colleagues </div><div>describes an easy-to-use risk of rupture calculator </div><div>developed by Abe DeAnda (Chief Resident 2000-</div><div>2001). If aortic dissection, RBG just adds 0.5 cm to </div><div>the descending thoracic aortic and abdominal aorta </div><div>diameter numbers. Several other calculator tools are </div><div>also on the spreadsheet.</div><div>    Reference the </div><div>Cardiac Surgery </div><div>APP Shared Box </div><div>folder for this </div><div>information.</div><div>Syntaxcore SYNTAX score II creates accurate mortality predictions </div><div>to guide the choice between PCI and CABG for </div><div>patients with multivessel coronary disease.</div><div>    http://</div><div>syntaxscore.</div><div>com/</div><div> </div><div>PRE-OP: NORMAL ECHO VALUES</div><div>Normal Echo Values</div><div>LV Diastolic Dimension 3.7-5.5cm</div><div>LV Systolic Dimension 2.0-4.0 cm</div><div>Interventricular septum (Diastole) 0.6-1.1 cm</div><div>LV Posterior Wall (Diastole) 1.8-2.2 cm</div><div>LVOT Diameter (Systole) 1.8-2.2cm</div><div>Aortic Root (Diastole) 2.0-3.7cm</div><div> 2.0-4.0cm</div><div> &lt;20cm2</div><div> 16-28ml</div><div>RV Diastolic Dimension 0.9-2.5cm</div><div> </div><div>Pulmonic Valve Echo Values</div><div>Mild 5-25mmHg</div><div>Moderate 25-49mmHg</div><div>Severe &gt;50mmHg</div><div> </div><div>Aortic Valve Echo Values</div><div>AS Grading Mean Gradient </div><div>(mmHg)</div><div>Peak Velocity (m/s) AVA (cm2)</div><div>Normal &lt; 10 &lt; 2.6 &gt;2.5</div><div>Mild 10-25 2.6-2.9 1.5-2.5</div><div>Moderate 20-45 3.0-4.0 1.0-1.5</div><div>Severe &gt;45 &gt;4.0 0.7-1.0</div><div>Critical &gt;50 &gt;4.0 &lt;0.7</div><div>AR Grading Central Jet width* Regurgitant Volume </div><div>(per beat) </div><div>EROA (eective </div><div>Regurgitant oriace </div><div>area)</div><div>Mild &lt; 25% of LVOT width &lt; 30mL &lt;0.1cm2</div><div>Moderate 25-65% of LVOT width 30-59mL 0.1-0.3cm2</div><div>Severe &gt;65% of LVOT width &gt;60mL &gt;0.3cm</div><div>Tricuspid Valve Echo Values</div><div>Signicant tricuspid stenosis</div><div>Mean pressure gradient &gt;/= 5mmHg</div><div>Valve area &lt;/= 1cm2</div><div>Tricuspid </div><div>Regurgitation</div><div>MILD MODERATE SEVERE</div><div>Jet area &lt; 5 5-10 &gt;10</div><div>RV/RA/IVC Size Normal Normal or dilated Usually dialates</div></div><div></div></div>
<div><div><img><div>120 Reference Material Reference Material 121</div><div>Mitral Valve Echo Values</div><div>MS grading Valve Area Mean gradient Pulmonary artery </div><div>pressure (mmHg)</div><div>Mild &gt;1.5 cm2 &lt;5mmHg &lt;30mmHg</div><div>Moderate 1.0-1.5 cm2 5-10mmHg 30-50mmHg</div><div>Severe &lt;1.0cm2 &gt;10mmHg &gt;50mmHg</div><div>MR grading  Jet area Regurgitant Volume EROA (eective </div><div>Regurgitant oriace </div><div>area)</div><div>Mild &lt;20% of LA area &lt;30mL &lt;0.2cm2</div><div>Moderate 20-40% of LA area 30-59mL 0.2-0.39 </div><div>Severe &gt;40% of LA area &gt;60mL &gt;0.40cm2</div><div>PRE-OP: OBTAINING CONSENT/PROCEDURE LIST</div><div>Procedure Correct verbiage for Consent</div><div>CABG </div><div></div><div>• Does not need to include IMA (LIMA/RIMA) </div><div>Consent must specify conduit harvesting when applicable:</div><div>EVH= Endoscopic vein harvest</div><div>RAH= Endoscopic radial artery harvest </div><div>CABG </div><div>MIDCAB </div><div>possible sternotomy, cardiopulmonary bypass on standby</div><div>TAVR Transcatheter aortic valve replacement</div><div>• Include approach (transfemoral, transapical, or transaortic) </div><div>• Also include cardiopulmonary bypass on standby </div><div>• Also include transesophageal echocardiogram</div><div>Mini MVR Right anterior thoracotomy; mitral valve/replacement repair on </div><div>cardiopulmonary bypass, possible sternotomy. </div><div>Mini AVR Minimally invasive aortic valve repair/replacement; on cardiopulmonary bypass</div><div>Hybrid MAZE Bilateral video assisted thoracoscopy; pulmonary vein isolation; with additional </div><div></div><div>MAZE; cardiopulmonary bypass on standby</div><div>Cox Maze Maze procedure on cardiopulmonary bypass</div><div>Myectomy/</div><div>Myotomy</div><div>Myectomy/myotomy with possible mitral valve repair/replacement on </div><div>cardiopulmonary bypass</div><div>Myocardial bridge </div><div></div><div></div><div>Redo stern Redo sternotomy</div><div>LAA Excision </div><div>Laser lead </div><div>extraction</div><div>Laser lead extraction with possible pacemaker generator change; possible </div><div>sternotomy; Cardiopulmonary bypass on standby</div><div></div><div>TEVAR (CT surgery </div><div>attending is </div><div>surgical consent </div><div>attending, Dr. Dake </div><div>does not sign this </div><div>procedure consent)</div><div></div><div>• Do not include Lumbar drain (Anesthesia will consent separately)</div><div>VSARR or Tirone </div><div>David (T-David)</div><div>Valve sparing aortic root replacement, possible aortic valve replacement on </div><div>cardiopulmonary bypass </div><div>Aortic replacement Include following when applicable: ascending aortic replacement, descending </div><div>aortic replacement, total arch replacement, hemi-arch replacement, elephant </div><div></div><div>Aortic root  Aortic root replacement including aortic valve replacement on cardiopulmonary </div><div>bypass</div><div>TAAA Thoracoabdominal aortic aneurysm repair on cardiopulmonary bypass </div><div>SACP &amp; PHCA Under Deep Circulatory Arrest</div><div>Heart transplant Heart transplant on cardiopulmonary bypass</div><div>VAD Ventricular assist device insertion on cardiopulmonary bypass </div><div>• Include type of device: Heartmate II or Heartware</div><div> </div><div> </div><div>Procedure consent must be signed by someone who can perform the </div><div>procedure listed</div><div> Ex: Valve replacement = Attending/resident</div><div> Ex: Cardioversion/Pigtail placement = APP</div><div> </div><div>ICU consent can be signed by APP</div><div> </div><div>Consent is good for 1 year</div><div> </div><div>Make sure all abbreviations are completely spelled out. NO ABBREVIATIONS.  </div><div> </div><div>Check blood consent box on both forms and give patient transfusion packet (If </div><div>the patient refuses blood transfusion, use the additional blood refusal form)</div><div> </div><div>Median sternotomy DOES NOT need to be included on expected “standard </div><div>sternotomy” consents.  ONLY on “Possible Sternotomy” cases (i.e. anterior </div><div>thoracotomy, then “possible sternotomy” should also be included).</div><div> </div><div>NO SCRATCHES, CROSS THROUGHS, OR SCRIBBLES ALLOWED ON CONSENT</div><div>PRE-OP: PFT AND CAROTID US INTEPRETATION</div><div>Carotid Duplex Ultrasound Criteria for Grading Internal Carotid Artery Stenosis</div><div>Degree of </div><div>Stenosis (%)</div><div>ICA PSV (cm/2) ICU/CCA PSV </div><div>Ratio</div><div>ICA EDV (cm/2) Plaque Estimate </div><div>(%)</div><div>Normal &lt; 125 &lt;2.0 &lt;40 None</div><div>&lt;50 &lt;125 &lt;2.0 &lt;40 &lt;50</div><div>50-69 125-230 2.0-4.0 40-100 &gt;50</div><div>&gt;70 to less than </div><div>near occlusion</div><div>&gt;230 &gt;4.0 &gt;100 &gt;50</div><div>Near occlusion High, low, or not </div><div>detected</div><div>Variable Variable Visible</div><div>Total occlusion Not detected Not applicable Not detected Visible, no lumen</div><div>*Plaque estimate (diameter reduction) with gray scale and color Doppler ultrasound. ICA = internal </div><div>carotid artery; CCA= common carotid artery; PSV = peak systolic velocity; EDV = end- diastolic velocity</div><div>*Intervention may be required prior to cardiac surgery on cardiopulmonary bypass if degree of </div><div>stenosis is &gt; 90% unilateral or &gt; 75% bilateral due to increased stroke risk </div><div>Normal Value of Pulmonary Function Tests</div><div>** FEV1    80% to 120% </div><div>FVC 80- 120%</div><div>Absolute FEV1/FVC ratio Within 5% of the predicted ratio</div><div>TLC 80-120%</div><div>FRC 75-120%</div><div>RV 75-120%</div><div>** DLCO </div><div>Also known as TLCO or Dsb </div><div>&gt;60% to  &lt;120%</div><div>**These are key for interpreting</div><div>Spirometry</div><div>Low FEV1/FVC</div><div>Obstruction</div><div>Bronchodilator</div><div>FEV1 unchanged/</div><div>partially </div><div>improved</div><div>(asthma or COPD)</div><div>Obstruction </div><div>Normalizes </div><div>(asthma)</div><div>DLCO</div><div>Low (COPD/</div><div>Emphysema/</div><div>bronchiolitis)</div><div>Normal/High</div><div>(asthma or COPD)</div><div>Normal</div><div>? Asthma</div><div>Bronchoprovocation </div><div>challenge</div><div>FEV1 </div><div>Decreased </div><div>(asthma more </div><div>likely)</div><div>No Change in FEV1 </div><div>(asthma unlikely)</div><div>DLCO</div><div>Low (anemia, </div><div>early ILD, </div><div>pulmonary </div><div>vascular </div><div>disease) </div><div>Normal/</div><div>High</div><div>Normal</div><div>Normal FEV1/</div><div>FVC</div><div>Low VC</div><div>Restriction</div><div>Confirm with </div><div>lung volumes</div><div>DLCO</div><div>Low</div><div>(ILD)</div><div>Normal (chest </div><div>wall/</div><div>neuromuscular)</div><div>Maximum </div><div>inspiratory/</div><div>expiratory </div><div>pressures</div><div>Low</div><div>(neuromuscular)</div></div><div></div></div>
<div><div><img><div>122 Reference Material Reference Material 123</div><div>PRE-OP: PERIPROCEDURAL  </div><div>ANTICOAGULATION BRIDGING</div><div><div>Brand Name </div></div><div>(Generic Name) Half Life/Onset of Action Last dose of medication Before Surgery:</div><div><div>If indicated: When To Start Lovenox </div><div>(dosing=1mg/kg)</div></div><div><div>#            </div><div>syringes</div></div><div>Notes Cath procedures</div><div>Coumadin </div><div><div>(Warfarin)         </div><div>Once daily dosing </div></div><div>20-60hours/3-5 days 5 days before date of surgery</div><div><div>Start 2 days after d/c coumadin (inj Q12 until day </div><div>before surgery.  Day before surgery just ONE </div><div>injection in the morning)</div></div><div>5</div><div><div>Example:  surgery date 4/10; last dose </div><div>Coumadin 4/5; off all one day, 4/6; start </div><div>Lovenox Q12 on 4/7; last Lovenox injec on </div><div>4/9 (morning before sx)</div></div><div><div>Hold 5 days prior for femoral access, </div><div>and if pt mod-high risk for clot bridge </div><div>to Lovenox.  Hold 2 days prior for </div></div><div>radial access</div><div>Eliquis </div><div><div>(Apixaban)               </div></div><div>BID dosing </div><div>9-14hours/3-4 hours</div><div><div>5 days before date of surgery              </div><div>(If CrCl &lt; 50 Hold 6-7 doses)</div></div><div><div>Start 1 day after d/c anticoagulant (inj Q12 until day </div><div>before surgery.  Day before surgery just ONE </div><div>injection in the morning)</div></div><div>7</div><div><div>Example:  surgery date 4/10; last dose </div><div>Eliquis 4/5(am); start Lovenox Q12 on 4/6; </div><div>last Lovenox injec on 4/9 (morning before </div></div><div>surgery)</div><div><div>Hold x 2 days:  the day before and </div><div>the day of Cath</div></div><div>Xarelto </div><div><div>(Rivorxaban)                </div><div>Once daily dosing</div></div><div>11-13 hours/2-4 hours</div><div><div>3 days before date of surgery              </div><div>(If CrCl &lt; 30 Hold 3 doses)</div></div><div><div>Start 1 day after d/c anticoagulant (inj Q12 until day </div><div>before surgery.  Day before surgery just ONE </div><div>injection in the morning)</div></div><div>3</div><div><div>Example:  surgery date 4/10; last dose </div><div>Xarelto 4/7(am); start Lovenox Q12 on 4/8; </div><div>last Lovenox injec on 4/9 (morning before </div></div><div>surgery)</div><div><div>Hold x 2 days:  the day before and </div><div>the day of Cath</div></div><div>Pradaxa </div><div><div>(Dabigatran)              </div></div><div>BID dosing </div><div>12-17hours /1 hour</div><div><div>5 days before date of surgery              </div></div><div><div>Start 1 day after d/c anticoagulant (inj Q12 until day </div><div>before surgery.  Day before surgery just ONE </div><div>injection in the morning)</div></div><div>7</div><div><div>Example:  surgery date 4/10; last dose </div><div>Pradaxa 4/5(am); start Lovenox Q12 on </div><div>4/6; last Lovenox injec on 4/9 (morning </div></div><div>before surgery)</div><div><div>Hold the night before and morning of </div><div>procedure.  Last dose will be in the </div><div>morning the day before Cath</div></div><div>SAVAYSA</div><div><div> (endoxaban)               </div><div>Once daily dosing </div></div><div>10-14 hours/ 1-2 hours</div><div><div>3 days before date of surgery               </div><div>(If CrCl &lt; 30 Hold 3-4 doses)</div></div><div><div>Start 1 day after d/c anticoagulant (inj Q12 until day </div><div>before surgery.  Day before surgery just ONE </div><div>injection in the morning)</div></div><div>3</div><div><div>Example: surgery date 4/10; last dose </div><div>Savaysa 4/7( AM); Lovenox BID 4/8 1 </div><div>lovenox inj AM only on 4/9. </div></div><div><div>Hold x2 days: the day before and the </div></div><div>day of Cath</div><div>Plavix (Clopidogrel)</div><div>5 days before date of surgery</div><div><div>Start 1 day after anticoagulant held (inj Q12 until </div><div>day before surgery.  Day before surgery just ONE </div><div>injection in the morning)</div></div><div>7</div><div><div>Only bridge for pt&amp;apos;s taking Plavix for A.fib.  </div><div>If taking for Stents, hold 5 days before </div><div>surgery and do not bridge</div></div><div>PLETAL (cilostazol)</div><div><div>11-13 hours, reach steady state blood </div><div>levels within a few days.</div></div><div>5 days before date of surgery Does not need bridging</div><div>Asprin</div><div><div>If having valve surgery d/c 2 days before surgery date.  </div><div>If having CABG stop day before</div></div><div>Does not need bridging</div><div><div>If taking ASA 325mg, have patient </div><div>decrease dose to 81 mg as soon as </div><div>procedure scheduled</div></div><div>EFFIENT (prasugrel)</div><div>7 hours /4 hours 5-7 days before date of surgery Does not need bridging</div><div><div>Pre operative bridging with lovenox is required for all mechanical heart valves* &amp;  is only need for atrial fibrillation when CHAD score is High** . For low clot risk,  hold anticoagulant per chart above. </div></div><div><div>Medications to CONTINUE           </div><div>to take morning of surgery</div></div><div>Medications to STOP before surgery</div><div><div>CHADS SCORE</div><div> Lovenox to Coumadin</div></div><div><div>Anti-seizure meds</div></div><div><div>ASA:      </div><div>Valve Surgery= Last Dose 2 days before surgery       </div><div>CABG only: Stop day before surgery      CABG &amp; </div><div>Valve=Stop day before surgery    (Please follow </div><div>attending preference if different)</div></div><div><div>1 pt for each risk factor present:                            </div><div>CHF, HTN, DM, PAD or MI, Age 65-74, </div><div>Female                    </div><div>2 pts for each risk factor present</div></div><div>:                           </div><div><div>Age &gt; 74 years old, Prior stroke or TIA or </div><div>thromboembolism        </div></div><div><div>1. Resume oral </div><div>anticoagulant and </div><div>lovenox evening after </div><div>procedure if no bleeding          </div><div>2. Resume oral </div><div>anticoagulant  + lovenox </div><div>post procedure day 1-3            </div></div><div><div>Anti-Psych meds </div></div><div><div>Blood Thinners: see above</div><div>SCORE / RISK**</div></div><div><div>Beta-blockers</div></div><div><div>NSAIDS: stop 7 days before surgery</div><div>0-2 = LOW</div></div><div><div>Depression meds</div></div><div><div>Insulin:  Insulin Am dose is normal the day before </div><div>surgery. Insulin PM dose is </div></div><div>½ dose the evening before </div><div><div>surgery. Nothing on the morning of surgery</div></div><div> 3-4 = MODERATE</div><div><div>Inhalers</div></div><div><div>Metformin; stop 48 hours before surgery</div><div>5-6 = HIGH</div></div><div><div>Immunosuppressive meds</div></div><div><div>Stop ALL vitamins;1 week prior to surgery</div><div>TIA IN PREVIOUS 3 MONTHS = HIGH</div></div><div><div>Methadone</div></div><div><div>Fish oil; stop 5 days before surgery</div><div>SEVRE VALVULAR DISEASE = HIGH</div></div><div><div>Nitrates; (Imdur)</div></div><div><div>Herbs; stop asap (many of these have anti-coag effects)</div></div><div><div>Parkinson&amp;apos;s meds</div></div><div><div>Maltaq (dronedarone); DO NOT take day of surgery, </div><div>last dose is day before surgery.</div></div><div><div>Proton Pump Inhibitors (PPI&amp;apos;s)</div></div><div>*If Presence of Mechanical Mitral valve:  References:</div><div><div>Thyroid meds               </div><div>Birth Control Pills</div></div><div><div>1. Last dose coumadin 7 days prior to surgery   </div><div>2. Bridge with lovenox as above        </div><div>3. Admit to observation day prior to surgery for </div><div>heparin drip (to be stopped 6 hours before </div><div>surgery). </div></div><div><div>Pernod, G., Godier, A., Gozalo, C., </div><div>Tremey, B., Sie, P. (2010). French clinical </div><div>practice guidelines on the management of </div><div>patients on vitamin K antagonists in at-risk </div><div>situations (overdose, risk of bleeding, and </div><div>active bleeding). Thrombosis Research, </div><div>126, e 167-e174. </div></div><div><div>Brunett, A.E., Mahan, C.E., Vaquez, </div><div>S.R.,Oertel, L.B., Gardcia, D.A., &amp; </div><div>Ansell, J. (2016) Guidance for the </div><div>practical management of direct oral </div><div>anticoagulants (DOACs) in VTE </div><div>Treatment. Journal of Thromb </div><div>Thrombolysis, 41 : 206-232. </div></div><div><div>Last updated 12/2016</div></div><div><div>                   Pre-procedure Anticoagulation Bridging Recommendations                                                                                                                                                                </div><div>for Cardiac surgery</div></div><div><div>3. Check INR post </div><div>proceudre day 4 and DC </div><div>lovenox if INR theraputic</div></div><div>POST-OP: IMAGING</div><div>Modality Inpatient Contact Info Misc</div><div>Echocardiogram  </div><div>(viewed in Xcelera)</div><div>Scheduling: 5-4160, 5-4159, </div><div>3-8988</div><div>Reading room: 3-9503</div><div>o  Use TAVR or TMVR echo order when </div><div>appropriate</div><div>CT (+/- angio) scan  </div><div>(viewed in Centricity)</div><div>Scheduling: 3-6885</div><div>Body reading room: 4-9617</div><div>CVI reading room: 6-2424</div><div>Chest reading room: 3-1346</div><div>Neuro reading room: 4-3145</div><div>o  Gated: evaluates coronaries (Note </div><div></div><div>comments) </div><div>o  Pre and post op aortic disease </div><div>include in comments: Please </div><div>perform with 3D measurements </div><div>and images for treatment </div><div>planning and surveillance (use </div><div>smart phrase CTANGIO3DIMAGES)</div><div> </div><div>mapping) used for pre-op Maze </div><div>o  Consider need for CT chest vs CT </div><div>Chest/Abdomen/Pelvis</div><div>CT CORONARY ANGIO  </div><div>(viewed in Centricity)</div><div>Scheduling: 3-6885</div><div>CVI reading room: 6-2424</div><div>o  Limited study- concentrated on heart </div><div>and coronary arteries (does not </div><div>include thoracic aorta)</div><div>o  Will always be completed gated </div><div> </div><div>in comments. If patient is in atrial </div><div></div><div></div><div>MRI (viewed in </div><div>Centricity)</div><div>Scheduling: 3-6855</div><div>Body reading room: 6-8591</div><div>Cardiac reading room: </div><div>6-2424</div><div>Neuro reading room:4-3145</div><div>Vascular lab: 5-5227</div><div>o  For Aortic Disease, include comment: </div><div>Please perform cardiac MRI (gated) </div><div>with cross hatching, refer to Dr. </div><div>Fleishman if unsure of protocol. </div><div>US Carotid </div><div>(viewed in Centricity)</div><div>Vascular lab: 5-5227</div><div>Spirometry with DLCO </div><div>(results in Epic)</div><div>Inpatient: 3-6371</div><div>Adult pulmonary clinic: </div><div>5-7061</div><div>o  PFTs can be performed by Inpatient </div><div>beside respiratory therapist (during </div><div></div><div>FDG PET CT Clinical </div><div>Cardiac Viability with </div><div>resting myocardial </div><div>perfusion scan (viewed </div><div>in Centricity)</div><div>Scheduling: 3-6885</div><div>Body reading room: 4-9617</div><div>CVI reading room: 6-2424</div><div>Chest reading room: 3-1346</div><div>o  Include in comments: testing </div><div>myocardial viability in CAD patient as </div><div>pre-op work up for CABG</div><div>Venous Ultrasound </div><div>(viewed in Centricity)</div><div>Scheduling: 3-6855</div><div>Reading room: 8-2401</div><div>Arterial Exam/ABIs in </div><div>Vascular clinic (viewed </div><div>in Centricity)</div><div>Vascular lab: 5-5227</div><div>Tagged WBC scan  </div><div>(viewed in Centricity)</div><div>Nuclear Med scheduling: </div><div>4-4278</div><div>Nuclear Med reading room: </div><div>8-2414</div><div>Nuclear Med techs: 4-5684</div><div> </div><div>o  Nuclear- bone</div><div>Cardiac cath  </div><div>(viewed in LifeImage)</div><div>Cath lab extension: 3-7676</div><div>Cath lab recovery: 3-9317</div><div>o  To schedule inpatient, page </div><div>interventional cardiologist on call</div><div>EKG lab 3-7121</div><div>1-4987</div><div>o  Places long term cardiac monitors on </div><div>discharge</div><div>X-ray 62198</div><div>Scheduling: 37030</div><div>Reading room: 87996</div><div>Endoscopy 5-8117</div></div><div></div></div>
<div><div><img><div>124 Reference Material Reference Material 125</div><div>POST-OP: ABG INTERPRETATION</div><div>pH  /  pCO2 /  paO2 /  Sat % /  Base Decit /  Bicarb</div><div>Normal range 7.35 – 7.45</div><div>&lt; 7.35 Acidosis</div><div>•  Look at pCO2</div><div>  o  If High </div><div>  respiratory acidosis</div><div>  o  If normal </div><div>  metabolic acidosis</div><div>•  How to Fix it: </div><div>  o  Respiratory acidosis: </div><div> •  Intubated: increase RR, tidal volume to  </div><div> increase minute ventilation</div><div> •  Extubated: decrease sedation, Bipap to  </div><div> increase ventilation</div><div>  o  Metabolic acidosis:</div><div> •  Bicarbonate supplementation</div><div> •  Further workup for source: Fluid status,  </div><div> BMP, lactate, etc</div><div>&gt; 7.45 Alkalosis</div><div>•   Look at pCO2</div><div>  o  If Low </div><div>  respiratory alkalosis</div><div>  o  If Normal </div><div> Metabolic alkalosis</div><div>•  How to Fix it</div><div>  o  Respiratory alkalosis:</div><div>  •  If intubated: decrease RR, tidal volume</div><div>  •  If extubated: control pain, anxiety,  </div><div> cause of hyperventilation (hypoxia?)</div><div>  o  Metabolic alkalosis:</div><div>  •  Further workup for source: BMP, PRBC  </div><div> transfusion, overdiuresis, etc </div><div>pCO2 Normal range: 35-45</div><div>pCO2 &lt; 35 Respiratory alkalosis</div><div>•  See pH box (Alkalosis)</div><div>pCO2 &gt;45 Respiratory acidosis</div><div>•  See pH box (Acidosis)</div><div>Base Decit normal: +/-2 mEq/L; Bicarb normal 22-30</div><div>This is calculated, not measured on the ABG</div><div>Metabolic Acidosis:</div><div>•  See pH box (Acidosis) above</div><div>Metabolic Alkalosis: high bicarbonate, positive base excess</div><div>•  See pH box (Alkalosis) below</div><div>PaO2 Normal range 60-200mmHg; Sat % Normal range 92-100%</div><div>Increasing O2 content</div><div>•  Increasing FiO2</div><div>•  Increasing NC LPM</div><div>CXR/Ultrasound to assess for</div><div>•  Pneumothorax</div><div> </div><div>•  Hemothorax</div><div>•  Pneumonia</div><div>Increase PEEP (on ventilator or CPAP/BiPap) for </div><div>alveolar recruitment</div><div>Mobilize secretions:</div><div>•  Chest PT</div><div>•  Suctioning</div><div>•  Mucolytics (ie Mucomyst)</div><div>Improve VQ matching</div><div>•  Inhaled bronchodilators (albuterol)</div><div>•  Inhaled vasodilators (Flolan, iNO)</div><div>•  IPPV, incentive spirometer, acapella for </div><div>alveolar recruitment</div><div>•  Consider stopping potential shunting </div><div>agents inhibiting hypoxic vasoconstriction: </div><div>Clevidipine, Nicardipine, Nitroprusside, NTG, </div><div></div><div>POST-OP: ADVANCED HEMODYNAMIC </div><div>MONITORING &amp; PULMARY ARTERY CATHETERS</div><div>Parameter Normal Value</div><div>Cardiac Output (CO) 4-8 L/min</div><div>Cardiac Index (CI) 2.2-4 L/min/m2</div><div>CVP (central venous pressure aka Right atrial pressure) 3-8 mmHg</div><div>PA (pulmonary artery) Pressure Systolic 15-30 mmHg (PAS)</div><div>Diastolic 5-12 mmHg (PAD)</div><div>Mean 9-16 (PAM)</div><div>PCWP (pulmonary capillary wedge pressure)  4-12 mmHg</div><div>PVR (pulmonary vascular resistance) 37-250 dynes/sec/cm5</div><div>RV (right ventricular) Pressure Systolic 15-30 mmHg</div><div>Diastolic 3-8 mmHg</div><div>SVR (systemic vascular resistance) 800-1200 dynes/sec/cm5</div><div>Preload:</div><div> </div><div>Decreased volume, decreased preload</div><div> </div><div>Increased volume, increased preload which may increase MAP and CO</div><div>Aerload: the resistance that the heart has to overcome, during every beat, to </div><div></div><div>Cardiac index: the volume of blood pumped by the heart, per minute, per meter </div><div>square of body surface area. Cardiac Output = HR x Stroke Volume</div><div> </div><div>Increased CO/CI: high circulating volume, increased strength of contraction, </div><div>early septic shock, vasodilatory state</div><div> </div><div>Decreased CO/CI: hypovolemia or decrease in ventricular strength of </div><div>contraction</div><div>CVP: used to approximate Right Ventricular End Diastolic Pressure and assesses </div><div></div><div> </div><div>Low CVP: hypovolemia, decreased venous return</div><div> </div><div>High CVP: hypervolemia, right sided heart failure, tamponade </div><div>Mean Arterial Pressure (MAP): Arterial pressure in the vessels perfusing organs. </div><div></div><div>systemic vascular resistance (SVR). MAP = [(2 x diastolic)+systolic] / 3</div><div> </div><div>Low MAP: hypovolemia, low cardiac output, or low SVR</div><div> </div><div>High MAP: hypervolemia, high cardiac output, or high SVR</div><div>Systemic Vascular Resistance (SVR): measurement of impedance or resistance </div><div></div><div> </div><div>Increased SVR: hypothermia, vasoconstrictors, hypovolemia, low cardiac </div><div>output state</div><div> </div><div>Decreased SVR: hyperthermia, vasodilators, acidosis, early septic shock  </div><div>Parameters for RV Function/Failure: used in context of overall clinical picture</div><div>Step-up: mean PA pressure – CVP</div><div> &gt;10: adequate RV function</div><div> &lt; 10: concern for RV dysfunction</div><div>PAPi: pulmonary artery pulsatility index = (PA Systolic – PA Diastolic) / CVP</div><div> &gt;2: adequate RV function</div><div> 1-2: at risk for RV failure</div><div> &lt; 1: RV failure</div></div><div></div></div>
<div><div><img><div>126 Reference Material Reference Material 127</div><div>Figure 1 PA Catheter Waveforms</div><div>Pulmonary Artery Pressure (PA Pressure): Blood pressure in the  </div><div>pulmonary artery</div><div> </div><div></div><div></div><div>Pulmonary Vascular Resistance: measurement of impedance or resistance of </div><div></div><div> </div><div>Increased PVR: hypoxia, hypercapnia, pulmonary vascular disease, PE</div><div>Pulmonary Capillary Wedge Pressure (PCWP): used to approximate LVEDP  </div><div></div><div></div><div> </div><div>High wedge pressure: LV failure, tamponade (cardiac compression), or </div><div>volume overload </div><div>Management of Hemodynamic Derangements</div><div>MAP CVP CO/CI SVR Treatment approach</div><div>    Volume</div><div>Normal  Normal  Diuretic</div><div>    Inotrope</div><div>    Vasodilator</div><div>    Inotrope/Vasodilator/IABP</div><div> Normal   Vasoconstrictor</div><div>References: </div><div>PA Catheter Waveform image: https://www.studyblue.com/notes/note/n/hemodynamic-monitoring/</div><div>deck/3727974</div><div>Bojar, RM. (2011) Manual of perioperative care in adult cardiac surgery. (5th edition).</div><div>POST-OP: COMMON ICU DRIPS</div><div>Inotropes/Vasopressors</div><div>Receptor Location Action</div><div>Alpha Adrenergeic Vascular walls</div><div>also found in the heart</div><div>Vasoconstriction</div><div>Increase duration of </div><div>contraction</div><div>Beta 1 Adrenergic Heart Increase inotropy and </div><div>chronotropy, minimal </div><div>vasoconstriction</div><div>Beta 2 Adrenergic Blood vessels vascular and nonvascular </div><div>smooth muscle relaxation</div><div>Dopamine renal, splanchnic </div><div>(mesenteric), coronary, and </div><div>cerebral vascular beds</div><div>vasodilatation</div><div>Drug Mechanism of Action Dose Side eects</div><div>Epinephrine potent beta-1 adrenergic receptor activity </div><div>moderate beta-2 and alpha-1 adrenergic </div><div></div><div>0.01-.2 mcg/</div><div>kg/min</div><div>Increases heart rate</div><div>Can induce </div><div>tachyarrhythmias and </div><div>ischemia</div><div>Dopamine 1 to 2 mcg/kg per minute</div><div>•  Selective vasodilatation of renal,  </div><div>  mesenteric, cerebral, and coronary beds</div><div>•  may increases urine output d/t  </div><div> </div><div>  and by inhibiting aldosterone and renal </div><div>  tubular sodium </div><div>5 to 10 mcg/kg per minute</div><div>•  stimulates beta-1 adrenergic receptors w/  </div><div>  increased cardiac output (stroke volume)</div><div>•  mild alpha adrenergic receptor activation  </div><div>  increases SVR</div><div>&gt;10 mcg/kg per minute</div><div>•  stimulation of alpha-adrenergic receptors,  </div><div>  causing vasoconstriction with an increased  </div><div>  SVR</div><div>1-20mcg/kg/</div><div>min</div><div>tachycardia, arrhythmias </div><div></div><div>mcg/kg/minute</div><div>Milrinone Selective phosphodiesterase (PDE) inhibitor </div><div>in cardiac and vascular tissue, resulting in </div><div>vasodilation (pulmonary and systemic) and </div><div>increased inotropy with little chronotropic </div><div>activity.</div><div>.1-.5mcg/kg/</div><div>min</div><div>Caution </div><div>with renal </div><div>impairment</div><div>May cause peripheral </div><div>vasodilation, </div><div>hypotension, and/or </div><div>ventricular arrhythmia</div><div>Dobutamine Stimulates beta-1 adrenergic receptor, </div><div>increases inotropy and chronotropy and </div><div></div><div>2 to 20 mcg/</div><div>kg/minute</div><div>Can cause hypotension</div><div>Vasopressin Increases cyclic adenosine monophosphate </div><div>(cAMP). Direct vasoconstrictor without </div><div></div><div>SVR &amp; MAP</div><div>.01-.04 units/</div><div>min</div><div>May decrease stroke </div><div>volume and cardiac </div><div>output in myocardial </div><div>dysfunction or precipitate </div><div>ischemia in coronary </div><div>artery disease.</div><div>Norepinephrine Stimulates both alpha-1 and beta-1 adrenergic </div><div>receptors; potent vasoconstriction &amp; modest </div><div>increase in cardiac output</div><div>1-20mcg/min </div><div>Phenylephrine Pure alpha-adrenergic agonist. Causes </div><div>vasoconstriction with minimal cardiac inotropy </div><div>or chronotropy.</div><div>10-300mcg/</div><div>min</div><div>May decrease stroke </div><div>volume and cardiac </div><div>output in patients with </div><div>cardiac dysfunction</div><div></div><div>Isuprel Stimulates beta-1 adrenergic receptors.</div><div>Inotropic and chronotropic agent</div><div>1-10 mcg/min </div><div>adrenergic receptor </div><div>causes vasodilation and a </div><div>decrease in MAP</div></div><div></div></div>
<div><div><img><div>128 Reference Material Reference Material 129</div><div>Vasodilators</div><div>Drug Mechanism of Action Dose Side eects</div><div>Clevidipine Calcium channel blocker, ultra short-acting </div><div>selective arteriolar vasodilator, reduce </div><div></div><div>pressures or causing</div><div>1-16 mg/hr Pulmonary shunt </div><div>physiology and hypoxia </div><div>from inhibition of hypoxic </div><div>vasoconstriction</div><div>Nicardipine A short-acting calcium channel blocker 2.5-15mg/hr   Contraindicated in </div><div>severe AS</div><div>Sodium </div><div>Nitroprusside</div><div>An arterial and venous vasodilator that </div><div></div><div>immediate onset of action</div><div>0.1- 3mcg/</div><div>kg/min</div><div>Prolong use (&gt;72hrs) and </div><div>high dose (&gt;3mcg/kg/</div><div>min) can cause cyanide </div><div>and thiocyanate toxicity</div><div>Nitroglycerine A direct vasodilator, primarily venodialtor, </div><div>arteriodilator at high dose. </div><div>Adjunct therapy for HTN</div><div>0.1-2 mcg/</div><div>kg/min</div><div>Esmolol </div><div>blocking agent</div><div>Dose: 25-</div><div>300mcg/kg/</div><div>min</div><div>Large volume infusion, </div><div>may contribute to volume </div><div>overload</div><div>Labetalol </div><div></div><div>Blocker. </div><div>0.5-3 mg/min</div><div>Hydralazine A direct-acting arteriolar vasodilator  10-20mg IV </div><div>push</div><div>Avoid in patients with </div><div>ischemic heart disease </div><div>and dissecting aneurysm</div><div>POST-OP: COMMON PO MEDS</div><div>Beta Blockers</div><div>Drug Usual Dose Misc Info</div><div>Atenolol 25-50mg PO qd Beta 1 selectivity, better for HR control </div><div>Metoprolol 2.5-100mg qD Beta 1 selectivity, better for HR control </div><div>Toprol XL 25-100mg qD Beta 1 selectivity, better for HR control</div><div>Avoid long acting BB in ICU, choose short acting </div><div>for easier titration. </div><div>Carvedilol  3.125-25mg BID Beta and Alpha blockage, better for Systolic HF</div><div>Labetolol 100-400mg PO QID Beta 2 and Alpha blockade</div><div>Nevibolol (Bystolic)  5-40mg PO qD Beta 1 selectivity</div><div>Beta Calcium Channel Blockers</div><div>Drug Usual Dose Misc Info</div><div>Dihydropryidines: potent vasodilators, little or no eect on contractility or conduction</div><div>     Amlodipine 2.5-10mg PO qD Mainly for HTN &amp; angina</div><div>     Nicardipine 20-40mg PO TID Mainly for HTN &amp; angina</div><div>     Nifedipine 10-30mg PO/SL TID Mainly for HTN &amp; angina</div><div>Non dihydropryidines: eect cardiac contractility and conduction</div><div>     Diltiazem 30-60mg PO TID</div><div>180-360mg qD if long acting</div><div>Heart rate control/HTN</div><div>     Verapamil 80-160mg PO TID Useful for angina</div><div>Nitrates</div><div>Drug Usual Dose Misc Info</div><div>Isosorbide </div><div>mononitrate (Imdur)</div><div>20mg PO qD Watch for Headache</div><div>Isosorbide dinitrate </div><div>(Isordil)</div><div>5-40mg PO TID Watch for Headache</div><div>Nitropaste 1-3 in q3-4 hr Watch for Headache</div><div>ACE inhibitors</div><div>(Avoid in acute renal dysfunction, adjust dose for moderate renal failure)</div><div>Drug Usual Dose Misc Info</div><div>Losartan (Cozaar) 25-100mg PO qD or in 2 divided </div><div>doses</div><div>Valsartan  (Diovan) 80-160mg PO qD</div><div>Irbesartan (Avapro) 150-300mg PO qD</div><div>Cadesartan (Atacand) 8-32mg PO qD or in 2 divided </div><div>doses</div><div>Alpha Blockers</div><div>Drug Usual Dose Misc Info</div><div>Alpha 1 antagonist</div><div>     Doxazosin (Cardura) 1.0-8mg PO qD Good for BPH</div><div>     Prazosin (Minipress) 1.0-7.5mg PO BID</div><div>     Terazosin (hytrin) 1-20mg PO qD Good for BPH, Slows HR, watch for  </div><div>orthostatic h0tn</div><div>Alpha 2 antagonist</div><div>     Clonidine (Catapres) 0.1-0.3mg PO BID Slows HR, good for nicotine withdrawal sx.  </div><div>Rebound tachycardia/hypertension if stopped</div><div>Antiarrhythmics</div><div>Drug Usual Dose Misc Info</div><div>Amiodarone  400mg PO TID, wean to </div><div>200mg qd</div><div>Class III, prolongs action potential duration</div><div>Digoxin 0.125-0.25mg PO qd Leads to increased contractility through inhibition </div><div>of the Na/K+ ATPase pump, promotes calcium </div><div></div><div>Direct suppression of AV node conduction </div><div>Monitor digoxin levels</div><div>Sotalol 80mg PO TID Class III, prolongs action potential duration</div></div><div></div></div>
<div><div><img><div>130 Reference Material Reference Material 131</div><div>Diuretics</div><div>Drug Usual Dose Misc Info</div><div>Loop diuretics</div><div>Furosemide (Lasix) 10-100mg QID Needs k+ replacement</div><div>Bumex 0.5-10mg daily Needs k+ replacement</div><div>If not responding to high dose Lasix, consider </div><div>switching to Bumex</div><div>Thiazides</div><div>HCTZ (Hydrodiuril) 50-100mg qD</div><div>Chlorothiazide (Diuril) 500mg IV qD</div><div>Metolazone </div><div>(Zaroxolyn)</div><div>5-20mg qD</div><div>Potassium sparing:</div><div>Eplerenone (Inspra) 25-50mg qD</div><div>Spironolactone </div><div>(Aldactone)</div><div>25mg qD</div><div>Carbonic Anhydrase Inhibitor</div><div>Acetazolamide </div><div>(Diamox)</div><div>250-500mg IV q6h Increased renal excretion of bicarbonate (used in </div><div>metabolic/contraction alkalosis)</div><div>Bojar, R.M. (2011) Manual of perioperative care in adult cardiac surgery. (5th Edition).</div><div>POST-OP: DIAGNOSIS TRANSLATION EXAMPLES</div><div>Diagnosis Translation Examples</div><div>When documenting: Consider:</div><div>NPO, tube feeding, TPN, nutrition note: </div><div>diagnosis doc</div><div>Severe protein-calorie malnutrition, underweight</div><div>Altered mental status, Delirium Encephalophathy, type: acute delirium and etiology/cause</div><div>Chest pain Cause of chest pain, CHF, MI, CAD</div><div>CHF, ESHD Acuity and type of CHF</div><div>Myocardial infarction  NSTEMI, STEMI (artery involved)</div><div>Hgb 7.5; 1L EBL, 2U PRBC given Acute blood loss anemia </div><div>Elevated BUN/Creatinine Acute Kidney Injury and or/ ATN</div><div>NA 125/150 with monitor and/or treatment Hyponatremia/Hypernatremia</div><div>5,3”, 297 lbs BMI &gt; 40, Morbid obesity, overweight</div><div>WBC: 2.0, RBC 2.50, Plt: 75, on chemo Pancytopenia due to chemo</div><div>Hypoxia, Hypoxic, Hypercapnic Respiratory Failure (Acuity and Type)</div><div>Urosepsis, Meeting 2 out of 4 SIRS criteria Sepsis due to UTI</div><div>Pneumonia Pneumonia, specify etiology and/or causative organism</div><div>Fever Link cause of fever</div><div>Hypotensive require vasoactive drugs Shock and Type of Shock (Cardiogenic, Hypovolemic, post op, etc)</div><div>POST-OP: IICU ADMISSION REQUIREMENTS</div><div>iICU Admission Criteria</div><div>IV infusions </div><div>(patient must </div><div>have 3 or less)</div><div> </div><div>Dopamine: max rate 10 mcg/kg/min via central line</div><div> </div><div>Milrinone 0.375mcg/kg/min max</div><div> </div><div>Amiodarone: central line administration strongly  </div><div>preferred. Therapy via PIV for 24 hours max. </div><div> </div><div>Argatroban, heparin </div><div> </div><div>Insulin continuous infusion </div><div> </div><div>Diltiazem</div><div> </div><div>Ketamine</div><div> </div><div>Esmolol (D1, CSU, B2 only)</div><div> </div><div>Labetolol</div><div> </div><div>Nitroglycerin (for controlling chest pain, 1 hour max)</div><div>Temporary </div><div>Pacemakers</div><div> </div><div>Semi-Permanent Pacemakers </div><div> “Floating lead”, Transvenous – not allowed</div><div> “Fixed lead”, with external generator- allowed</div><div> Underlying rhythm/rate irrelevant </div><div> </div><div> </div><div>Temporary Epicardial Wires</div><div> If patient is pacer dependent, underlying heart </div><div>rate must be &gt; 40 and be hemodynamically stable</div><div>CPAP/BiPAP</div><div> </div><div>Nasal CPAP &amp; BIPAP for patients established on a </div><div>nighttime CPAP/BiPAP (nasal mask) at home for OSA</div><div> </div><div>Nasal CPAP &amp; BIPAP as a new therapy for respiratory </div><div></div><div>evaluation and for a maximum duration of 4 hours. </div><div>Requires consultation of ICU team</div><div> </div><div>Full face mask CPAP &amp; BiPAP for patients with OSA is </div><div>permitted if treatment is an established home therapy and </div><div>patient is able to remove mask</div><div>High Flow </div><div>Nasal Cannula</div><div> </div><div>HFNC can be accepted once patients are on stable </div><div></div><div> </div><div>Patient must be evaluated every 4 hours for increasing </div><div>oxygen requirements </div><div>Pericardial </div><div>Drains</div><div> </div><div>All Allowed</div><div>Post Cath </div><div>procedure </div><div>patients</div><div> </div><div>Fast Track TAVRS</div><div> </div><div>Post cardiac cath</div></div><div></div></div>
<div><div><img><div>132 Reference Material Reference Material 133</div><div>POST-OP: INR GOALS</div><div>Bioprosthetic </div><div>Aortic Valve</div><div>Bioprosthetic Mitral </div><div>Valve Replacement</div><div>Mechanical Aortic </div><div>Composite Valve</div><div>Mechanical Aortic </div><div>Valve Standard </div><div>Mechanical Mitral </div><div>Valve </div><div>Trans-catheter </div><div>Aortic Valve </div><div>Replacement</div><div>Atrial Fibrillation </div><div>Only</div><div>VTE Prophylaxis </div><div>INR Range (Goal) 1.5-2.5 2.0-3.0 2.5-3.5 (3.0) 2.0-3.0</div><div>Level of Evidence B B B B</div><div>Size of Treatment </div><div></div><div>Class I Class I Class I Class I</div><div>Duration Lifelong VKA Lifelong VKA Lifelong VKA</div><div>Level of Evidence A A A</div><div>Post-op </div><div>Anticoagulation</div><div></div><div>surgery once post-</div><div>operative bleed no </div><div>longer an issue.</div><div>(No bridge with </div><div>Heparin)</div><div></div><div>surgery once post-</div><div>operative bleed no </div><div>longer an issue.</div><div>(No bridge with </div><div>Heparin)</div><div></div><div>surgery once post-</div><div>operative bleed </div><div>no longer an issue. </div><div>(Bridge with </div><div>Heparin Post Op  </div><div>24-36 Hours)</div><div>Dual antiplatelet </div><div>with clopidogrel </div><div>75mg for 6 months  </div><div>if not on Coumadin</div><div>Unfractionated </div><div>Heparin 5000 Units </div><div>Subcutaneously </div><div>every  8 hours </div><div>unless patient is </div><div>bleeding (100 cc </div><div>per hour or more) </div><div>from Chest tubes</div><div>ASA Y/N (dose) Y (81-325mg) Y (75-100mg) Y (75-100mg) Y (75-100mg) Y (75-100mg) Y (75-100mg) - </div><div>lifelong</div><div>(75mg-325mg)</div><div>Level of Evidence B A A A C</div><div>Size of Treatment </div><div></div><div>Class IIa Class I Class I Class I Class IIb</div><div> </div><div>HITT = heparin induced thrombocytopenia thrombosis</div><div>TIPS FOR CARDIAC SURGERY (Blue/Green) ANTICOAGULATION</div><div>*If patient has more than one indication for Coumadin use the highest </div><div>INR goal.</div><div>IF MECHANICAL MVR:  patients should be started on heparin/argatroban drip </div><div>postop day 1 if no bleeding for bridging to Coumadin.</div><div>IF TEMPORARY PACING WIRES ARE STILL IN: DO NOT LET INR GET ABOVE 2.0 </div><div>UNTIL THEY ARE REMOVED.  Stay on heparin/argatroban drip until pacing wires </div><div>removed.</div><div>Heparin/Argatroban drip needs to be stopped for 6 hours prior to pacing wire </div><div></div><div>IF STARTING OTHER ANTICOAGULANTS (like Xarelto, Eliquis, Pradaxa, etc.) DO </div><div>NOT START UNTIL TEMPORARY PACING WIRES ARE REMOVED.  IF indicated, use </div><div>heparin/argatroban drip until pacing wires are removed if indicated.</div><div>If on multiple blood thinning agents (ie  Aspirin, Plavix, and Coumadin), discuss </div><div>with Cardiac Surgery that this is okay.</div><div>All patients are treated if blood test for HIT is positive, whether symptomatic or </div><div>not.  Length of therapy should depend on Hematologist’s recommendation.  </div><div> </div><div>*Additional risk factors for thromboembolic events (AF, previous thromboembolism, LV </div><div>dysfunction, or hypercoagulable state) or an older-generation mechanical AVR (such as </div><div>ball-in-cage).</div><div>§ It is recommended to not start VKA until platelets have substantially recovered (i.e., </div><div>usually to at least 150X109/L).  VKA should initially be given in low doses (maximum, </div><div>5 mg of warfarin) over using higher doses (Grade 1C).  If VKA has already been started </div><div>when diagnosed with HIT, vitamin K should be administered (Grade 2C).  VKA should be </div><div>overlapped with a nonheparin anticoagulant for a minimum of 5 days and until the INR is </div><div>within target range (Grade 1C).</div><div>1)  Guyatt GH, Akl EA, Crowther M, et al. American College of Chest Physicians Antithrombotic </div><div>Therapy and Prevention of Thrombosis Panel. Executive summary: antithrombotic Therapy </div><div>and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based </div><div>Clinical Practice Guidelines.  Chest. 2012 Feb;141(2 Suppl):7S-47S. </div><div>2)  January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management </div><div>of Patients With Atrial Fibrillation: Executive Summary: A Report of the American College </div><div>of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart </div><div>Rhythm Society. J Am Coll Cardiol. 2014 Mar 28. Pii:S0735-1097(14)01739-2.</div><div>3)  Kearon C, Akl E, Comerota A, et al. Antithrombotic therapy for VTE disease: Antithrombotic </div><div>Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians </div><div>Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb; 141 (2 Suppl):e419S-94S.</div><div>4)  Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced </div><div>thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American </div><div>College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb; </div><div>141(2suppl):e495s-530S.</div><div>5)  Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of </div><div>patients with valvular heart disease; a report of the American College of Cardiology/American </div><div>Heart Association Task Force on Practice Guidelines. J Thorac Cardiovas Surg. 2014 Jul; </div><div>148(1):e1-e132. </div></div><div></div></div>
<div><div><img><div>134 Reference Material Reference Material 135</div><div>POST-OP: PROPHYLACTIC MEDICATIONS  </div><div>(GI, VA-PNA, DVT, INFECTION)</div><div>Common Prophylactic Medications</div><div>Pre Op </div><div>(day of surgery)</div><div>ICU iICU</div><div>VA- PNA</div><div>•  Peridex 0.12%, 15mL </div><div>swish and spit</div><div>•  Peridex 0.12%, 15mL swish and spit </div><div>while intubated</div><div>•  N/A</div><div>DVT</div><div>•  No DVT prophylaxis </div><div>indicated</div><div>•  SCDs</div><div>•  Heparin 5000 units subQ q8 hours</div><div>•  SCDs</div><div>•  Consider subq </div><div>Heparin if not able </div><div>to ambulate</div><div>Surgical </div><div>Prophylaxis </div><div>•  2g cefazolin  </div><div>(3g if &gt;120kg)</div><div>•  Weight dosed </div><div>vancomycin if PCN </div><div>allergy</div><div>•  Antimicrobial shower </div><div>x2 (PM and AM) before </div><div>surgery with either </div><div>chlorhexidine sponges </div><div>(per patient) or wipes </div><div>(per nurse)</div><div>•  2g cefazolin (3g if &gt;120kg) x 3 doses </div><div>(24 hours)</div><div>•  Weight dosed vancomycin if PCN </div><div>allergy x2 doses (24 hours)</div><div>•  N/A</div><div>Lumbar </div><div>Drain</div><div> </div><div></div><div>placed</div><div> </div><div>drain in place</div><div>•  N/A</div><div>GI</div><div>•  N/A •  IV or PO acid suppression therapy for:</div><div>  o  Mechanical ventilation &gt; 48 hours</div><div>  o  Plt count &lt; 50, INR &gt; 1.5, or PTT 2x  </div><div>  baseline</div><div>  o  Spinal cord injury</div><div>  o  Solid organ transplantation  </div><div>  perioperatively in the ICU setting </div><div>  o  Use of two antiplatelet agents </div><div>  o  Any two of the following: Sepsis,  </div><div>  ICU stay &gt; 10 days, occult bleeding  </div><div>  lasting &gt; 6 days, high dose steroids </div><div>*Steroid use with no other risk factors </div><div>and NPO status are NOT indications for </div><div>stress ulcer prophylaxis</div><div>•  Acid suppression </div><div>therapy only if </div><div>patient previously </div><div>took at home for </div><div>GERD</div><div>•  Literature DOES </div><div>NOT support stress </div><div>ulcer prophylaxis </div><div>outside of the ICU </div><div>environment</div><div>POST-OP: SUPPLEMENTAL O2 &amp; VENTILATOR </div><div>MANAGEMENT</div><div>Oxygen Administration</div><div>1.  Nasal cannula</div><div>a.  </div><div>i.  FiO2 = 20% + (4 x O2 L/min)</div><div>b.  </div><div>2.  Face mask</div><div>a.  </div><div>to determine an accurate FiO2 delivery since 75% of inspired volume is </div><div>room air</div><div>3.  Venti mask</div><div>a.  Delivers a precise oxygen concentration in increments of 24, 28, 31, 35, </div><div>and 40%</div><div>b.  Inspired volume is a mix of room air and oxygen. Exhaled air is allowed to </div><div>exit the mask therefore CO2 retention is minimal</div><div>4.  Non-rebreather mask</div><div>a.  </div><div>b.  There is a one way valve that prevents the patient from breathing in room </div><div>air.  This ensures that a high oxygen concentration is delivered.  Risk of </div><div>CO2 retention</div><div>5.  </div><div>hypoxemia</div><div>a.  FiO2 range 20-100%, Flow range 20-50 L/min</div><div></div><div>b.  </div><div>Consider transitioning to regular nasal cannula once FiO2 weaned to 40-</div><div></div><div>Non-Invasive Positive Pressure Ventilation (NIPPV)</div><div>1.  Continuous Positive Airway Pressure (CPAP)</div><div>a.  Noninvasive ventilation mode that delivers positive pressure throughout </div><div>the respiratory cycle through specialized face or nasal masks</div><div>b.  Prescriber must specify PEEP and FiO2</div><div>2.  Bilevel Positive Airway Pressure (Bipap)</div><div>a.  Noninvasive ventilation mode that delivers </div><div>b.  Prescriber must set end-expiratory pressure (EPAP or PEEP) and IPAP  </div><div>c.  If Bipap is delivered using Drager or LTV vent, the ordered PS is additive </div><div>to the level of PEEP.  i.e. PS 10 cmH2O &amp; PEEP 5 cmH2O will deliver a total </div><div>IPAP of 15cmH2O  </div><div>d.  PS is not an additive to PEEP on Respironics Vision and V-60 devices</div><div>e.  Consider placing NG/OG tube if IPAP &gt; 20 cm H2O</div><div>Ventilator Modes: the most frequently used modes in the CVICU are </div><div>VC-AC, VC-SIMV and PSV</div><div>1.  Volume-Controlled Ventilation (VCV) </div><div>a.  VCV is volume-limited and time-cycled. </div><div>b.  Prescriber must set a desired tidal volume, respiratory rate</div><div>c.  The vent will deliver the set VT with every breath (machine or patient </div><div>triggered).  Airway pressure aka peak inspiratory pressure (PIP) will vary </div><div>based on lung mechanics (resistance/compliance)</div><div>d.  Vent setting parameters</div><div>i.  Minute ventilation 8-10 L/min</div><div>ii.  Tidal Volume (VT) 8-10 mL/kg (&lt; 6 mL/kg for ARDS)</div><div>iii. Plateau airway pressures &lt; 30 cm H2O</div><div>2.  Pressure-Controlled Ventilation (PCV)</div><div>a.  PCV is pressure-limited and time-cycled.  </div><div>b.  Prescriber must set desired pressure limit, respiratory rate, and </div><div>inspiratory time (I:E ratio)</div><div>c.  </div><div></div><div>pressure for the duration of the inspiratory time.  VT will vary based on </div><div>lung mechanics</div><div>d.  Vent setting parameters</div><div>i.  Peak inspiratory pressure &lt; 35 cm H2O</div><div>3.  Assist Control Ventilation (ACV)</div><div>a.  ACV can be either pressure or volume limited</div><div>b.  The ventilator delivers the same set parameters for both mandatory and </div><div>patient triggered breaths.  </div></div><div></div></div>
<div><div><img><div>136 Reference Material Reference Material 137</div><div>4.  Synchronized Intermittent Mandatory Ventilation (SIMV)</div><div>a.  Assisted breaths are synchronized to coincide with spontaneous </div><div></div><div>5.  Pressure-Support Ventilation (PSV)</div><div>a.  </div><div>b.  The prescriber sets the pressure support level</div><div>c.  Each breath is patient triggered and the tidal volume is determined by </div><div></div><div>6.  Airway Pressure Release Ventilation (APRV) </div><div>a.  Alternates between high/low airway pressure and is time-cycled (not </div><div>patient triggered).  Most time is spent at high pressure with a brief cycle </div><div>to low pressure.  Purpose of this type of ventilation is to keep alveoli </div><div>recruited</div><div>7.  Inverse Ratio Ventilation (IRV)</div><div>a.  This mode of ventilation uses a prolonged inspiratory time (2:1) in </div><div>order to help prevent alveolar collapse.  May be used for patients </div><div>with refractory hypoxemia with conventional modes of ventilation.  </div><div></div><div>PEEP: Peak end expiratory pressure</div><div>1.  Therapeutic Uses: </div><div>a.  Patients admitted to ICU on ventilator will be set on PEEP 5cm H20</div><div>i.  PEEP 5 considered a substitute for loss of normal breathing </div><div>“Physiologic PEEP” caused by the presence of the ETT (endotracheal </div><div>tube)</div><div>ii.  Usually well tolerated hemodynamically, not much recruitment/O2 </div><div></div><div>b.  Increasing PEEP to increase PaO2</div><div>i.  Increasing PEEP (by 2-5cm H20 increments) will increase mean airway </div><div>pressure and open previously closed alveoli</div><div>ii.  Increases lung surface area participating in gas exchange</div><div>iii. Decreases VQ/intrapulmonary shunting by improving ventilation to </div><div>perfused lung</div><div>iv. As lung recruitment and PaO2 improves, FiO2 may be weaned</div><div>c.  Cautions with high PEEP</div><div>i.  Increased intrathoracic pressure decreases venous return to the heart</div><div>ii.  Increased PEEP leads to increased PVR, leading to more strain on RV</div><div>iii. Decreased venous return and depressed RV performance may lead to </div><div></div><div>iv. Should not be used in patients with COPD (leads to increased VQ </div><div>mismatch)</div><div>v.  Monitor for signs of “barotrauma:” </div><div>1.  Caused by alveolar overdistention</div><div>2.  May present as: pneumothorax, subcutaneous emphysema, </div><div>pneumomediastinum</div><div>Lung Mechanics</div><div>1.  End-inspiratory Peak pressure</div><div>a.  </div><div>the airways, and elasticity of lungs and chest wall</div><div>2.  End-inspiratory Plateau pressure</div><div>a.  Pplat is a direct measurement of the elasticity of the lungs and chest wall </div><div>(compliance)</div><div>b.  </div><div>3.  Tips</div><div>a.  If peak pressure is elevated and plateau pressure is unchanged, there is </div><div>an increased resistance in the airways which may be due to secretions in </div><div>the ETT, mucous plug, or acute bronchospasm</div><div>b.  If both peak and plateau pressures are elevated, there is decreased </div><div>compliance of the lungs and/or chest wall.  Causes may include </div><div>pneumothorax, atelectasis, acute pulmonary edema, worsening </div><div>pneumonia, or ARDS</div><div>c.  If peak pressure is decreased, there is a problem with an air leak in the </div><div>ventilator system</div><div>d.  PEEP increases plateau pressure</div><div>CV-ICU Interdisciplinary Rapid Extubation Protocol (I-REP)</div><div>1.  Assess patient to determine if patient meets vent weaning criteria</div><div>a.  Weaning criteria: </div><div>i.  SpO2 &gt; 92% on FiO2 &lt; 60%</div><div>ii.  PEEP &lt; 8 cm H2O</div><div>iii. Temp &gt; 35C</div><div>iv. Hemodynamically stable</div><div>v.  Chest tube output stable</div><div>vi. Spontaneous breathing noted (if patient not over-breathing, </div><div>then reduce respiratory rate by 50% for up to 5 min to assess for </div><div>spontaneous breathing)</div><div>2.  If patient meets weaning criteria then reduce respiratory rate to zero as </div><div>tolerated while maintaining EtCO2 &lt; 50.  </div><div>a.  Goal PSV -  PS 10, PEEP 5, and normal work of breathing with RSBI &lt; 100</div><div>3.  If patient does not tolerate PSV, return to previous vent settings and reassess</div><div>4.  If tolerates PSV, check ABG and assess neuro to see if patient meets </div><div>extubation criteria.</div><div>a.  Extubation criteria</div><div>i.  SpO2 &gt; 92% on FiO2 &lt; 50%</div><div>ii.  EtCO2 stable and within baseline +/- 10%</div><div>iii. pH &gt; 7.3</div><div>iv. PS 10 and PEEP 5</div><div>v.  RSBI &lt; 100 with normal work of breathing</div><div>vi. If patient does not meet criteria, reassess every 15 min for a total of 3 </div><div>cycles</div><div>5.  If extubation criteria are met, then ok to extubate.  If patient is morbidly obese </div><div>or has a h/o OSA then extubate to CPAP 8-10 cm or Bipap 10/5 for 2 hours</div><div>6.  If patient is receiving inhaled Flolan, extubate to HFNC to continue Flolan </div><div>administration </div><div>Miscellaneous </div><div>1.  Do not change any ventilator settings unless in an emergency.  Please notify </div><div>respiratory therapy team for all ventilator changes</div><div>2.  Rapid-shallow breathing index (RBSI) = RR / Liters of Tidal Volume</div><div>a.  Goal RSBI &lt; 100</div><div>b.  Indicator for appropriateness for extubation (along with mental status, </div><div>amount of secretions, strength of cough, etc)</div><div>3.  Indirect Calorimetry</div><div>a.  Nutrition is important because too few calories causes respiratory muscle </div><div>catabolism and muscle weakness.  Too many calories (particularly carbs) </div><div>increases metabolic rate and can result in respiratory muscle fatigue or </div><div>hypercapnia due to increased CO2 production</div><div>b.  b.  Indirect calorimetry is a measurement of resting energy expenditure </div><div>based on oxygen consumption (VO2) and carbon dioxide production (VCO2)</div></div><div></div></div>
<div><div><img><div>138 Reference Material Reference Material 139</div><div>POST-OP: VAD BOWEL REGIMEN PROTOCOL</div><div>Standards of Practice for VAD patients to reduce Post-po Ileus</div><div>VAD Quality Improvement</div><div>Vincenta M. Grassano, RD, CNSC</div><div>Heart Failure Service/D1</div><div>1.  Initiate bowel regimen the day of admission (Pre-op)</div><div>a.  Senna 2 tabs BID</div><div>b.  Docusate 100mg BID</div><div>2.  Escalate bowel regimen if no BM within 24 hours of surgery</div><div>a.  Bisacodyl 10mg per rectum x1 occurrence</div><div>b.  Magnesium Citrate 300mL x1 occurrence (not for patients with renal </div><div>dysfunction)</div><div>c.  Check potassium and magnesium</div><div>3.  Adhere to Pre-Op diet regimen</div><div>a.  Patient to receive diet order for recommended PO Diet or TF </div><div>(carbohydrate containing meal) up to 24 hours before surgery</div><div>b.  MD order for Liquid Diet (carbohydrate containing liquids ie juice or </div><div>Ensure clear) up to 6 hours prior to surgery rather than NPO</div><div>c.  Patient to be NPO 6 hours prior to surgery</div><div>CVICU Service / Immediate Post-op</div><div>1.  Resume bowel regimen POD #0</div><div>a.  Senna syrup 10mL via feeding tube BID</div><div>b.  Increase docusate solution 200mg via feeding tube BID</div><div>c.  Add Miralax 1 packet BID</div><div>d.  Bisacodyl 10mg per rectum daily</div><div>2.  Keofeed placed if unable to extubate by POD #2</div><div>a.  Allows for early nutrition</div><div>b.  Allows for immediate administration of bowel regimen/medications</div><div>3.  Initiation of Nutrition by POD #2  </div><div>(with the potential to meet estimated needs)</div><div>a.  If intubated initiate tube feeds</div><div>b.  Initiate Full liquid or Regular diet (sugar free clear liquid and clear liquid </div><div>diet do not have potential to meet estimated needs)</div><div>c.  Supplements if needed</div><div>4.  Escalate bowel regimen POD #4 if no bowel movement or atus</div><div>a.  Lactulose 20mg TID (NOTE: can cause abdominal discomfort and </div><div>cramping)</div><div>b.  Either: </div><div>i.  Mineral oil enema</div><div>ii.  Magnesium citrate (150-300mL) *(not for patients with renal </div><div>dysfunction)</div><div>5.  KUB POD #5 if no BM of Flatus</div><div>6.  Taper down regimen if multiple bowel movements s/p bowel regimen</div><div>a.  Docusate solution/capsule 200mg BID: continue as scheduled</div><div>b.  Senna syrup 10mg BID: change scheduled to PRN</div><div>c.  Miralax 1 packet BID: change scheduled to PRN</div><div>POST-OP: END OF LIFE CARE</div><div>Use these guidelines to transition a patient to comfort care and </div><div>perform discharge as deceased documentation </div><div>1.  Family, patient (if able), ICU team and surgical team agree to withdraw care</div><div>2.  Discontinue all orders in Epic (including medications, labs, nursing care </div><div>orders, etc)</div><div>3.  Order the IP ICU End of Life Order Set (#1791) in Epic</div><div>a.  Choose the appropriate analgesics and anxiolytics as discussed with ICU </div><div>attending</div><div>b.  Order the Comfort Care code status within the order set </div><div>4.  Work with the ICU Attending, bedside nurse and respiratory care to determine </div><div>the sequence of support withdrawal</div><div>5.  Work with the resource/charge RN to have Chaplain services available</div><div>6.  Resource/charge nurse will notify the Transplant Donor Network</div><div>7.  Once the patient has passed, you or another licensed provider should </div><div>examine the patient and declare Time of Death </div><div>a.  Make note of this time, you will use it multiple times in documentation</div><div>b.  You or the ICU attending should approach the next of kin about autopsy </div><div>request</div><div>8.   Discharge as Deceased Documentation</div><div>a.  Use the Discharge Navigator and choose the “Discharge as Deceased” tab </div><div>located at the top of the Discharge Navigator</div><div>b.  Fill in the Death Certicate Worksheet by selecting “New Reading” and </div><div></div><div>i.  This will be used by Chaplain services to complete the Death </div><div></div><div>ii.  Call the Coroner (408-793-1900) to report the death</div><div>1.  They will ask you the patient’s address (located in Demographics)</div><div>2.  They will ask Cause of Death and brief synopsis of what happened</div><div>3.  Document the case/release number and the name of the person </div><div>you talked to in the appropriate space in Epic</div><div>iii. Complete the “Cause of Death” Documentation</div><div>1.  “Cardiopulmonary arrest” is Not a viable diagnosis</div><div>2.  When in doubt, ask the ICU attending what to list</div><div>c.  Complete the Deceased Summary within the navigator</div><div> </div><div>ii.  Select the ICU Attending as the cosigner</div><div>d.  Complete the Discharge Summary</div><div> </div><div>ii.  Delete non-applicable sections as needed</div><div>iii. Same information as the Deceased Summary, may copy-paste </div><div>iv. List the Surgical attending as the cosigner </div><div>9.  Write the Discharge Order</div><div>a.  Disposition: Deceased</div></div><div></div></div>
<div><div><img><div>140 Reference Material Reference Material 141</div><div>POST-OP: PATIENT PROGRESSION CHECKLIST</div><div>Patient Progression Towards Discharge</div><div> </div><div>Pain- well controlled with oral meds</div><div> Remove OnQ (Bupivicaine pump) 1 day prior to discharge))</div><div> </div><div>Remove devices (Chest tubes, Pacer wires, Foley, A-line)</div><div> </div><div>Transition to PO Medications</div><div> ASA, statin</div><div> Beta-Blocker if applicable</div><div> Need for Anticoagulation? Transition to PO anticoagulants</div><div> Adequate diuresis? Transition to PO diuretics</div><div> Do any medications require prior authorization? (Consult with Case </div><div>manager)</div><div> </div><div>Commonly prescribed medications requiring prior authorization </div><div>include: NOAC (Eliquis, xarelto), oxycontin</div><div> </div><div>Tolerating diet, BM since surgery</div><div> Post-operative imaging (consult with chief resident/surgical attending) </div><div> CT scan +/- Echo (surgeon and operation dependent)</div><div> 2-view CXR (done in radiology suite) at dry weight prior to discharge</div><div> </div><div></div><div> </div><div>PT eval: Home vs. home with home health therapy vs. Skilled Nursing Facility</div><div> Consult with E-29 Case Manager to start referral process if needed</div><div> Contact: 650-847-7453 (work cell-phone)</div><div> </div><div>Cardiac rehab: Discharge teaching</div><div> Cardia Rehab ghost pager: 1-5736 </div><div> </div><div>Establish follow up appointments with Nurse Coordinator (PCP, Cardiologist, </div><div>INR clinic, etc). Contact via cell-phone:</div><div> Dr. Boyd, Dr. Ha: Sally Eastman 650-627-6373</div><div> Dr. Woo: Ashley Liang 650-683-0114</div><div> Dr. Lee, Dr. Hiesinger: Pres Lorenzo 650-850-2828</div><div> Dr. Fischbein, Miller: Judi Lachenmyer 650-498-7731 (ext 87731) </div><div>NOTES</div></div><div></div></div>
<div><div><img><div>142 Reference Material Reference Material 143</div><div>NOTES NOTES</div></div><div></div></div>
<div><div><img><div>144 Reference Material</div><div>DEPARTMENT OF CARDIOTHORACIC  </div><div>SURGERY HANDBOOK—VERSION II</div><div>Faculty Advisors:</div><div>Y. Joseph Woo, MD</div><div>Jack H. Boyd, MD</div><div>Charles Hill, MD</div><div>Charlene Kell, EMBA, BSN, RN, CCRN, FACHE, NEA-BC</div><div>Anson M. Lee, MD</div><div>Kapilkumar N. Patel, MD</div><div> </div><div>Contributing Authors:</div><div>Scarlette Aliga-Cabamungan, MS, RN, AGACNP-BC</div><div>Irina Axelrod, PA-C</div><div>Christopher J. Bilbao, DO</div><div>Sarah Booth, ACNPC-AG, MSN, CCRN</div><div>Zoe Chan, PA-C</div><div>Kristie Duoss, MSN, ACNP-BC</div><div>Clara George, NP</div><div>Hilary C. Hammond, MMS, PA-C</div><div>Christine Hartley, RN, MS, ACNP-BC</div><div>Aleya Hyderi, PA-C</div><div>Kelly Juarez, MPAS, PA-C</div><div>Yukfung Lee, PA-C</div><div>Xin Ma, MMS, PA-C </div><div>Erica Mikhli, PA-C</div><div>Shari Miller, PA-C, FAPACVS</div><div>Mykl Morrissey, MSN, RN, AGACNP-BC</div><div>Richard Quitevis, MS, RN, AGACNP-BC</div><div>Hardeep Reddick, MBA, PA-C</div><div>Suzanne Sewell, MSN, RN, FNP-BC</div><div>Joe Simmons, MS,ACNP-BC</div><div>Tim Shieh, PA-C</div><div>Y. Kevin Zeng, MS, AGACNP-BC, RN</div><div> </div><div>Contributing Editors: </div><div>Megan Atashroo, MSN, RN-FA, FNP-BC</div><div>Mary Sheridan Bilbao, MPAS, PA-C, FAPACVS</div><div>Corinne Pogemiller, MMSc, PA-C</div><div>Emily Tognozzi, MMS, PA-C</div><div>Disclaimers:</div><div>Although care has been taken to ensure the accuracy of content of this </div><div>handbook, it should not be a substitute for clinical judgment. Neither the </div><div>authors nor editors assume any liability for injuries and or damage related to this </div><div>publication.</div><div>For internal use only, not for sale or re-distribution. Use for intended audience </div><div>only. Not for patient education.  </div></div><div></div></div>
</div>
<div>
<img>
</div>
</body>
</div>></div><div> </div><div>Grade 2 - PaO2/FiO2 between 200 and 300</div><div> </div><div>Grade 3 - PaO2/FiO2 &lt;200</div><div> Treatment</div><div> </div><div>Treatment is focused on providing supportive care</div><div> </div><div>For hypoxemia, increase FiO2 and PEEP.  </div><div> </div><div>Consider increasing sedation to improve ventilator synchrony</div><div> </div><div>Avoid neuromuscular blockade (risk for myopathy)</div><div> </div><div>Inhaled pulmonary vasodilators such as iNO and Flolan are used to </div><div>improve ventilation-perfusion mismatch and lower mean pulmonary </div><div>artery pressures</div><div> </div><div>Use lung protective ventilation strategies with low tidal volume</div><div> </div><div>Diuresis for goal CVP &lt; 5</div><div> </div><div>Consider extracorporeal membrane oxygenation (ECMO) for patients </div><div>with severe PGD who do not respond to maximal conventional </div><div>treatment and inhaled pulmonary vasodilators</div><div> </div><div></div><div> </div><div>Acute Rejection</div><div> Acute cellular rejection</div><div> </div><div>A1 – Repeat biopsy in 4-6 weeks</div><div> </div><div>Treat based on clinical symptoms</div><div> </div><div>A2-A3</div><div> </div><div>Methylprednisone 10 mg/kg IV daily x 3d</div><div> </div><div>Valvyte 900 mg PO daily x14d</div><div> </div><div>Repeat biopsy in 4-6 weeks</div><div> </div><div>A4</div><div> </div><div>Methylprednisone 10 mg/kg IV daily x3d</div><div> </div><div>Valcyte 900 mg PO daily x14d</div><div> </div><div>Prednisone taper dose 1 mg/kg over 14d then back to baseline dose</div><div> </div><div>Repeat biopsy in 4-6 weeks</div><div> Acute antibody mediated rejection (AMR)</div><div> </div><div>Day 1-5</div><div> </div><div>Plasmapheresis daily x5d.  One volume exchange with albumin.  If </div><div></div><div> </div><div>Day 6-7</div><div> </div><div>IVIG 1 gm/kg (IBW) x2d.  </div><div> </div><div>Premedicate with Tylenol 650 mg PO and Benadryl 50 mg PO/IV </div><div>with each dose</div><div> </div><div>Days 8 &amp; 15</div><div> </div><div>Rituximab 375 mg/sq meter BSA IV weekly x2 weeks</div><div> </div><div>For refractory AMR</div><div> </div><div>Consider the following:</div><div> </div><div></div><div>Rituximab and RATG dose.</div><div> </div><div>If patient has worsening AMR, can give 3-5 doses of RATG (1.5mg/</div><div>kg/day) QOD.        </div><div> </div><div>Bortezomib IV</div><div> </div><div>Photopheresis  </div><div>References:</div><div>Moten et al. (2013). Postoperative Transplant in the Critical Care Unit. American Association of Critical </div><div>Care Nurses, 24(4): 345-350. </div><div></div><div>Lung Transplant Protocol        </div></div><div></div></div>
<div><div><img><div>44 Post-Op Management Post-Op Management 45</div><div>POST-OP: NEUROLOGIC: DELIRIUM</div><div> </div><div>Represents an acute change in a patient’s mental status that is associated </div><div>with a global impairment in cognitive function</div><div> </div><div>Common, incidence 8-10% overall (up to 20% in elderly patients)</div><div> </div><div>Etiology frequently not clear</div><div> may result from microembolization associated with CPB and associated </div><div>aortic manipulations</div><div> may result from mild cerebral hypo perfusion</div><div> </div><div></div><div>Common Contributing Causes:</div><div> </div><div>medication toxicity (including benzodiazepines and analgesics_</div><div> </div><div>metabolic disturbances</div><div> </div><div>Prolonged ICU stay</div><div> </div><div>alcohol withdrawal</div><div> </div><div>low cardiac output syndromes</div><div> </div><div></div><div>threshold for cerebral infarction</div><div> </div><div>hypoxia</div><div> </div><div>sepsis</div><div> </div><div>recent/new stroke</div><div>Manifestations:</div><div> </div><div></div><div>wake cycle</div><div> </div><div>lethargy or agitation</div><div> </div><div>paranoia and hallucinations</div><div>Evaluation:</div><div> </div><div>Consider psych consult for severe delirium </div><div> </div><div>review of current medications and drug levels</div><div> </div><div>identify possible history of recent alcoholism or substance abuse</div><div> </div><div></div><div> </div><div>ABG, electrolytes, BUN, creatinine, CBC, Mg, calcium, cultures</div><div>Management:</div><div> </div><div></div><div> </div><div>correct metabolic abnormalities</div><div> </div><div>stop inappropriate medications</div><div> </div><div>select appropriate medication to control agitation in the delirious state</div><div> Haldol 2.5-5mg PO/IV q6h most commonly prescribed (risk of torsades)</div><div> </div><div>check daily EKG to eval QTC</div><div> </div><div>sometimes makes delirium worse!</div><div> Seroquel 12.5-50mg, TID </div><div> Precedex drip may be needed while in the ICU. Consider PO version </div><div>(Tenex) </div><div> Zyprexa 5-10 mg daily</div><div> </div><div></div><div> </div><div>Use melatonin 3-6 mg qhs to help reorient sleep/wake cycle</div><div> </div><div>When in doubt, call psychiatry to aid in management</div><div> </div><div>Benzos may exacerbate acute delirium and should be used only when </div><div>managing concurrent alcohol withdrawal</div><div> </div><div>Manage suspected alcohol withdrawal</div><div> Benzos usually indicated for several days then should be gradually </div><div>tapered</div><div> </div><div>extubation if self-destructive behavior</div><div> Also give thiamine 100 mg bid and folic acid 1 mg daily</div><div>References:</div><div>Bojar, Robert M. (2011) Manual of Perioperative Care in Adult Cardiac Surgery. (5th  edition).</div><div>POST-OP: NEUROLOGIC: PAIN CONTROL</div><div>Standing Pain medication orders:</div><div>Acetaminophen</div><div>Dosing:</div><div> </div><div>650 - 1000 mg, oral/rectal, every 6-8 hours (IV Tylenol should never be used)</div><div> Abnormal liver function: 500 mg every 6 hours</div><div>Gabapentin</div><div>Dosing:</div><div> </div><div>CrCl &gt; 60: 300 mg, oral, three times daily</div><div> </div><div>CrCl &gt; 15 but &lt; 60: 100 mg, oral, three times daily</div><div> </div><div>CrCl &lt; 15 and dialysis: 100 mg, oral, daily</div><div> If patient not sedated and having pain, it is reasonable to titrate </div><div>gabapentin to 600 mg TID or higher over 2-3 days</div><div> </div><div>Works well in adjunt with Tylenol</div><div> </div><div></div><div>discharge</div><div> </div><div></div><div>PRN Pain Medication Orders:  </div><div>(must specify indication mild, moderate, or severe)</div><div>Oxycodone  5-15 mg, oral, every 3 hours as needed </div><div>Hydromorphone  0.2-0.5 mg, intravenous, every 2 hours as needed</div><div>Tramadol  50 mg q6h prn CrCl &lt;30: avoid use</div><div> Next step if Tylenol not enough. Usually best for mild to moderate pain</div><div> </div><div>Roxicodone  5-15 mg q4h prn</div><div> Next step if Tylenol and tramadol not enough for pain. Usually best for </div><div>moderate to severe pain. </div><div> </div><div>drowsiness/delirium </div><div> </div><div>Delirium more prevalent in elderly</div><div>Percocet  5/325 mg 1-2 tab PO q4h prn pain</div><div> Good for severe pain not relieved with roxicodone</div><div> Do not use if patient already on standing Tylenol given risk of Tylenol </div><div>overdose</div></div><div></div></div>
<div><div><img><div>46 Post-Op Management Post-Op Management 47</div><div>Dilaudid  2-4 mg PO q4h prn pain, 0.5-1mg IV q3h prn pain, PCA</div><div> Used if pain not relieved by roxicodone</div><div> Also great for acute pain exacerbations</div><div> If require PCA, contact pain service to help manage </div><div>Oxycodone 10-20mg PO q12 hours</div><div> Consider if not achieving adequate PO pain control with short acting </div><div>Roxicodone</div><div> Scheduled q12 intervals. Short acting Roxicodone can be taken in </div><div>addition for breakthrough pain</div><div>Ibuprofen  400 mg, oral, every 6 hours as needed (Needs surgical team approval)</div><div> CrCl &gt; 30 but &lt; 60 or age &gt; 65: 200 mg, oral, every 6 hours as needed</div><div> CrCl &lt;30: avoid use</div><div> Avoid use with dual antiplatelet therapy</div><div>Ketorolac  15-30 mg, intravenous, every 6 hours as needed (Needs surgical team </div><div>approval)</div><div></div><div> CrCl &lt;30: avoid use</div><div> Avoid use with dual antiplatelet therapy</div><div> Only if oral route unavailable; otherwise give oral pain medication</div><div>IV pain medication IS NOT the rst line for patients on the oor. Consider increasing </div><div>the dose of oral meds for better control. The goal is to prepare the patient for </div><div>discharge to home.</div><div>Additional medications you may see that you can consider:</div><div>Fentanyl  25-50mg IV </div><div> Reserve for severe pain not relieved by roxicodone</div><div> Commonly given prior to chest tube removal for pain prevention, but the </div><div>jury is out on whether this is necessary or not!</div><div> Caution with this given heavily sedating </div><div>Lidocaine infusion  </div><div> Commonly started by ICU team</div><div> Requires checking daily lidocaine levels</div><div> Contraindications:</div><div> </div><div>First and second degree heart block due to risk of worsening heart </div><div>block. </div><div> </div><div> </div><div></div><div>numbness and unusual sensations around mouth, metallic taste in </div><div>mouth, ringing in the ears, or lightheadedness and dizziness</div><div> </div><div></div><div>nausea and vomiting, severe dizziness, decreased hearing, tremors, </div><div>changes in blood pressure and pulse. </div><div> </div><div>At serum levels greater than 12 mcg/ml: drowsiness, confusion, </div><div>muscle twitching, convulsions, loss of consciousness, cardiac </div><div>arrhythmias, cardiac arrest</div><div> </div><div>Ketamine  0.1 mg/kg/hr drip, intravenous, continuous</div><div> Consult acute pain service</div><div>Local/Regional anesthetic pain modalities</div><div>Epidural</div><div> Managed by pain service</div><div> Commonly used for TAAA</div><div>Bupivacaine via On Q pump</div><div> See reference page 109</div><div> Commonly used for anterior thoracotomy</div><div>Paravertebral Nerve Block</div><div> Managed by pain service</div><div> Commonly used for myocardial bridge </div><div>POST-OP: NEUROLOGIC: SEIZURES</div><div>A seizure is a “single event characterized by the abnormal excessive synchronized </div><div></div><div>(Kurle, 2010). </div><div>Etiology:</div><div> </div><div>The most common cause of seizures is stroke, 43% within 24 hours of the </div><div>stroke</div><div> 8.9% - hemispheric stroke</div><div> 8.6% – ischemic stroke</div><div> 10.6% - hemorrhagic stroke</div><div> </div><div>Intraoperative hypoxia, or air or particulate emboli, metabolic </div><div>encephalopathy, cerebral edema</div><div> </div><div>Medications</div><div> Lidocaine</div><div> Tranexamic acid (a pro-coagulant not used at SHC).  Amicar is used at </div><div></div><div>seizures (though higher rates of renal dysfunction) (Martin, 2011).</div><div> Cefazolin (a rare complication), especially in patients with renal </div><div></div><div>function</div><div>Incidence:</div><div> </div><div>0.1% (CABG) to 5% (complex aortic) (Goldstone et al, 2011, Manji et al, 2011, </div><div>McGarvey et al, 2013)</div><div> </div><div>59% experience 1 recurrence (Manji, 2011), 89% of those are within 24 hours</div><div> </div><div>Most likely to occur between hours 5-8 postoperatively (Manji, 2012)</div><div>Risk factors </div><div> </div><div>Intraop:</div><div> Duration of aortic cross-clamp time</div><div> </div><div> Deep hypothermic circulatory arrest</div><div> Open chamber surgery</div><div> Complex aortic repair (Sharma, 2014, Goldstone, 2011)</div><div> </div><div>Postop:</div><div> Metabolic derangements (McGarvey, 2013)</div></div><div></div></div>
<div><div><img><div>48 Post-Op Management Post-Op Management 49</div><div>Considerations</div><div>Preoperative Note patients with preexisting seizure disorders and consult Neuro </div><div>Critical Care prior to surgery to make a postop plan.</div><div>Intraoperative These procedures may decrease the incidence of neurologic </div><div>complications (Goldstone et al, 2011):</div><div> </div><div>Epi-aortic scanning before aortic cannulation</div><div> </div><div></div><div> </div><div>Cerebral oxygen saturation monitoring</div><div> </div><div>Retrograde cerebral perfusion with hypothermia or deep </div><div>hypothermia during circulatory arrest</div><div> </div><div>Echocardiography-guided de-airing</div><div>Postoperative</div><div> </div><div>Review of medications and labs to identify  </div><div>pro-convulsive agents or toxic serum levels</div><div> </div><div>Generally are isolated events.  </div><div> </div><div></div><div></div><div>Neuro Critical Care team</div><div>* The terms simple partial, complex partial, and secondarily generalized are no </div><div>longer used</div><div>Classication Origin Clinical </div><div>manifestations</div><div>Guide to </div><div>treatment</div><div>Focal seizure </div><div>(previously </div><div>‘partial’)</div><div>Origin and spread </div><div>limited to one </div><div>hemisphere, </div><div>arising from the </div><div>subcortical or </div><div>neocortical regions</div><div>Can involve twitching of </div><div>a limb, a sense of fear, an </div><div>unpleasant smell (aura) </div><div>and patients may be </div><div>conscious of having them </div><div>(Schachter, 2016).</div><div>EEG, CT head, </div><div>consider Keppra </div><div>load and BID </div><div>therapy. Lorazepam </div><div>if not self-limiting.</div><div>Generalized Starts in both </div><div>hemispheres </div><div>at once, arising </div><div>from a cortical </div><div>or subcortical </div><div>region, may be </div><div>asymmetric</div><div>Most commonly tonic-</div><div>clonic (previously known </div><div>as grand mal, with </div><div>convulsive jerking in all </div><div>limbs), absence (previously </div><div>known as petit mal, with </div><div>staring or lip smacking, </div><div>and myoclonic seizures </div><div>(muscle spasms, can be </div><div></div><div>EEG, CT head, </div><div>consider Keppra </div><div>load and </div><div>BID therapy. </div><div>Lorazepam, if not </div><div>self-limiting.</div><div>Status epilepticus </div><div>(SE)</div><div>Any type of seizure </div><div>can evolve into </div><div></div><div>“more than 30 </div><div>minutes of either </div><div>continuous seizure </div><div>activity or two or </div><div>more sequential </div><div>seizures without </div><div>full recovery of </div><div>consciousness </div><div>between </div><div>(American Epilepsy </div><div>Society Guideline, </div><div>2016)”.</div><div>Characterized as </div><div>convulsive or non-</div><div>convulsive.  This is a </div><div>medical emergency.</div><div>1st line – lorazepam </div><div>or diazepam</div><div>2nd line – </div><div>fosphenytoin</div><div>3rd line –  </div><div>general anesthesia</div><div>* See below for </div><div>doses</div><div>Treatment</div><div> </div><div>Pharmacologic treatment is not always necessary</div><div>seizure, especially if the etiology is obvious and addressed (ie, metabolic </div><div>derangement).</div><div> </div><div>Patients with focal neurological decits, epileptiform discharges on </div><div>EEG or structural brain lesions are at higher risk for repeat seizures and </div><div>should receive anticonvulsive therapy (Kurle &amp; Rutecki, 2010).</div><div>Pharmacological treatment:</div><div> </div><div>Loading followed by a maintenance dose of levetiracetam (Keppra) is </div><div></div><div></div><div> Do</div><div> </div><div>Additional antiepileptic pharmacotherapy based on the EEG, CT, and clinical </div><div>manifestations of the seizure(s) and response to treatment.</div><div> </div><div>To break a seizure:</div><div> 1st line: IV lorazepam</div><div></div><div> </div><div></div><div>depression</div><div> 2nd line: IV fosphenytoin at 20mg/kg, (can also do VPA 40mg/kg or </div><div>Keppra 60mg/kg load – discuss with NCC). Fosphenytoin is better </div><div>tolerated over Phenytoin.</div><div> 3rd line, general anesthesia with propofol or Versed gtts.</div><div>Seizures must be dierentiated from myoclonus (4 types)</div><div> </div><div>Physiologic (muscle jerks when falling asleep, causes no disability)</div><div> </div><div></div><div> </div><div>Epileptic (myoclonic jerks in the setting of epilepsy)</div><div> </div><div>Symptomatic (occurring in the setting of a separate neurological disorder) </div><div>(Caviness, 2015).</div><div>Calling a consult:</div><div> </div><div>Neuro Critical Care Pager number: 14061</div><div> </div><div>Describe the seizure-like activity</div><div> Evolution: describe the pattern (ie did it start with gaze deviation and </div><div>unilateral shaking which then spread to the opposite side)</div><div> Bilateral or convulsive involvement</div><div> What were the eyes doing (nystagmus, gaze deviation etc)</div><div> Termination: spontaneously or with Ativan</div><div> Physical exam ndings</div><div> </div><div>Autonomic changes in absence or focal seizures: tachycardia, </div><div>diaphoresis, excess salivation, pupillary dilation, incontinence (Kurle &amp; </div><div>Rutecki, 2010).</div><div> </div><div>Tonic-clonic seizures: hypertension, tachycardia, metabolic acidosis, </div><div>hypoxia, hypercarbia (Kurle &amp; Rutecki, 2010).</div><div>Diagnostic studies:</div><div> </div><div>Head CT without contrast: Perform early to identify potentially reversible </div><div>causes (Goldstone, 2011)</div><div> </div><div>Continuous EEG: identify a focal area of seizure activity or the presence of </div><div>non-convulsive status epilepticus (Marcuse, 2014)</div><div> </div><div>MRI: </div><div>devices (LVAD, ECMO etc), Epicardial wires, certain ICD/PPMs etc.</div></div><div></div></div>
<div><div><img><div>50 Post-Op Management Post-Op Management 51</div><div>POST-OP: NEUROLOGIC: SPINAL CORD ISCHEMIA </div><div>Who’s at risk? </div><div></div><div>branching arteries (Intercostal arteries) providing blood supply to the spinal cord, </div><div>potentially resulting in spinal cord hypoperfusion, ischemia and infarction</div><div>4.  Endovascular repair </div><div>a.  Incidence: SCI may occur in up to 4% of cases</div><div>b.  </div><div>5.  Open repair</div><div>a.  Incidence: SCI may occur in up to 8% of cases</div><div>b.  </div><div>Intra-op Measures to prevent spinal cord ischemia:</div><div>1.  Minimize spinal cord ischemic time</div><div>2.  Increase tolerance to ischemia </div><div>a.  Deliberate mild systemic hypothermia</div><div>b.  Ischemic preconditioning (“staged repair”) to allow development of </div><div>collateralization of blood supply</div><div>3.  Augment spinal cord perfusion</div><div>a.  Deliberate proximal and distal HTN</div><div>b.  CSF drainage (via lumbar drain placement pre-procedure)</div><div>c.  Reimplantation of spinal arteries</div><div>d.  Preserve subclavian artery and hypogastric artery</div><div>4.  Early detection of spinal cord ischemia</div><div>a.  Intra-operative neurophysical monitoring (MEP motor evoked potentials, </div><div>SSEP somatosensory evoked potentials)</div><div>b.  Early and serial post-op neuro exam</div><div>Post-op ICU Measures to prevent spinal cord ischemia</div><div>1.  CSF Drainage:</div><div>a.  Lumbar drain typically placed pre-operatively by anesthesia.  </div><div>See page 106.</div><div>b.  Goal to optimize cerebral perfusion pressure (CPP): perfusion to spinal </div><div>cord</div><div>1. Measured as CPP = Mean Arterial Pressure – ICP</div><div>2. We can decrease ICP by removing CSF, thus improving CPP</div><div>c.  Goal ICP ~10 mmHg (refer to ICU Lumbar drain protocol)</div><div>1. Lumbar drain is set open to drain at 10mmHg (14cm H20)</div><div>2. When/if ICP is greater than 10mmHg, the lumbar drain will act as a </div><div>“pop-o” valve and CSF will drain</div><div>d.  Must be careful to not OVER DRAIN CSF too rapidly</div><div>1. Symptomatic intracranial hypotension:</div><div>a. Headache</div><div>b. Subdural hematoma</div><div>2. Goal: may drain up to 10mL at a time, not to exceed 20mL/hr</div><div>2.  Augment Mean Arterial Blood Pressure</div><div>a.  Goal hemodynamic parameters must be discussed with the surgical </div><div>attending, as the patient may have residual aneurysm/dissection or </div><div>bleeding to take into consideration when establishing goal MAP</div><div>b.  </div><div>used to augment MAP</div><div>c.  Typical MAP goal 90-100, CPP goal &gt;80</div><div>3.  Early detection through close neurologic monitoring</div><div>a.  </div><div>b.  Q1H Pupillometry while CSF is drained</div><div>4.  May establish blood transfusion goal for Hct &gt;25 to optimize perfusion</div><div>5.  Lumbar drain removal</div><div>a.  </div><div>b.  POD 2: Clamp x 24 hours</div><div>1. Continue to monitor neuro exam, if changes, resume CSF drainage</div><div>c.  POD 3: Remove if neuro exam intact, monitor for HA or CSF drainage post </div><div>removal. Flat for 6 hours post drain removal </div><div>If The Exam Changes:</div><div>1.  Alert ICU attending and surgical team immediately</div><div>2.  Increase MAP/CPP</div><div>a.  Increase dose of vasopressors</div><div>b.  Consider blood/volume transfusion</div><div>3.  Drain CSF (safely) to decrease ICP and increase CPP</div><div>a.  Goal ICP &lt;10 </div><div>b.  Drainage not to exceed 20mL/hr</div><div>4.  Perform thorough neurologic exam</div><div>a.  </div><div>b.  </div><div>5.  Consider consult to neurocritical care</div><div>6.  Consider advanced imaging (CT/MRI) when stabilized to assess extent of </div><div>infarct</div><div>References:</div><div>References Bojar, Robert M. (2011) Manual of Perioperative Care in Adult Cardiac Surgery. (5th edition).</div><div> </div></div><div></div></div>
<div><div><img><div>52 Post-Op Management Post-Op Management 53</div><div>POST-OP: NEUROLOGIC: STROKE / CVA</div><div>Risk Factors:</div><div>Pre-Op: </div><div> </div><div>History of previous stroke or TIA (44% of patients with history of stroke </div><div></div><div> </div><div>Comorbidities: HTN, DM, Smoking, PVD, Renal dysfunction</div><div> </div><div></div><div> </div><div>Age &gt; 75 (risk of up to 10%)</div><div> </div><div>Carotid disease (Risk is less in unilateral stenosis but as high as 10-15% in </div><div>bilateral stenosis &gt; 75%)</div><div> </div><div>Emergent surgery (Type A dissection)</div><div>Intra Op: </div><div> </div><div></div><div>CBP &gt; 2 hours</div><div> </div><div>High transfusion requirement (especially platelets)</div><div> </div><div>LV thrombus</div><div> </div><div>Air embolization from opening of cardiac chamber</div><div> </div><div>Peri-operative HTN or cardiac arrest</div><div>Post op:</div><div> </div><div></div><div>Pre-Op &amp; Perioperative prevention:</div><div> </div><div>Avoid hypotension, continue pre-operative ASA, consider need for pre-op </div><div>carotid studies </div><div>Incidence/Mechanism:</div><div> </div><div>Embolic, most common (~ 2/3 of post op strokes)</div><div> </div><div>Cerebral hyper perfusion  </div><div> </div><div>Hemorrhagic  </div><div>Presentation:</div><div> </div><div>Think BE FAST (Balance, Eyes (vision changes), Face drooping, Arm </div><div>weakness, STime — how long since onset of symptoms)</div><div>Physical Exam:</div><div> </div><div>Full Neuro exam (CN 2-12)</div><div> Strengths of extremities</div><div> Pupil exam</div><div> </div><div>“ Blown pupil:” something acutely bad is happening on one side (rising </div><div>ICP compresses area that holds one of optic nerves)</div><div> </div><div>“Fixed and dilated” pupils – indicate a prolonged hypoxic injury to the </div><div>brain. </div><div> Tongue midline</div><div>Work-up:</div><div> </div><div>Call Stroke code (dial 211)</div><div> </div><div>CT head without contrast, to rule in/out hemorrhage</div><div> </div><div></div><div> </div><div>MRI/MRA brain with perfusion sequences (Stroke protocol) </div><div> </div><div>Carotid Doppler US study to evaluate for carotid occlusive disease</div><div>Medical Management</div><div> </div><div>Blood pressure parameters as determined by consulting teams, but </div><div>SBP should not exceed 180mmHg for ischemic and 140-160mmHg for </div><div>hemorrhagic cases</div><div> </div><div>Glucose control between 80-140 mg/dL as elevated levels &gt; 200 mg/dL during </div><div></div><div>neurologic outcome</div><div> </div><div>Avoid hyperthermia</div><div> </div><div>DC all anticoagulation as patient’s condition can worsen, or can be </div><div>contraindication for tPA administration</div><div> </div><div>ASA 162mg or 325mg orally or rectally</div><div> </div><div>Antiepileptic therapy as determined by consulting teams</div><div>Indications for surgery</div><div>General guidelines:</div><div> </div><div>Patients with large hemispheric stroke involving more than two-thirds of MCA </div><div>territory (usually only on right-side)</div><div> </div><div>Development of herniation syndrome (i.e. ipsilateral weakness on side of </div><div>stroke, lower cranial neuropathies, lethargy)</div><div> </div><div>Uncontrolled intracranial pressure, as dictated by monitor</div><div>Surgical Procedures: </div><div> </div><div>Suboccipital craniectomy/craniotomy (for posterior circulation)</div><div> </div><div>Craniotomy/Craniectomy for evacuation of hematoma</div><div> </div><div>Hemicraniectomy</div><div> </div><div>Carotid endarterectomy</div><div>Reference:</div><div>Winn, H. Richard.  Youman’s Neurological Surgery, 6th ed.  2011.</div><div>CARDIAC: ATRIAL FIBRILLATION &amp;  </div><div>ELECTROLYTE REPLACEMENT</div><div>Classication of AF:</div><div> </div><div>Paroxysmal (self-terminating) vs Persistent (sustained &gt; 7d) vs Permanent  </div><div>(typically &gt; 1 year and when cardioversion has failed or is forgone)</div><div> </div><div>Valvular (rheumatic MV disease, prosthetic valve, or valve repair) vs Non </div><div>valvular</div><div> </div><div>Lone AF = age &lt; 60 and w/o clinical or echo evidence of cardiac disease </div><div>(including HTN)</div><div> </div><div></div><div>patients</div><div>Management of AF: (see below for treatment algorithm)</div><div> </div><div></div><div> </div><div>For unstable patient, cardiovert immediately if able</div><div> </div><div>If the patient continues to have episodes, consider anticoagulation  </div><div>(see CHADs score below)</div><div>Post-operative Electrolyte Goals:</div><div>Potassium (K+) 5.0</div><div>Magnesium (Mg+) 2.5</div><div>Calcium (CA+) 8.0</div></div><div></div></div>
<div><div><img><div>54 Post-Op Management Post-Op Management 55</div><div>Rate Control for AF: (goal HR 60-80, 90-115 with exertion)</div><div>Agent Acute IV Maint (PO) Comments</div><div>Metoprolol (BB) 5mg over 2min, </div><div>may repeat </div><div>q5min x3</div><div>25-100mg BID </div><div>or TID</div><div>↓BP (Rx w/</div><div>glucagon). </div><div>Watch for CHF &amp; </div><div>Bronchospasm </div><div>Preferred if CAD</div><div>Amiodarone 150mg over 10 </div><div>min. Then 1mg/</div><div>min 6 hours, </div><div>0.5mg/min for </div><div>18 hours</div><div>400mg TID with </div><div>taper</div><div>Diltiazem (CCB) 0.25mg/kg over </div><div>2 min, may </div><div></div><div>min. 5-15mg/h </div><div>infusion</div><div>120-360mg/d in </div><div>divided doses</div><div></div><div>gluc). Watch for </div><div>CHF. Preferred if </div><div></div><div>levels</div><div>Verapamil (CCB) 5-10mg over 2 </div><div>min, may repeat </div><div>in 30 min</div><div>120-360mg/d in </div><div>divided doses</div><div></div><div>gluc). Watch for </div><div>CHF. Preferred if </div><div></div><div>levels</div><div>Propranolol (BB) 1mg q2min 80-240mg/d in </div><div>divided doses</div><div></div><div>glucagon). </div><div>Watch for CHF &amp; </div><div>Bronchospasm</div><div>Preferred if CAD</div><div>Digoxin  0.25mg q2h up to </div><div>1.5mg</div><div>0.125- 0.375mg </div><div>qday (adjust for </div><div>CrCl)</div><div>Consider in HR </div><div>or Low BP. Poor </div><div>exertional HR crtl.</div><div>Rhythm Control: </div><div>Amiodarone </div><div>(Class III)</div><div>5-7mg/kg IV </div><div>over 30-60min </div><div>1mg/min to </div><div>achieve 10g load</div><div>200-400mg qD </div><div>(most eective </div><div>drug)</div><div>↑QT but TdP </div><div>rare. Pulm, liver, </div><div>thyroid toxicity. </div><div>Check PFTs, </div><div>LFTs, TFTs</div><div>Sotalol (Class III) n/a 90-160mg BID </div><div></div><div>Propafenone </div><div>(Class IC)</div><div>600mg PO x1 150-300mg TID PreRx w/</div><div>AVN blocker. </div><div>Contraindic. If </div><div>structural or </div><div>ischemic heart </div><div>disease</div><div>Procainamide 10-15mg/kg IV </div><div>over 1 hr</div><div>1-2g bid of slow </div><div>release</div><div></div><div>PreRx w/AVN </div><div>blocker</div><div>Consider need for Anticoagulation:</div><div> </div><div></div><div> </div><div>Risk of stroke ~ 4.5% per year in non valvular AF. Risk factors include: prior </div><div>stroke, TIA, DM, HTN, Older age (&gt;/= 65), HF, CAD, EF &lt; 35%</div><div> </div><div>Who to treat: </div><div> Utilize CHAD Score to evaluate patient’s risk and need for anticoagulation</div><div> </div><div>(with no history), consider need for short term (2-3 months post op) </div><div>anticoagulation (discuss with attending)</div><div>Agent Class Dosing Time to </div><div>Peak  </div><div>Anticoag- </div><div>ulation</div><div>Half-</div><div>life</div><div>Renal </div><div>Excretion </div><div>(%)</div><div>Antidote</div><div>Warfarin </div><div>(Coumadin)</div><div>Vit K </div><div>Antagonist</div><div>0.5-10mg </div><div>QD</div><div>3-5 days 40 </div><div>hours</div><div>0 Vitamin K</div><div>Clopidogrel (Plavix) Platelet </div><div>inhibitor</div><div>75mg  </div><div>QD</div><div>Prasugrel (Effient) Platelet </div><div>inhibitor</div><div>5-10mg </div><div>QD</div><div>7  </div><div>hours</div><div>Dabigatran </div><div>(Pradaxa)</div><div>Direct </div><div>Thrombin </div><div>inhibitor</div><div>150mg </div><div>BID</div><div>1-2 hours 14-17 </div><div>hours</div><div>-80 None</div><div>Rivaroxaban </div><div>(Xarelto)</div><div>Factor-Xa </div><div>Inhibitor</div><div>15-20mg </div><div>QD</div><div>2.5-4hours 11-13 </div><div>hours</div><div>35 None</div><div>Apixaban </div><div>(Eliquis)</div><div>Factor-Xa </div><div>Inhibitor</div><div>2.5-5mg </div><div>BID</div><div>3 hours 8-15 </div><div>hours</div><div>25 None</div><div>Endoxaban </div><div>(Savaysa)</div><div>Factor-Xa </div><div>Inhibitor</div><div>60mg  </div><div>QD</div><div>1-2 hours 9-12 </div><div>hours</div><div>60 None</div><div>CHAD Score (&gt;2 equals indication for anticoagulation)</div><div>C </div><div>dysfunction)</div><div>H Hypertension</div><div>A  (2) Age &gt;/= 75</div><div>D DM</div><div>S (2) Prior stroke or TIA or thromboembolism</div><div>V Vascular disease (PAD, MI)</div><div>A Age 65-74</div><div>Sc Sex category female</div><div>References:</div><div>Bojar, Robert M. (2011) Manual of Perioperative Care in Adult Cardiac Surgery. (5th  edition).</div></div><div></div></div>
<div><div><img><div>56 Post-Op Management Post-Op Management 57</div><div>CT Surgery Post</div><div>Op Atrial</div><div>Fibrillation</div><div>Treatment</div><div>Algorithm</div><div>CHRONIC?</div><div>NEW ONSET? (will occur in 30-</div><div>40% of patients)</div><div>-The goal is always first NSR</div><div>-If NSR cannot be attained, the</div><div>goal then becomes rate control</div><div>STABLE?</div><div>UNSTABLE?</div><div>Amiodarone</div><div>150mg/min bolus +</div><div>drip @ 1mg/min</div><div>OR</div><div>Diltiazem 0.25mg/</div><div>kg bolus + drip @</div><div>5mg/hr (titrate to</div><div>heart rate)</div><div>DCCV</div><div>(direct current</div><div>cardioversion)</div><div>Successful =</div><div>Converts to</div><div>Sinus</div><div>Unsuccessful</div><div>= Remains in</div><div>Afib</div><div>Continue Amio/</div><div>Diltiazem drip until</div><div>loaded</div><div>Repeat DCCV</div><div>Continue Amio/</div><div>Diltiazem drip until</div><div>loaded</div><div>Transition to PO</div><div>Amiodarone</div><div>starting with</div><div>400mg PO TID</div><div>Consider Daily</div><div>EKG to eval QT</div><div>interval.</div><div>AF reoccurs?</div><div>1. Restart Amio/</div><div>Diltiazem bolus +</div><div>drip</div><div>2. Consider</div><div>DCCV</div><div>3. Evaluate the </div><div>need for </div><div>Anticoagulation </div><div>Remains in NSR &gt;</div><div>24-48 hours</div><div>Discharge home</div><div>with amio taper</div><div>Amiodarone</div><div>150mg/min bolus +</div><div>drip @ 1mg/min</div><div>OR</div><div>Diltiazem 0.25mg/</div><div>kg bolus + drip @</div><div>5mg/hr (titrate to</div><div>heart rate)</div><div>Afib persists</div><div>&gt; 24 hours</div><div>Converts to</div><div>Sinus</div><div>Continue amio drip</div><div>@ 1mg/min for 6</div><div>hours followed by</div><div>0.5mg/min for 18</div><div>hours</div><div>If HR or BP ↓, first</div><div>decrease drip to</div><div>0.5mg early. If no</div><div>resolution, stop</div><div>drip.</div><div>S/P MAZE</div><div>Goal is RATE</div><div>CONTROL</div><div>1. Restart Home</div><div>meds</div><div>2. Restart home</div><div>anticoagulation</div><div>NSR</div><div>Heart rate &gt; 60</div><div>Heart rate &lt; 60</div><div>Hold home rate</div><div>controlling/</div><div>antiarrhythmic</div><div>medications</div><div>Restart home rate</div><div>controlling/</div><div>antiarrhythmic</div><div>medications</div><div>(Amio, Sotolol, etc)</div><div>NO MAZE</div><div>Atrial fibrillation</div><div>(will occur in 30%</div><div>of patients)</div><div>Restart home</div><div>Antiarrhythmic/</div><div>anticoagulation</div><div>medications</div><div>MEDICATION DOSING  </div><div>Amiodarone bolus = 150mg/min over 10 min (max 6-8 boluses in first </div><div>24 hours)</div><div>Amiodarone drip = 1mg/min x 6 hours, then decrease to 0.5mg/min </div><div>x 18 hours (this will load the patient with 1g in the first 24 hours)</div><div>If patient becomes hypotensive (occurs in 25% of patients) decrease </div><div>the drip to 0.5mg/min early. </div><div>After 24 hours on the drip, transition to 400-1200mg PO per day in 2-</div><div>3 divided doses. Continue</div><div> this loading dose until you have reached </div><div>10g total (between IV and PO). Then decrease to maintenance dose </div><div>of 200-400mg/day</div><div>If QTC interval &gt; 500ms, decrease or discontinue Amiodarone. </div><div>Hypotension is more likely to occur in daily doses of Amiodarone &gt; </div><div>2g/day. Amiodarone drip should be stopped if 2</div><div>nd</div><div> degree heart </div><div>block or higher occurs or if long pauses are present. </div><div>Loading dose of Amiodarone = 10g</div><div>D</div><div>iltiazem bolus = 0.25mg/kg over 2 min</div><div>Diltiazem drip = 5mg/hour and titrate based on heart rate</div><div>Due to strong negative inotropic effect, IV Beta blockers should be </div><div>avoided. </div><div>For patients with</div><div>chronic atrial</div><div>fibrillation who have</div><div>undergone MAZE</div><div>procedure, 90% will</div><div>be in NSR at 1 year</div><div>post operatively</div><div>Restart home</div><div>medications/</div><div>anticoagulation</div><div>References</div><div>Lee, Richard. Atrial fibrillation and flutter </div><div>after cardiac surgery. In: UpToDate, Saperia, </div><div>SM (Ed.), UpToDate, Waltham, MA, 2016. </div><div>Only consider DCCV for post op</div><div>MAZE patients if patient is</div><div>unstable or rate is very fast</div><div>(DCCV will usually not work until</div><div>patient is 4 weeks post op)</div><div>Continue to</div><div>use IV Amio</div><div>bolus until</div><div>HR &lt; 10</div><div>ANTICOAGULATION</div><div>1. Depends on attending preferences </div><div>2. Should be considered for any patient having paroxysmal atrial </div><div>fibrillation with CHAD score &gt; 2</div><div>SPECIAL CONSIDERATIONS</div><div>Those with a Low EF or mechanical Mitral valve may benefit from </div><div>early DCCV even if they are stable. </div><div>CARDIAC: HEART BLOCKS</div><div>Post-operative transient disturbances of AV nodal conduction are </div><div>more common in patients with:</div><div> </div><div>Low EF, HTN</div><div> </div><div>Severe CAD </div><div> </div><div>Long Aortic clamp time</div><div> </div><div>Low intra-op myocardial temperatures</div><div> </div><div>Aortic/mitral/tricuspid valve replacement/repair</div><div>Post-operative conduction abnormalities may occur because of:</div><div> </div><div>Myocardial edema</div><div> </div><div>Suturing</div><div> </div><div>Debridement near AV node/His bundle</div><div>First Degree AV Block</div><div> </div><div>Prolongation of PR interval</div><div> </div><div>Treatment considerations: </div><div> Epicardial DDD pacing</div><div> Avoid nodal-blocking agents</div><div>Second Degree AV Block: Mobitz Type I (Wenckebach)</div><div> </div><div>Progressive PR prolongation leading to non-conducting P wave with no QRS </div><div>complex</div><div> </div><div>Treatment considerations:</div><div> Epicardial DDD pacing </div><div> Avoid nodal blocking agents</div><div>         http://www.zuniv.net/physiology/book/chapter11.html</div><div>Second Degree AV Block: Mobitz Type II</div><div> </div><div>Constant PR intervals and  </div><div>intermittent dropped QRS  </div><div>complexes (no warning!)</div><div> </div><div></div><div>system</div><div> </div><div>More likely to progress to  </div><div>complete heart block</div><div> </div><div>Treatment considerations:</div><div> Epicardial DDD pacing</div><div> Stop all nodal blocking agents</div><div> Consider permanent </div><div>pacemaker</div><div>Third Degree (Complete) Heart Block:</div><div> </div><div>Failure of AV conduction of any atrial activity (AV disassociation)</div><div> </div><div>Variable rates for P and QRS complexes</div><div> </div><div>Treatment considerations:</div><div> Epicardial DDD Pacing</div><div> </div><div>If atria in AF/A.utter must use VVI pacing</div><div> Stop all nodal blocking agents</div><div> Consider permanent pacemaker</div><div>Heart Block Poem</div><div>If the R is far from P,  </div><div>then you have a First Degree</div><div>Longer, longer, longer—DROP! </div><div>Then you have a Wenckebach</div><div>If some P’s don’t go through,  </div><div>then you have a Mobitz II</div><div>If P’s and Q’s don’t agree,  </div><div>then you have a Third Degree </div></div><div></div></div>
<div><div><img><div>58 Post-Op Management Post-Op Management 59</div><div>AV Junctional Rhythm/Junctional Tachycardia</div><div> </div><div>Occurs when junctional tissue has faster intrinsic rate than the sinus node</div><div> </div><div>“Junctional escape rhythm:” HR &lt; 60bpm </div><div> </div><div>“Junctional tachycardia:” HR 70-130 bpm</div><div> </div><div>Could be associated with decreased cardiac output due to lack of </div><div>synchronous atrial and ventricular contractions</div><div> </div><div>Diagnosis: regular rate with no visible P-waves or retrograde P waves</div><div> </div><div>Treatment considerations:</div><div> Stop all nodal blocking agents</div><div> Chronotropic Beta-1 agonists to stimulate SA node (ie Isuprel, Dopamine, </div><div>Epinephrine)</div><div> Epicardial atrial or DDD pacing</div><div>For more information on Medtronic temporary pacemaker box,</div><div> See page 106.</div><div>CARDIAC: CHEST PAIN</div><div>The most important etiology in the dierential diagnosis is myocardial ischemia. </div><div>Fortunately, it is very uncommon in the post op cardiac surgery patient.</div><div>Patient Exam:</div><div> </div><div>Can the pain be reproduced by palpitation, positional changes, or deep </div><div>inspiration? If so, much less likely to be ischemic in nature. The most </div><div>common cause of chest pain following cardiac surgery is musculoskeletal in </div><div>nature. </div><div>Obtain Ekg: </div><div> </div><div>Compare with pre op and early post op EKGs</div><div> </div><div></div><div>If You Suspect True Angina Follow Mona:</div><div> </div><div>Morphine</div><div> </div><div>O2 via Nasal Cannula</div><div> </div><div>Nitroglycerin (0.4 SL or 1” Nitro Paste)</div><div> </div><div>ASA 325mg</div><div> </div><div>Beta Blocker (metoprolol 5mg IV, may repeat in 5 min. </div><div> </div><div>Cardiac Enzymes for 24 hours (q8H x3) --Troponin/Ck-MB, CK</div><div>Consider: </div><div> </div><div>Did the patient of angina pre op? If so, is the pain the same as the pain now? </div><div> </div><div>Any pre operative cath to review? </div><div> </div><div></div><div> </div><div></div><div>pneumothorax, pneumonia, pulmonary embolism, sternal wound infection, </div><div>aortic dissection, GERD</div><div>For inpatient cardiac catherization procedures, page the interventional </div><div>cardiology fellow on call to arrange.</div><div>CARDIAC: PERICARDIAL TAMPONADE</div><div>Pathophysiology: </div><div> </div><div></div><div></div><div> </div><div></div><div>Manifestations / Physical Exam:</div><div> </div><div></div><div> </div><div></div><div> </div><div>Sudden stop in chest tube output</div><div> </div><div>Equilibration diastolic pressures</div><div> </div><div></div><div>early diastole) </div><div> </div><div></div><div>Diagnostics:</div><div> </div><div></div><div> (If you have started 2 inotropes, and given volume, and the patient is </div><div>doing badly (CI &lt; 2.0), you must rule out tamponade)</div><div> </div><div>Chest xray (widened mediastinum)</div><div> </div><div>CBC, Coagulation studies </div><div>Treatment:</div><div> </div><div>Give volume, start an inotrope, alert surgical team</div><div> </div><div>Assure chest tube patency</div><div> If visible clot within chest tube obstructing drainage, discuss with surgical </div><div>resident/fellow about using suction catheter to suction out the chest </div><div>tube with sterile technique</div><div> </div><div>If patient acutely decompensating, may require re-sternotomy in the  </div><div>ICU or OR</div><div>Delayed tamponade: </div><div> </div><div></div><div>usually resolve completely</div><div> </div><div></div><div>clinical symptoms as patients enter a low cardiac output state </div><div> Gradual increase in creatinine/BUN</div><div> Gradual increase in heart rate</div><div> Gradual decrease in urine output</div><div> Decrease in exercise tolerance</div><div> </div><div>Diagnostics: Echocardiogram gold standard</div><div> </div><div>Treatment: as above if unstable. If stable, consider pericardial window vs </div><div>need to re-open chest in operating room</div><div> </div></div><div></div></div>
<div><div><img><div>60 Post-Op Management Post-Op Management 61</div><div>CARDIAC: RIGHT VENTRICULAR FAILURE</div><div>Pathophysiology</div><div> </div><div>The RV is a thin-walled, crescent-shaped structure characterized by low </div><div>resistance, high compliance, and low impedence</div><div> </div><div></div><div> </div><div>Ventriculoarterial coupling is a major determinant of RV function</div><div>Etiology</div><div>1.  Preexisting RV dysfunction secondary to severe coronary disease, pulmonary </div><div>hypertension, valvular heart disease, and/or RV infarction</div><div>2.  Postsurgical RV dysfunction secondary to long cardiopulmonary bypass </div><div>(CPB) time, suboptimal myocardial protection, and/or coronary embolism</div><div>3.  </div><div>excessive blood transfusions, pulmonary embolism, protamine reaction, </div><div>ischemia-reperfusion injury, tension pneumothorax</div><div>4.  RV pressure overload secondary to intrinsic pulmonary disease, pulmonary </div><div>embolism, and/or acute respiratory distress syndrome (ARDS)</div><div>Diagnosis</div><div> </div><div>High right atrial pressure (RAP) and pulmonary capillary wedge (PCW) </div><div>pressure.  Note this is unreliable when LV dysfunction is also present</div><div> </div><div>May consider TTE to assess IVC, tricuspid regurgitation, right ventricle size, </div><div>and septal positioning to guide volume status.  </div><div> </div><div>Monitor CVP tracing.  With worsening TR and RV dilation, will see rising V </div><div>wave on CVP tracing.  </div><div> </div><div>Calculate step-up (mean PA pressure - CVP pressure)</div><div> Goal &gt; 10</div><div> </div><div>Calculate pulmonary artery pulsatility index (PAPi)</div><div> Studied to predict RVAD need in LVAD patients</div><div> PAPi = (systolic PA pressure - diastolic PA pressure) / CVP</div><div> </div><div>PAPi &gt;2: good RV function</div><div> </div><div>PAPi 1-2: at risk for RV failure</div><div> </div><div>PAPi &lt;1: RV failure</div><div> </div><div>For more information on Advanced hemodynamic monitoring and PA </div><div>catheters see page 125.</div><div>Management</div><div>1.  Prevent elevated pulmonary vascular resistance</div><div>a.  Avoid hypoxemia, hypercapnia, and acidosis which increase PVR</div><div>2.  Optimize preload</div><div>a.  Fluid Administration</div><div>i.  Administer crystalloids/colloids and/or blood products slowly for low </div><div>cardiac output as long as CVP is low or within target range  </div><div>ii.  Do not give additional volume if the cardiac output/blood pressure </div><div>does not improve since additional volume may lead to worsening RV </div><div>function according to Frank-Starling mechanism</div><div>b.  Fluid removal</div><div>i.  Initiate diuretics promptly for volume overload and RV dilation/TR.  </div><div>Start with Lasix bolus of 10-50 mg IV.  If no response to bolus, consider </div><div>rebolus, starting Lasix infusion, and/or adding Diuril IV.  </div><div>ii.  If no response to Lasix/Diuril, consider switching to Bumex infusion </div><div>or starting Nesiritide infusion.  (Note Nesiritide causes systemic </div><div></div><div>with loop diuretics).  </div><div>iii. If all the above interventions fail, initiate dialysis.</div><div>3.  </div><div>a.  Flolan: inhaled epoprostenol </div><div>i.  Prostacyclin inhibitor that is a pulmonary vasodilator</div><div>ii.  Starting dose 0.05 mcg/kg/min.  When weaning therapy, titrate down </div><div>by 0.01 mcg/kg/min as tolerated</div><div></div><div>be stopped if suspected </div><div>b.  iNO</div><div>i.  Selective pulmonary vasodilator only available in aerosol </div><div>administration.  </div><div>ii.  Use only if patient not responsive to inhaled Flolan</div><div>iii. Starting dose 20 ppm.  When weaning therapy, titrate down by 5 </div><div></div><div></div><div>c.  </div><div>i.  Phosphodiesterase (PDE) inhibitor that is both a pulmonary and </div><div>systemic vasodilator.</div><div>ii.  Available in oral doses of 5-20 mg TID</div><div>4.  Optimize cardiac output</div><div>a.  Dopamine</div><div> </div><div>doses.</div><div>ii.  Drip rate ranges between 1-5 mcg/kg/min.  May transfer out of ICU on </div><div>4 mcg/kg/min</div><div>b.  Epinephrine</div><div> </div><div>kg/min</div><div>ii.  Drip rate ranges between 0.01-0.2 mcg/kg/min.  Drip titrated by 0.01 </div><div>mcg/kg/min</div><div>iii. Important considerations</div><div>1.  May cause arrthymias at higher doses</div><div>2.  Closely monitor CVP/CI/lactates when titrating drip rate</div><div>c.  Milrinone </div><div>i.  PDE III inhibitor. Provides inotropy and reduces PVR/SVR</div><div>ii.  Drip rate ranges between 0.1 – 0.5 mcg/kg/min</div><div>iii. Important considerations</div><div>1.  Long half-life of 1.5-2 hours</div><div>d.  Dobutamine</div><div> </div><div>SVR</div><div>ii.  Drip rate ranges between 1-20 mcg/kg/min.  Half-life 2 minutes</div><div>iii. Important considerations</div><div>1.  Causes mild tachycardia and hypotension</div><div>2.  Increases myocardial oxygen demand</div><div> </div><div>5.  Optimize right heart perfusion pressure</div></div><div></div></div>
<div><div><img><div>62 Post-Op Management Post-Op Management 63</div><div>a.  </div><div>b.  Vasopressin</div><div>i.  May cause pulmonary vasodilation at low doses</div><div>ii.  Drip rate ranges between 0.01-0.04 units/min</div><div>c.  Norepinephrine</div><div> </div><div>ii.  Does increase PVR at higher doses</div><div>iii. Drip rate ranges between 1-20 mcg/min</div><div>d.  Phenylephrine</div><div> </div><div>ii.  Like Norepinephrine dose increase PVR at high doses</div><div>iii. Infusion rates 5-200 mcg/min</div><div>6.  Monitor adequate end organ perfusion:</div><div>a.  SvO2 (either from CCO swan or VBG)</div><div>b.  Lactate </div><div>c.  UOP/Creatinine</div><div>d.  LFT’s (R heart failure leads to hepatic congestion)</div><div>7.  </div><div>consider mechanical circulatory support</div><div>a.  RVAD</div><div>b.  VA ECMO</div><div>CARDIAC: SYSTOLIC ANTERIOR MOTION (SAM) </div><div>OF THE MITRAL VALVE</div><div> </div><div></div><div>systole.  Typically seen in patients with HOCM or mitral valve repair.</div><div> </div><div>Consider in setting of worsening hypotension with increased inotropic </div><div>support</div><div> </div><div></div><div>intraventricular septum, papillary muscle displacement, and redundant </div><div></div><div>Clinical pearls:</div><div>To prevent SAM, the goal is to slow the heart rate to prolong the LV lling time </div><div> </div><div>Avoid inotropic support, use vasopressors in setting of hypotension</div><div> </div><div>Avoid hypovolemia, cautious use of diuretic therapy</div><div> </div><div>Once stabilized, consider beta blocker therapy for long term treatment </div><div> </div><div>Reference page 24  </div><div>CARDIAC: VASOPLEGIA</div><div> </div><div>Persistent hypotension despite adequate cardiac output from low systemic </div><div>vascular resistance</div><div> </div><div></div><div>response. Risk factors include history of use of ACE inhibitors, ARBs, CCBs, </div><div>Amiodarone, B-blockers, and Heparin.</div><div> </div><div>Treatment:</div><div> </div><div> PhenylephrineNorepinephrine</div><div></div><div>needed</div><div> Methylene Blue (1-2mg/kg bolus) inhibits NO synthase and is used in </div><div>the treatment of refractory hypotension</div><div>CARDIAC: HEART FAILURE</div><div>post surgery because most </div><div>post surgical state. However </div><div>there are some principals that can help you manage the patients. </div><div>Medications: </div><div> </div><div>Do not hold heart failure medications (beta blockers, ACE inhibitors, </div><div>spironolactone) for low blood pressure. Accept a lower blood pressure </div><div>for heart failure patients consider giving them even if your systolic blood </div><div>pressure is in the 90’s (even in the high 80’s in some cases). </div><div> </div><div></div><div>may be harmful in asymptomatic patients with low LVEF and no symptoms of </div><div></div><div> </div><div>Beta blockers: </div><div> Beta blockers should be used in all patients with a reduced EF to prevent </div><div>symptomatic HF, even if they do not have a history of MI.  </div><div> Consider Coreg instead of Metoprolol for beta blockade: one study </div><div></div><div>Metoprolol for heart failure with reduced EF </div><div> </div><div>Aerload reduction:</div><div> </div><div>reduction due to kidney dysfunction. The kidneys will appreciate better </div><div></div><div>problem</div><div> </div><div>patients who cannot tolerated ACEs or ARBs or who are African American </div><div> ACE inhibitors should be used in all patients with a reduced EF to prevent </div><div>symptomatic HF, even if they do not have a history of MI. </div><div> </div><div>Diuretics: See volume management below </div><div>Volume Management: </div><div> </div><div>Don’t over-diurese patients with preserved ejection fraction. They are very </div><div>responsive to volume and cardiac output can disproportionately drop with </div><div>minimal changes in preload. </div><div> </div><div>Consider Aldactone or Eplerenone for patients that are on a beta blocker and </div><div>ace inhibitor without hyperkalemia</div><div> </div><div>Lasix is a threshold drug- titrate daily dose until you see a response (for </div><div>example- if no response to 20mg daily, increase40mg daily instead of 20mg </div><div>BID). While inpatient, use IV. </div><div> </div><div>20mg lasix IV = 40 PO = 1 Bumex IV= 10 Torsemide PO </div><div> </div><div>Consider Diuril or Metolazone for patients who are diuretic resistant</div><div> </div><div>If hyponatremic, it is likely a hypervolemic issue. Diuresis is the appropriate </div><div>response, rather than giving salt tabs</div><div> </div><div>No pre hydration for cardiac catheterization or CT scan</div><div>Consults: </div><div> </div><div>Consider consult to heart failure CNS for assistance with complex patients or </div><div>if you have questions. They are also a great education resource for patients. </div><div>Enter as epic order.</div></div><div></div></div>
<div><div><img><div>64 Post-Op Management Post-Op Management 65</div><div>PULMONARY: PLEURAL EFFUSIONS</div><div>Type of </div><div>Pleural </div><div>Eusion</div><div>Denition Presentation: Common </div><div>causes</div><div>Pleural Fluid </div><div>Interpretation </div><div>(Lights Criteria)</div><div>Diagnosis Treatment </div><div>Transudate</div><div> </div><div></div><div>capillaries from: hydrostatic </div><div>psi/increased pressure </div><div>(CHF, etc) </div><div> </div><div></div><div>from nutrition, nephrotic </div><div>syndrome, cirrhosis)</div><div> </div><div>Usually occurs bilaterally </div><div>Small eusion: </div><div>likely </div><div>asymptomatic </div><div>Larger eusion: </div><div>dyspnea, cough, </div><div>hypoxia</div><div>Physical exam: </div><div>percussion </div><div></div><div></div><div>absent breath </div><div>sounds over </div><div></div><div> </div><div>CHF (most </div><div>common - </div><div>90%)</div><div> </div><div>Cirrhosis</div><div> </div><div>Nephrosis</div><div> </div><div>Protein ≤ 3 gm% </div><div> </div><div></div><div>protein/serum </div><div>protein&lt;0.5</div><div> </div><div></div><div>serum LDH &lt; 0.6 </div><div> </div><div></div><div>&lt; 2/3 upper limit </div><div>normal</div><div> </div><div>CXR PA &amp; Lateral, </div><div>lateral decubitus</div><div> </div><div>CT may be indicated </div><div>to evaluate etiology of </div><div></div><div> </div><div>US-Guided Diagnostic </div><div>horacentesis  </div><div>c.  </div><div>protein &amp; lactate </div><div>hydrogenase </div><div></div><div>transudates vs. </div><div>exudates. </div><div>d. b) PH, total &amp; </div><div></div><div>counts, glucose, </div><div>cytology, gram </div><div>stain, culture, etc </div><div></div><div>exudate subtypes (if </div><div>indicated)</div><div> </div><div>Correct underlying condition</div><div> </div><div>Common in immediate post op setting, </div><div>consider need for diuresis</div><div> </div><div>Therapeutic thoracentesis for severe dyspnea</div><div>Exudate</div><div> </div><div></div><div>abnormal capillaries leaking </div><div></div><div>drainage such as cancer).</div><div> </div><div>Exudates imply local pleural </div><div>diseases</div><div> </div><div>Exudates – subtypes: </div><div>e.  Empyema’s: direct </div><div>infection of an exudates. </div><div>f.  Hemothorax: gross blood </div><div>in pleural space from </div><div>trauma. </div><div>g.  Chylothorax: thoracic </div><div>duct disruption causes </div><div>cholesterol complex </div><div>accumulation, usually </div><div>associated with </div><div>lymphoma and thoracic </div><div>surgery.</div><div> </div><div>Can occur bilaterally or </div><div>Unilaterally </div><div>Usually </div><div>inammatory </div><div>causes:</div><div> </div><div>Bacterial </div><div>Pneumonia</div><div> </div><div>Cancer</div><div> </div><div>Trauma</div><div> </div><div>Protein ≥ 3 gm% </div><div> </div><div></div><div>protein/serum </div><div>protein &gt; 0.5</div><div> </div><div></div><div>serum LDH &gt; 0.6</div><div> </div><div></div><div>&gt; 2/3 upper limit </div><div>normal</div><div>Exudates associated with pneumonias = </div><div>parapneumonic pleural eusions. </div><div>Step 1: treat pneumonia. </div><div></div><div> </div><div></div><div></div><div>antibiotic.  </div><div> </div><div></div><div></div><div>thoracostomy  (chest tube) or surgery. </div><div> </div><div></div><div>decortication usually)</div><div>Exudates associated with malignancy = </div><div>malignant pleural eusions (Lung or breast </div><div>cancer common)</div><div>Treatment options:</div><div> </div><div>Treat the cancer</div><div> </div><div></div><div>may help with symptoms (shortness of breath, </div><div>dyspnea, etc). </div><div> </div><div>Pleurodesis.</div><div>PULMONARY: PNEUMOTHORAX</div><div>Presence of air or gas in the pleural cavity (ie, the potential space between the </div><div>visceral and parietal pleura of the lung), which can impair oxygenation and/or </div><div>ventilation</div><div>1.  Etiology</div><div>a.  Entering the pleural space during surgery or with sternal wire placement</div><div>b.  Ruptured bleb in patient with underlying lung disease</div><div>c.  Barotrauma from alveolar overdistention during mechanical ventilation </div><div>may manifest as pneumothorax, subcutaneous emphysema or </div><div>pneumomediastinum </div><div>2.  Clinical manifestations</div><div>a.  Hypoxia, dyspnea, tachypnea</div><div>b.  Airleak on chest tube: may indicate loose connections along the drainage </div><div>system or pneumothorax</div><div>c.  Subcutaneous emphysema: may develop if air exists under positive </div><div>pressure where the pleura has been violated. </div><div>d.  Tension pneumothorax: collapsed lung causing cardiac compression, </div><div></div><div>output</div><div>e.  </div><div> </div><div>3.   Treatment considerations</div><div>a.  </div><div>assure chest tube is attached to suction, look for kinks in tubing</div><div>b.  </div><div>oxygen and consider placement of chest tube/pigtail </div><div>c.  If patient asymptomatic and pneumothorax small, appropriate to </div><div>observe with serial chest x-rays</div><div>References:</div><div>Bojar, Robert M. (2011) Manual of Perioperative Care in Adult Cardiac Surgery. (5th  edition).</div><div> </div><div>PULMONARY: PULMONARY HYPERTENSION</div><div>1.  Etiology: related to primary pulmonary arterial HTN or secondary to </div><div>elevations of pressure in the pulmonary venous and capillary systems</div><div>a.  Chronic Pulmonary HTN</div><div>i.  Congenital heart disease, Connective tissue disease (lupus, </div><div>rheumatoid arthritis, scleroderma), Medication/toxin induced</div><div>ii.  Chronic thromboembolic disease</div><div>iii. Lung disease: </div><div> </div><div>OSA</div><div>2.  Result of pulmonary vascular remodeling from chronic hypoxia and </div><div></div><div>iv. Le Heart Disease: </div><div>venous pressure</div><div>1.  LV systolic or diastolic heart failure</div><div>2.  Mitral and aortic valve disease </div><div>b.  Acute Pulmonary HTN</div><div>i.  Protamine reaction</div><div>1.  Type 3 protamine reaction may result in severe pulmonary </div><div>vasoconstriction, systemic vasodilation and acute right heart </div><div>failure </div></div><div></div></div>
<div><div><img><div>66 Post-Op Management Post-Op Management 67</div><div>2.  Typically improves within 10 minutes of stopping protamine</div><div>ii.  Acidosis/Hypoxemia: lead to increased pulmonary vascular </div><div>resistance</div><div>iii. Tension Pneumothorax</div><div>iv. Pulmonary embolism</div><div>v.  Acute MR (ie papillary muscle rupture)/LV failure leading to high LA </div><div>pressure and pulmonary edema</div><div></div><div>2.  Treatment in the acute setting</div><div>a.  Identify underlying cause/contributing factors</div><div>b.  Pulmonary Vasodilators</div><div>i.  Indications: severe pulmonary hypertension (mPAP &gt; 25 mmHg; RAP &gt; </div><div>15 mmHg; CI &lt; 2.0 L/min), right ventricular failure, ARDS with persistent </div><div>hypoxia (P:F &lt; 200), and post-op lung transplant with reperfusion </div><div></div><div>ii.  Inhaled aerosol results in dilation of the pulmonary vascular bed </div><div>thereby reducing pulmonary artery pressure, pulmonary vascular </div><div>resistance, and right ventricular aerload. This results in improved </div><div>in VQ mismatch and oxygenation.  </div><div>1.  Flolan (epoprosteronol) *Preferred*</div><div>  a.  Available as IV or aerosol administration.  IV administration  </div><div> (rarely used) causes systemic vasodilation</div><div>  b.  Starting dose 0.05 mcg/kg/min.  When weaning therapy,  </div><div> titrate down by 0.01 mcg/kg/min every hour as tolerated </div><div>2.  iNO</div><div>  a.  Only available in aerosol administration.  </div><div>  b.  Starting dose 20 ppm.  When weaning therapy, titrate down by </div><div></div><div></div><div>iii. Sildenal: PDE inhibitor prevents degradation of cGMP and reduces </div><div>pulmonary vascular tone</div><div>a.  Starting dose 10-20mg TID</div><div> </div><div></div><div>Sussex, UK: Wiley-Blackwell</div><div> </div><div>PULMONARY: ACUTE RESPIRATORY DISTRESS </div><div>SYNDROME (ARDS)</div><div>1.  Pathophysiology</div><div>a.  </div><div>lungs</div><div>b.  </div><div>capillaries</div><div>c.  Results in non-cardiogenic interstitial edema</div><div>d.  </div><div>e.  Hypoxic and ventilator failure </div><div>2.  Pre-disposing conditions: </div><div>a.  </div><div> </div><div>however ARDS only occurs in &lt;1% of patients undergoing open heart </div><div>surgery</div><div>ii.  Sepsis</div><div>3.  Diagnostic Criteria</div><div>a.  Acute onset</div><div>b.  </div><div>c.  PCWP &lt;18, or no clinical evidence of L heart failure, non-cardiogenic </div><div>pulmonary edema</div><div>d.  </div><div>i.  P/F ratio = PaO2 ÷ FiO</div><div>1.  Ex: PaO2 90 on FiO2 40% = 90 ÷ 0.4 = 225</div><div>ii.  P/F &lt; 200 is associated with signicant shunt and indicates ARDS</div><div>iii. P/F 200-300 indicates acute lung injury</div><div>4.  Management</div><div>a.  Optimize hemodynamics and volume status, diurese when indicated</div><div>b.  Optimize nutrition</div><div>c.  </div><div></div><div>d.  Lung Protective Ventilation (LPV) Protocol: Limits ventilator induced </div><div>lung injury</div><div>i.  Purpose: To maximize gas exchange using low tidal volumes (4-6 mL/</div><div>kg) and minimizing plateau pressures (&lt; 30 cm H2O) in all patients </div><div>with ARDS</div><div> </div><div></div><div>iii. Goals: VT 6 mL/kg, pH 7.30 – 7.45, Pplat &gt; 30 cm H2O, EIP</div><div>iv. Prescriber must determine ventilator mode (VCV or PCV) and PEEP </div><div>(standard or high)</div><div>v.  Volume Control Ventilation (VCV)</div><div>1.  Set VT at 8 mL/kg using patient’s predicted body weight (PBW).  </div><div>Slowly decrease VT by 1 mL/kg until target VT is achieved </div><div>2.  Set respiratory rate to baseline minute ventilation (do not exceed 35 </div><div>breaths/min)</div><div>3.  Add PEEP at 5-7 cm H2O to goal PaO2 &gt; 55 and SaO2 &gt; 88% (see </div><div>table below)</div><div>4.  Adjust VT to achieve target plateau pressure (Pplat)</div><div>  a.  If Pplat &gt; 30 cm H2O, decrease VT by 1 mL/kg until Pplat &lt; 30 or  </div><div> VT 4 mL/kg</div><div>  b.  If Pplat &lt; 25 and VT &lt; 6 mL/kg, increase VT by 1 mL/kg until Pplat  </div><div> &gt; 25 or VT 6 mL/kg</div><div>  c.  If Pplat &lt; 30 and vent dysnchrony, may increase VT by 1 mL/kg to  </div><div> 8 mL/kg and/or increase sedation</div><div>5.  Adjust respiratory rate to achieve target pH </div><div>6.  If pH &lt; 7.30, increase RR to max 35 breaths/min</div><div>7.  If pH &lt; 7.15 and RR 35 breaths/min, increase VT by 1 mL/kg to a max </div><div>of 8 mL/kg until pH &gt; 7.15</div><div>vi.  Pressure Control Ventilation (PCV)</div><div>1.  PCV is similar to above however end-inspiratory pressure (EIP) is </div><div>adjusted to achieve goal VT (tidal volume).</div><div>2.  If EIP &lt; 10 cm H2O and VT &gt; 7 mL/kg, increase EIP in order to </div><div>increase to a maximum EIP 35 cm H2O </div><div>3.  If EIP is decreased to 10 cm H2O &gt; PEEP and VT &gt; 7 mL/kg or if </div><div>patient exhibiting increased work of breathing, consider increasing </div><div>sedation.  If unable to increase sedation, may increase VT by 1 mL/</div><div>kg to max VT 8 mL/kg.</div><div>4.  Once work of breathing decreased, decreased EIP back to target VT </div><div>5-7 mL/kg</div></div><div></div></div>
<div><div><img><div>68 Post-Op Management Post-Op Management 69</div><div>vii. PEEP/FiO2 titration</div><div>1.  Goal SaO2 88-95% or PaO2 55-80%</div><div>FiO2 30% 40% 50% 60% 70% 80% 90% 100%</div><div>Standard PEEP 5 5-8 8-10 10 10-14 14 14-18 18-20</div><div>High PEEP 8-10 10-12 12-14 14-16 16-18 18-20 20-22 22-24</div><div>Sources:</div><div></div><div>UK: Wiley-Blackwell</div><div>Marino, P. (2009). The Little ICU Book. Philadelphia, PA: Lippincott Williams &amp; Wilkins</div><div> </div><div>PULMONARY: ATELECTASIS</div><div>Atelectasis: collapse or closure of a lung resulting in reduced or absent gas </div><div>exchange</div><div>1.  Etiology:</div><div>a.  Obstructive: blockage in the proximal airway leads to nonventilated </div><div>alveoli that collapse</div><div>b.  Passive/Compressive:</div><div></div><div>c.    pain (splinting), over-sedation, or prolonged </div><div>supine positioning</div><div>2.  Clinical manifestations</div><div>a.  Hypoxia, dyspnea</div><div>b.  </div><div>c.  Fever, elevated WBC count, PNA</div><div>3.  Treatment considerations</div><div>a.  Identify and address underlying causes: </div><div>i.  Achieve adequate pain control, decrease sedation</div><div> </div><div>iii. Assess for evidence of PNA and treat appropriately</div><div>b.  Alveolar Recruitment Maneuvers: </div><div>i.  Using increased PEEP via ventilator or CPAP </div><div>1.  Increase mean airway pressure to open closed alveoli to increase </div><div>surface area for gas exchange</div><div>2.  Decrease VQ mismatch/intrapulmonary shunting (improves </div><div>ventilation to perfused areas)</div><div>ii.  Incentive spirometer. Goal volume &gt;1L.</div><div>1.  Maintains Functional Reserve Capacity (FRC)</div><div>2.  Prevents and improves atelectasis</div><div>c.  Bronchial Hygiene Therapy (“Pulmonary Toilet”)</div><div>1.  Purpose: To help loosen and mobilize pulmonary secretions </div><div>2.  Indications: mobilization of retained secretions, atelectasis, optimize </div><div>delivery of bronchodilators</div><div>3.  Contraindications: hemodynamic instability, recent facial/oral/cranial </div><div></div><div>active hemoptysis, nausea/vomiting, radiographic evidence of bled/</div><div>bullae, fractured ribs or unstable chest, untreated pneumothorax, and </div><div>compromised cardiac status or arrhythmias.</div><div>4.  Therapies (may be combined with bronchodilating nebulizers for  </div><div></div><div>Acapella Intrapulmonary Percussive </div><div>Ventilation (IPV)</div><div>Chest Physiotherapy (CPT)</div><div>A resistive/vibratory device </div><div>that is used to open the </div><div>airways and provide </div><div>oscillating vibrations to help </div><div>loosen secretions</div><div>Pneumatic device that </div><div>delivers pressurized </div><div>minibursts of gas at rates of </div><div>100-225 cycles per minute </div><div>through a mouthpiece to </div><div>achieve alveolar recruitment</div><div>Technique that uses manual </div><div>or mechanical external </div><div>percussion and vibration </div><div>to loosen secretions and </div><div>promote clearance</div><div>Sources:</div><div></div><div>UK: Wiley-Blackwell</div><div>Adams, G. (2006). On Call Surgery, 3rd Edition. Philadelphia, PA: Saunders Elsevier</div><div>Marino, P. (2009). The Little ICU Book. Philadelphia, PA: Lippincott Williams &amp; Wilkins</div><div>GI: ACUTE HEPATIC DYSFUNCTION</div><div>About 25% of patients will develop transient hyperbilirubinemia aer open heart </div><div>surgery, but fewer than 1% of patients will have signicant hepatocellular damage </div><div>leading to chronic hepatitis or liver failure</div><div>1.  Risk Factors</div><div>a.  Preexisting liver disease: </div><div>i.  Elevated liver enzymes (AST/ALT), elevated bilirubin, or evidence of </div><div>synthetic dysfunction (low albumin, high INR)</div><div>ii.  Elevated bilirubin in patient w/hx CHF is strongest predictor of post-op </div><div>liver dysfunction</div><div>b.  Comorbidities: CHF (high right sided pressure leading to congestive </div><div>hepatomegaly), DM, HTN</div><div>c.  Preoperative cardiogenic shock: may have evidence of “shock liver” prior </div><div>to surgery</div><div>d.  Operative risk factors:</div><div>i.  Long cardiopulmonary bypass time</div><div>ii.  Complex operations (ie combined CABG-valve, multiple valves)</div><div>iii. Multiple blood transfusions</div><div>e.  Post-operative risk factors</div><div>i.  Low cardiac output syndrome</div><div>ii.  Use of multiple inotropes/IABP</div><div>II.  Etiology: may result from either decreased liver perfusion or systemic </div><div>congestion</div><div>Hepatocellular Necrosis Hyperbilirubinemia</div><div> </div><div>Low cardiac output states (requiring </div><div>inotropes/vasopressors) </div><div> decreased </div><div>hepatic perfusion</div><div> </div><div>Right heart failure/severe TR </div><div>chronic passive hepatic congestion</div><div> </div><div>Medications (Tylenol, Plavix, statins)</div><div> </div><div>Post-transfusion hepatitis/CMV (late </div><div>manifestation)</div><div> </div><div>Hemolysis (paravalvular leak, long </div><div>pump run, sepsis, multiple transfusions, </div><div>ECMO, drugs)</div><div> </div><div>Intrahepatic cholestasis (hepatitis, </div><div>hepatocellular necrosis, TPN, bacterial </div><div>infections, medications, benign </div><div>cholestasis)</div><div> </div><div>Extrahepatic congestion (biliary tract </div><div>obstruction)</div></div><div></div></div>
<div><div><img><div>70 Post-Op Management Post-Op Management 71</div><div>2.  Clinical manifestations</div><div>a.  Jaundice</div><div>b.  Coagulopathy</div><div>c.  Refractory acidosis</div><div>d.  Hypoglycemia</div><div>e.  Renal failure (hepatorenal syndrome)</div><div>f.  Encephalopathy</div><div>3.  Work-up: in addition to basic labs/LFT’s consider further investigation with the </div><div>following</div><div>a.  Order Total and Fractionated bilirubin: </div><div>i.  Mostly Conjugated (Direct): biliary obstruction (stone, mass, PSC) or </div><div>cholestasis (sepsis/hypoperfusion states, cholestasis, TPN)</div><div>ii.  Mostly Unconjugated (Indirect): hemolysis, hepatic congestion/</div><div>decreased bili uptake (heart failure)</div><div>b.  Assess for hemolysis: LDH, haptoglobin, plasma free hemoblogin, </div><div>reticulocyte count</div><div>c.  Assess for right heart failure/ </div><div>TR: echo</div><div>d.  Assess for biliary obstruction/cholecystitis: Alk Phos, right upper </div><div></div><div>i.  Acute Cholecystitis: gall bladder wall thickening, stranding, </div><div></div><div>ii.  Stone/obstruction: stone, ductal dilitation</div><div>e.  Review medications for hepatotoxicity</div><div>f.  Assess for acute hepatitis: hepatitis panel</div><div>g.  Assess for synthetic dysfunction: coag panel, albumin, glucose, lactate</div><div>h.  Assess for encephalopathy: exam, ammonia level</div><div>4.  Management: elevated bilirubin usually benign and self-limited post-operative </div><div>occurrence. Will gradually improve with normal hemodynamics unless severe </div><div>underlying liver pathology is present</div><div>a.  Address underlying cause</div><div>i.  Right heart failure/TR: Refer to “Right Heart Failure” section</div><div>ii.  Bilary obstruction, consider:</div><div>1.  ERCP/MRCP: for stone in common bile duct w/acute cholangitis (GI </div><div>medicine consult)</div><div>2.  Percutaneous cholecystostomy tube (placed by IR)</div><div>3.  Cholecystectomy (General surgery consult)</div><div>b.  Monitor and treat hypoglycemia</div><div>c.  Judicious reversal of coagulopathy if present</div><div>d.  Avoid hepatotoxic medications</div><div>e.  If Ammonia elevated and evidence of encephalopathy: consider </div><div>Lactulose 30 Q8</div><div>f.  Monitor for lactic acidosis (impaired lactate metabolism) and correct pH </div><div>with sodium bicarb when indicated</div><div>Sources:</div><div></div><div>UK: Wiley-Blackwell</div><div>Roy-Chowdhury, N. Diagnostic approach to the adult with jaundice or asymptomatic </div><div>hyperbilirubinemia. www.uptodate.com</div><div>GI: CONSTIPATION AND ILLEUS</div><div>Cardiac Surgery Post-Operative Bowel regimen:</div><div>Medication Dose Frequency Onset of Action</div><div>Docusate (Colace)  200mg PO BID 24-72 hours</div><div>Polyethylene Glycol (Miralax) 17g Packet Daily 1-4 days</div><div>Senna (Senokot) 2 tabs PO qHS PRN 6-12 hours</div><div>Bisacodyl (Dulcolax) Suppository 10mg Rectal Daily PRN 15-60 minutes</div><div>Magnesium hydroxide (MOM) 30mL Oral Q8 hours PRN</div><div>Magnesium Citrate 150-300mL Oral Once 30 minutes- 3 hours</div><div>Lactulose 20mg TID Up to 24 -48 hours</div><div>Stanford BOMB Sterile water for </div><div>irrigation 300mL, </div><div>magnesium citrate </div><div>200mL, Glucerin Bulk </div><div>100% 199mL</div><div>Once Immediate</div><div> </div><div>*For VAD bowel regimen protocol see reference materials VAD BOWEL REGIMEN </div><div>page 138.</div><div>Ileus Management:</div><div> </div><div>Management of ileus starts with correction of underlying medical conditions, </div><div>such as sepsis, electrolyte abnormalities, particularly hypokalemia, </div><div>hyponatremia, and hypomagnesemia. </div><div> </div><div>Consider need for NG or rectal tube for decompression. For severe illeus- </div><div>consider consult to general surgery or GI. </div><div> </div><div>Bowel regimen for ileus management can include BID suppository/enema. </div><div>DO NOT USE PERISTALTIC AGENTS FOR ILLEUS MANAGEMENT. </div><div> </div><div>For protracted ileus, contrast studies may be required to rule out mechanical </div><div>obstruction.</div><div> </div><div>Discontinue and limit the use of medications that produce ileus (eg, opiates, </div><div>narcotics), and use (NSAIDs) instead (unless contraindicated). </div><div> </div><div>Advisable to delay oral feeding until ileus resolves clinically. Consider need </div><div></div><div> </div><div>Most cases of postoperative ileus resolve with watchful waiting and </div><div>supportive treatment. </div><div>see page 91.</div><div>GI: POST-OPERATIVE GI BLEEDING</div><div>1.  Upper GIB: may present as hematemesis, bloody NG/OG tube output, or melena </div><div>a.  Most commonly from: </div><div>i.  Stress ulcers (peptic, duodenal, gastric)</div><div>ii.  Esophagogastritis</div><div>b.  </div><div>reperfusion injury and increased gastric acidity from any of the following:</div><div> </div><div> </div><div>3.  Low cardiac output states</div></div><div></div></div>
<div><div><img><div>72 Post-Op Management Post-Op Management 73</div><div>4.  Critical illness</div><div>c.  Risk Factors</div><div>i.  Pre-operative: older age, history if PUD/GERD</div><div>ii.  Intra-operative: long duration of CPB, valve operations, re-operations</div><div>iii. Post-operative: low CO, prolonged mechanical ventilation (&gt;48 hours), </div><div>coagulopathy, anticoagulation, anti-platelet therapy</div><div>d.  Preventative measures</div><div> </div><div>mucosa that helps maintain mucosal structural and functional </div><div>integrity </div><div>ii.  Acid suppression</div><div>1. Indications for stress ulcer prophylaxis</div><div> </div><div>echanical ventilation for </div><div>&gt;48 hours</div><div> </div><div>Spinal cord injury</div><div> </div><div>Use of 2 anti-plt agents </div><div>(Plavix, ASA, cilostazol, </div><div>ticagrelor, dipyridamole)</div><div> </div><div>Coagulopathy (Plt &lt;50, INR </div><div>&gt;1.5, or PTT 2x baseline)</div><div> </div><div>Solid organ transplant in </div><div>ICU setting</div><div> </div><div>Any 2 of the following:</div><div> Sepsis</div><div> ICU stay &gt;7 days</div><div> Occult bleed lasting &gt;6 days</div><div> High dose steroids w/daily dose </div><div> </div><div> &gt;250mg hydrocortisone</div><div> </div><div> &gt;50mg </div><div>methylprednisolone</div><div> </div><div>&gt;60mg prednisone</div><div> </div><div>&gt;10mg dexamethasone</div><div> </div><div>Hx GERD/GI ulcers/acid suppressant </div><div>therapy</div><div>2. Proton pump inhibitors (PPI’s):</div><div>H2 blockers in reducing incidence of hemorrhagic gastritis and </div><div>ulceration</div><div>a.  Pantoprazole 40mg IV/PO daily</div><div>b.  Use is not without risk!</div><div> </div><div> ii.  PPI use is independent risk factor for nosocomial PNA</div><div> iii.  May cause hypomagnasemia</div><div>3. H2 Blockers: </div><div>a.  Famotidine 20mg IV Q12</div><div>b.  Associated with thrombocytopenia</div><div>e.  Treatment considerations:</div><div> </div><div>1. Correct coagulopathy when indicated</div><div>2. Consider DDAVP for suspected platelet dysfunction if uremia is present</div><div>3. Transfuse blood if hemodynamically unstable </div><div>ii.  Monitor vital signs for shock. Assess volume status</div><div>iii. Flush NG/OG tube if present</div><div>iv. If bleeding continues, patient is hemodynamically unstable and/or </div><div>there is an inappropriate response to blood transfusion consider </div><div>GI consult for EGD (esophagogastroduodenoscopy)</div><div> </div><div></div><div>vi. Acid suppression (treatment dosing):</div><div>1. Pepcid 20mg IV q8</div><div>2. Protonix 80mg IV push + continuous infusion 8mg/hr </div><div>2.  Lower GIB: dark to bright red blood from the rectum. Color of blood is </div><div>associated with the length of time in the GI tract</div><div>a.  Etiologies: </div><div>i.  Hemorrhoids</div><div>ii.  Mesenteric ischemia/ischemic colitis</div><div>1.  Periods of prolonged hypoperfusion from</div><div>a.  Low cardiac output state</div><div>b.  Atherosclerotic embolism or mesenteric thrombosis</div><div>2.  May present as profound ileus, abdominal pain out of proportion </div><div>3.  May be associated with elevated lactate, GIB, sepsis (bacterial </div><div>translocation)</div><div>iii. Diverticulosis</div><div>iv. Arteriovenous malformations (AVM’s): See LVAD post-operative </div><div>considerations</div><div>v.  Ulceration/tissue breakdown from rectal tube</div><div>b.  Work up:</div><div>i.  Examine patient looking for hemorrhoid or tissue breakdown</div><div>ii.  Consider placing NG/OG tube to assess for presence of upper GIB</div><div>iii. </div><div>1. Correct coagulopathy when indicated</div><div>2. Consider DDAVP for suspected platelet dysfunction if uremia is </div><div>present</div><div>3. Transfuse blood if hemodynamically unstable </div><div>iv. If bleeding continues, patient is hemodynamically unstable and/or </div><div>there is an inappropriate response to blood transfusion consider </div><div>GI consult for EGD and/or sigmoidoscopy/colonoscopy </div><div>1.  If these are negative, source may be small bowel</div><div>v.  KUB/CT scan to assess for evidence of ischemic bowel</div><div>1.  Pneumotosis (air in the bowel wall), venous gas, bowel wall </div><div>thickening</div><div> </div><div>vi. Radionuclide scanning (ie tagged RBC scan) to localize source of bleed</div><div>vii. Angiography: </div><div>1.  May be diagnostic and therapeutic if bleeding can be localized</div><div> </div><div>detection</div><div>Sources:</div><div></div><div>UK: Wiley-Blackwell</div><div>Adams, G. (2006). On Call Surgery, 3rd Edition. Philadelphia, PA: Saunders Elsevier</div><div>Marino, P. (2009). The Little ICU Book. Philadelphia, PA: Lippincott Williams &amp; Wilkins</div><div>GI: MALNUTRITION (TUBE FEEDING/TPN)</div><div>Tube Feeding: </div><div> </div><div>Consult with dietician to evaluate adequate oral intake vs need for tube </div><div>feeding.</div><div> </div><div>Use IP GEN Tube Feeding order set to place the following orders:</div><div> Consult to nutrition </div><div> Place KOF (Small bore feeding tube)</div><div> </div><div>If Feeding tube placed via super user RN with Cortrak, no need for KUB </div></div><div></div></div>
<div><div><img><div>74 Post-Op Management Post-Op Management 75</div><div>to evaluate location</div><div> </div><div>If feeding tube is placed without use of Cortrak, obtain KUB to ensure tip </div><div>of feeding tube is post pyloric</div><div> </div><div>If feeding tube is unable to be placed post pyloric, consider use of </div><div>Reglan to promote motility. </div><div> </div><div>In some cases, trickle tube feeds may be started while the tip </div><div>of feeding tube is in the stomach (beware of increased risk of </div><div>aspiration)</div><div> Tube feeds are typically started @ 20cc/hr and increased by 20 q8 hours </div><div>until goal rate is achieved. (Trickle or trophic TF rate 10-20cc/hr)</div><div> Obtain daily labs: CMP, Phos, Mag, Pre albumin (3x weekly)</div><div> Glucose management via subQ insulin (Glucose checks q6) or insulin drip </div><div>TPN= Total parenteral nutrition </div><div> </div><div></div><div>Prolonged ileus. Consult with dietician to assess nutrition needs. </div><div> </div><div>Needs central access (TPN is administered via dedicated line), consider need </div><div>for PICC line placement. </div><div> </div><div>TPN must be ordered by 1400.  Use IP GEN TPN/PPN Adult Protocol order set  </div><div>to place the following orders</div><div> Consult to nutrition  </div><div> PICC Line placement if needed for adequate access</div><div> TPN + Lipids</div><div> Obtain daily labs: CMP, Phos, Mag, Triglycerides</div><div> Glucose control via insulin placed in TPN mixture or Insulin drip (some </div><div>patients may require both)</div><div> </div><div></div><div>dysturbances, loss of gut barrier, acalculus cholecystitis, refeeding syndrome, </div><div>&amp;  hyperosmolality</div><div>GU/FEN: ACID BASE DISTURBANCES </div><div>The normal buering systems of the body (bicarbonate, hemoglobin, phosphate, </div><div>and protein) are frequently overwhelmed by disease states or altered from the </div><div>eects of cardiopulmonary bypass.</div><div>reference see page 124.</div><div>Metabolic Acidosis: </div><div>accumulation of acids in the serum. </div><div>1.  Anion Gap = Na – (Cl + HCO3).  Normal AG 8-12 mmol/L. </div><div>a.  Correct for hypoalbuminemia.  AG + (2.5 x (4-albumin)).   </div><div>Elevated AG &gt; 13 mmol/L</div><div>High Anion Gap Acidosis Normal Anion Gap Acidosis</div><div> </div><div>Lactic acidosis (see below)</div><div> </div><div>Renal failure (reduced acid </div><div>secretion)</div><div> </div><div>Rhabdomyolysis</div><div> </div><div>Medications (ASA, ethylene, </div><div>methanol)</div><div> </div><div>Ketoacidosis</div><div> </div><div>Diarrhea (high bicarb loss)</div><div> </div><div>Renal Tubular Acidosis (loss of bicarb </div><div>resorption)</div><div> </div><div>Carbonic anhydrase inhibitors (ie Diamox, </div><div>increased bicarb secretion by kidneys)</div><div> </div><div>Hyperchloremia (increased HCl acid in </div><div>blood)</div><div> </div><div>Blood transfusions (addition of aci</div><div>2.  Lactic acidosis</div><div>a.  Type A: Impaired tissue oxygenation and anaerobic metabolism from </div><div>circulatory failure </div><div>i.  ICU, immediate post-op considerations—May be result of:</div><div>1.  Pre-existing renal dysfunction</div><div>2.  Long pump runs</div><div>3.  Intraoperative vasopressor use</div><div>4.  Inadequate O2 delivery during bypass that contributes to </div><div>splanchnic and renal ischemia with acidosis perpetuated by a low </div><div>cardiac output syndrome</div><div>ii.  Several days post-op—May be result of:</div><div>1.  Mesenteric ischemia</div><div>2.  Sepsis</div><div>3.  Acute hepatic dysfunction (decreased lactate utilization)</div><div>4.  Low cardiac output state, malperfusion</div><div>b.  Type B: Not associated with tissue hypoxia. Low-dose Epinephrine </div><div></div><div>acid production. </div><div>i.  Not commonly seen</div><div>ii.  Consider when cardiac output is adequate and lactic acidosis seems </div><div>out of proportion with tissue perfusion</div><div>3.  Adverse Eects of Acidosis: typically do not occur until pH is &lt; 7.2</div><div>a.  Cardiovascular: </div><div>i.  Decreased contractility and cardiac output, decreased liver and renal </div><div>perfusion</div><div> </div><div>iii. Increased Pulmonary Vascular Resistance (may lead to Right heart </div><div>failure)</div><div></div><div>decreased SVR</div><div>v.  Increased risk of ventricular arrhythmias</div><div>b.  Respiratory:</div><div>i.  Decreased respiratory muscle strength</div><div>ii.  Dyspnea/tachypnea from compensatory mechanism</div><div>c.  Metabolic:</div><div>i.  Hyperglycemia (tissue insulin resistance)</div><div>ii.  Hyperkalemia</div><div>d.  Neurologic:</div><div>i.  Inhibition of brain metabolism</div><div>ii.  Obtundation/coma</div><div>4.  Treatment of Metabolic Acidosis</div><div>a.  Identify and treat the underlying cause</div><div>i.  Assess tissue perfusion and cardiac output: VBG/SvO2, Echo, PA </div><div>catheter CO/CI</div><div> </div><div>iii. Assess for mesenteric ischemia: lactate, abdominal exam, KUB/CT</div><div>iv. Assess for sepsis: CBC, pro-calcitonin, cultures, fever curve</div><div>b.  Bicarbonate supplementation</div><div>i.  Normalizing pH may improve cardiac function, improve </div><div></div><div>ii.  Goal is to raise the pH, not to correct bicarbonate levels</div><div>iii. Keep in mind that IV Sodium bicarb may result in:</div><div>1.  Hypernatremia—monitor serial labs, consider D5W/free water </div><div>supplementation</div></div><div></div></div>
<div><div><img><div>76 Post-Op Management Post-Op Management 77</div><div>2.  Fluid overload from hyperosmolarity—monitor CVP/exam, diurese </div><div>when appropriate</div><div> </div><div>SvO2</div><div>4.  Increased CO2 production from metabolism of bicarbonate</div><div>a.  May result in respiratory acidosis if patient not adequately </div><div>ventilated</div><div>b.  Monitor ABG, increase respiratory rate on ventilator if able</div><div>Respiratory Acidosis</div><div>1.  Common etiologies: accumulation of CO2 in blood due to hypoventilation</div><div>a.  Medications: narcotics, benzodiazepines, residual anesthesia, paralytics</div><div>b.  Stroke/intracranial bleed</div><div>c.  Acute airway obstruction: sleep apnea, aspiration</div><div>d.  Hx parenchymal lung disease (O2 delivery may decrease respiratory </div><div>drive): COPD</div><div>e.  Splinting/Limit of inspiration due to pain</div><div>f.  Pneumothorax</div><div>Management:</div><div>a.  Treat reversible causes: obtain CXR, consider head CT for acutely altered </div><div>mental status</div><div>b.  Consider Narcan for narcotic overdose: Narcan 0.1-0.2 mg q2 minutes </div><div>for partial reversal</div><div>c.  umazenil 0.2mg IV q30 </div><div>seconds-1min</div><div>d.  Treat hypoventilation</div><div>i.  BiPap support ventilation (See Respiratory Care under references)</div><div>ii.  Consider intubation </div><div>Metabolic Alkalosis</div><div>1.  Common etiologies:</div><div>a.  Excessive diuresis leading to</div><div>i.  Potassium loss: directly increases bicarb resorption</div><div>ii.  Depletion of H+ ions and Chloride (acid loss)</div><div>iii. “Contraction alkalosis” = Hypovolemia: stimulates aldosterone </div><div></div><div>increased bicarb resorption</div><div>b.  Acid loss from high NG tube output/emesis</div><div>c.  Sub-Acute/Chronic respiratory acidosis: renal response to chronic </div><div>acidosis (ie increased bicarbonate synthesis) takes 12 hours to become </div><div>apparent and is maximum at 3-5 days</div><div>d.  Excessive bicarbonate administration, or administration of agents </div><div>metabolized to bicarb </div><div>i.  Citrate (in blood products) may result in metabolic alkalosis</div><div>ii.  Lactate (in LR)</div><div>2.  Adverse Eects of Alkalosis (pH &gt;7.45)</div><div>a.  </div><div>b.  </div><div>acidosis)</div><div>c.  </div><div>d.  </div><div>potential hypoxia</div><div>3.  Treatment of Acute Metabolic Alkalosis</div><div>a.  </div><div>b.  Gastris losses: acid suppressant therapy (H2 blockers or PPI’s)</div><div>c.  Patients with total body water overload (ie post-operative or CHF) </div><div>consider:</div><div>i.  Diamox (acetazolamide): carbonic anhydrase inhibitor that inhibits </div><div>bicarbonate resorption in proximal tubule</div><div>1.  Weak diuretic when used alone</div><div>2.  Consider use in conjunction with loop diuretic</div><div>ii.  K-sparing diuretic (spironolactone/eplerenone)</div><div>Respiratory Alkalosis</div><div>1.  Common Etiologies: decreased CO2 in blood stream due to hypoventilation</div><div>a.  Hypoxia (increased respiratory drive)</div><div>b.  Anxiety</div><div>c.  Pain</div><div>d.  Fever/infection/sepsis</div><div>2.   Management: treat underlying cause  </div><div>Sources: </div><div></div><div>UK: Wiley-Blackwell</div><div>Adams, G. (2006). On Call Surgery, 3rd Edition. Philadelphia, PA: Saunders Elsevier </div><div>GU/FEN: KIDNEY DISEASE</div><div>Acute Kidney Injury</div><div>Denition:</div><div> </div><div>Increase in serum creatinine by 0.3mg/dL or more within 48 hours  </div><div>or</div><div> </div><div>Increase in serum creatinine to 1.5 times baseline or more within the last 7 days  </div><div>or</div><div> </div><div>Urine output less than 0.5 mL/kg/h for 6 hours</div><div>Cause:</div><div> </div><div></div><div>hypotension, hypovolemic, HF, renal artery stenosis, renal vein thrombosis, </div><div>Cardiac tamponade</div><div> </div><div>due to</div><div> </div><div></div><div> </div><div></div><div> </div><div></div><div> </div><div>Intra Renal: Problems with the kidney itself, ATN/AIN</div><div> </div><div>Postrenal:</div><div>kidney stone, BPH, obstructed urinary catheter etc; a bladder scan or a post </div><div>void residual to rule out urinary retention</div><div>Diagnosis:</div><div> </div><div></div><div> </div><div>Urinalysis: presence of protein (albumin), hemoglobin, granular casts, or </div><div>epithelial cell casts may indicate AKI</div><div> </div><div>Urine sodium:</div><div> FENa:</div><div>an oliguric patient (not accurate if patient has received recent diuretic </div><div>therapy) </div><div>FENa, % = (UNA x SCr/ SNA X UCr) x 100 </div><div>  FENa &lt; 1 = pre renal disease </div><div>  FENa &gt; 2 = ATN </div></div><div></div></div>
<div><div><img><div>78 Post-Op Management Post-Op Management 79</div><div> FEU-rea (used for patient who have received recent diuretic therapy) </div><div>FEU-rea, % = ((SCr x Urine Urea) x 100)) / BUN x Urine Creatinine </div><div>  FEU-rea &lt; 35% = pre renal disease </div><div>  FEU-rea &gt; 50% = ATN</div><div> </div><div>Oliguria: &lt; 0.3ml/kg per hour or &lt; 500mL/day of urine output</div><div> </div><div>Anuria: </div><div> </div><div>Renal US: evaluate for urinary tract obstruction, renal mass, and kidney size </div><div>(diagnosis hydronephrosis)</div><div>Treatment: </div><div> </div><div> Focused on removing the cause of the kidney injury/ failure. </div><div> Discontinue nephrotoxic medications (NSAIDS, Iodinated contrast, </div><div>metformin, some antibiotics such as gentamicin.)</div><div> Correct low BP or use inotropic meds to increase heart function to </div><div>provide good renal perfusion </div><div> Avoid IV contrast if possible while creatinine is still up trending</div><div> Correct urinary tract obstruction if present (ie insertion of foley catheter)</div><div> </div><div>Continue to trend creatinine and electrolytes closely (cautious electrolyte </div><div>replacement)</div><div> </div><div>Monitor volume status closely to ensure adequate hydration without volume </div><div>overload  </div><div> Diuretics may be used for a limited period to relive signs and symptoms </div><div>of volume overload. </div><div> </div><div> </div><div>Indications for dialysis: (consult renal) A-E-I-O-U! </div><div> A: Acidosis (pH &lt; 7.1 in those that cannot tolerate correction with sodium </div><div>bicarb)</div><div> E: Electrolyte Disturbances (ie. Hyperkalemia when k &gt; 6.5 and refractory </div><div>to medical management)</div><div> I: Ingestion/Intoxication</div><div> O: Overload. (Refractory to diuretics)</div><div> U: Uremia (altered mental status, uremic platelets)</div><div>Chronic Kidney Disease  </div><div>Denition:</div><div>Stage Description </div><div>Stage I With normal of high GFR (GFR &gt; 90mL/min)</div><div>Stage II Mild CKD (GFR = 60-89mL/min)</div><div>Stage IIIa Moderate CKD (GFR = 45-59mL/min)</div><div>Stage IIIb Moderate CKD (GFR = 30-44mL/min)</div><div>Stage IV Severe CKD (GFR = 15-29mL/min)</div><div>Stage V End Stage CKD (GFR &lt; 15mL/min)</div><div>Always document stage 3 ckd or higher in h&amp;p, progress notes, and </div><div>discharge summary</div><div>Post op management: </div><div> </div><div>Monitor post op creatinine closely. Not uncommon to see rising creatinine </div><div>in the initial post op period (Acute on Chronic Kidney Injury) but creatinine </div><div>should return to baseline by discharge if managed properly </div><div> Ensure adequate blood pressure for renal perfusion</div><div> Avoid nephrotoxic agents (NSAIDs, metformin, certain antibiotics)</div><div>References: </div><div>Okusa, M.D., Palevsky, P.M., &amp; Scheidan, A.M. (2016). Overview of the management of acute kidney injury </div><div>(acute renal failure). Up to date. </div><div>GU/FEN:SODIUM IMBALANCES</div><div>HYPERNATREMIA, serum NA &gt;145</div><div> </div><div>Etiologies:</div><div> Tube feeding due to lack of free water</div><div> Excessive water loss from diuresis or diarrhea</div><div> Salt loading from medications (saline drips, sodium bicarb, albumin)</div><div> </div><div>To treat</div><div> Add free water to tube feed formula in divided doses (ie 200mL q6h)</div><div> Add D5W infusion</div><div> And/or encourage water intake if able to take PO</div><div> </div><div></div><div> </div><div>Determine Rate of Correction</div><div> Chronic Hypernatremia: present for &gt;48 hours</div><div> </div><div>Correct Sodium by NO MORE THAN 10-12mEq/day</div><div> </div><div>Rapid correction—at risk for cerebral edema (encephalopathy, </div><div>lethargy, seizures)</div><div> Acute Hypernatremia: present for &lt; 48 hours</div><div> </div><div>Correct Sodium to normal over 24 hours</div><div> </div><div>Monitor serum sodium frequently and adjust free water intake as necessary </div><div>HYPONATREMIA, serum NA &lt;135 </div><div>[mild 130-135, moderate 120-129, severe &lt;120]</div><div> </div><div>Need to determine type of hyponatremia:</div><div> Hypervolemic: Na dilution from excessive total body water</div><div> </div><div>Volume overload, CHF, cirrhosis</div><div> Hypovolemic: Na and/or water loss</div><div> </div><div>Diarrhea, thiazide diuretics</div><div> Normovolemic hyponatremia </div><div> </div><div>Low salt intake, SIADH: syndrome of inappropriate antidiuretic </div><div>hormone (Dx of exclusion)</div><div> </div><div>Low serum sodium in our postop patients usually indicates total body water </div><div>overload (hypervolemic hyponatremia)</div><div> </div><div>In our patient population, most of concern when Na &lt;130. Otherwise usually </div><div>just monitor</div><div> </div><div>Symptoms help determine need to treat (ie headache, nausea, vomiting, </div><div>fatigue, gait disturbances, and confusion)</div><div> </div><div>Aim to correct serum Sodium by 4-6mEq/day, no more than 8mEq/day</div><div> </div><div>Risk of rapid correction: osmotic demyelination </div><div> </div><div></div><div> </div><div>If on IV medications, consider giving them in NS versus the standing D5W – </div><div>will need to discuss this with the pharmacy</div><div> If euvomic/hypovolemic hyponatremia: also consider giving salt tablets </div><div>three times daily with meals.</div><div> Also can treat with hypertonic 3% saline. If have to go this route, consult </div><div>nephrology. </div><div> </div><div>Monitor serum sodium frequently</div><div> </div></div><div></div></div>
<div><div><img><div>80 Post-Op Management Post-Op Management 81</div><div>HEMATOLOGY: ACUTE BLOOD LOSS ANEMIA AND </div><div>POST-OPERATIVE BLEEDING</div><div>Acute blood loss anemia and bleeding are expected aer cardiac surgery </div><div>(especially for cases on cardiopulmonary bypass)</div><div>Contributing factors to post op bleeding: </div><div>Platelets</div><div>Hemodilution occurs when the circuit is primed and this alone can reduce </div><div>platelets by 30-50% (Bojar, 2011).  And the longer a patient is on bypass, the more </div><div></div><div>mechanical stress of going through the circuit, as well.</div><div>Heparinization: </div><div>protamine itself can will transiently reduce the platelet count by about 30%.  </div><div></div><div>on board.  HIT always becomes a concern in a patient who is thrombocytopenic </div><div>and has received heparin.  This is an even higher risk in pts who have been on </div><div>heparin gtts prior to going into surgery and should be evaluated by testing for </div><div>antibodies if the patient is showing signs of both bleeding and clotting. (For more </div><div>information on HIT see page *** Section IV &gt; 6 &gt; 3. HIT)</div><div>Fibrinolysis: </div><div>extent can be evaluated using aPTT, INR and D-Dimer but those are very non-</div><div></div><div>Incomplete surgical hemostasis: with accompanying chest wall bleeding or </div><div></div><div>anyone with friable tissues.</div><div>Preop medications can also play a role in postop bleeding.  Any patient who’s </div><div>had ASA in the last 7 days will have circulating platelets that are no longer </div><div></div><div>fondiparanux within 48hrs prior to surgery may have worse postop bleeding since </div><div>neither can be completely reversed with heparin. </div><div>Managing a bleeding patient:  </div><div>Chest Tubes</div><div> </div><div>Milk tubes as needed </div><div> </div><div>Careful assessment of hourly output</div><div>Warm patient</div><div> </div><div>Hypothermia causes impaired platelet function and suppression of </div><div>coagulation cascade</div><div> </div><div>Active warming may be contraindicated in some patients</div><div>Control HTN</div><div> </div><div>SNP, NTG, nicardipine, etc.</div><div>Sedation/Pain Control</div><div> </div><div>Continue sedation/analgesia until bleeding slows and patient is stable for </div><div>weaning/extubation</div><div>Re-Exploration</div><div> </div><div>Consider re-exploration for</div><div> &gt;400ml/hr x 1hr</div><div> &gt;300ml/hr x 2-3hrs</div><div> &gt;200ml/hr x 4 hrs</div><div>Always consider Cardiac Tamponade as a dierential diagnosis, especially in the </div><div>immediate post-operative period. For more information on pericardial tamponade </div><div>see see page 59.</div><div>Lab Values to monitor:</div><div>PT/INR</div><div> </div><div></div><div> </div><div></div><div> </div><div>Treat elevated INR with FFP</div><div>PTT</div><div> </div><div></div><div> </div><div>If elevated PTT in isolation or with slight elevation in INR consider treatment </div><div>with Protamine </div><div>Platelet Count</div><div> </div><div>CPB can decrease platelet count as well as cause platelet dysfunction</div><div> </div><div>Consider platelet transfusion in bleeding patient with platelet &lt;100k or if </div><div>patients were taking ASA , Plavix, or IIB/IIIA inhibitors pre-op or are uremic</div><div>Fibrinogen</div><div> </div><div>Promotes platelet aggregation and enhances platelet adhesion to the </div><div>endothelium</div><div> </div><div>Consider transfusion of cryo if Fibrinogen &lt;100 in bleeding patient</div><div>TEG</div><div>For TEG interpretation see page 83.</div><div>Blood Products/Transfusion Threshold</div><div>PRBCs</div><div> </div><div>Clarify transfusion threshold with surgeon</div><div> </div><div>Consider maintaining Hct  ~25 in an actively bleeding patient</div><div> </div><div>Each unit should increase Hct by ~3%</div><div>CellSaver</div><div> </div><div>May contain a small amount of heparin but is devoid of clotting factors</div><div> </div><div></div><div>Platelets</div><div> </div><div>Each unit should increase platelet count by ~42-60k per 6-pk</div><div>FFP</div><div> </div><div>Contains all clotting factors</div><div> </div><div>4 units of FFP will increase clotting factors by~10%</div><div>Cryoprecipitate</div><div> </div><div></div><div> </div><div></div><div> </div><div></div><div>Medications</div><div>Protamine</div><div> </div><div>Given for elevated PTT d/t residual heparin or release of heparin from tissue </div><div>stores</div><div> </div><div>25-50mg</div><div> </div><div>Half-life 5min, elimination from blood stream in 20-30min</div><div> </div><div>Excessive use of Protamine may increase ACT, cause platelet dysfunction, </div><div></div></div><div></div></div>
<div><div><img><div>82 Post-Op Management Post-Op Management 83</div><div>DDAVP</div><div> </div><div>Increases the levels of certain factors (VIII precursors, von Wildebrand’s, </div><div>tissue-type plasminogen activator)</div><div> </div><div></div><div> </div><div>Can cause hypotension and peripheral vasodilatation</div><div>Feiba</div><div> </div><div>Factor Eight Inhibitor Bypassing Activity</div><div> </div><div>Developed to treat bleeding in pts with Hemophilia A/B. </div><div> </div><div></div><div></div><div> </div><div></div><div>mostly when pts are given &gt;200units/kg/day.  </div><div> </div><div>Start with a quarter dose, or 250 units, up to a full dose of 1000 units for </div><div>severe bleeding.  </div><div> </div><div>FEIBA is made from human plasma, so the same risk of transmission of </div><div>infectious disease is present as when you are giving blood products. </div><div> </div><div>Novo Seven</div><div> </div><div>Promotes localized hemostasis at site of tissue injury and improves INR</div><div> </div><div>Can cause systemic thrombosis</div><div>Imaging</div><div>CXR</div><div> </div><div></div><div>indicative of clot around the great vessels</div><div>Echo</div><div> </div><div>TTE or TEE </div><div>Stable acute blood loss anemia</div><div> </div><div></div><div>like “Expected acute blood loss anemia”</div><div> </div><div>Cont to monitor H/H daily or every other day. H/H usually returns to patients </div><div></div><div> </div><div>Treatment: (once able to tolerate PO medications)</div><div> Ferrous Sulfate, Slow FE 140mg PO BID</div><div> Vitamin C 500mg PO BID</div><div> Consider need for epogen injection for severe anemia</div><div> Oral Iron and Vit C are usually continued for 1 month post operatively </div><div>HEMATOLOGY: TEG</div><div>TEG® Clot phase Normal Values Abnormalities Treatment</div><div>R Time Clot initiation</div><div></div><div>4.6 - 8.8 min </div><div>Shortened in hypercoagulable states.</div><div>Increased R time </div><div>= FFP</div><div>K Clot Kinetics</div><div>Time taken to achieve a certain level of clot strength</div><div>1.2 - 2.4 min </div><div>and platelet dysfunction.</div><div>Alpha </div><div>Angle</div><div>Clot Kinetics</div><div></div><div>takes place ( rate of clot formation)</div><div>57.7 - 72.9 deg </div><div>thrombocytopenia, and platelet dysfunction.</div><div>Decreased Angle </div><div>= Cryo</div><div>MA Clot Strength</div><div>Maximal clot strength achieved via GP IIb/IIIa-</div><div></div><div>59.3 - 76.5 mm </div><div></div><div>thrombocytopenia</div><div>Decreased MA = </div><div>Platelets</div><div>G Clot Strength</div><div>Maximal clot strength achieved via GP IIb/IIIa-</div><div></div><div>6.4 - 15.0 k d/</div><div>sec</div><div>Abnormally high in platelet hypercoagulability.</div><div>EPL </div><div>(Estimated </div><div>Percent of </div><div>Lysis)</div><div>Clot Lysis</div><div></div><div>0 - 15 %  Fibrinolysis  = </div><div>Aprotonin or </div><div>Transexamic Acid</div></div><div></div></div>
<div><div><img><div>84 Post-Op Management Post-Op Management 85</div><div>HEMATOLOGY: HEPARIN INDUCED </div><div>THROMBOCYTOPENIA (HIT)</div><div>Epidemiology:</div><div> </div><div>1-5% of adults treated with heparin, and a smaller proportion of those who </div><div>are treated with low-molecular weight heparin, will develop heparin-induced </div><div>thrombocytopenia (HIT).</div><div> </div><div>HIT is associated with a high risk of venous and arterial thrombosis if heparin </div><div>is not withdrawn</div><div>Diagnosis:</div><div> </div><div>The initial signal is a drop in</div><div>noticed, use the 4 T’s score to calculate the likelihood of HIT. </div><div> </div><div>If post op platelet count is low, continue to observe and wait until at least POD </div><div>#3 prior to sending HIT panel</div><div>1.  Thrombocytopenia</div><div> </div><div> </div><div> </div><div>2.  Timing</div><div> </div><div></div><div> </div><div></div><div> </div><div></div><div>3.  Thrombosis</div><div> </div><div> </div><div></div><div> Other causes of thrombocytopenia  </div><div> </div><div> </div><div> </div><div>4.  Other causes of thrombocytopenia: </div><div> </div><div> </div><div> </div><div>Clinical Manifestations</div><div> </div><div>Thrombocytopenia, but rarely with bleeding events</div><div> </div><div>Markedly elevated rate of thromboembolic events (venous &gt; arterial [4:1 </div><div>ratio])</div><div> </div><div></div><div>7 days)</div><div>Diagnosis</div><div> </div><div>HIT functional assay</div><div> </div><div>To order: User HIT panel to order HIT antibody (anti-platelet factor 4 or PF4) </div><div>AND Functional assay</div><div> </div><div>Interpretation:</div><div>0-3 points = Low probability</div><div>4-5 points = Intermediate </div><div>probability</div><div>6-8 points = High probability </div><div> </div><div> If the PF4 results are indeterminate (0.4-2.0), the functional assay may be </div><div> </div><div>We typically sent functional assay at the same time as HIT antibody as </div><div>the functional assay is a send out lab that requires 48-72 hours for results. </div><div>Acute Treatment:</div><div> </div><div>When HIT is suspected, a HIT antibody and functional assay should be sent, </div><div>and all heparin should be discontinued immediately. </div><div> </div><div>An alternative anticoagulant should be started, EVEN IF THERE IS NO OTHER </div><div>REASON FOR ANTICOAGULATION. We typically use Argatroban.</div><div> </div><div>Obtain bilateral LE ultrasounds to rule out occult DVT, which can dictate a </div><div>longer course of anticoagulation (3-6 months if thrombosis present vs &lt; 1 </div><div>month if no thrombosis present)</div><div>Long term treatment</div><div> </div><div></div><div> </div><div></div><div>until platelet recovery (usually greater than 100). Early initiation of coumadin </div><div>has been shown to exacerbate thrombosis and should be avoided. </div><div> </div><div></div><div>be overlapped for 3-5 days. Coumadin should be continued for at least 1 </div><div>month. </div><div> </div><div>As a general rule, patients with documented HIT should not be exposed to </div><div>heparin again.</div><div> </div><div>However, it has been shown that heparin may be used again in patients who </div><div>were previously HIT antibody positive if the patient no longer has a positive </div><div>HIT ELISA antibody titer and the use of heparin is absolutely necessary (ex </div><div>cardiopulmonary bypass) </div><div>References: </div><div>Cuker A &amp; Clines DB. (2012). How I treat heparin induced thrombocytopenia. Blood.  119: 2209-2218. </div><div> </div><div>HEMATOLOGY: DEEP VEIN THROMBOSIS</div><div>Denition:</div><div> </div><div>Condition in which a blood clot (thrombus) forms in a view. The clot can limit </div><div></div><div> </div><div>Thrombus most commonly occurs in the deep veins in the legs, thigh, or </div><div>pelvis (Deep Vein Thrombosis, or DVT)</div><div>Risk Factors: </div><div> </div><div>Obesity, smoking, heart failure, history of previous DVT, immobility, cancer, </div><div>some medications (such as: erythropoietin, birth control pills, hormone </div><div>replacement therapy)</div><div> </div><div>Undergoing a surgical procedure increases risk of DVT development</div><div> </div><div>Diagnosis: </div><div> </div><div>Classis symptoms include: swelling, pain, warmth, and redness of the </div><div></div><div> </div><div>Symptoms are usually asymmetrical. Symmetrical swelling is unlike to </div><div>represent DVT</div><div> </div><div></div><div></div><div>increase risk of developing a DVT (therefore treatment with anticoagulation is </div><div>not indicated)</div><div> </div><div>US RADIOLOGY VEIN (UPPER/</div><div>LOWER/BILATERAL) EXTERMITIES RULE OUT DVT</div></div><div></div></div>
<div><div><img><div>86 Post-Op Management Post-Op Management 87</div><div> </div><div></div><div> </div><div>D-dimer may also be elevated in patients with DVT </div><div>Prevention &amp; Treatment </div><div> </div><div>The main goal of treatment is to prevent a pulmonary embolism, preventing </div><div>DVT from becoming larger, and preventing new blood clots from forming</div><div> </div><div>Primary treatment is anticoagulation for a minimum of 3 months</div><div> Low molecular weight heparin (SubQ heparin or lovenox)</div><div> Unfractionated heparin (continuous heparin drip)</div><div> Direct oral anticoagulation: Rivaroxaban (Xarelto), Dabigatran (Sayaysa), </div><div>and Apixaban (Eliquis) </div><div> Coumadin with goal INR 2-3</div><div> </div><div>Post op DVT prevention includes</div><div> Bilatearl LE SCDs on all patients</div><div> SubQ heparin (if no contraindication) on patients while in the ICU. </div><div>Continue for high risk patients while on iICU. </div><div> See reference material see page 134.</div><div>References: </div><div>Pai, M, Douketis, J. (2017) Patient education: deep vein thrombosis (DVT) beyond the basics. Up to date. </div><div> </div><div>INFECTIOUS DISEASE: SEPSIS</div><div>Sepsis</div><div> </div><div></div><div> </div><div>Include two or more of the following:</div><div> Temperature &gt; 38°C or &lt; 36°C</div><div> Heart rate &gt; 90 bpm</div><div> Respiratory rate &gt; 20 bpm</div><div> WBC count &gt; 12,000/mm3 or &lt; 4,000/mm3 or &gt; 10% immature </div><div>neutrophils</div><div> </div><div>Clinical signs of organ dysfunction</div><div> Neuro: altered LOC, hypo/hyperthermia</div><div> Pulmonary: hypoxemia, ARDS</div><div> Cardiac: hypotension</div><div> Renal: AKI (Cr &gt; 2 mg/dL)</div><div> GI: hyperbilirubinemia &gt; 2 mg/dL</div><div> </div><div> Hyperlactatemia </div><div>Septic Shock</div><div> </div><div>Severe sepsis with hypotension that does not resolve with adequate volume </div><div>resuscitation</div><div> </div><div></div><div>Sepsis Screening Tool</div><div> </div><div>Goals of Resuscitation</div><div> </div><div></div><div> </div><div>Goals:</div><div> CVP 8-12 mmHg, MAP &gt; 65 mmHg, urine output &gt; 0.5 mL/kg/hr, ScvO2 &gt; </div><div>70% or SvO2 &gt; 65%, normal lactate levels</div><div>Surviving Sepsis Bundle</div><div> </div><div>Resuscitation</div><div> </div><div>large volumes of crystalloids are required</div><div> </div><div>to maintain MAP &gt; 65</div><div> </div><div> Add Epinephrine if additional agent needed to maintain MAP</div><div> Vasopressin can be used in combination with Norepinephrine if unable </div><div>to maintain MAP</div><div> Consider Dopamine in selected patients with marked LV dysfunction.  Not </div><div>recommended for renal protection</div><div> </div><div>or CO suboptimal</div><div> </div><div>pressures and MAP.  </div><div> </div><div>Diagnosis</div><div> Obtain cultures before start of antimicrobial therapy if does not delay </div><div>treatment (&gt; 45 min)</div><div> Blood cultures (one percutaneous and one from each vascular device in </div><div>place &gt; 48 hours)</div><div> Other possible sites of infection (CSF, sputum, urine, etc.)</div><div> </div><div> </div><div>Antimicrobial Therapy</div><div> Administer broad spectrum antibiotics within one hour of diagnosis</div><div> Empiric combination antimicrobial therapy for neutropenic patients or </div><div>highly multidrug-resistant infections</div><div> Empiric antifungal therapy for high risk invasive candidiasis</div><div> Reassess antibiotics daily for descalation</div><div> Limit antimicrobial therapy to 7-10 days *</div><div> Limit empiric combination therapy to 3-5 days</div><div> Narrow coverage following susceptibility results</div><div> Stop antimicrobial therapy if cause of SIRS is uninfectious</div><div> </div><div>Source Control</div><div> </div><div> Radiographic imaging if needed</div><div> Remove intravascular devices if potentially infected</div><div> </div><div> Surgical resection of infected tissues</div><div> </div><div>Other Support Modalities</div><div> Mechanical ventilation</div><div> Glucose control</div><div> Renal replacement therapy</div><div> Blood product administration</div><div> Nutrition</div><div> Deep vein thrombus prophylaxis</div><div> Stress ulcer prophylaxis</div><div> </div><div>resuscitation and vasopressor therapy.  Indicated if random cortisol level </div><div>&lt;18 mg/dL in patients with septic shock</div><div> </div></div><div></div></div>
<div><div><img><div>88 Post-Op Management Post-Op Management 89</div><div>INFECTIOUS DISEASE: CELLULITIS</div><div>Microbiology:</div><div> </div><div>Most common pathogens are beta-hemolytic streptococci (groups A, B, C, G, </div><div>and F), Staphylococcus aureus, including MRSA and gram-negative aerobic </div><div>bacilli</div><div> </div><div>Staphylococcus aureus: Periorbital and orbital cellulitis and IV drug users</div><div> </div><div>Pseudomonas aeruginosa: Diabetics and other immunocompromised </div><div>patients</div><div> </div><div>Aeromonas hydrophila and Vibrio vulnicus: Cellulitis caused by waterborne </div><div>pathogens</div><div> </div><div>Pasteurella multocida and Capnocytophaga canimorsus: Cellulitis preceded </div><div>by bites</div><div> </div><div>Streptococcus iniae: Immunocompromised hosts</div><div> </div><div>Rare causes: Mycobacterium, fungal (mucormycosis, aspergillosis, syphilis)</div><div>Diagnosis: </div><div> </div><div>For patients with signs of systemic disease (fever or hypothermia, hear rate </div><div>[HR] &gt;100 bpm, or systolic blood pressure [SBP] &lt;90 mm Hg) include blood </div><div>cultures, drug susceptibility, CBC, creatinine, bicarbonate, CPK, and CRP </div><div>levels </div><div> </div><div>Consider use of CT or MRI if suspicious for deeper infection (osteomyelitis/</div><div>mediastinis)</div><div>Treatment</div><div>Medication (see Stanford Antibiogram).</div><div>First Line</div><div>Treat 5–15 days or longer, depending on response, and guided by culture when </div><div></div><div>cellulitis (5) [B]. Empiric therapy should be guided by local resistance patterns. </div><div></div><div> </div><div></div><div>streptococci and methicillin-susceptible S. aureus)</div><div>  Oral dicloxacillin, cephalexin, clindamycin, or IV cefazolin, oxacillin, or </div><div>nafcillin.</div><div> </div><div>Parenteral therapy if severely ill or unable to tolerate oral therapy</div><div> </div><div>cephalosporin; if penicillin-allergic, use clindamycin or vancomycin.</div><div> </div><div>Necrotizing fasciitis and gas gangrene</div><div> Parenteral clindamycin and penicillin.</div><div> </div><div>In patients with recurrent infection underlying predisposing conditions, </div><div>previous episode of proven MRSA infection, or systemic toxicity, use agents </div><div>with activity against MRSA</div><div> Parenteral vancomycin, daptomycin, linezolid or oral trimethoprim-</div><div>sulfamethoxazole (TMP/SMX), doxycycline or minocycline, or clindamycin </div><div>(3)[C].</div><div> </div><div>Mild early-suspected streptococcal etiology</div><div> Penicillin G, 600,000 U, and then IM procaine penicillin at 600,000 U </div><div>q8h–12h.</div><div> </div><div>Recurrent streptococcal cellulitis</div><div> Penicillin IV 250 mg b.i.d., or if penicillin-allergic, use erythromycin 250 </div><div>mg b.i.d.</div><div>Alert</div><div> </div><div>If community-acquired MRSA is a concern, treatment options (7–14 days) </div><div>include trimethoprim/sulfamethoxazole: DS (160 mg TMP and 800 mg of SMX) </div><div>1–2 PO b.i.d. daily; doxycycline: 100 mg PO b.i.d., or clindamycin: 300–600 mg </div><div>PO t.i.d.</div><div>Second Line</div><div> </div><div>Mild infection:</div><div> </div><div>If Penicillin allergy: Erythromycin 500 mg PO q6h</div><div> </div><div></div><div>cellulitis at current estimated MRSA levels.</div><div> </div><div>0.5 mg/kg/d for 5–8 days) if partial response to antibiotics in hemorrhagic or </div><div>bullous cellulitis</div><div>Ongoing Care</div><div>Follow-Up Recommendations</div><div> </div><div>Repeat blood count if patient is toxic. Repeat lumbar puncture in case of </div><div>meningitis.</div><div> </div><div>Consider prophylaxis of deep vein thrombosis.</div><div> </div><div></div><div>bacterial antigens. Symptomatic improvement usually occurs in 24–48 hours, </div><div>but visible improvement may take up to 72 hours.</div><div> </div><div>INFECTIOUS DISEASE: PNEUMONIA</div><div>Description</div><div>Community-acquired pneumonia (CAP): Lower-respiratory tract infection not </div><div>acquired in a hospital, long-term care facility, or during other recent contact with </div><div>the health care system </div><div>Hospital-acquired pneumonia (HAP): Pneumonia that occurs 48 hours or more </div><div></div><div>Ventilator-associated pneumonia (VAP): Pneumonia that develops more than </div><div></div><div>Health care–associated pneumonia (HCAP): Pneumonia that occurs in a </div><div>nonhospitalized patient with extensive health care contact, such as:</div><div> </div><div>IV therapy or wound care within the past 30 days</div><div> </div><div>Residing in a nursing home or long-term care facility</div><div> </div><div>Hospitalization in an acute care hospital for 2 or more days within the  </div><div>past 90 days</div><div> </div><div>Visited a hospital or hemodialysis clinic within the past 30 days (2)</div><div>Evaluation</div><div> </div><div>Symptoms: fever, chills, cough, increased sputum, SOB, pleuritic CP. Note </div><div>that the presenting symptoms can be subtle – weakness, malaise, AMS</div><div> </div><div></div><div> </div><div>Other studies:</div><div> Blood culture – before antibiotic administration</div><div> ABG when patient is severely dyspneic or tachypneic</div><div> Consider testing for Legionella (culture and urinary assay), Mycoplasma </div><div>(cold agglutinins), Pneumoccocus (urine antigen), Chlamydia (acute and </div><div>convalescent serology), or respiratory viral panel if clinical course atypical </div><div>or enigmatic</div></div><div></div></div>
<div><div><img><div>90 Post-Op Management Post-Op Management 91</div><div> Sputum gram stain and culture: while controversial, it is helpful if </div><div>performed before antibiotics; an adequate sample has &gt;25 PMNs and &lt; </div><div>10 epithelial cells.</div><div> Consider HIV testing if never previously tested or risk factors for HIV</div><div> In Immunocompromised patients, consider diagnostic workup for </div><div>opportunistic pathogens (PCP, TB, fungi)</div><div> </div><div></div><div>microbiologic diagnosis reduces mortality compared to empiric treatment. </div><div>Management</div><div> </div><div>Antibiotic regimen depends on severity of illness, potential for resistant </div><div>organisms or opportunistic pathogens</div><div> </div><div>Consult hospital antibiogram and antibiotic guidelines. Adjust for renal/</div><div></div><div>within 4-6 hours of presentation</div><div> </div><div>Pseudomonas risk factors: structural lung disease (bronchiectasis), </div><div>corticosteroid therapy (&gt;10 mg of prednisone per day), broad spectrum </div><div>antibiotics for &gt; 7 d in the past month, recent hospitalization, malnutrition</div><div> </div><div>Community acquired MRSA risk: immunocompromised, injection drug use, </div><div></div><div>necrotizing pneumonia</div><div> </div><div>High risk of multi-drug resistant (MDR) pathogens: late-onset HAP or VAP </div><div></div><div>last 90 days, high frequency of antibiotic resistance in the community, </div><div>immunocompromised, or any risk factor for HCAP above. </div><div>Medication</div><div>Patient Subset Common organisms Example empiric antibiotic therapy</div><div>CAP</div><div>- Inpatient</div><div>- Not in ICU</div><div> </div><div>Typical: Streptococcus </div><div>pneumoniae, Haemophilus </div><div>inuenzae, </div><div> </div><div>Atypical: Legionella sp., </div><div>Mycoplasma pneumoniae, </div><div>Chlamydophila pneumoniae</div><div></div><div>Doxycycline 100mg PO BID</div><div>(if severe penicillin allergy, consider </div><div></div><div>CAP</div><div>- Inpatient</div><div>- In ICU</div><div>ASSESS risk of </div><div>MDR pathogen </div><div>(see above)</div><div>As above plus drug resistant S. </div><div>penumoniae, Staphylococcus </div><div>aureus, other gram-negative rods</div><div></div><div>Azithromycin 500mg PO/IV x 1 then</div><div>250mg PO/IV qday</div><div>If risk for CAMRSA: ADD Vancomycin</div><div>If risk for Pseudomonas, Pipercillin/</div><div>tazobactam 4.5 gm IV q 6h replaces </div><div></div><div>HCAP, HAP, VAP </div><div>(any acuity)</div><div>Assess risk of </div><div>MDR pathogen </div><div>(see above)</div><div>Staphylococcus aureus, </div><div>Pseudomonas aeruginosa, </div><div>drug-resistant Streptococcus </div><div>pneumoniae, and other resistant </div><div>gram-negative rods. </div><div></div><div>risk factors for MDR pathogens – </div><div>empiric therapy should account for </div><div>each individual’s risk factors and </div><div>level of acuity. </div><div>Low Risk of MDR pathogens:</div><div></div><div>Doxycycline 100mg PO BID AND</div><div>Vancomycin and change doxycycline to </div><div>azithromycin in ICU patients. </div><div>High Risk of MDR pathogens:</div><div>Vancomycin AND</div><div>Pipercillin/tazobactam 4.5gm IV q6h AND</div><div></div><div>INFECTIOUS DISEASE:  </div><div>C. DIFF (CLOSTRIDIUM DIFFICULT)</div><div>Causes: </div><div> </div><div>Produces enterotoxin ( toxin A ) and cytotoxic ( toxin B )</div><div> </div><div>Associated with ALL antibiotics and hospitalization itself</div><div>Symptoms:  a variety of syndromes are possible from asymptomatic infection -&gt; </div><div>diarrhea -&gt; pseudomembranous (PMC) -&gt; toxin mega colon -&gt; fulminant colitis. </div><div> </div><div>Flu-like symptoms:  Fever, chills, abdominal pain, watery diarrhea. </div><div> </div><div>Fecal incontinence common.</div><div>Diagnose: </div><div> </div><div></div><div> </div><div></div><div>a false positive sample</div><div> </div><div>Order only for patients who have had several watery stools. Cannot be </div><div>retested before 7 days.</div><div> </div><div></div><div>48 hours. </div><div>Treatment:  </div><div> </div><div>d/c antibiotic if possible</div><div> </div><div>place in contact isolation</div><div> </div><div>Mild: Metronidazole ( Flagyl ) IV</div><div> </div><div>Moderate –severe: Vancomycin oral</div><div>DO NOT USE ANTI-PERISTALTIC AGENTS FOR C-DIFF. </div><div>INFECTIOUS DISEASE: </div><div>URINARY TRACT INFECTION</div><div>Denitions:</div><div> </div><div>Lower UTI: Urethritis, cystitis</div><div> </div><div>Upper UTI: Pyelonephritis, renal/perinephric abscess</div><div> </div><div>Uncomplicated UTI: Lower UTI in a non-pregnant woman with normal GU </div><div>anatomy</div><div> </div><div>Complicated UTI: Anyone else including upper UTI in women, any UTI in men, </div><div>pregnant women or women with structural or neurological GU disease.</div><div>Etiology/Risk Factors:</div><div> </div><div>Organisms: SEEEKS PP: Serratia, E.Coli (80%), Enterobacter, Entercoccus, </div><div>Klebsiella, Staph. Saprophyticus, Proteus, Pseudomonas</div><div> </div><div>Risk Factors: Female (short urethra), sexual intercourse, indwelling </div><div>urinary catheters, or recent instrumentation, diaphragm/spermicide use, </div><div></div></div><div></div></div>
<div><div><img><div>92 Post-Op Management Post-Op Management 93</div><div>Treatment:</div><div> </div><div>Uncomplicated UTI: </div><div> </div><div>resistance is &gt; 20%</div><div> </div><div>Lower UTI in Pregnant women: </div><div> Amoxicillin/Clauvulanate (Augmentin) and Cephalexin are preferred</div><div> </div><div>Complicated lower UTI: Remove catheter/stent if present (high incidence of </div><div>Pseudomonas and Candida). </div><div> </div><div> </div><div>Uncomplicated pyelonephritis: Low grade fever, WBC count only slightly </div><div>elevated, no nausea/vomiting. </div><div> </div><div>Augmentin for 14 days. </div><div>ENDOCRINE: ACUTE HYPERGLYCEMIA AND </div><div>DIABETES MANAGEMENT</div><div>1.  General Pre op considerations: </div><div>a.  Always obtain hemoglobin A1c on pre op labwork</div><div>b.  For outpatients: instruct them to hold oral meds on the same morning </div><div>of OR day; if they are on basal  insulin, only give 1/3 -1/2 does the night </div><div>before or on the same morning of OR. </div><div>c.  </div><div>continue home DM meds( except metformin) &amp; insulin the night before </div><div>surgery; hold oral meds and only give 1/2 -1/3 does basal insulin on the </div><div>same morning  of OR.</div><div>2.  Hyperglycemia occurs in virtually all CT surgery patients due to:</div><div>a.  A.  Increased extracellular glucose, decreased insulin secretions and </div><div>increase peripheral resistance to insulin due to: </div><div>o  exposure to extracorporeal circulation</div><div>o  hypothermia</div><div>o  release of endogenous catecholamines, cortisol, and glucagon</div><div>b.  Post-op goal blood glucose is &lt; 180 mg/dL</div><div>c.  For patients with known high HgbA1c pre op or for any patient </div><div>whose glucose is diicult to manage, low threshold to consult </div><div>Endocrine. </div><div>3.  Patients will be admitted to the CVICU on an insulin drip. Patient should </div><div>remain on an insulin drip until blood glucose remains within target range </div><div>with stable drip titrations (+/- no more than 1 for past 4 hours)</div><div>a.  </div><div> </div><div>b.  </div><div>NS @ 50mL/hr and d/c D5 ½ NS.</div><div>Preparation Onset Peak action Duration</div><div>Rapid Acting</div><div>Insulin Lispro (Humulog)</div><div>Insulin aspart (NovoLog)</div><div> </div><div>9-30 min </div><div>15 min</div><div> </div><div>30 min-2.5 hrs </div><div>30 min-1 hr</div><div> </div><div>3-4 hrs </div><div>1-3 hrs</div><div>Short Acting</div><div>Regular insulin </div><div>30 min- 1 hr 2-5 hrs 3-8 hrs</div><div>Intermediate Acting</div><div>NPH</div><div>1-4 hrs 4-10 hrs 10-16 hrs</div><div>Long Acting</div><div>Insulin glargine (Lantus)</div><div>2-4 hrs None 24 hrs</div></div><div></div></div>
<div><div><img><div>94 Post-Op Management Post-Op Management 95</div><div>c.  Special Circumstances</div><div>4.  Preparing for discharge: </div><div>a.  For patients with no previous history of diabetes, the goal is to wean </div><div></div><div>i.  If no formal diagnosis of Diabetes, but pre op A1C &gt; 6.4%, consider </div><div>consult to endocrine or initiation of oral anti diabetic agents</div><div>ii.  If  a patient is being discharged home with any new diabetic </div><div>medications (oral or injection), Diabetes education must be ordered </div><div>(~2 days prior to discharge) and completed by with DM Nurse or the </div><div>bedside RN</div><div>iii. Diabetic teach orders in Epic</div><div>1.  “Diabetes education” = Bedside Nursing</div><div>a.  Can also place nursing communication order for RN to initiate </div><div>DM Teaching Video</div><div>2.  Nsg Referral to Diabetes RN = CNS Specialist (*Preferred)</div><div>b.  For those patients with diabetes, slowly restart any oral anti-diabetic </div><div>agents and or insulin. Patients will likely be on much lower doses of </div><div>medications or insulin at discharge than at pre op</div><div>i.  Medications can slowly be up titrated as needed in the outpatient </div><div>setting as patients diet and appetite returns to normal</div><div>ii.  Oral Antidiabetic agents: </div><div>1.  Metformin</div><div>a.  Contraindicated in the prescence of renal dysfunction (Creat &gt; </div><div>~1.5)</div><div>b.  Metformin should temporarily be held pre and post </div><div>administration of IV contrast </div><div>c.  Typically held 48 hours prior to any major surgery. Resume </div><div></div><div>returned to baseline. </div><div>2.  Sulfonylureas (Glipizide, Glimepiride, Glyburide)</div><div>a.  Stimulates insulin release from pancreas</div><div>b.  Glipizide does not have an active metabolite, better choice for </div><div>those with renal failure</div><div>c.  Overall, increased incidence of causing hypoglycemia</div><div>3.  Thiazolidinediones ( Actos, Avandia)</div><div>a.  May exacerbate heart failure! Avoid use in most cardiac patients </div></div><div></div></div>
<div><div><img><div>96 Post-Op Management</div><div>ENDOCRINE: ADRENAL INSUFFICIENCY</div><div>Denition:</div><div> </div><div>Most commonly occurs in critically ill patients due to subnormal </div><div>corticosteroid production. </div><div>Diagnosis: </div><div> </div><div>Total (random) serum cortisol: Low </div><div> </div><div>Morning serum cortisol concentration: Low (&gt; 3mch/dL)</div><div> </div><div>CTH Stimulation test:</div><div> </div><div> Administration of ACTH (1-24) or Cosyntropin:</div><div> </div><div>Stanford high dose test (250mcg)</div><div> </div><div>A normal response is a rise in serum cortisol concentration 30-60 </div><div></div><div> </div><div>A normal response to high dose ACTH stimulation test excludes </div><div></div><div> </div><div>Low dose test (1mcg)</div><div> </div><div>A normal response is a rise in serum cortisol concentration 20-30 </div><div></div><div>Treatment: Stress Dose Steroids</div><div> </div><div>Consider treatment when patient on &gt;2 pressors with hemodynamic </div><div>instability</div><div> </div><div>Replacement with hydrocortisone:</div><div> 50mg IV Q6 hours or 100mg IV q8 hours</div><div> </div><div>Consider quick taper (over 3-5 days) once hemodynamics improve </div><div>References: </div><div></div></div><div></div></div>
<div><div><img><div>Procedures/Devices 97</div><div>PROCEDURES: ATRIAL ELECTROGRAMS</div><div> </div><div></div><div></div><div> </div><div>Requires the presceince of atrial temporary epicardial wires </div><div>To perform:</div><div> </div><div>Obtain standard ECG for baseline/comparison</div><div> </div><div>For Atrial ECG: Attach the two arm leads to the atrial wires (all other leads </div><div>attached normally)</div><div> A bipolar ECG will be recorded in Lead I and unipolar ECG in Lead II or III</div><div> </div><div>Interpretation: Evaluate atrial activity in relation to QRS complex </div><div>Interpretation examples:</div><div> </div><div>Normal Sinus rhythm: Large atrial spike on Atrial ECG will correlate  </div><div>with P waves</div><div> </div><div>Junctional: No atrial spike present on Atrial ECG</div><div> </div><div></div><div>PROCEDURES:  </div><div>DIRECT CURRENT CARDIOVERSION (DCCV)</div><div>Supplies/Equipment</div><div>5.  </div><div>6.  </div><div>7.  EKG machine </div><div>8.  Monitoring equipment at bedside (bedside telemetry with 5 lead system, </div><div></div><div>oxygen access and mask, pulse oximetry, ambubag)</div><div>Procedure</div><div>Pre-Procedure Care Steps:</div><div>1.  </div><div>a. 12 lead EKG</div><div>b. Patent intravenous venous line (IV)</div><div>c.  Patient is connected to the following: telemetry with a 5-lead EKG </div><div></div><div>equipment, oxygen is available/operational, ambu bag at bedside</div><div>2.  Keep patient NPO for approximately 6 hours prior to procedure</div><div>3.  </div><div>4.  Obtain written informed consent</div><div>5.  </div><div></div></div><div></div></div>
<div><div><img><div>98 Procedures/Devices Procedures/Devices 99</div><div>For patients on Telemetry unit requiring DCCV: (must be performed by </div><div>Cardiac Anesthesia)</div><div>1.  Page, call, or text ICU Cardiac Anesthesia Attending on call directly to set </div><div>up cardioversion</div><div>2.  Call OR to book the case in the OR (this is for ICU attending billing </div><div>purposes)</div><div>Cardiac anesthesia on call for the OR should only be contacted for cardioversion </div><div>if ICU Attending is unable to perform the procedure.</div><div>PROCEDURES: PACER WIRE (PW) REMOVAL</div><div>Pre Removal Checklist: </div><div>1.  Are PW capped with no evidence of rhythm issues on telemetry for 24 hours? </div><div></div><div>2.  If pacing wires have not been capped yet, any pacing activity in last 24 hrs? </div><div>(Check with primary nurse and telemetry monitor). If not &gt; cap pacing wires. </div><div>3.  If PW already capped, for how long? (Usually require wires to be capped for at </div><div>least 4-6 hours before removal)</div><div>4.  Is patient on any anti-coagulation including Heparin sub Q/ IV infusion, </div><div>Argatroban, Plavix, Coumadin, Pradaxa, Xarelto, Eliquis etc?</div><div>i.  In general, we do not start non-reversible anticoagulant agents (Plavix/</div><div>Pradaxa/Eliquis/Xarelto, etc.) until PW already removed</div><div>ii.  If novel OAC agent has been started, check with surgical team regarding </div><div>timing of holding medication prior to PW removal </div><div>iii.  If on SubQ heparin, hold Sub Q heparin 6-8 hrs before PW removal</div><div>iv.  If on heparin/argatroban gtt, hold gtt for 6 hrs before PW removal, and </div><div></div><div>v.  If on Coumadin, slowly titrate Coumadin dose until PW out, and only </div><div>remove PW with INR &lt; 2.0.</div><div>5.  Was PW sutured in or oversewn to heart? Double check sign-out list and </div><div>notes. *** In this case PW are to be CUT AT SKIN, not pulled ***</div><div>6.  Has plan to remove PW been discussed with attending or chief resident? </div><div>During Removal:</div><div> </div><div>Maintain smooth and steady strength</div><div> </div><div></div><div></div><div>swab</div><div>Aer Removal:</div><div> </div><div>Notify both patient &amp; primary RN to keep patient in bed for at least 1 hour </div><div></div><div> </div><div>Instruct RN to watch for warning signs and symptoms of tamponade such as:</div><div> Lightheadedness</div><div> Dizziness</div><div> Diaphoresis</div><div> Chest discomfort</div><div> Decreased BP</div><div> Increased HR</div><div> </div><div></div><div>6.  </div><div>i.  Anticoagulation:</div><div>•  If duration of atrial arrhythmia &lt; 48 hours, no anticoagulation required</div><div>•  If duration of atrial arrhythmia &gt; 48 hours, consider anticoagulation in </div><div>conjunction with CHADs score</div><div>ii.  K+ - consider replacement if K+ &lt; 3.4</div><div>7.  Review baseline vital signs and SaO2 from pulse oximeter</div><div>8.  </div><div>9.  If temporary pacing wires present- ensure attached to external pacemaker </div><div>box and turn pacemaker box on (consider placing patient on back up VVI </div><div>mode)</div><div>10. </div><div></div><div>placement is at least six (6) inches away from implanted device</div><div>11. </div><div>i.  </div><div></div><div>attending provider’s discretion)</div><div>ii.  </div><div>iii.  Press “Sync” button and ensure R wave aligns with synchronized </div><div>marker</div><div>iv.  Press record button to ensure recording paper is operational</div><div>Procedure Steps:</div><div>1.  Perform “Time out”</div><div>2.  Anesthesiologist/ICU APP administers anesthetic agent via IV with O2 on </div><div>patient</div><div>3.  Vitals signs and SaO2 are recorded every minute by RN</div><div>4.  When anesthesiologist/ICU APP determines patient is adequately sedated, </div><div>he/she acknowledges to the APP that patient is ready for DCCV</div><div>5.  The APP performs the following:</div><div>i.  Press the “Charge” button and states loudly, “Charging”</div><div>ii.  States loudly, “All clear!” and visually sweeps the bed to ensure no one </div><div>is touching the bed and waits for other team members to verify they are </div><div>clear</div><div>iii.  Press and hold the “Shock” button</div><div>6.  </div><div>communicates with anesthesiologist to verify vital signs are stable</div><div>7.  If patient remains in sinus rhythm, anterior/posterior pads are removed from </div><div></div><div>from patient</div><div>8.  If patient has early re-initiation of atrial arrhythmia or remains in an atrial </div><div>arrhythmia, DCCV procedure is repeated with a higher number of joules.  APP </div><div></div><div>energy for the maximum of 3 shocks.</div><div>9.  The APP follows current ACLS protocol for asystole, high degree AV block or </div><div>ventricular arrhythmias and pages Attending Physician</div><div>10. The APP completes the following:</div><div>i.  Reviews post procedure EKG</div><div>ii.  Any medication reconciliation, if applicable</div><div>iii.  Document via Procedure Note: Include medication administered, # of </div><div>joules, # of shocks, post procedure rhythm, and any adverse events. </div></div><div></div></div>
<div><div><img><div>100 Procedures/Devices Procedures/Devices 101</div><div>If the chest tube has purse strings: </div><div>1.  With scalpel, cut the holding suture which is tied around the chest tube and </div><div>the purse strings on the distal end, make sure leave enough purse string </div><div>length to tie. </div><div>2.  </div><div>3.  Instruct the patient to take deep breath in and hold breath. (*Tubes may be </div><div>pulled at end inspiration or end expiration, the important point is that the </div><div>patient is not inspiring as the tube comes out) </div><div>4.  Pull chest tube smoothly and quickly</div><div>5.  </div><div>removal, operator immediately tie down the purse string with surgical knots </div><div>X3 and cut excess string with scalpel </div><div>6.  Remind patient to breath normally as soon as chest tube is removed </div><div>7.  Cover the CT site vaseline gauze with dry dressing and tape </div><div>If the patient does not have purse string to tie:</div><div>1.  Cut the holding string and cover the insertion site with Vaseline gauze quickly </div><div>while removing  the chest tube </div><div>2.  Cover the Vaseline gauze with dry dressing and make sure the whole dressing </div><div>is sealed well with 2inch paper tapes for @ least 48 hrs before remove </div><div>dressing or shower</div><div>If chest tube is pigtail catheter placed per IR</div><div>1.  See Pigtail removal</div><div>Check list post chest tube removal:</div><div> </div><div>Dispose all sharps in sharps container; dispose CT drainage unit into doubled </div><div>red trash bag</div><div> </div><div>If concern or suspect post CT removal PTX, need to check CXR immediately; if </div><div>no concern for PTX, do not need to check CXR</div><div> </div><div></div><div>extreme pain, postop PTX etc.) during or postop procedure</div><div>Post chest tube removal patient education:</div><div> </div><div>Keep occlusive dressing or stiches on for at least 48 hrs, then remove and </div><div>clean site in shower (CT stich could be removed prior to discharge or on clinic </div><div>visit time)</div><div> </div><div>No soaking in bathtub for 1 week</div><div> </div><div>CT insertion site will be assessed at follow up MD visit in 1-2 weeks </div><div> </div><div></div><div>increasing erythema on CT sites</div><div>Pigtail Removal (placed by IR) </div><div>PROCEDURES: RAPID SEQUENCE INDUCTION</div><div>Simultaneous administration of a sedative and a neuromuscular blocking </div><div></div><div>to facilitate emergent endotracheal intubation and to minimize the risk of </div><div>aspiration.  </div><div>Administer:  </div><div>1) SEDATIVE; 2) PARALYTIC; 3) FLUSH</div><div>(Most Common combination is Etomidate and Rocuronium +/- propofol for side </div><div>eect prole)</div><div>If the patient starts to exhibit s/sx of tamponade  </div><div>follow these steps:</div><div>1.  1.  If patient only has symptoms, but BP and HR are stable:</div><div>i.  Order STAT Echo </div><div>ii.  Call Echo lab (x54160) to notify them of order and that the purpose is to </div><div>rule out tamponade</div><div>iii.  Continue to monitor patient &amp; vitals closely. Run BP checks Q15 min.</div><div>iv.  Notify chief resident or attending</div><div>v.  As soon as there is a change in vital signs, follow step 3. </div><div>2.  If the patient’s BP starts to drop, but general condition is OK</div><div>i.  </div><div>ii.    Order STAT Echo, call Echo lab and notify as above.  </div><div>iii.    Notify chief resident and attending that you have suspicion for </div><div>possible tamponade </div><div>iv.    Call ICU team for possible transfer to back to ICU</div><div>3.  </div><div>decompensating quickly, take all steps as listed above but notify on call </div><div>attending and OR that emergent surgery is needed. If patient goes into </div><div>cardiac arrest or mental status starts to change, etc </div><div>i.  Activate Open chest code and rapid transfusion protocol. </div><div>ii.  Open chest at bedside ASAP to release pressure on heart  </div><div>• </div><div>•  Direct CPR/cardiac massage if cardiac arrest</div><div>•  Straight to OR</div><div>Chest Tube Removal:  </div><div>Things to consider before CT removal:</div><div> </div><div>If drainage &lt; 150 cc/24 hrs (some surgeons are OK with drainage&lt;  200cc/24 </div><div></div><div> </div><div>Is there any air leak from chest tube? </div><div> </div><div> If chest tube with persistent air leak, may switch to  water seal overnight </div><div>and check CXR next AM, if no new  PTX or previous existing PTX in stable </div><div>size-&gt; may remove chest tube (sometimes needs to  clamp chest tube 1st </div><div>and repeat CXR to rule out new PTX/increasing  PTX size before removal)</div><div> </div><div>Is there any PTX on CXR?</div><div> </div><div>Assess pain control need: usually give fentanyl 25-50 mcg IV or dilaudid 0.2mg </div><div>IV before procedure </div><div> </div><div>Grab materials to use: suture removal set or scalpel; multiple 4x4 gauzes; </div><div>Vaseline gauze; hem clamp;  2 inch wide paper tapes; blue chux ; 2 red </div><div>biohazard trash bag</div><div> </div><div>Usually needs a 2nd person (RN or PA/NP colleague to hold chest tube site </div><div>tissue together before knots are tied or Vaseline gauze is placed)</div><div>Procedure:</div><div> </div><div>Place patient in bed with comfortable position and explain to the patient </div><div>about the procedure process </div><div> </div><div>Remove chest tube site dressing and assess the wound</div><div> </div><div>If there are 2-3  tubes connected together with  Y-connector, need to clamp </div><div></div><div>chest tube removal </div></div><div></div></div>
<div><div><img><div>102 Procedures/Devices Procedures/Devices 103</div><div>PROCEDURES: BRONCHOSCOPY</div><div>Indications for bronchoscopy:</div><div> </div><div>Hypoxemia</div><div> </div><div>Suspected airway obstruction</div><div> </div><div>New CXR opacity</div><div> </div><div>Copious secretions</div><div> </div><div>To obtain Bronchial Alveolar Lavage (BAL)/sputum culture</div><div> </div><div>Pulmonary toileting</div><div>Setting up a bronchoscopy:</div><div> </div><div>Discuss with attending on ideal time and indication</div><div> </div><div>Decide bronchoscope (full cart) vs ambuscope (smaller screen, smaller </div><div>scope)</div><div> Full cart bronchoscope indicated for:</div><div> </div><div>Thick secretions, copious secretions</div><div> </div><div>Copious bloody secretions</div><div> </div><div>Attending preference</div><div> </div><div>Call x37709 (RT bat phone for charge RT). They will ask the following:</div><div> Patient name, location</div><div> Attending provider</div><div> Indication</div><div> Scope required (ambuscope vs bronchoscope)</div><div>Aer the bronchoscopy:</div><div> </div><div></div><div> </div><div>Fill out the order requisition:</div><div> Pneumonia diagnosis code: 498</div><div> Gram stain and culture for BAL </div><div> </div><div> </div><div>Order post-bronchoscopy CXR </div><div>DEVICES: IABP</div><div>Indications</div><div> </div><div>Cardiogenic shock</div><div> </div><div>Unstable angina</div><div> </div><div>Intractable ventricular dysrhythmias</div><div> </div><div>Threatening extension of MI</div><div> </div><div>Prophylactic support for PCI</div><div> </div><div>Prophylactic support for OR induction</div><div> </div><div>Post-op myocardial dysfunction</div><div> </div><div>Inability to wean from CPB</div><div> </div><div>RV support during LVAD implantation</div><div> </div><div>Contraindicated in Aortic regurgitation, Aortic dissection, or with severe aortic </div><div>of peripheral atherosclerosis </div><div>Placement/Position</div><div> </div><div>1-2cm below L subclavian artery and above the renal artery branches</div><div> </div><div>Tip should be between the 2nd &amp; 3rd Intercostal space on CXR</div><div>Sedatives</div><div>Drug </div><div>Name</div><div>Class Benets Contra-</div><div>indications</div><div>Notes Dose</div><div>Etomidate Imidazole </div><div>derivative</div><div>Excellent </div><div>sedation </div><div>with little </div><div>hypotension</div><div>Known to </div><div>suppress </div><div>adrenal cortisol </div><div>production</div><div>Use cautiously </div><div>if patient </div><div>has sepsis; </div><div>initial dose of </div><div>glucocorticoid </div><div>may be needed</div><div>0.3 mg/kg</div><div>Ketamine Phencyclidine </div><div>derivative, </div><div>dissociative </div><div>anesthetic</div><div>Stimulates  </div><div>catecholamine </div><div>release </div><div>Bronchodilation</div><div>Use in patients </div><div>with elevated </div><div>ICP or elevated </div><div>blood pressure is </div><div>controversial</div><div>May be an </div><div>excellent </div><div>induction agent </div><div>for patients with </div><div>bronchospasm, </div><div>septic </div><div>shock, AND </div><div>hemodynamic </div><div>compromise</div><div>1 to 2 mg/kg</div><div>Midazolam Benzo- </div><div>diazepines</div><div>Potent dose-</div><div>related amnesic </div><div>properties</div><div>Dose-related </div><div>myocardial </div><div>depression </div><div>can result in </div><div>hypotension</div><div>0.2 to 0.3 </div><div>mg/kg</div><div>Propofol Alkylphenol </div><div>derivative</div><div>Bronchodilation No absolute </div><div>contraindications </div><div>Dose-related </div><div>hypotension</div><div>Paralytics</div><div>Drug Name Class Contraindications Notes Dose</div><div>Succinylcholine Depolarizing </div><div>agent binds to </div><div>postsynaptic ACh </div><div>receptors causing </div><div>continuous </div><div>stimulation</div><div>Hx or family hx of malignant </div><div>hyperthermia </div><div>Hyperkalemia or risk of </div><div>developing hyperkalemia </div><div>Upregulation of ACh </div><div>receptors predisposes pts to </div><div>hyperkalemia</div><div>Neuromuscular disease </div><div>involving denervation </div><div>(muscular dystrophy, stroke </div><div>&gt;72hrs, spinal cord injury </div><div>&gt;72hrs, muscular dystrophy, </div><div>ALS)</div><div>Rhabdomyolysis</div><div>Burn &gt; 72 hours old</div><div>Inherited myopathies</div><div>Crush injuries &gt;72hrs</div><div>Severe infection w/ exotoxin </div><div>(tetanus, botulism)</div><div>Note: Succinylcholine is safe </div><div>in myasthenia gravis</div><div>paralysis occurs </div><div>in 45 to 60 </div><div>seconds</div><div>duration approx. </div><div>6- 10 min. </div><div>1.5 mg/kg IV</div><div>Rocuronium Nondepolarizing </div><div>agent.</div><div>Competitively </div><div>inhibits ACh </div><div>receptors </div><div>preventing </div><div>depolarization </div><div>Paralysis occurs </div><div>in approximately </div><div>45 to 60 seconds</div><div>duration approx. </div><div>45 minutes</div><div>1.0 mg/kg</div><div>IBW</div><div>Vecuronium Nondepolarizing </div><div>agent.</div><div>Paralysis occurs </div><div>w/in 2.5-3 min</div><div>Duration 25-40 </div><div>min.</div><div>0.08-0.1 </div><div>mg/kg</div></div><div></div></div>
<div><div><img><div>104 Procedures/Devices Procedures/Devices 105</div><div>Possible Reasons for Poor Augmentation</div><div> </div><div>Patient’s native stroke volume &gt; IABP volume</div><div> </div><div>Indication of readiness to wean from IABP</div><div> </div><div>Balloon too small?</div><div> </div><div>Low SVR</div><div> </div><div>Hypovolemia</div><div> </div><div>IABP positioned too low</div><div> </div><div>Kinked catheter</div><div>Triggers</div><div>Autopilot Mode </div><div> </div><div>Machine selects EKG and AP (arterial pressure) source, trigger mode and </div><div>timing method as well as optimizes timing</div><div> </div><div>Machine continuously monitors the patient and chooses the best trigger </div><div>mode based on patient condition</div><div>EKG</div><div> </div><div>Pre-set trigger mode</div><div>EKG Peak</div><div> </div><div>Best for wide complex rhythm</div><div> </div><div>Best for HR&gt;130bpm</div><div> </div><div>A Fib</div><div> </div><div>Best choice for varying R-R intervals</div><div> </div><div></div><div>Arterial Pressure</div><div> </div><div>Best trigger when EKG is unavailable or has lots of artifact</div><div> </div><div>Triggered by the systolic up-stoke of the arterial pressure waveform</div><div> </div><div>Should be used during CPR</div><div>A Pace</div><div> </div><div>Triggered by the atrial pacing spike</div><div> </div><div>Can only be used if patient 100% A paced</div><div>V Pace</div><div> </div><div>Triggered by the ventricular spike</div><div> </div><div>Can be used if patient V paced or AV paced</div><div> </div><div>Pt must be 100% paced</div><div>Internal </div><div> </div><div></div><div>activity</div><div> </div><div>Used in situation when there is no cardiac output and no EKG</div><div>During CPR</div><div> </div><div>Arterial pressure trigger should be selected as this will synchronize counter </div><div>pulsation to cardiac compressions</div><div>IABP Complications:</div><div> </div><div>Distal limb ischemia (most common complication occurring in 10-15% of </div><div>patients) and compartment syndrome</div><div> </div><div>Infection and sepsis </div><div> </div><div>Thrombocytopenia</div><div> </div><div> </div><div> Balloon rupture, may lead to helium embolus</div><div> </div><div>Risk and complications of insertion:</div><div> </div><div>coverage</div><div> If balloon is too low = decreased visceral organ perfusion (decreased </div><div>urine output) </div><div> Aortic dissection during insertion </div><div>Basic Principles</div><div> </div><div></div><div>just prior to systole</div><div> </div><div></div><div>aortic valve closure</div><div> </div><div>This combination favorable alters the myocardial oxygen supply: demand </div><div>ratio (Increased myocardial perfusion with less work)</div><div> </div><div></div><div> </div><div>May be indicated in RV failure:</div><div> Improvement in RV perfusion from diastolic augmentation </div><div> Improvement in LV function from unloading </div><div>Deation phase of IABP leads to</div><div> </div><div></div><div> </div><div>Increased stroke volume</div><div> </div><div>Enhanced forward cardiac output</div><div>Ination phase of IABP leads to</div><div> </div><div></div><div> </div><div>Increased diastolic pressure</div><div> </div><div>Potential for increased coronary collateral circulation</div><div> </div><div>Increased systemic perfusion</div><div>Timing</div><div>Ination</div><div> </div><div>Rapid rise in aortic pressure which increases O2 supply to coronaries</div><div> </div><div></div><div> </div><div>Augmented pressure should be &gt; systolic pressure</div><div>Deation</div><div> </div><div>Reduce aortic and end diastolic pressure, improving CO</div><div> </div><div>Assisted end diastolic blood pressure &lt;/= unassisted end diastolic blood pressure</div><div> </div><div>Assisted peak systolic pressure should be &lt;unassisted peak systolic pressure   </div><div>IABP tracing at 1:2 ratio. IABP end diastolic pressure is lower than the patient’s </div><div>aortic end diastolic pressure. The balloon assisted peak systolic pressure is lower </div><div>than the systolic pressure that is generated without a preceding assisted beat. </div></div><div></div></div>
<div><div><img><div>106 Procedures/Devices Procedures/Devices 107</div><div>placed. The ventricular wire is the shorter one. Occasionally, 2 ventricular </div><div>wires are placed (will be equal length) » either one can be used as the ground </div><div>lead.</div><div> </div><div>The ventricular wire is inserted into the negative pole of the temporary </div><div>external pacemaker. The skin wire is inserted in the positive pole.</div><div>Unipolar vs. Bipolar </div><div> </div><div>Unipolar wires consist of a single negative wire attached to the epicardium </div><div>and an additional wire in the subcutaneous tissue (positive). </div><div> </div><div>Bipolar system  consist of a single wire with two conductors (positive and </div><div>negative) which are both attached directly to the epicardium</div><div> </div><div>threshold to obtain capture and is less sensitive to electrical interference </div><div>when sensing compared to unipolar system. </div><div>General Concepts </div><div>Stimulation or Capture Threshold</div><div> </div><div>Refers to the amount of energy delivered by the pulse generator in order to </div><div>initiate depolarization  (measured in milliamps).</div><div> The usual starting point is 10mA and slowly increased until capture is </div><div>achieved.  </div><div> </div><div></div><div>electrodes.</div><div>How to determine appropriate output threshold setting:</div><div> </div><div>Set RATE at least 10 ppm above patient’s intrinsic rate.</div><div> </div><div>Decrease OUTPUT: Slowly turn OUTPUT dial counterclockwise until ECG </div><div>shows loss of capture.</div><div> </div><div>Increase OUTPUT: Slowly turn OUTPUT dial clockwise until ECG shows </div><div>consistent capture.</div><div>This value is the stimulation threshold.</div><div> </div><div>Set OUTPUT to a value 1.5-2 times greater than the stimulation Threshold value.</div><div>This provides at least a 2:1 safety margin.</div><div>Troubleshooting Failure to Capture</div><div> </div><div>Possible Causes</div><div> </div><div> </div><div>Increase mA till capture</div><div> Low battery</div><div>IABP removal </div><div>See IABP removal Hosptial Protocol on IntraNet. </div><div>References</div><div>Bojar, Robert M. (2011) Manual of Perioperative Care in Adult Cardiac Surgery. (5th edition). </div><div> </div><div>DEVICES: LUMBAR DRAINS</div><div>1.  Placed pre-operatively by cardiac anesthesia or Neuro IR if patient has </div><div>complex anatomy</div><div>2.  Use “Lumbar Drain” order set</div><div>3.  Post-operative lumbar drain management:</div><div>i.  Zero the transducer at right atrium phlebostatic level</div><div>ii.  Set the Transducer to 10mmHg</div><div>•  Leave the stopcock closed to the transducer except when measuring </div><div>hourly pressure</div><div>•  Keep the drain open to the patient to allow to continuous drainage</div><div>•  When the ICP is above 10mmHg, the drain will act as a pressure  </div><div></div><div>iii.  Goal is to drain ~10mL/hr when ICP &gt;10. Not to exceed drainage  </div><div>of 20mL/hr</div><div>iv.  </div><div>v.  Maintain strict bed rest with HOB at 30 degrees or less while actively </div><div>draining</div><div>vi.  </div><div>patient and reopen when destination reached.</div><div>4.  For more information on ICP and prevention of spinal cord ischemia see </div><div>“Spinal Cord Ischemia page 50 under III. Post-operative Managament</div><div> </div><div>DEVICES: TEMPORARY PACEMAKERS</div><div>Nomenclature</div><div>1st letter — chamber/chambers paced: A= atria, V= ventricle,  </div><div>D- dual (atria and ventricle)</div><div>2nd letter — chamber/chambers sensed: A= atria, V= ventricle,  </div><div>D- dual (atria and ventricle)</div><div>3rd letter — how the pacemaker responds to an event:  I= inhibit, T- trigger</div><div>Temporary  Pacing Techniques </div><div>Transvenous</div><div>Placed through introducer into the right ventricle. Routinely placed in TAVR pts </div><div>with Corevalves d/t increased risk for the development of heart block as the valve </div><div>continues to expand post deployment.</div><div>Transcutaneous</div><div></div><div>positions. Disadvantages include requiring higher pacing thresholds and patient </div><div>discomfort.</div><div>Epicardial Leads</div><div> </div><div>The wires in the right subcostal region are atrial and in the  subcostal </div><div>region are ventricular.</div><div> Minimally invasive valve surgeries the A and V wires will be in the same position. </div><div> </div><div>Typically, a single ventricular wire (pacing lead) and a skin wire (ground) are </div></div><div></div></div>
<div><div><img><div>108 Procedures/Devices Procedures/Devices 109</div><div>Modes of Pacing:     </div><div>Mode Advantages Disadvantages</div><div>AAI</div><div> </div><div>Single lead</div><div> </div><div>AV synchrony maintained</div><div> </div><div>Able to assess ST changes</div><div> </div><div>Unable to use in AF</div><div> </div><div>Ventricular bradycardia may </div><div>occur in prescense of high </div><div>grade AV block</div><div> </div><div>Instability of single atrial lead</div><div> </div><div>Higher risk of thin atrial wall</div><div>VVI</div><div> </div><div>Requires a single lead</div><div> </div><div>Useful in prescense of AF and </div><div>high grade AV block</div><div> </div><div>AV synchrony lost </div><div> </div><div>Unable to assess ST changes</div><div> </div><div>Loss of atrial kick</div><div> </div><div>Risk of pacemaker syndrome</div><div>DDO</div><div> </div><div>AV synchrony maintained</div><div> </div><div>Use in AF and high grade AV </div><div>block</div><div> </div><div>Heart rate responsive</div><div> </div><div>Possible decreased </div><div>thrombotic events</div><div> </div><div>Pacemaker mediate endless-</div><div>loop tachycardia possible</div><div> </div><div>Pacemaker syndrome if </div><div>incorrectly set up</div><div> </div><div>May not be able to assess ST’s</div><div>DDI</div><div> </div><div>Uses two pacing leads (right </div><div>atrium and right ventricle) to </div><div>maintain minimum rate in </div><div>each cavity</div><div> </div><div>Used in the presence of sinus </div><div>bradycardia with possible AV </div><div>conduction disorders or with </div><div>frequent atrial arrhythmia</div><div> </div><div>Must feel comfortable setting </div><div>rate and AV node delay</div><div> </div><div></div><div> </div><div>For removal of temporary pacing wires, page 99 (section V, procedures, CT and </div><div>PW removal) </div><div>References: http://www.medtronic.com/us-en/index.html</div><div> </div><div>DEVICES: ON Q PUMPS</div><div> </div><div>Non-narcotic pain relief system designed to deliver local anesthetic to or near </div><div>the surgical site via catheters. </div><div> </div><div>The epidural or intrathecal route uses small quantities of medication to </div><div></div><div>provide targeted pain relief via multiple holes along the infusion segment of </div><div></div><div>distribution. </div><div> </div><div>Placed intra-operatively by the surgeon or APP for primarily patients receiving </div><div>anterior thoracotomy incisions</div><div>Placing the Catheter</div><div>1.  Gently hold T-handle and remove protective guard. </div><div>2.  Introducer Needle: Insert (bevel up) through the skin approximately 3-5 cm </div><div>from surgical site </div><div>3.  Advance introducer to desired location for catheter placement. Introducers </div><div>with Luer lock may be connected to a syringe to aspirate or inject a bolus of </div><div></div><div>4.  While holding T-handle 1, withdraw trocar 2 from sheath </div><div> </div><div>Change battery</div><div> </div><div> </div><div>Attempt to reverse the polarity of the leads by swapping the position </div><div>of the metal leads into the pacemaker cord</div><div> Electrolyte abnormalities</div><div>Sensitivity</div><div> </div><div>Sensing refers to the ability of the generator to detect (“see”) and recognize </div><div>the intrinsic impulses of the myocardial tissue and to appropriately respond </div><div>to what it detects.</div><div> </div><div>Sensitivity setting is measured in millivolts. </div><div> Typical atrial 0.4 mV</div><div> Typical ventricular 2.0 mV</div><div> </div><div>Programming a higher sensitivity (higher number) makes the pacemaker  </div><div>less sensitive to intrinsic cardiac activity.</div><div> </div><div>Programming a lower sensitivity (lower number) causes the pacemaker to be </div><div>more sensitive to intrinsic cardiac activity.</div><div>How to determine appropriate sensitivity setting:</div><div>1.  Set rate at least 10 ppm below patient’s intrinsic rate.</div><div>2.  Adjust output: Set OUTPUT to 0.1 mA (A OUTPUT for atrial threshold; V </div><div>OUTPUT for ventricular threshold).</div><div>3.  Highlight SENSITIVITY (atrial or ventricular) </div><div>4.  Decrease SENSITIVITY: Slowly turn MENU PARAMETER dial </div><div></div><div>5.  Increase SENSITIVITY: Slowly turn MENU PARAMETER dial clockwise </div><div> </div><div>This value is the sensing threshold.</div><div>6.  Set SENSITIVITY to half (or less) the threshold value. </div><div>This provides at least a 2:1 safety margin.</div><div>7.  Restore RATE and OUTPUT to previous values.</div><div>Trouble Shooting Sensitivity</div><div>Failure to sense is when the generator does not recognize the heart’s intrinsic </div><div>impulses.</div><div> </div><div>Pacemaker not sensitive enough to patient’s intrinsic rhythm.</div><div> Increase the sensitivity by lowering the mV</div><div> </div><div></div><div> </div><div></div><div> Attempt to reverse the polarity of the leads by swapping the position of </div><div>the metal leads into the pacemaker cord</div><div> </div><div>Low battery.</div><div> </div><div>Malfunction of pacemaker or cable.</div><div>Over-sensing: Pacer sees too much (QRS, T wave, P wave and baseline)</div><div> </div><div>Decrease sensitivity by increasing the mV</div><div>Checking underlying rhythm</div><div> </div><div>Safest method is to slowly turn down the rate as opposed to  disconnecting </div><div>the leads from generator or pausing the pacemaker as this gives time for the </div><div>patient’s native conduction system to emerge</div></div><div></div></div>
<div><div><img><div>110 Procedures/Devices Procedures/Devices 111</div><div> Sponge (item # 195925)</div><div> </div><div></div><div>regular wound vac upon discharge</div><div>Discharging a patient home with Wound VAC</div><div> </div><div>Ensure Case management is involved early to ensure insurance authorization </div><div>and supply delivery</div><div> </div><div>If short term Vac therapy is needed, consider Vac Via</div><div> Can use placed on a patient for up to 4 days and then switched to wet-to-</div><div>dry dressings if Vac is no longer needed</div><div>Vac Tips:</div><div> </div><div>Stanford Policy states wound Vac changes are to be done Monday, </div><div>Wednesday and Friday.</div><div> Use clinical judgment if wound vac was placed at an odd time. Product </div><div></div><div> </div><div>Cut the sponge to the size of the wound or larger never smaller than the </div><div>wound so that the drape does not stick directly to the wound.</div><div> </div><div>Cut a big hole for track pad at least the size of a quarter.</div><div> </div><div></div><div> </div><div>When placing Wound VAC in clinic:</div><div> </div><div>If the VAC is a new placement- the patient will be Admitted to Observation for </div><div>wound vac placement and supply authorization via case manager (DO NOT </div><div>ADMIT VIA ED)</div><div> </div><div>If the VAC is established- patient should bring own supplies from home for in </div><div>clinic changes</div><div>Prevena:</div><div> </div><div>For use with closed incisions</div><div> </div><div>Should be placed at the time of wound closure in the OR, can also be placed </div><div>later</div><div> </div><div>The pump battery lasts for 7 days.</div><div> </div><div>Dressing should be removed and wound checked prior to discharge </div><div>(even if before battery dies)</div><div> </div><div>When the battery dies, the pump can be thrown away and the patient </div><div>removes the dressing and resumes normal wound care</div><div> </div><div>Risk for poor wound healing criteria (i.e. use of provena should be </div><div>considered)</div><div> Obesity (BMI&gt;36)</div><div> Diabetes (insulin-dependent, dialysis, or previous diabetic-induced  </div><div>organ damage) </div><div> COPD (forced expiratory volume in 1 second &lt; 80%)  </div><div> Bilateral IMA take-down  </div><div> COPD history</div><div> Corticosteroid use</div><div> Abnormally high preoperative creatinine ( &gt; 90th percentile) </div><div> More intraoperative blood transfusions (3 or more)  </div><div> Longer length of operation (&gt;4 hrs.) </div><div> Previous known poor wound healing episode </div><div>5.  Advance catheter through sheath until entire infusion segment is within </div><div>desired location </div><div>6.  Coil catheter and secure with adhesive strips </div><div>7.  Apply occlusive dressing over insertion site and coiled catheter. Keep </div><div></div><div>8.  Connect catheter to pump tubing.</div><div>Post-operative period: </div><div> </div><div>Pumps are not managed by pain service (do not page Pain service with </div><div>questions), they are managed by the primary team</div><div> </div><div>The pump works by administering a continuous infusion of bupivacaine </div><div>locally at the site of the incision. </div><div> </div><div>The pump is used in adjunct with analgesics (Tylenol, oxycodone, fentanyl, </div><div>dilaudid). While OnQ pump in place avoid concurrent use with other </div><div>similar agents, i.e. Lidocaine infusions </div><div> </div><div>Medication order: Bupivacaine 0.25% in 270mL @ 2mL/hr</div><div>Removal: </div><div> </div><div></div><div>medicine moving through the tubing. You may notice the outside bag on the </div><div>ball getting looser with wrinkles over time</div><div> </div><div>The pump should be removed 24 hours before discharge to allow for time to </div><div>ensure adequate pain control using oral pain medications</div><div> </div><div>To Remove: remove the dressing, remove small suture anchoring pump to </div><div>skin, and pull the clear catheter. The tube should come out easily. If it is hard </div><div>to remove or starts to stretch, stop and call your doctor right away.</div><div> The end of the tube should have a colored tip so you know that it is all </div><div>out. If the end of the tube does not have a colored tip, call your doctor </div><div>right away.</div><div> The entire unit should be disposed of in the red biohazard bins.</div><div>References: Clark, K. (2010). On-q catheters and introducers. ON-Q Pain Relief System. Retrieved </div><div>from http://www.halyardhealth.com/media/155090/14-60-603-0-04.pdf. </div><div>DEVICES: WOUND VAC</div><div>Vera o:</div><div> </div><div>Preferred over regular wound Vac for inpatients (may heal area faster)</div><div> Normal saline is the solution of choice. Any topically approved solution </div><div>can be placed into the Vac</div><div> </div><div> </div><div>Typical Settings: </div><div> -125mmHg</div><div> 0-20 min wash every 2-4 hours</div><div> </div><div>Grey foam can be used for packing tunneling areas or undermining that is </div><div>hard to visualize</div><div> </div><div>General principles: </div><div> When changing the Vac, use the pad to estimate how much saline is </div><div></div><div> </div><div> </div><div></div><div> </div><div>Supplies needed (Central supply # 35047</div><div> 1000mL container (item # 86309)</div><div> Cassette ( item #195927)</div></div><div></div></div>
<div><div><img><div>112 Reference Material Reference Material 113</div><div>SURGEON PREFERENCES</div><div>Surgeon </div><div>Preferences</div><div>Clinic</div><div>Woo</div><div>o  Review all images and review surgical plan prior to clinic</div><div> </div><div>o  2 week</div><div>Boyd</div><div>o  Echo within 3-6 months for Valves</div><div>o  Cath within 6 months (if CAD), within 1 year if most recent was clean/Valve</div><div>o  CTa within 3-6 months for Ascending aorta</div><div>o  Calculate STS score on all patients pre clinic (use most recent or normal </div><div>creatinine)</div><div>o  Calculate Syntax score for all CAD patients </div><div>o  All notes completed same day of clinic</div><div> </div><div>thromboembolic event </div><div>For inpatient CABG consults— see Boyd Consult H&amp;P document</div><div>Lee</div><div>o  Calculate STS score on all patients pre clinic (use most recent or normal creatinine)</div><div>o  Echo within 3 months</div><div>o  Cath within 6 months (if CAD), within 1 year if most recent was clean/Valve</div><div>o  CTa within 3-6 months for Ascending aorta</div><div>o  CTa (vs CT L atrial mapping) needed for all patient with prior history of ablation/</div><div>MAZE</div><div>o  If pacemaker, obtain make, model, implantation date</div><div>o  Calculate STS score on all patients pre-clinic (use most recent or normal </div><div>creatinine)</div><div>o  PFTs if any smoking history in last 10 years</div><div>o  Carotid US if carotid bruit on exam, h/o prior TAI or stroke, age &gt; 65, smoking </div><div>history, or family history of stroke </div><div>o  Obtain bilateral LE duplex US if history of vein stripping </div><div>o  All notes completed same day of clinic</div><div>o  DO NOT HOLD ASA PRE-OPERATIVELY</div><div>o  Post ops: </div><div>  o  MAZE:</div><div>  o  1-month POV – need ECG during clinic visit (may need TTE if patient’s  </div><div> most recent TTE prior to discharge had LVEF&lt; 40%). </div><div>  o  3-month POV -needs 72 hour Ziopatch as close to clinic visit as possible  </div><div> and a TTE prior to visit. </div><div>  o  6-month POV – needs 72 hour Ziopatch as close to clinic visit as possible. </div><div>  o  12- month POV –needs 72 hour Ziopatch as close to clinic visit as possible. </div><div>  o  Annually with 72 hour Ziopatch. VALVE follow up at 1 mos with Echo,  </div><div> then annually</div><div>  o  CABG fu at 1 mos (Echo only needed if EF decreased at discharge or  </div><div>  &lt; 40% pre op)</div><div>  o  Aortic surgery patients: FU @ 1, 3,6, and 12 months with CT scan</div><div>Fischbein o  Pre op</div><div>o  No Tissue consent for Aorta patients </div><div>Miller</div><div>Hiesinger o  Review all images and review surgical plan prior to clinic</div><div>SURGEON PREFERENCES, CONTINUED</div><div>Surgeon </div><div>Preferences</div><div>ICU Tele</div><div>Woo o  DC labs early if able</div><div>o  Post op CT c/a/p prior to discharge on </div><div>Acute Type A dissections only</div><div>o  Ok to DC home same day PW removed</div><div>Boyd</div><div>o  CABG patients 75mg Plavix daily x1 </div><div>year</div><div>o  All patients 200mg PO amio daily </div><div></div><div>o  SubQ heparin for  DVT prophylaxis </div><div>if no contraindication</div><div>o  Endocrine consult to manage DM if </div><div>elevated A1c</div><div>o  Daily senna started while in ICU</div><div>o  FAST TRACK (all uncomplicated </div><div>CABG with normal EF)</div><div>POD #1:0600;  Cordis/</div><div>Swan out by 1000 (even if still on </div><div></div><div></div><div></div><div>and Plavix</div><div>POD #2: Daily labs on case by case </div><div>basis. Transfer out of ICU</div><div>Overall considerations:</div><div>insulin gtt and start diet as early </div><div>as possible, ok to eat POD #0. Ok </div><div>to remove foley POD 1 even if on </div><div>diuretics. If waiting in ICU for tele </div><div>bed, ensure PT/OT and patient </div><div>mobilization.</div><div>o  DC labs early if able </div><div>o  CABG patients 75mg Plavix daily x1 year</div><div>o  All patients 200mg PO amio daily for </div><div></div><div>o  No Iron on discharge</div><div>o  Remove PW prior to CT</div><div>o  SubQ heparin for DVT prophylaxis if no </div><div>contraindication </div><div>o  No imaging needed prior to discharge</div><div>o  Acute Type A dissection post op CT @ </div><div>1month follow up appointment </div><div>o  Endocrine consult to manage DM if </div><div>elevated A1c</div><div>o  For routine CABG, goal is discharge by </div><div>at least POD #5</div><div>o  For myocardial bridge, DC Paravertebral </div><div>catheter POD #3 with goal of discharge </div><div>by POD #4 </div><div>Lee o  No IV amio gtt, boluses only</div><div>o  No nicotine patch for CABG</div><div>o  Avoid Reglan (due to black box </div><div>warning and association with </div><div>tardive dyskinesia)</div><div>o  No IV amio gtt, boluses only</div><div>o  No nicotine patch for CABG</div><div>o  Coreg no better than metoprolol for </div><div>Heart failure patients </div><div>o  For LAA excision:  Inspra 25mg BID </div><div>o  Avoid Reglan (due to black box warning </div><div>and association with tardive dyskinesia)</div><div>Fischbein o  Do not wean inotropes without </div><div>discussing directly </div><div>o  For patients on high dose pressors </div><div>or with high oxygen requirements, </div><div>discuss PO diet directly before </div><div>initiating </div><div>o  For post op CABG patients, </div><div>continue NTG while on Epi if blood </div><div>pressure allows</div><div>o  Start Epogen/Iron/Vit C in ICU for </div><div>post op anemia </div><div>o  IV Lasix and KCL while inpatient</div><div>o  Leave central line in place</div><div>o  PW remain in place until day prior to </div><div>discharge</div><div>o  Prior to discharge:</div><div>  o  Echo all valves </div><div>  o  CT all aortas (with 3D    </div><div>  measurements </div><div>o  Must approve all discharges</div><div>o  No IV hydralazine in dissections</div><div>o  PW out prior to CT if possible </div><div>Miller o   Avoid hydralazine in Aortic </div><div>Dissections/Aneurysm</div><div>o  Prior to discharge:</div><div>  o  Echo all valves (once PW removed </div><div>and within 2kg pre op wt)</div><div>  o  CT all aortas (with 3D </div><div>  measurements</div><div>o  Must approve all discharges</div><div>o  No IV hydralazine dissections</div><div>o  For LAA excision: Inspra 25mg BID</div><div>Hiesinger o  Post op imaging per patient- not </div><div>standard</div></div><div></div></div>
<div><div><img><div>114 Reference Material Reference Material 115</div><div>CARDIAC SURGERY PROCEDURE CLEARANCE</div><div>Dental Guidelines</div><div>Pre-op:</div><div> </div><div>Dental clearance will be obtained by schedules via clearance letter</div><div> </div><div>To be cleared for cardiac surgery: </div><div> Dental exam in last 6 months</div><div> No evidence of current dental infection or anticipated dental care needed </div><div>within the next 6 months (Excluding restoration or dentures) </div><div>Post-Op:</div><div> </div><div>Patients with valve repair or CABG SHOULD NOT have dental cleaning or work </div><div>done for at least 3 months post-op.</div><div> </div><div></div><div>material implanted SHOULD NOT have dental cleaning or work done for </div><div>at least 6 months post-op and should take prophylactic oral antibiotics, </div><div>prescribed from their dentist, before any procedures. (AHA guidelines)</div><div> </div><div>Patients are encouraged to follow up with their cardiologist recommendation </div><div>before proceeding with dental work and regarding the need for prophylactic </div><div>antibiotics. </div><div>Colonoscopy/Sigmoidoscopy Guidelines</div><div>Post-Op:</div><div> </div><div>Patients SHOULD NOT have an elective colonoscopy for at least 6 months  </div><div>post op</div><div> </div><div>Prophylactic antibiotics (usually IV given within 30 minutes of procedure) </div><div>should be considered for high risk patients only (presence of prosthetic heart </div><div></div><div>history of endocarditis)</div><div> </div><div>Prophylaxis IS NOT recommended for patients with the following: isolated </div><div>ASD, ASD s/p repair with patch, post op CABG, valvar dysfunction, mitral valve </div><div>prolapse, presence of cardiac pacemaker </div><div>References:</div><div>Oliver, G., Lowry, A., Vernava, A., Hicks, T., Burnstein, M., et. Al. (2000).  Antibiotics prophylaxis clinical </div><div>practice guideline: supporting documentation. The American Society of Colon and Rectal Surgeons. </div><div>PRE-OP: CHECK LIST</div><div> </div><div>H&amp;P </div><div> Completed within 24 hours of procedure</div><div>OR</div><div> Completed within 30 days, with H&amp;P interval within 24 hours of </div><div>procedure</div><div> </div><div>Consent (good for 1 year) </div><div> Procedure</div><div> ICU</div><div> Tissue/Study</div><div> Refusal of blood products if patient does NOT consent to blood </div><div>transfusion</div><div> </div><div>Pre op labs/imaging (must be completed at Stanford within 30 days of </div><div>surgery)</div><div> </div><div> CMP</div><div> PT, PTT</div><div> HgbA1c</div><div> Phosphorus</div><div> Urinalysis, screen for culture</div><div> Type and Screen (for outpatient, clot should be extended for 30 days.  </div><div>For inpatient, must be within 72 hours of procedure)</div><div> RBCS (Refer to page 116 to know how many units to order ahead)</div><div> EKG</div><div> CXR (2V preferred) </div><div> </div><div>Day of surgery orders (found in order set #4658): </div><div> Surgical preparation- clipping, antimicrobial showers x 2, Mepilex to </div><div>sacrum</div><div> Surgical prophylaxis with antibiotics (ON CALL)</div><div> Peridex mouthwash (ON CALL)</div><div> DVT prophylaxis </div><div> </div><div>Misc pre op</div><div> Anticoagulation bridging with Lovenox</div><div> Radial artery harvest work up</div><div> Dental clearance </div><div> Any other studies needed (Cath, Echo, CT, etc)</div><div>TAAA Repair specic:</div><div>Patients are pre-admitted day before surgery for lumbar drain, epidural, and </div><div>bowel prep.</div><div> Page pain service to place epidural preferably day before it is needed </div><div>(2-PAIN)</div><div> </div><div> Clear diet</div><div> Bowel prep</div><div> </div></div><div></div></div>
<div><div><img><div>116 Reference Material Reference Material 117</div><div>PRE-OP:CARDIAC SURGERY PATIENT BLOOD </div><div>MANAGEMENT PROGRAM</div><div>(Ref: Info redistributed from CV Clinical Outcomes; 2011: Stanford Maximum Surgical </div><div>Blood Order Schedule (MSBOS) Criteria)</div><div>Procedure: Type &amp; Screen and </div><div>Type &amp; Cross (Y/N)</div><div>Cardiac Surgery </div><div>recommended # RBC </div><div>units order pre-op</div><div>Combo Sx: “Low Risk” Group:   </div><div>(Includes: Iso CABG, Open &amp; Mini Valve Repair/Replace)</div><div>1st Sx: IsoCABG</div><div>Y 2</div><div>1st Sx: Open AVR</div><div>Y 2</div><div>TAVR (TFem, TApical, </div><div>TAortic)</div><div>Y 4</div><div>1st Sx: Valve + CABG OR </div><div>Multiple Valves</div><div>Y 4</div><div>1st Sx: AoRoot (no arch) </div><div>Combo TD, CVG, AscAo</div><div>Y 4</div><div>1st Sx: TD +/- Asc Arch</div><div>Y 4</div><div>1st Sx: CVG +/- Acs Arch </div><div>Y 4</div><div> 1st Sx: Asc + Arch (no valve) </div><div>+/- descending </div><div>Y 4</div><div>Redo Sx:  CABG + Valve </div><div>Y 4</div><div>Combo Sx: “High Risk” Group:  </div><div>(Includes: Redo TD, Redo CVG, any 1st or Redo Arch Replace, Open Desc Ao, </div><div>and 1st or Redo TAAA)  </div><div>Redo Sx:  TD +/- Arch</div><div>Y 6</div><div>Redo Sx:  CVG +/- Arch</div><div>Y 6</div><div>Redo Sx:  CVG, No Arch</div><div>Y 6</div><div>Redo Sx:  Asc +/- Arch</div><div>Y 6</div><div>Open Desc. Ao (All)</div><div>Y 6</div><div>Open TAAA (All)</div><div>Y 6</div><div> </div><div>*Key:</div><div></div><div></div><div>TD= Tyrone David (aka: David V, Valve Sparing)</div><div>Patients with Heparin allergy or HIT; document in H&amp;P note and inform perfusion on </div><div>surgical day. (Patient with Heparin allergy will receive Argatroban, Bivalirudin  </div><div>or heparin.)</div><div>Pre-Op Blood Saving:</div><div> </div><div>Autologous Donation: Patients can donate their own blood, can donate 6 </div><div>weeks before surgery, increase folic acid, vitamin C, iron supply (ask your </div><div>attending surgeon if this is preferred)</div><div> </div><div>Jehovah’s Witness: Patients Witnesses’ refusal of transfusions of whole </div><div>blood or its four primary components—red cells, white cells, platelets and </div><div>plasma; can use use of fractions such as albumin, immunoglobulins and </div><div>hemophiliac preparations &amp; cell saver. (WatchTower Society)</div><div> Bloodless medicine program in process 1/2017. Refer to updated protocol </div><div>for current pre-operative guidelines for patients who refuse blood </div><div>transfusion.</div><div> </div><div>Herbal Products: Potential interactions to avoid (JACC, 2010), (Alfalfa, </div><div>Angelica, Bilberry, Garlic, Ginger, Ginko, Ginseng, Echinacea, Licorice, St. </div><div>Johns Wart).  Can cause interactions with cardiac medications &amp; increase </div><div>bleeding during surgery.</div><div>Intra-Op Blood Saving:</div><div> </div><div>Blood clotting agent/blood derived fraction agents (Coseal/Tisseal/Floseal)</div><div> </div><div>Perfusion: </div><div> Cell Saver:  recovering blood lost during surgery and re-infusing it into </div><div>the patient. It is a major form of autotransfusion. Cell processors are </div><div>red cell washing devices that collect anticoagulated shed or recovered </div><div>blood, wash and separate the red blood cells (RBC) by centrifugation, and </div><div>reinfuse the RBC. </div><div> </div><div> </div><div>PRE-OP: CLASSIFICATIONS</div><div>CCS Functional Classication of Angina</div><div>Class Description</div><div>Class I Angina only during strenuous or prolonged physical activity</div><div>Class II Slight limitation, with angina only during vigorous physical activity</div><div>Class III Symptoms with everyday living activities  (i.e. moderate limitation)</div><div>Class IV Inability to perform any activity without angina or angina at rest </div><div>(i.e. severe limitation)</div><div>Staging Kidney Disease: always document CKD Stage 3 or greater</div><div>Stage Description</div><div>Stage I With normal of high GFR (GFR &gt; 90mL/min)</div><div>Stage II Mild CKD (GFR = 60-89mL/min)</div><div>Stage IIIa Moderate CKD (GFR = 45-59mL/min)</div><div>Stage IIIb Moderate CKD (GFR = 30-44mL/min)</div><div>Stage IV Severe CKD (GFR = 15-29mL/min)</div><div>Stage V End Stage CKD (GFR &lt; 15mL/min)</div><div>GFR calculator Website:</div><div>http://www.davita.com/gfr-calculator/</div><div>http://www.kidney.org/professionals/KDOQI/gfr_calculator</div></div><div></div></div>
<div><div><img><div>118 Reference Material Reference Material 119</div><div>ACC/AHA Classication of CHF</div><div>The ACC/AHA created four classications from risk for develop the </div><div>disease to severe disability.</div><div>Stage Description</div><div>A (High risk for </div><div>developing CHF)</div><div>Hypertension, DM, Family history, CAD</div><div>B (Asymptomatic HF) Previous myocardial infarction (heart attack), valvular </div><div></div><div>C (Symptomatic HF) Structural heart disease, fatigue, low tolerance level for </div><div>physical activity</div><div>D (Refractory  </div><div>end-stage HF)</div><div>Severe limitations. Experience symptoms even  </div><div>while at rest.</div><div>NYHA Functional Classication</div><div>The NYHA classied heart failure into classes base on functional </div><div>limitations and severity.</div><div>Class FUNCTIONAL CAPACITY: Patient Symptoms</div><div>I (Normal) Few observable sx, no limitations in ordinary physical activity</div><div>II (Mild) Mild observable sx and slight limitation during ordinary activity. </div><div>Comfortable at rest.</div><div>III (Moderate) Marked limitation in physical activity due to symptoms even </div><div>during less than ordinary activity. Comfortable only at rest.</div><div>IV (Severe) End-stage heart failure. Severe limitations. Experience </div><div>symptoms even while at rest.</div><div>Class OBJECTIVE ASSESSMENT</div><div>A No evidence of cardiovascular disease. No symptoms and no </div><div>limitation in ordinary physical activity.</div><div>B Objective evidence of minimal cardiovascular disease. Mild </div><div>symptoms and slight limitation during ordinary activity. </div><div>Comfortable at rest.</div><div>C Objective evidence of moderately severe cardiac disease. </div><div>Marked limitation in activity due to symptoms, even during less </div><div>than ordinary activity. Comfortable only at rest.</div><div>D Objective evidence of severe cardiovascular disease. Severe </div><div>limitations. Experiences symptoms even while at rest.</div><div>For Example:</div><div>A patient with minimal or no symptoms but a large pressure gradient across the </div><div></div><div>Function capacity I, Objective Assessment D</div><div>A patient with severe angina syndrome but angiographically normal coronary </div><div>Functional Capacity IV, Objective Assessment A</div><div>Other Helpful Scores/Resources</div><div>NYHA Class </div><div>Website:</div><div>http://www.heart.org/HEARTORG/Conditions/</div><div>HeartFailure/AboutHeartFailure/Classes-of-Heart-</div><div>Failure_UCM_306328_Article.jsp</div><div>Griepp Score The 1997 ATS paper by Randy Griepp and colleagues </div><div>describes an easy-to-use risk of rupture calculator </div><div>developed by Abe DeAnda (Chief Resident 2000-</div><div>2001). If aortic dissection, RBG just adds 0.5 cm to </div><div>the descending thoracic aortic and abdominal aorta </div><div>diameter numbers. Several other calculator tools are </div><div>also on the spreadsheet.</div><div>    Reference the </div><div>Cardiac Surgery </div><div>APP Shared Box </div><div>folder for this </div><div>information.</div><div>Syntaxcore SYNTAX score II creates accurate mortality predictions </div><div>to guide the choice between PCI and CABG for </div><div>patients with multivessel coronary disease.</div><div>    http://</div><div>syntaxscore.</div><div>com/</div><div> </div><div>PRE-OP: NORMAL ECHO VALUES</div><div>Normal Echo Values</div><div>LV Diastolic Dimension 3.7-5.5cm</div><div>LV Systolic Dimension 2.0-4.0 cm</div><div>Interventricular septum (Diastole) 0.6-1.1 cm</div><div>LV Posterior Wall (Diastole) 1.8-2.2 cm</div><div>LVOT Diameter (Systole) 1.8-2.2cm</div><div>Aortic Root (Diastole) 2.0-3.7cm</div><div> 2.0-4.0cm</div><div> &lt;20cm2</div><div> 16-28ml</div><div>RV Diastolic Dimension 0.9-2.5cm</div><div> </div><div>Pulmonic Valve Echo Values</div><div>Mild 5-25mmHg</div><div>Moderate 25-49mmHg</div><div>Severe &gt;50mmHg</div><div> </div><div>Aortic Valve Echo Values</div><div>AS Grading Mean Gradient </div><div>(mmHg)</div><div>Peak Velocity (m/s) AVA (cm2)</div><div>Normal &lt; 10 &lt; 2.6 &gt;2.5</div><div>Mild 10-25 2.6-2.9 1.5-2.5</div><div>Moderate 20-45 3.0-4.0 1.0-1.5</div><div>Severe &gt;45 &gt;4.0 0.7-1.0</div><div>Critical &gt;50 &gt;4.0 &lt;0.7</div><div>AR Grading Central Jet width* Regurgitant Volume </div><div>(per beat) </div><div>EROA (eective </div><div>Regurgitant oriace </div><div>area)</div><div>Mild &lt; 25% of LVOT width &lt; 30mL &lt;0.1cm2</div><div>Moderate 25-65% of LVOT width 30-59mL 0.1-0.3cm2</div><div>Severe &gt;65% of LVOT width &gt;60mL &gt;0.3cm</div><div>Tricuspid Valve Echo Values</div><div>Signicant tricuspid stenosis</div><div>Mean pressure gradient &gt;/= 5mmHg</div><div>Valve area &lt;/= 1cm2</div><div>Tricuspid </div><div>Regurgitation</div><div>MILD MODERATE SEVERE</div><div>Jet area &lt; 5 5-10 &gt;10</div><div>RV/RA/IVC Size Normal Normal or dilated Usually dialates</div></div><div></div></div>
<div><div><img><div>120 Reference Material Reference Material 121</div><div>Mitral Valve Echo Values</div><div>MS grading Valve Area Mean gradient Pulmonary artery </div><div>pressure (mmHg)</div><div>Mild &gt;1.5 cm2 &lt;5mmHg &lt;30mmHg</div><div>Moderate 1.0-1.5 cm2 5-10mmHg 30-50mmHg</div><div>Severe &lt;1.0cm2 &gt;10mmHg &gt;50mmHg</div><div>MR grading  Jet area Regurgitant Volume EROA (eective </div><div>Regurgitant oriace </div><div>area)</div><div>Mild &lt;20% of LA area &lt;30mL &lt;0.2cm2</div><div>Moderate 20-40% of LA area 30-59mL 0.2-0.39 </div><div>Severe &gt;40% of LA area &gt;60mL &gt;0.40cm2</div><div>PRE-OP: OBTAINING CONSENT/PROCEDURE LIST</div><div>Procedure Correct verbiage for Consent</div><div>CABG </div><div></div><div>• Does not need to include IMA (LIMA/RIMA) </div><div>Consent must specify conduit harvesting when applicable:</div><div>EVH= Endoscopic vein harvest</div><div>RAH= Endoscopic radial artery harvest </div><div>CABG </div><div>MIDCAB </div><div>possible sternotomy, cardiopulmonary bypass on standby</div><div>TAVR Transcatheter aortic valve replacement</div><div>• Include approach (transfemoral, transapical, or transaortic) </div><div>• Also include cardiopulmonary bypass on standby </div><div>• Also include transesophageal echocardiogram</div><div>Mini MVR Right anterior thoracotomy; mitral valve/replacement repair on </div><div>cardiopulmonary bypass, possible sternotomy. </div><div>Mini AVR Minimally invasive aortic valve repair/replacement; on cardiopulmonary bypass</div><div>Hybrid MAZE Bilateral video assisted thoracoscopy; pulmonary vein isolation; with additional </div><div></div><div>MAZE; cardiopulmonary bypass on standby</div><div>Cox Maze Maze procedure on cardiopulmonary bypass</div><div>Myectomy/</div><div>Myotomy</div><div>Myectomy/myotomy with possible mitral valve repair/replacement on </div><div>cardiopulmonary bypass</div><div>Myocardial bridge </div><div></div><div></div><div>Redo stern Redo sternotomy</div><div>LAA Excision </div><div>Laser lead </div><div>extraction</div><div>Laser lead extraction with possible pacemaker generator change; possible </div><div>sternotomy; Cardiopulmonary bypass on standby</div><div></div><div>TEVAR (CT surgery </div><div>attending is </div><div>surgical consent </div><div>attending, Dr. Dake </div><div>does not sign this </div><div>procedure consent)</div><div></div><div>• Do not include Lumbar drain (Anesthesia will consent separately)</div><div>VSARR or Tirone </div><div>David (T-David)</div><div>Valve sparing aortic root replacement, possible aortic valve replacement on </div><div>cardiopulmonary bypass </div><div>Aortic replacement Include following when applicable: ascending aortic replacement, descending </div><div>aortic replacement, total arch replacement, hemi-arch replacement, elephant </div><div></div><div>Aortic root  Aortic root replacement including aortic valve replacement on cardiopulmonary </div><div>bypass</div><div>TAAA Thoracoabdominal aortic aneurysm repair on cardiopulmonary bypass </div><div>SACP &amp; PHCA Under Deep Circulatory Arrest</div><div>Heart transplant Heart transplant on cardiopulmonary bypass</div><div>VAD Ventricular assist device insertion on cardiopulmonary bypass </div><div>• Include type of device: Heartmate II or Heartware</div><div> </div><div> </div><div>Procedure consent must be signed by someone who can perform the </div><div>procedure listed</div><div> Ex: Valve replacement = Attending/resident</div><div> Ex: Cardioversion/Pigtail placement = APP</div><div> </div><div>ICU consent can be signed by APP</div><div> </div><div>Consent is good for 1 year</div><div> </div><div>Make sure all abbreviations are completely spelled out. NO ABBREVIATIONS.  </div><div> </div><div>Check blood consent box on both forms and give patient transfusion packet (If </div><div>the patient refuses blood transfusion, use the additional blood refusal form)</div><div> </div><div>Median sternotomy DOES NOT need to be included on expected “standard </div><div>sternotomy” consents.  ONLY on “Possible Sternotomy” cases (i.e. anterior </div><div>thoracotomy, then “possible sternotomy” should also be included).</div><div> </div><div>NO SCRATCHES, CROSS THROUGHS, OR SCRIBBLES ALLOWED ON CONSENT</div><div>PRE-OP: PFT AND CAROTID US INTEPRETATION</div><div>Carotid Duplex Ultrasound Criteria for Grading Internal Carotid Artery Stenosis</div><div>Degree of </div><div>Stenosis (%)</div><div>ICA PSV (cm/2) ICU/CCA PSV </div><div>Ratio</div><div>ICA EDV (cm/2) Plaque Estimate </div><div>(%)</div><div>Normal &lt; 125 &lt;2.0 &lt;40 None</div><div>&lt;50 &lt;125 &lt;2.0 &lt;40 &lt;50</div><div>50-69 125-230 2.0-4.0 40-100 &gt;50</div><div>&gt;70 to less than </div><div>near occlusion</div><div>&gt;230 &gt;4.0 &gt;100 &gt;50</div><div>Near occlusion High, low, or not </div><div>detected</div><div>Variable Variable Visible</div><div>Total occlusion Not detected Not applicable Not detected Visible, no lumen</div><div>*Plaque estimate (diameter reduction) with gray scale and color Doppler ultrasound. ICA = internal </div><div>carotid artery; CCA= common carotid artery; PSV = peak systolic velocity; EDV = end- diastolic velocity</div><div>*Intervention may be required prior to cardiac surgery on cardiopulmonary bypass if degree of </div><div>stenosis is &gt; 90% unilateral or &gt; 75% bilateral due to increased stroke risk </div><div>Normal Value of Pulmonary Function Tests</div><div>** FEV1    80% to 120% </div><div>FVC 80- 120%</div><div>Absolute FEV1/FVC ratio Within 5% of the predicted ratio</div><div>TLC 80-120%</div><div>FRC 75-120%</div><div>RV 75-120%</div><div>** DLCO </div><div>Also known as TLCO or Dsb </div><div>&gt;60% to  &lt;120%</div><div>**These are key for interpreting</div><div>Spirometry</div><div>Low FEV1/FVC</div><div>Obstruction</div><div>Bronchodilator</div><div>FEV1 unchanged/</div><div>partially </div><div>improved</div><div>(asthma or COPD)</div><div>Obstruction </div><div>Normalizes </div><div>(asthma)</div><div>DLCO</div><div>Low (COPD/</div><div>Emphysema/</div><div>bronchiolitis)</div><div>Normal/High</div><div>(asthma or COPD)</div><div>Normal</div><div>? Asthma</div><div>Bronchoprovocation </div><div>challenge</div><div>FEV1 </div><div>Decreased </div><div>(asthma more </div><div>likely)</div><div>No Change in FEV1 </div><div>(asthma unlikely)</div><div>DLCO</div><div>Low (anemia, </div><div>early ILD, </div><div>pulmonary </div><div>vascular </div><div>disease) </div><div>Normal/</div><div>High</div><div>Normal</div><div>Normal FEV1/</div><div>FVC</div><div>Low VC</div><div>Restriction</div><div>Confirm with </div><div>lung volumes</div><div>DLCO</div><div>Low</div><div>(ILD)</div><div>Normal (chest </div><div>wall/</div><div>neuromuscular)</div><div>Maximum </div><div>inspiratory/</div><div>expiratory </div><div>pressures</div><div>Low</div><div>(neuromuscular)</div></div><div></div></div>
<div><div><img><div>122 Reference Material Reference Material 123</div><div>PRE-OP: PERIPROCEDURAL  </div><div>ANTICOAGULATION BRIDGING</div><div><div>Brand Name </div></div><div>(Generic Name) Half Life/Onset of Action Last dose of medication Before Surgery:</div><div><div>If indicated: When To Start Lovenox </div><div>(dosing=1mg/kg)</div></div><div><div>#            </div><div>syringes</div></div><div>Notes Cath procedures</div><div>Coumadin </div><div><div>(Warfarin)         </div><div>Once daily dosing </div></div><div>20-60hours/3-5 days 5 days before date of surgery</div><div><div>Start 2 days after d/c coumadin (inj Q12 until day </div><div>before surgery.  Day before surgery just ONE </div><div>injection in the morning)</div></div><div>5</div><div><div>Example:  surgery date 4/10; last dose </div><div>Coumadin 4/5; off all one day, 4/6; start </div><div>Lovenox Q12 on 4/7; last Lovenox injec on </div><div>4/9 (morning before sx)</div></div><div><div>Hold 5 days prior for femoral access, </div><div>and if pt mod-high risk for clot bridge </div><div>to Lovenox.  Hold 2 days prior for </div></div><div>radial access</div><div>Eliquis </div><div><div>(Apixaban)               </div></div><div>BID dosing </div><div>9-14hours/3-4 hours</div><div><div>5 days before date of surgery              </div><div>(If CrCl &lt; 50 Hold 6-7 doses)</div></div><div><div>Start 1 day after d/c anticoagulant (inj Q12 until day </div><div>before surgery.  Day before surgery just ONE </div><div>injection in the morning)</div></div><div>7</div><div><div>Example:  surgery date 4/10; last dose </div><div>Eliquis 4/5(am); start Lovenox Q12 on 4/6; </div><div>last Lovenox injec on 4/9 (morning before </div></div><div>surgery)</div><div><div>Hold x 2 days:  the day before and </div><div>the day of Cath</div></div><div>Xarelto </div><div><div>(Rivorxaban)                </div><div>Once daily dosing</div></div><div>11-13 hours/2-4 hours</div><div><div>3 days before date of surgery              </div><div>(If CrCl &lt; 30 Hold 3 doses)</div></div><div><div>Start 1 day after d/c anticoagulant (inj Q12 until day </div><div>before surgery.  Day before surgery just ONE </div><div>injection in the morning)</div></div><div>3</div><div><div>Example:  surgery date 4/10; last dose </div><div>Xarelto 4/7(am); start Lovenox Q12 on 4/8; </div><div>last Lovenox injec on 4/9 (morning before </div></div><div>surgery)</div><div><div>Hold x 2 days:  the day before and </div><div>the day of Cath</div></div><div>Pradaxa </div><div><div>(Dabigatran)              </div></div><div>BID dosing </div><div>12-17hours /1 hour</div><div><div>5 days before date of surgery              </div></div><div><div>Start 1 day after d/c anticoagulant (inj Q12 until day </div><div>before surgery.  Day before surgery just ONE </div><div>injection in the morning)</div></div><div>7</div><div><div>Example:  surgery date 4/10; last dose </div><div>Pradaxa 4/5(am); start Lovenox Q12 on </div><div>4/6; last Lovenox injec on 4/9 (morning </div></div><div>before surgery)</div><div><div>Hold the night before and morning of </div><div>procedure.  Last dose will be in the </div><div>morning the day before Cath</div></div><div>SAVAYSA</div><div><div> (endoxaban)               </div><div>Once daily dosing </div></div><div>10-14 hours/ 1-2 hours</div><div><div>3 days before date of surgery               </div><div>(If CrCl &lt; 30 Hold 3-4 doses)</div></div><div><div>Start 1 day after d/c anticoagulant (inj Q12 until day </div><div>before surgery.  Day before surgery just ONE </div><div>injection in the morning)</div></div><div>3</div><div><div>Example: surgery date 4/10; last dose </div><div>Savaysa 4/7( AM); Lovenox BID 4/8 1 </div><div>lovenox inj AM only on 4/9. </div></div><div><div>Hold x2 days: the day before and the </div></div><div>day of Cath</div><div>Plavix (Clopidogrel)</div><div>5 days before date of surgery</div><div><div>Start 1 day after anticoagulant held (inj Q12 until </div><div>day before surgery.  Day before surgery just ONE </div><div>injection in the morning)</div></div><div>7</div><div><div>Only bridge for pt&amp;apos;s taking Plavix for A.fib.  </div><div>If taking for Stents, hold 5 days before </div><div>surgery and do not bridge</div></div><div>PLETAL (cilostazol)</div><div><div>11-13 hours, reach steady state blood </div><div>levels within a few days.</div></div><div>5 days before date of surgery Does not need bridging</div><div>Asprin</div><div><div>If having valve surgery d/c 2 days before surgery date.  </div><div>If having CABG stop day before</div></div><div>Does not need bridging</div><div><div>If taking ASA 325mg, have patient </div><div>decrease dose to 81 mg as soon as </div><div>procedure scheduled</div></div><div>EFFIENT (prasugrel)</div><div>7 hours /4 hours 5-7 days before date of surgery Does not need bridging</div><div><div>Pre operative bridging with lovenox is required for all mechanical heart valves* &amp;  is only need for atrial fibrillation when CHAD score is High** . For low clot risk,  hold anticoagulant per chart above. </div></div><div><div>Medications to CONTINUE           </div><div>to take morning of surgery</div></div><div>Medications to STOP before surgery</div><div><div>CHADS SCORE</div><div> Lovenox to Coumadin</div></div><div><div>Anti-seizure meds</div></div><div><div>ASA:      </div><div>Valve Surgery= Last Dose 2 days before surgery       </div><div>CABG only: Stop day before surgery      CABG &amp; </div><div>Valve=Stop day before surgery    (Please follow </div><div>attending preference if different)</div></div><div><div>1 pt for each risk factor present:                            </div><div>CHF, HTN, DM, PAD or MI, Age 65-74, </div><div>Female                    </div><div>2 pts for each risk factor present</div></div><div>:                           </div><div><div>Age &gt; 74 years old, Prior stroke or TIA or </div><div>thromboembolism        </div></div><div><div>1. Resume oral </div><div>anticoagulant and </div><div>lovenox evening after </div><div>procedure if no bleeding          </div><div>2. Resume oral </div><div>anticoagulant  + lovenox </div><div>post procedure day 1-3            </div></div><div><div>Anti-Psych meds </div></div><div><div>Blood Thinners: see above</div><div>SCORE / RISK**</div></div><div><div>Beta-blockers</div></div><div><div>NSAIDS: stop 7 days before surgery</div><div>0-2 = LOW</div></div><div><div>Depression meds</div></div><div><div>Insulin:  Insulin Am dose is normal the day before </div><div>surgery. Insulin PM dose is </div></div><div>½ dose the evening before </div><div><div>surgery. Nothing on the morning of surgery</div></div><div> 3-4 = MODERATE</div><div><div>Inhalers</div></div><div><div>Metformin; stop 48 hours before surgery</div><div>5-6 = HIGH</div></div><div><div>Immunosuppressive meds</div></div><div><div>Stop ALL vitamins;1 week prior to surgery</div><div>TIA IN PREVIOUS 3 MONTHS = HIGH</div></div><div><div>Methadone</div></div><div><div>Fish oil; stop 5 days before surgery</div><div>SEVRE VALVULAR DISEASE = HIGH</div></div><div><div>Nitrates; (Imdur)</div></div><div><div>Herbs; stop asap (many of these have anti-coag effects)</div></div><div><div>Parkinson&amp;apos;s meds</div></div><div><div>Maltaq (dronedarone); DO NOT take day of surgery, </div><div>last dose is day before surgery.</div></div><div><div>Proton Pump Inhibitors (PPI&amp;apos;s)</div></div><div>*If Presence of Mechanical Mitral valve:  References:</div><div><div>Thyroid meds               </div><div>Birth Control Pills</div></div><div><div>1. Last dose coumadin 7 days prior to surgery   </div><div>2. Bridge with lovenox as above        </div><div>3. Admit to observation day prior to surgery for </div><div>heparin drip (to be stopped 6 hours before </div><div>surgery). </div></div><div><div>Pernod, G., Godier, A., Gozalo, C., </div><div>Tremey, B., Sie, P. (2010). French clinical </div><div>practice guidelines on the management of </div><div>patients on vitamin K antagonists in at-risk </div><div>situations (overdose, risk of bleeding, and </div><div>active bleeding). Thrombosis Research, </div><div>126, e 167-e174. </div></div><div><div>Brunett, A.E., Mahan, C.E., Vaquez, </div><div>S.R.,Oertel, L.B., Gardcia, D.A., &amp; </div><div>Ansell, J. (2016) Guidance for the </div><div>practical management of direct oral </div><div>anticoagulants (DOACs) in VTE </div><div>Treatment. Journal of Thromb </div><div>Thrombolysis, 41 : 206-232. </div></div><div><div>Last updated 12/2016</div></div><div><div>                   Pre-procedure Anticoagulation Bridging Recommendations                                                                                                                                                                </div><div>for Cardiac surgery</div></div><div><div>3. Check INR post </div><div>proceudre day 4 and DC </div><div>lovenox if INR theraputic</div></div><div>POST-OP: IMAGING</div><div>Modality Inpatient Contact Info Misc</div><div>Echocardiogram  </div><div>(viewed in Xcelera)</div><div>Scheduling: 5-4160, 5-4159, </div><div>3-8988</div><div>Reading room: 3-9503</div><div>o  Use TAVR or TMVR echo order when </div><div>appropriate</div><div>CT (+/- angio) scan  </div><div>(viewed in Centricity)</div><div>Scheduling: 3-6885</div><div>Body reading room: 4-9617</div><div>CVI reading room: 6-2424</div><div>Chest reading room: 3-1346</div><div>Neuro reading room: 4-3145</div><div>o  Gated: evaluates coronaries (Note </div><div></div><div>comments) </div><div>o  Pre and post op aortic disease </div><div>include in comments: Please </div><div>perform with 3D measurements </div><div>and images for treatment </div><div>planning and surveillance (use </div><div>smart phrase CTANGIO3DIMAGES)</div><div> </div><div>mapping) used for pre-op Maze </div><div>o  Consider need for CT chest vs CT </div><div>Chest/Abdomen/Pelvis</div><div>CT CORONARY ANGIO  </div><div>(viewed in Centricity)</div><div>Scheduling: 3-6885</div><div>CVI reading room: 6-2424</div><div>o  Limited study- concentrated on heart </div><div>and coronary arteries (does not </div><div>include thoracic aorta)</div><div>o  Will always be completed gated </div><div> </div><div>in comments. If patient is in atrial </div><div></div><div></div><div>MRI (viewed in </div><div>Centricity)</div><div>Scheduling: 3-6855</div><div>Body reading room: 6-8591</div><div>Cardiac reading room: </div><div>6-2424</div><div>Neuro reading room:4-3145</div><div>Vascular lab: 5-5227</div><div>o  For Aortic Disease, include comment: </div><div>Please perform cardiac MRI (gated) </div><div>with cross hatching, refer to Dr. </div><div>Fleishman if unsure of protocol. </div><div>US Carotid </div><div>(viewed in Centricity)</div><div>Vascular lab: 5-5227</div><div>Spirometry with DLCO </div><div>(results in Epic)</div><div>Inpatient: 3-6371</div><div>Adult pulmonary clinic: </div><div>5-7061</div><div>o  PFTs can be performed by Inpatient </div><div>beside respiratory therapist (during </div><div></div><div>FDG PET CT Clinical </div><div>Cardiac Viability with </div><div>resting myocardial </div><div>perfusion scan (viewed </div><div>in Centricity)</div><div>Scheduling: 3-6885</div><div>Body reading room: 4-9617</div><div>CVI reading room: 6-2424</div><div>Chest reading room: 3-1346</div><div>o  Include in comments: testing </div><div>myocardial viability in CAD patient as </div><div>pre-op work up for CABG</div><div>Venous Ultrasound </div><div>(viewed in Centricity)</div><div>Scheduling: 3-6855</div><div>Reading room: 8-2401</div><div>Arterial Exam/ABIs in </div><div>Vascular clinic (viewed </div><div>in Centricity)</div><div>Vascular lab: 5-5227</div><div>Tagged WBC scan  </div><div>(viewed in Centricity)</div><div>Nuclear Med scheduling: </div><div>4-4278</div><div>Nuclear Med reading room: </div><div>8-2414</div><div>Nuclear Med techs: 4-5684</div><div> </div><div>o  Nuclear- bone</div><div>Cardiac cath  </div><div>(viewed in LifeImage)</div><div>Cath lab extension: 3-7676</div><div>Cath lab recovery: 3-9317</div><div>o  To schedule inpatient, page </div><div>interventional cardiologist on call</div><div>EKG lab 3-7121</div><div>1-4987</div><div>o  Places long term cardiac monitors on </div><div>discharge</div><div>X-ray 62198</div><div>Scheduling: 37030</div><div>Reading room: 87996</div><div>Endoscopy 5-8117</div></div><div></div></div>
<div><div><img><div>124 Reference Material Reference Material 125</div><div>POST-OP: ABG INTERPRETATION</div><div>pH  /  pCO2 /  paO2 /  Sat % /  Base Decit /  Bicarb</div><div>Normal range 7.35 – 7.45</div><div>&lt; 7.35 Acidosis</div><div>•  Look at pCO2</div><div>  o  If High </div><div>  respiratory acidosis</div><div>  o  If normal </div><div>  metabolic acidosis</div><div>•  How to Fix it: </div><div>  o  Respiratory acidosis: </div><div> •  Intubated: increase RR, tidal volume to  </div><div> increase minute ventilation</div><div> •  Extubated: decrease sedation, Bipap to  </div><div> increase ventilation</div><div>  o  Metabolic acidosis:</div><div> •  Bicarbonate supplementation</div><div> •  Further workup for source: Fluid status,  </div><div> BMP, lactate, etc</div><div>&gt; 7.45 Alkalosis</div><div>•   Look at pCO2</div><div>  o  If Low </div><div>  respiratory alkalosis</div><div>  o  If Normal </div><div> Metabolic alkalosis</div><div>•  How to Fix it</div><div>  o  Respiratory alkalosis:</div><div>  •  If intubated: decrease RR, tidal volume</div><div>  •  If extubated: control pain, anxiety,  </div><div> cause of hyperventilation (hypoxia?)</div><div>  o  Metabolic alkalosis:</div><div>  •  Further workup for source: BMP, PRBC  </div><div> transfusion, overdiuresis, etc </div><div>pCO2 Normal range: 35-45</div><div>pCO2 &lt; 35 Respiratory alkalosis</div><div>•  See pH box (Alkalosis)</div><div>pCO2 &gt;45 Respiratory acidosis</div><div>•  See pH box (Acidosis)</div><div>Base Decit normal: +/-2 mEq/L; Bicarb normal 22-30</div><div>This is calculated, not measured on the ABG</div><div>Metabolic Acidosis:</div><div>•  See pH box (Acidosis) above</div><div>Metabolic Alkalosis: high bicarbonate, positive base excess</div><div>•  See pH box (Alkalosis) below</div><div>PaO2 Normal range 60-200mmHg; Sat % Normal range 92-100%</div><div>Increasing O2 content</div><div>•  Increasing FiO2</div><div>•  Increasing NC LPM</div><div>CXR/Ultrasound to assess for</div><div>•  Pneumothorax</div><div> </div><div>•  Hemothorax</div><div>•  Pneumonia</div><div>Increase PEEP (on ventilator or CPAP/BiPap) for </div><div>alveolar recruitment</div><div>Mobilize secretions:</div><div>•  Chest PT</div><div>•  Suctioning</div><div>•  Mucolytics (ie Mucomyst)</div><div>Improve VQ matching</div><div>•  Inhaled bronchodilators (albuterol)</div><div>•  Inhaled vasodilators (Flolan, iNO)</div><div>•  IPPV, incentive spirometer, acapella for </div><div>alveolar recruitment</div><div>•  Consider stopping potential shunting </div><div>agents inhibiting hypoxic vasoconstriction: </div><div>Clevidipine, Nicardipine, Nitroprusside, NTG, </div><div></div><div>POST-OP: ADVANCED HEMODYNAMIC </div><div>MONITORING &amp; PULMARY ARTERY CATHETERS</div><div>Parameter Normal Value</div><div>Cardiac Output (CO) 4-8 L/min</div><div>Cardiac Index (CI) 2.2-4 L/min/m2</div><div>CVP (central venous pressure aka Right atrial pressure) 3-8 mmHg</div><div>PA (pulmonary artery) Pressure Systolic 15-30 mmHg (PAS)</div><div>Diastolic 5-12 mmHg (PAD)</div><div>Mean 9-16 (PAM)</div><div>PCWP (pulmonary capillary wedge pressure)  4-12 mmHg</div><div>PVR (pulmonary vascular resistance) 37-250 dynes/sec/cm5</div><div>RV (right ventricular) Pressure Systolic 15-30 mmHg</div><div>Diastolic 3-8 mmHg</div><div>SVR (systemic vascular resistance) 800-1200 dynes/sec/cm5</div><div>Preload:</div><div> </div><div>Decreased volume, decreased preload</div><div> </div><div>Increased volume, increased preload which may increase MAP and CO</div><div>Aerload: the resistance that the heart has to overcome, during every beat, to </div><div></div><div>Cardiac index: the volume of blood pumped by the heart, per minute, per meter </div><div>square of body surface area. Cardiac Output = HR x Stroke Volume</div><div> </div><div>Increased CO/CI: high circulating volume, increased strength of contraction, </div><div>early septic shock, vasodilatory state</div><div> </div><div>Decreased CO/CI: hypovolemia or decrease in ventricular strength of </div><div>contraction</div><div>CVP: used to approximate Right Ventricular End Diastolic Pressure and assesses </div><div></div><div> </div><div>Low CVP: hypovolemia, decreased venous return</div><div> </div><div>High CVP: hypervolemia, right sided heart failure, tamponade </div><div>Mean Arterial Pressure (MAP): Arterial pressure in the vessels perfusing organs. </div><div></div><div>systemic vascular resistance (SVR). MAP = [(2 x diastolic)+systolic] / 3</div><div> </div><div>Low MAP: hypovolemia, low cardiac output, or low SVR</div><div> </div><div>High MAP: hypervolemia, high cardiac output, or high SVR</div><div>Systemic Vascular Resistance (SVR): measurement of impedance or resistance </div><div></div><div> </div><div>Increased SVR: hypothermia, vasoconstrictors, hypovolemia, low cardiac </div><div>output state</div><div> </div><div>Decreased SVR: hyperthermia, vasodilators, acidosis, early septic shock  </div><div>Parameters for RV Function/Failure: used in context of overall clinical picture</div><div>Step-up: mean PA pressure – CVP</div><div> &gt;10: adequate RV function</div><div> &lt; 10: concern for RV dysfunction</div><div>PAPi: pulmonary artery pulsatility index = (PA Systolic – PA Diastolic) / CVP</div><div> &gt;2: adequate RV function</div><div> 1-2: at risk for RV failure</div><div> &lt; 1: RV failure</div></div><div></div></div>
<div><div><img><div>126 Reference Material Reference Material 127</div><div>Figure 1 PA Catheter Waveforms</div><div>Pulmonary Artery Pressure (PA Pressure): Blood pressure in the  </div><div>pulmonary artery</div><div> </div><div></div><div></div><div>Pulmonary Vascular Resistance: measurement of impedance or resistance of </div><div></div><div> </div><div>Increased PVR: hypoxia, hypercapnia, pulmonary vascular disease, PE</div><div>Pulmonary Capillary Wedge Pressure (PCWP): used to approximate LVEDP  </div><div></div><div></div><div> </div><div>High wedge pressure: LV failure, tamponade (cardiac compression), or </div><div>volume overload </div><div>Management of Hemodynamic Derangements</div><div>MAP CVP CO/CI SVR Treatment approach</div><div>    Volume</div><div>Normal  Normal  Diuretic</div><div>    Inotrope</div><div>    Vasodilator</div><div>    Inotrope/Vasodilator/IABP</div><div> Normal   Vasoconstrictor</div><div>References: </div><div>PA Catheter Waveform image: https://www.studyblue.com/notes/note/n/hemodynamic-monitoring/</div><div>deck/3727974</div><div>Bojar, RM. (2011) Manual of perioperative care in adult cardiac surgery. (5th edition).</div><div>POST-OP: COMMON ICU DRIPS</div><div>Inotropes/Vasopressors</div><div>Receptor Location Action</div><div>Alpha Adrenergeic Vascular walls</div><div>also found in the heart</div><div>Vasoconstriction</div><div>Increase duration of </div><div>contraction</div><div>Beta 1 Adrenergic Heart Increase inotropy and </div><div>chronotropy, minimal </div><div>vasoconstriction</div><div>Beta 2 Adrenergic Blood vessels vascular and nonvascular </div><div>smooth muscle relaxation</div><div>Dopamine renal, splanchnic </div><div>(mesenteric), coronary, and </div><div>cerebral vascular beds</div><div>vasodilatation</div><div>Drug Mechanism of Action Dose Side eects</div><div>Epinephrine potent beta-1 adrenergic receptor activity </div><div>moderate beta-2 and alpha-1 adrenergic </div><div></div><div>0.01-.2 mcg/</div><div>kg/min</div><div>Increases heart rate</div><div>Can induce </div><div>tachyarrhythmias and </div><div>ischemia</div><div>Dopamine 1 to 2 mcg/kg per minute</div><div>•  Selective vasodilatation of renal,  </div><div>  mesenteric, cerebral, and coronary beds</div><div>•  may increases urine output d/t  </div><div> </div><div>  and by inhibiting aldosterone and renal </div><div>  tubular sodium </div><div>5 to 10 mcg/kg per minute</div><div>•  stimulates beta-1 adrenergic receptors w/  </div><div>  increased cardiac output (stroke volume)</div><div>•  mild alpha adrenergic receptor activation  </div><div>  increases SVR</div><div>&gt;10 mcg/kg per minute</div><div>•  stimulation of alpha-adrenergic receptors,  </div><div>  causing vasoconstriction with an increased  </div><div>  SVR</div><div>1-20mcg/kg/</div><div>min</div><div>tachycardia, arrhythmias </div><div></div><div>mcg/kg/minute</div><div>Milrinone Selective phosphodiesterase (PDE) inhibitor </div><div>in cardiac and vascular tissue, resulting in </div><div>vasodilation (pulmonary and systemic) and </div><div>increased inotropy with little chronotropic </div><div>activity.</div><div>.1-.5mcg/kg/</div><div>min</div><div>Caution </div><div>with renal </div><div>impairment</div><div>May cause peripheral </div><div>vasodilation, </div><div>hypotension, and/or </div><div>ventricular arrhythmia</div><div>Dobutamine Stimulates beta-1 adrenergic receptor, </div><div>increases inotropy and chronotropy and </div><div></div><div>2 to 20 mcg/</div><div>kg/minute</div><div>Can cause hypotension</div><div>Vasopressin Increases cyclic adenosine monophosphate </div><div>(cAMP). Direct vasoconstrictor without </div><div></div><div>SVR &amp; MAP</div><div>.01-.04 units/</div><div>min</div><div>May decrease stroke </div><div>volume and cardiac </div><div>output in myocardial </div><div>dysfunction or precipitate </div><div>ischemia in coronary </div><div>artery disease.</div><div>Norepinephrine Stimulates both alpha-1 and beta-1 adrenergic </div><div>receptors; potent vasoconstriction &amp; modest </div><div>increase in cardiac output</div><div>1-20mcg/min </div><div>Phenylephrine Pure alpha-adrenergic agonist. Causes </div><div>vasoconstriction with minimal cardiac inotropy </div><div>or chronotropy.</div><div>10-300mcg/</div><div>min</div><div>May decrease stroke </div><div>volume and cardiac </div><div>output in patients with </div><div>cardiac dysfunction</div><div></div><div>Isuprel Stimulates beta-1 adrenergic receptors.</div><div>Inotropic and chronotropic agent</div><div>1-10 mcg/min </div><div>adrenergic receptor </div><div>causes vasodilation and a </div><div>decrease in MAP</div></div><div></div></div>
<div><div><img><div>128 Reference Material Reference Material 129</div><div>Vasodilators</div><div>Drug Mechanism of Action Dose Side eects</div><div>Clevidipine Calcium channel blocker, ultra short-acting </div><div>selective arteriolar vasodilator, reduce </div><div></div><div>pressures or causing</div><div>1-16 mg/hr Pulmonary shunt </div><div>physiology and hypoxia </div><div>from inhibition of hypoxic </div><div>vasoconstriction</div><div>Nicardipine A short-acting calcium channel blocker 2.5-15mg/hr   Contraindicated in </div><div>severe AS</div><div>Sodium </div><div>Nitroprusside</div><div>An arterial and venous vasodilator that </div><div></div><div>immediate onset of action</div><div>0.1- 3mcg/</div><div>kg/min</div><div>Prolong use (&gt;72hrs) and </div><div>high dose (&gt;3mcg/kg/</div><div>min) can cause cyanide </div><div>and thiocyanate toxicity</div><div>Nitroglycerine A direct vasodilator, primarily venodialtor, </div><div>arteriodilator at high dose. </div><div>Adjunct therapy for HTN</div><div>0.1-2 mcg/</div><div>kg/min</div><div>Esmolol </div><div>blocking agent</div><div>Dose: 25-</div><div>300mcg/kg/</div><div>min</div><div>Large volume infusion, </div><div>may contribute to volume </div><div>overload</div><div>Labetalol </div><div></div><div>Blocker. </div><div>0.5-3 mg/min</div><div>Hydralazine A direct-acting arteriolar vasodilator  10-20mg IV </div><div>push</div><div>Avoid in patients with </div><div>ischemic heart disease </div><div>and dissecting aneurysm</div><div>POST-OP: COMMON PO MEDS</div><div>Beta Blockers</div><div>Drug Usual Dose Misc Info</div><div>Atenolol 25-50mg PO qd Beta 1 selectivity, better for HR control </div><div>Metoprolol 2.5-100mg qD Beta 1 selectivity, better for HR control </div><div>Toprol XL 25-100mg qD Beta 1 selectivity, better for HR control</div><div>Avoid long acting BB in ICU, choose short acting </div><div>for easier titration. </div><div>Carvedilol  3.125-25mg BID Beta and Alpha blockage, better for Systolic HF</div><div>Labetolol 100-400mg PO QID Beta 2 and Alpha blockade</div><div>Nevibolol (Bystolic)  5-40mg PO qD Beta 1 selectivity</div><div>Beta Calcium Channel Blockers</div><div>Drug Usual Dose Misc Info</div><div>Dihydropryidines: potent vasodilators, little or no eect on contractility or conduction</div><div>     Amlodipine 2.5-10mg PO qD Mainly for HTN &amp; angina</div><div>     Nicardipine 20-40mg PO TID Mainly for HTN &amp; angina</div><div>     Nifedipine 10-30mg PO/SL TID Mainly for HTN &amp; angina</div><div>Non dihydropryidines: eect cardiac contractility and conduction</div><div>     Diltiazem 30-60mg PO TID</div><div>180-360mg qD if long acting</div><div>Heart rate control/HTN</div><div>     Verapamil 80-160mg PO TID Useful for angina</div><div>Nitrates</div><div>Drug Usual Dose Misc Info</div><div>Isosorbide </div><div>mononitrate (Imdur)</div><div>20mg PO qD Watch for Headache</div><div>Isosorbide dinitrate </div><div>(Isordil)</div><div>5-40mg PO TID Watch for Headache</div><div>Nitropaste 1-3 in q3-4 hr Watch for Headache</div><div>ACE inhibitors</div><div>(Avoid in acute renal dysfunction, adjust dose for moderate renal failure)</div><div>Drug Usual Dose Misc Info</div><div>Losartan (Cozaar) 25-100mg PO qD or in 2 divided </div><div>doses</div><div>Valsartan  (Diovan) 80-160mg PO qD</div><div>Irbesartan (Avapro) 150-300mg PO qD</div><div>Cadesartan (Atacand) 8-32mg PO qD or in 2 divided </div><div>doses</div><div>Alpha Blockers</div><div>Drug Usual Dose Misc Info</div><div>Alpha 1 antagonist</div><div>     Doxazosin (Cardura) 1.0-8mg PO qD Good for BPH</div><div>     Prazosin (Minipress) 1.0-7.5mg PO BID</div><div>     Terazosin (hytrin) 1-20mg PO qD Good for BPH, Slows HR, watch for  </div><div>orthostatic h0tn</div><div>Alpha 2 antagonist</div><div>     Clonidine (Catapres) 0.1-0.3mg PO BID Slows HR, good for nicotine withdrawal sx.  </div><div>Rebound tachycardia/hypertension if stopped</div><div>Antiarrhythmics</div><div>Drug Usual Dose Misc Info</div><div>Amiodarone  400mg PO TID, wean to </div><div>200mg qd</div><div>Class III, prolongs action potential duration</div><div>Digoxin 0.125-0.25mg PO qd Leads to increased contractility through inhibition </div><div>of the Na/K+ ATPase pump, promotes calcium </div><div></div><div>Direct suppression of AV node conduction </div><div>Monitor digoxin levels</div><div>Sotalol 80mg PO TID Class III, prolongs action potential duration</div></div><div></div></div>
<div><div><img><div>130 Reference Material Reference Material 131</div><div>Diuretics</div><div>Drug Usual Dose Misc Info</div><div>Loop diuretics</div><div>Furosemide (Lasix) 10-100mg QID Needs k+ replacement</div><div>Bumex 0.5-10mg daily Needs k+ replacement</div><div>If not responding to high dose Lasix, consider </div><div>switching to Bumex</div><div>Thiazides</div><div>HCTZ (Hydrodiuril) 50-100mg qD</div><div>Chlorothiazide (Diuril) 500mg IV qD</div><div>Metolazone </div><div>(Zaroxolyn)</div><div>5-20mg qD</div><div>Potassium sparing:</div><div>Eplerenone (Inspra) 25-50mg qD</div><div>Spironolactone </div><div>(Aldactone)</div><div>25mg qD</div><div>Carbonic Anhydrase Inhibitor</div><div>Acetazolamide </div><div>(Diamox)</div><div>250-500mg IV q6h Increased renal excretion of bicarbonate (used in </div><div>metabolic/contraction alkalosis)</div><div>Bojar, R.M. (2011) Manual of perioperative care in adult cardiac surgery. (5th Edition).</div><div>POST-OP: DIAGNOSIS TRANSLATION EXAMPLES</div><div>Diagnosis Translation Examples</div><div>When documenting: Consider:</div><div>NPO, tube feeding, TPN, nutrition note: </div><div>diagnosis doc</div><div>Severe protein-calorie malnutrition, underweight</div><div>Altered mental status, Delirium Encephalophathy, type: acute delirium and etiology/cause</div><div>Chest pain Cause of chest pain, CHF, MI, CAD</div><div>CHF, ESHD Acuity and type of CHF</div><div>Myocardial infarction  NSTEMI, STEMI (artery involved)</div><div>Hgb 7.5; 1L EBL, 2U PRBC given Acute blood loss anemia </div><div>Elevated BUN/Creatinine Acute Kidney Injury and or/ ATN</div><div>NA 125/150 with monitor and/or treatment Hyponatremia/Hypernatremia</div><div>5,3”, 297 lbs BMI &gt; 40, Morbid obesity, overweight</div><div>WBC: 2.0, RBC 2.50, Plt: 75, on chemo Pancytopenia due to chemo</div><div>Hypoxia, Hypoxic, Hypercapnic Respiratory Failure (Acuity and Type)</div><div>Urosepsis, Meeting 2 out of 4 SIRS criteria Sepsis due to UTI</div><div>Pneumonia Pneumonia, specify etiology and/or causative organism</div><div>Fever Link cause of fever</div><div>Hypotensive require vasoactive drugs Shock and Type of Shock (Cardiogenic, Hypovolemic, post op, etc)</div><div>POST-OP: IICU ADMISSION REQUIREMENTS</div><div>iICU Admission Criteria</div><div>IV infusions </div><div>(patient must </div><div>have 3 or less)</div><div> </div><div>Dopamine: max rate 10 mcg/kg/min via central line</div><div> </div><div>Milrinone 0.375mcg/kg/min max</div><div> </div><div>Amiodarone: central line administration strongly  </div><div>preferred. Therapy via PIV for 24 hours max. </div><div> </div><div>Argatroban, heparin </div><div> </div><div>Insulin continuous infusion </div><div> </div><div>Diltiazem</div><div> </div><div>Ketamine</div><div> </div><div>Esmolol (D1, CSU, B2 only)</div><div> </div><div>Labetolol</div><div> </div><div>Nitroglycerin (for controlling chest pain, 1 hour max)</div><div>Temporary </div><div>Pacemakers</div><div> </div><div>Semi-Permanent Pacemakers </div><div> “Floating lead”, Transvenous – not allowed</div><div> “Fixed lead”, with external generator- allowed</div><div> Underlying rhythm/rate irrelevant </div><div> </div><div> </div><div>Temporary Epicardial Wires</div><div> If patient is pacer dependent, underlying heart </div><div>rate must be &gt; 40 and be hemodynamically stable</div><div>CPAP/BiPAP</div><div> </div><div>Nasal CPAP &amp; BIPAP for patients established on a </div><div>nighttime CPAP/BiPAP (nasal mask) at home for OSA</div><div> </div><div>Nasal CPAP &amp; BIPAP as a new therapy for respiratory </div><div></div><div>evaluation and for a maximum duration of 4 hours. </div><div>Requires consultation of ICU team</div><div> </div><div>Full face mask CPAP &amp; BiPAP for patients with OSA is </div><div>permitted if treatment is an established home therapy and </div><div>patient is able to remove mask</div><div>High Flow </div><div>Nasal Cannula</div><div> </div><div>HFNC can be accepted once patients are on stable </div><div></div><div> </div><div>Patient must be evaluated every 4 hours for increasing </div><div>oxygen requirements </div><div>Pericardial </div><div>Drains</div><div> </div><div>All Allowed</div><div>Post Cath </div><div>procedure </div><div>patients</div><div> </div><div>Fast Track TAVRS</div><div> </div><div>Post cardiac cath</div></div><div></div></div>
<div><div><img><div>132 Reference Material Reference Material 133</div><div>POST-OP: INR GOALS</div><div>Bioprosthetic </div><div>Aortic Valve</div><div>Bioprosthetic Mitral </div><div>Valve Replacement</div><div>Mechanical Aortic </div><div>Composite Valve</div><div>Mechanical Aortic </div><div>Valve Standard </div><div>Mechanical Mitral </div><div>Valve </div><div>Trans-catheter </div><div>Aortic Valve </div><div>Replacement</div><div>Atrial Fibrillation </div><div>Only</div><div>VTE Prophylaxis </div><div>INR Range (Goal) 1.5-2.5 2.0-3.0 2.5-3.5 (3.0) 2.0-3.0</div><div>Level of Evidence B B B B</div><div>Size of Treatment </div><div></div><div>Class I Class I Class I Class I</div><div>Duration Lifelong VKA Lifelong VKA Lifelong VKA</div><div>Level of Evidence A A A</div><div>Post-op </div><div>Anticoagulation</div><div></div><div>surgery once post-</div><div>operative bleed no </div><div>longer an issue.</div><div>(No bridge with </div><div>Heparin)</div><div></div><div>surgery once post-</div><div>operative bleed no </div><div>longer an issue.</div><div>(No bridge with </div><div>Heparin)</div><div></div><div>surgery once post-</div><div>operative bleed </div><div>no longer an issue. </div><div>(Bridge with </div><div>Heparin Post Op  </div><div>24-36 Hours)</div><div>Dual antiplatelet </div><div>with clopidogrel </div><div>75mg for 6 months  </div><div>if not on Coumadin</div><div>Unfractionated </div><div>Heparin 5000 Units </div><div>Subcutaneously </div><div>every  8 hours </div><div>unless patient is </div><div>bleeding (100 cc </div><div>per hour or more) </div><div>from Chest tubes</div><div>ASA Y/N (dose) Y (81-325mg) Y (75-100mg) Y (75-100mg) Y (75-100mg) Y (75-100mg) Y (75-100mg) - </div><div>lifelong</div><div>(75mg-325mg)</div><div>Level of Evidence B A A A C</div><div>Size of Treatment </div><div></div><div>Class IIa Class I Class I Class I Class IIb</div><div> </div><div>HITT = heparin induced thrombocytopenia thrombosis</div><div>TIPS FOR CARDIAC SURGERY (Blue/Green) ANTICOAGULATION</div><div>*If patient has more than one indication for Coumadin use the highest </div><div>INR goal.</div><div>IF MECHANICAL MVR:  patients should be started on heparin/argatroban drip </div><div>postop day 1 if no bleeding for bridging to Coumadin.</div><div>IF TEMPORARY PACING WIRES ARE STILL IN: DO NOT LET INR GET ABOVE 2.0 </div><div>UNTIL THEY ARE REMOVED.  Stay on heparin/argatroban drip until pacing wires </div><div>removed.</div><div>Heparin/Argatroban drip needs to be stopped for 6 hours prior to pacing wire </div><div></div><div>IF STARTING OTHER ANTICOAGULANTS (like Xarelto, Eliquis, Pradaxa, etc.) DO </div><div>NOT START UNTIL TEMPORARY PACING WIRES ARE REMOVED.  IF indicated, use </div><div>heparin/argatroban drip until pacing wires are removed if indicated.</div><div>If on multiple blood thinning agents (ie  Aspirin, Plavix, and Coumadin), discuss </div><div>with Cardiac Surgery that this is okay.</div><div>All patients are treated if blood test for HIT is positive, whether symptomatic or </div><div>not.  Length of therapy should depend on Hematologist’s recommendation.  </div><div> </div><div>*Additional risk factors for thromboembolic events (AF, previous thromboembolism, LV </div><div>dysfunction, or hypercoagulable state) or an older-generation mechanical AVR (such as </div><div>ball-in-cage).</div><div>§ It is recommended to not start VKA until platelets have substantially recovered (i.e., </div><div>usually to at least 150X109/L).  VKA should initially be given in low doses (maximum, </div><div>5 mg of warfarin) over using higher doses (Grade 1C).  If VKA has already been started </div><div>when diagnosed with HIT, vitamin K should be administered (Grade 2C).  VKA should be </div><div>overlapped with a nonheparin anticoagulant for a minimum of 5 days and until the INR is </div><div>within target range (Grade 1C).</div><div>1)  Guyatt GH, Akl EA, Crowther M, et al. American College of Chest Physicians Antithrombotic </div><div>Therapy and Prevention of Thrombosis Panel. Executive summary: antithrombotic Therapy </div><div>and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based </div><div>Clinical Practice Guidelines.  Chest. 2012 Feb;141(2 Suppl):7S-47S. </div><div>2)  January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management </div><div>of Patients With Atrial Fibrillation: Executive Summary: A Report of the American College </div><div>of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart </div><div>Rhythm Society. J Am Coll Cardiol. 2014 Mar 28. Pii:S0735-1097(14)01739-2.</div><div>3)  Kearon C, Akl E, Comerota A, et al. Antithrombotic therapy for VTE disease: Antithrombotic </div><div>Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians </div><div>Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb; 141 (2 Suppl):e419S-94S.</div><div>4)  Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced </div><div>thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American </div><div>College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb; </div><div>141(2suppl):e495s-530S.</div><div>5)  Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of </div><div>patients with valvular heart disease; a report of the American College of Cardiology/American </div><div>Heart Association Task Force on Practice Guidelines. J Thorac Cardiovas Surg. 2014 Jul; </div><div>148(1):e1-e132. </div></div><div></div></div>
<div><div><img><div>134 Reference Material Reference Material 135</div><div>POST-OP: PROPHYLACTIC MEDICATIONS  </div><div>(GI, VA-PNA, DVT, INFECTION)</div><div>Common Prophylactic Medications</div><div>Pre Op </div><div>(day of surgery)</div><div>ICU iICU</div><div>VA- PNA</div><div>•  Peridex 0.12%, 15mL </div><div>swish and spit</div><div>•  Peridex 0.12%, 15mL swish and spit </div><div>while intubated</div><div>•  N/A</div><div>DVT</div><div>•  No DVT prophylaxis </div><div>indicated</div><div>•  SCDs</div><div>•  Heparin 5000 units subQ q8 hours</div><div>•  SCDs</div><div>•  Consider subq </div><div>Heparin if not able </div><div>to ambulate</div><div>Surgical </div><div>Prophylaxis </div><div>•  2g cefazolin  </div><div>(3g if &gt;120kg)</div><div>•  Weight dosed </div><div>vancomycin if PCN </div><div>allergy</div><div>•  Antimicrobial shower </div><div>x2 (PM and AM) before </div><div>surgery with either </div><div>chlorhexidine sponges </div><div>(per patient) or wipes </div><div>(per nurse)</div><div>•  2g cefazolin (3g if &gt;120kg) x 3 doses </div><div>(24 hours)</div><div>•  Weight dosed vancomycin if PCN </div><div>allergy x2 doses (24 hours)</div><div>•  N/A</div><div>Lumbar </div><div>Drain</div><div> </div><div></div><div>placed</div><div> </div><div>drain in place</div><div>•  N/A</div><div>GI</div><div>•  N/A •  IV or PO acid suppression therapy for:</div><div>  o  Mechanical ventilation &gt; 48 hours</div><div>  o  Plt count &lt; 50, INR &gt; 1.5, or PTT 2x  </div><div>  baseline</div><div>  o  Spinal cord injury</div><div>  o  Solid organ transplantation  </div><div>  perioperatively in the ICU setting </div><div>  o  Use of two antiplatelet agents </div><div>  o  Any two of the following: Sepsis,  </div><div>  ICU stay &gt; 10 days, occult bleeding  </div><div>  lasting &gt; 6 days, high dose steroids </div><div>*Steroid use with no other risk factors </div><div>and NPO status are NOT indications for </div><div>stress ulcer prophylaxis</div><div>•  Acid suppression </div><div>therapy only if </div><div>patient previously </div><div>took at home for </div><div>GERD</div><div>•  Literature DOES </div><div>NOT support stress </div><div>ulcer prophylaxis </div><div>outside of the ICU </div><div>environment</div><div>POST-OP: SUPPLEMENTAL O2 &amp; VENTILATOR </div><div>MANAGEMENT</div><div>Oxygen Administration</div><div>1.  Nasal cannula</div><div>a.  </div><div>i.  FiO2 = 20% + (4 x O2 L/min)</div><div>b.  </div><div>2.  Face mask</div><div>a.  </div><div>to determine an accurate FiO2 delivery since 75% of inspired volume is </div><div>room air</div><div>3.  Venti mask</div><div>a.  Delivers a precise oxygen concentration in increments of 24, 28, 31, 35, </div><div>and 40%</div><div>b.  Inspired volume is a mix of room air and oxygen. Exhaled air is allowed to </div><div>exit the mask therefore CO2 retention is minimal</div><div>4.  Non-rebreather mask</div><div>a.  </div><div>b.  There is a one way valve that prevents the patient from breathing in room </div><div>air.  This ensures that a high oxygen concentration is delivered.  Risk of </div><div>CO2 retention</div><div>5.  </div><div>hypoxemia</div><div>a.  FiO2 range 20-100%, Flow range 20-50 L/min</div><div></div><div>b.  </div><div>Consider transitioning to regular nasal cannula once FiO2 weaned to 40-</div><div></div><div>Non-Invasive Positive Pressure Ventilation (NIPPV)</div><div>1.  Continuous Positive Airway Pressure (CPAP)</div><div>a.  Noninvasive ventilation mode that delivers positive pressure throughout </div><div>the respiratory cycle through specialized face or nasal masks</div><div>b.  Prescriber must specify PEEP and FiO2</div><div>2.  Bilevel Positive Airway Pressure (Bipap)</div><div>a.  Noninvasive ventilation mode that delivers </div><div>b.  Prescriber must set end-expiratory pressure (EPAP or PEEP) and IPAP  </div><div>c.  If Bipap is delivered using Drager or LTV vent, the ordered PS is additive </div><div>to the level of PEEP.  i.e. PS 10 cmH2O &amp; PEEP 5 cmH2O will deliver a total </div><div>IPAP of 15cmH2O  </div><div>d.  PS is not an additive to PEEP on Respironics Vision and V-60 devices</div><div>e.  Consider placing NG/OG tube if IPAP &gt; 20 cm H2O</div><div>Ventilator Modes: the most frequently used modes in the CVICU are </div><div>VC-AC, VC-SIMV and PSV</div><div>1.  Volume-Controlled Ventilation (VCV) </div><div>a.  VCV is volume-limited and time-cycled. </div><div>b.  Prescriber must set a desired tidal volume, respiratory rate</div><div>c.  The vent will deliver the set VT with every breath (machine or patient </div><div>triggered).  Airway pressure aka peak inspiratory pressure (PIP) will vary </div><div>based on lung mechanics (resistance/compliance)</div><div>d.  Vent setting parameters</div><div>i.  Minute ventilation 8-10 L/min</div><div>ii.  Tidal Volume (VT) 8-10 mL/kg (&lt; 6 mL/kg for ARDS)</div><div>iii. Plateau airway pressures &lt; 30 cm H2O</div><div>2.  Pressure-Controlled Ventilation (PCV)</div><div>a.  PCV is pressure-limited and time-cycled.  </div><div>b.  Prescriber must set desired pressure limit, respiratory rate, and </div><div>inspiratory time (I:E ratio)</div><div>c.  </div><div></div><div>pressure for the duration of the inspiratory time.  VT will vary based on </div><div>lung mechanics</div><div>d.  Vent setting parameters</div><div>i.  Peak inspiratory pressure &lt; 35 cm H2O</div><div>3.  Assist Control Ventilation (ACV)</div><div>a.  ACV can be either pressure or volume limited</div><div>b.  The ventilator delivers the same set parameters for both mandatory and </div><div>patient triggered breaths.  </div></div><div></div></div>
<div><div><img><div>136 Reference Material Reference Material 137</div><div>4.  Synchronized Intermittent Mandatory Ventilation (SIMV)</div><div>a.  Assisted breaths are synchronized to coincide with spontaneous </div><div></div><div>5.  Pressure-Support Ventilation (PSV)</div><div>a.  </div><div>b.  The prescriber sets the pressure support level</div><div>c.  Each breath is patient triggered and the tidal volume is determined by </div><div></div><div>6.  Airway Pressure Release Ventilation (APRV) </div><div>a.  Alternates between high/low airway pressure and is time-cycled (not </div><div>patient triggered).  Most time is spent at high pressure with a brief cycle </div><div>to low pressure.  Purpose of this type of ventilation is to keep alveoli </div><div>recruited</div><div>7.  Inverse Ratio Ventilation (IRV)</div><div>a.  This mode of ventilation uses a prolonged inspiratory time (2:1) in </div><div>order to help prevent alveolar collapse.  May be used for patients </div><div>with refractory hypoxemia with conventional modes of ventilation.  </div><div></div><div>PEEP: Peak end expiratory pressure</div><div>1.  Therapeutic Uses: </div><div>a.  Patients admitted to ICU on ventilator will be set on PEEP 5cm H20</div><div>i.  PEEP 5 considered a substitute for loss of normal breathing </div><div>“Physiologic PEEP” caused by the presence of the ETT (endotracheal </div><div>tube)</div><div>ii.  Usually well tolerated hemodynamically, not much recruitment/O2 </div><div></div><div>b.  Increasing PEEP to increase PaO2</div><div>i.  Increasing PEEP (by 2-5cm H20 increments) will increase mean airway </div><div>pressure and open previously closed alveoli</div><div>ii.  Increases lung surface area participating in gas exchange</div><div>iii. Decreases VQ/intrapulmonary shunting by improving ventilation to </div><div>perfused lung</div><div>iv. As lung recruitment and PaO2 improves, FiO2 may be weaned</div><div>c.  Cautions with high PEEP</div><div>i.  Increased intrathoracic pressure decreases venous return to the heart</div><div>ii.  Increased PEEP leads to increased PVR, leading to more strain on RV</div><div>iii. Decreased venous return and depressed RV performance may lead to </div><div></div><div>iv. Should not be used in patients with COPD (leads to increased VQ </div><div>mismatch)</div><div>v.  Monitor for signs of “barotrauma:” </div><div>1.  Caused by alveolar overdistention</div><div>2.  May present as: pneumothorax, subcutaneous emphysema, </div><div>pneumomediastinum</div><div>Lung Mechanics</div><div>1.  End-inspiratory Peak pressure</div><div>a.  </div><div>the airways, and elasticity of lungs and chest wall</div><div>2.  End-inspiratory Plateau pressure</div><div>a.  Pplat is a direct measurement of the elasticity of the lungs and chest wall </div><div>(compliance)</div><div>b.  </div><div>3.  Tips</div><div>a.  If peak pressure is elevated and plateau pressure is unchanged, there is </div><div>an increased resistance in the airways which may be due to secretions in </div><div>the ETT, mucous plug, or acute bronchospasm</div><div>b.  If both peak and plateau pressures are elevated, there is decreased </div><div>compliance of the lungs and/or chest wall.  Causes may include </div><div>pneumothorax, atelectasis, acute pulmonary edema, worsening </div><div>pneumonia, or ARDS</div><div>c.  If peak pressure is decreased, there is a problem with an air leak in the </div><div>ventilator system</div><div>d.  PEEP increases plateau pressure</div><div>CV-ICU Interdisciplinary Rapid Extubation Protocol (I-REP)</div><div>1.  Assess patient to determine if patient meets vent weaning criteria</div><div>a.  Weaning criteria: </div><div>i.  SpO2 &gt; 92% on FiO2 &lt; 60%</div><div>ii.  PEEP &lt; 8 cm H2O</div><div>iii. Temp &gt; 35C</div><div>iv. Hemodynamically stable</div><div>v.  Chest tube output stable</div><div>vi. Spontaneous breathing noted (if patient not over-breathing, </div><div>then reduce respiratory rate by 50% for up to 5 min to assess for </div><div>spontaneous breathing)</div><div>2.  If patient meets weaning criteria then reduce respiratory rate to zero as </div><div>tolerated while maintaining EtCO2 &lt; 50.  </div><div>a.  Goal PSV -  PS 10, PEEP 5, and normal work of breathing with RSBI &lt; 100</div><div>3.  If patient does not tolerate PSV, return to previous vent settings and reassess</div><div>4.  If tolerates PSV, check ABG and assess neuro to see if patient meets </div><div>extubation criteria.</div><div>a.  Extubation criteria</div><div>i.  SpO2 &gt; 92% on FiO2 &lt; 50%</div><div>ii.  EtCO2 stable and within baseline +/- 10%</div><div>iii. pH &gt; 7.3</div><div>iv. PS 10 and PEEP 5</div><div>v.  RSBI &lt; 100 with normal work of breathing</div><div>vi. If patient does not meet criteria, reassess every 15 min for a total of 3 </div><div>cycles</div><div>5.  If extubation criteria are met, then ok to extubate.  If patient is morbidly obese </div><div>or has a h/o OSA then extubate to CPAP 8-10 cm or Bipap 10/5 for 2 hours</div><div>6.  If patient is receiving inhaled Flolan, extubate to HFNC to continue Flolan </div><div>administration </div><div>Miscellaneous </div><div>1.  Do not change any ventilator settings unless in an emergency.  Please notify </div><div>respiratory therapy team for all ventilator changes</div><div>2.  Rapid-shallow breathing index (RBSI) = RR / Liters of Tidal Volume</div><div>a.  Goal RSBI &lt; 100</div><div>b.  Indicator for appropriateness for extubation (along with mental status, </div><div>amount of secretions, strength of cough, etc)</div><div>3.  Indirect Calorimetry</div><div>a.  Nutrition is important because too few calories causes respiratory muscle </div><div>catabolism and muscle weakness.  Too many calories (particularly carbs) </div><div>increases metabolic rate and can result in respiratory muscle fatigue or </div><div>hypercapnia due to increased CO2 production</div><div>b.  b.  Indirect calorimetry is a measurement of resting energy expenditure </div><div>based on oxygen consumption (VO2) and carbon dioxide production (VCO2)</div></div><div></div></div>
<div><div><img><div>138 Reference Material Reference Material 139</div><div>POST-OP: VAD BOWEL REGIMEN PROTOCOL</div><div>Standards of Practice for VAD patients to reduce Post-po Ileus</div><div>VAD Quality Improvement</div><div>Vincenta M. Grassano, RD, CNSC</div><div>Heart Failure Service/D1</div><div>1.  Initiate bowel regimen the day of admission (Pre-op)</div><div>a.  Senna 2 tabs BID</div><div>b.  Docusate 100mg BID</div><div>2.  Escalate bowel regimen if no BM within 24 hours of surgery</div><div>a.  Bisacodyl 10mg per rectum x1 occurrence</div><div>b.  Magnesium Citrate 300mL x1 occurrence (not for patients with renal </div><div>dysfunction)</div><div>c.  Check potassium and magnesium</div><div>3.  Adhere to Pre-Op diet regimen</div><div>a.  Patient to receive diet order for recommended PO Diet or TF </div><div>(carbohydrate containing meal) up to 24 hours before surgery</div><div>b.  MD order for Liquid Diet (carbohydrate containing liquids ie juice or </div><div>Ensure clear) up to 6 hours prior to surgery rather than NPO</div><div>c.  Patient to be NPO 6 hours prior to surgery</div><div>CVICU Service / Immediate Post-op</div><div>1.  Resume bowel regimen POD #0</div><div>a.  Senna syrup 10mL via feeding tube BID</div><div>b.  Increase docusate solution 200mg via feeding tube BID</div><div>c.  Add Miralax 1 packet BID</div><div>d.  Bisacodyl 10mg per rectum daily</div><div>2.  Keofeed placed if unable to extubate by POD #2</div><div>a.  Allows for early nutrition</div><div>b.  Allows for immediate administration of bowel regimen/medications</div><div>3.  Initiation of Nutrition by POD #2  </div><div>(with the potential to meet estimated needs)</div><div>a.  If intubated initiate tube feeds</div><div>b.  Initiate Full liquid or Regular diet (sugar free clear liquid and clear liquid </div><div>diet do not have potential to meet estimated needs)</div><div>c.  Supplements if needed</div><div>4.  Escalate bowel regimen POD #4 if no bowel movement or atus</div><div>a.  Lactulose 20mg TID (NOTE: can cause abdominal discomfort and </div><div>cramping)</div><div>b.  Either: </div><div>i.  Mineral oil enema</div><div>ii.  Magnesium citrate (150-300mL) *(not for patients with renal </div><div>dysfunction)</div><div>5.  KUB POD #5 if no BM of Flatus</div><div>6.  Taper down regimen if multiple bowel movements s/p bowel regimen</div><div>a.  Docusate solution/capsule 200mg BID: continue as scheduled</div><div>b.  Senna syrup 10mg BID: change scheduled to PRN</div><div>c.  Miralax 1 packet BID: change scheduled to PRN</div><div>POST-OP: END OF LIFE CARE</div><div>Use these guidelines to transition a patient to comfort care and </div><div>perform discharge as deceased documentation </div><div>1.  Family, patient (if able), ICU team and surgical team agree to withdraw care</div><div>2.  Discontinue all orders in Epic (including medications, labs, nursing care </div><div>orders, etc)</div><div>3.  Order the IP ICU End of Life Order Set (#1791) in Epic</div><div>a.  Choose the appropriate analgesics and anxiolytics as discussed with ICU </div><div>attending</div><div>b.  Order the Comfort Care code status within the order set </div><div>4.  Work with the ICU Attending, bedside nurse and respiratory care to determine </div><div>the sequence of support withdrawal</div><div>5.  Work with the resource/charge RN to have Chaplain services available</div><div>6.  Resource/charge nurse will notify the Transplant Donor Network</div><div>7.  Once the patient has passed, you or another licensed provider should </div><div>examine the patient and declare Time of Death </div><div>a.  Make note of this time, you will use it multiple times in documentation</div><div>b.  You or the ICU attending should approach the next of kin about autopsy </div><div>request</div><div>8.   Discharge as Deceased Documentation</div><div>a.  Use the Discharge Navigator and choose the “Discharge as Deceased” tab </div><div>located at the top of the Discharge Navigator</div><div>b.  Fill in the Death Certicate Worksheet by selecting “New Reading” and </div><div></div><div>i.  This will be used by Chaplain services to complete the Death </div><div></div><div>ii.  Call the Coroner (408-793-1900) to report the death</div><div>1.  They will ask you the patient’s address (located in Demographics)</div><div>2.  They will ask Cause of Death and brief synopsis of what happened</div><div>3.  Document the case/release number and the name of the person </div><div>you talked to in the appropriate space in Epic</div><div>iii. Complete the “Cause of Death” Documentation</div><div>1.  “Cardiopulmonary arrest” is Not a viable diagnosis</div><div>2.  When in doubt, ask the ICU attending what to list</div><div>c.  Complete the Deceased Summary within the navigator</div><div> </div><div>ii.  Select the ICU Attending as the cosigner</div><div>d.  Complete the Discharge Summary</div><div> </div><div>ii.  Delete non-applicable sections as needed</div><div>iii. Same information as the Deceased Summary, may copy-paste </div><div>iv. List the Surgical attending as the cosigner </div><div>9.  Write the Discharge Order</div><div>a.  Disposition: Deceased</div></div><div></div></div>
<div><div><img><div>140 Reference Material Reference Material 141</div><div>POST-OP: PATIENT PROGRESSION CHECKLIST</div><div>Patient Progression Towards Discharge</div><div> </div><div>Pain- well controlled with oral meds</div><div> Remove OnQ (Bupivicaine pump) 1 day prior to discharge))</div><div> </div><div>Remove devices (Chest tubes, Pacer wires, Foley, A-line)</div><div> </div><div>Transition to PO Medications</div><div> ASA, statin</div><div> Beta-Blocker if applicable</div><div> Need for Anticoagulation? Transition to PO anticoagulants</div><div> Adequate diuresis? Transition to PO diuretics</div><div> Do any medications require prior authorization? (Consult with Case </div><div>manager)</div><div> </div><div>Commonly prescribed medications requiring prior authorization </div><div>include: NOAC (Eliquis, xarelto), oxycontin</div><div> </div><div>Tolerating diet, BM since surgery</div><div> Post-operative imaging (consult with chief resident/surgical attending) </div><div> CT scan +/- Echo (surgeon and operation dependent)</div><div> 2-view CXR (done in radiology suite) at dry weight prior to discharge</div><div> </div><div></div><div> </div><div>PT eval: Home vs. home with home health therapy vs. Skilled Nursing Facility</div><div> Consult with E-29 Case Manager to start referral process if needed</div><div> Contact: 650-847-7453 (work cell-phone)</div><div> </div><div>Cardiac rehab: Discharge teaching</div><div> Cardia Rehab ghost pager: 1-5736 </div><div> </div><div>Establish follow up appointments with Nurse Coordinator (PCP, Cardiologist, </div><div>INR clinic, etc). Contact via cell-phone:</div><div> Dr. Boyd, Dr. Ha: Sally Eastman 650-627-6373</div><div> Dr. Woo: Ashley Liang 650-683-0114</div><div> Dr. Lee, Dr. Hiesinger: Pres Lorenzo 650-850-2828</div><div> Dr. Fischbein, Miller: Judi Lachenmyer 650-498-7731 (ext 87731) </div><div>NOTES</div></div><div></div></div>
<div><div><img><div>142 Reference Material Reference Material 143</div><div>NOTES NOTES</div></div><div></div></div>
<div><div><img><div>144 Reference Material</div><div>DEPARTMENT OF CARDIOTHORACIC  </div><div>SURGERY HANDBOOK—VERSION II</div><div>Faculty Advisors:</div><div>Y. Joseph Woo, MD</div><div>Jack H. Boyd, MD</div><div>Charles Hill, MD</div><div>Charlene Kell, EMBA, BSN, RN, CCRN, FACHE, NEA-BC</div><div>Anson M. Lee, MD</div><div>Kapilkumar N. Patel, MD</div><div> </div><div>Contributing Authors:</div><div>Scarlette Aliga-Cabamungan, MS, RN, AGACNP-BC</div><div>Irina Axelrod, PA-C</div><div>Christopher J. Bilbao, DO</div><div>Sarah Booth, ACNPC-AG, MSN, CCRN</div><div>Zoe Chan, PA-C</div><div>Kristie Duoss, MSN, ACNP-BC</div><div>Clara George, NP</div><div>Hilary C. Hammond, MMS, PA-C</div><div>Christine Hartley, RN, MS, ACNP-BC</div><div>Aleya Hyderi, PA-C</div><div>Kelly Juarez, MPAS, PA-C</div><div>Yukfung Lee, PA-C</div><div>Xin Ma, MMS, PA-C </div><div>Erica Mikhli, PA-C</div><div>Shari Miller, PA-C, FAPACVS</div><div>Mykl Morrissey, MSN, RN, AGACNP-BC</div><div>Richard Quitevis, MS, RN, AGACNP-BC</div><div>Hardeep Reddick, MBA, PA-C</div><div>Suzanne Sewell, MSN, RN, FNP-BC</div><div>Joe Simmons, MS,ACNP-BC</div><div>Tim Shieh, PA-C</div><div>Y. Kevin Zeng, MS, AGACNP-BC, RN</div><div> </div><div>Contributing Editors: </div><div>Megan Atashroo, MSN, RN-FA, FNP-BC</div><div>Mary Sheridan Bilbao, MPAS, PA-C, FAPACVS</div><div>Corinne Pogemiller, MMSc, PA-C</div><div>Emily Tognozzi, MMS, PA-C</div><div>Disclaimers:</div><div>Although care has been taken to ensure the accuracy of content of this </div><div>handbook, it should not be a substitute for clinical judgment. Neither the </div><div>authors nor editors assume any liability for injuries and or damage related to this </div><div>publication.</div><div>For internal use only, not for sale or re-distribution. Use for intended audience </div><div>only. Not for patient education.  </div></div><div></div></div>
</div>
<div>
<img>
</div>
</body>
</div>
